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ABSTRACT 
 
Cardiovascular diseases are among the leading causes of death worldwide and 
particularly in the developed World. The search for new therapeutic approaches for 
improving the functions of the damaged heart is therefore a critical endeavour. 
Myocardial infarction, which can lead to heart failure, is associated with irreversible loss 
of functional cardiomyocytes. The loss of cardiomyocytes poses a major difficulty for 
treating the damaged heart since terminally differentiated cardiomyocytes have very 
limited regeneration potential. Currently, the only effective treatment for severe heart 
failure is heart transplantation but this option is limited by the acute shortage of donor 
hearts. The high incidence of heart diseases and the scarcity donor hearts underline the 
urgent need to find alternative therapeutic approaches for treating cardiovascular 
diseases. 
 
Pluripotent embryonic stem (ES) cells can differentiate into functional cardiomyocytes. 
Therefore the engraftment of ES cell-derived functional cardiomyocytes or cardiac 
progenitor cells into the damaged heart to regenerate healthy myocardial tissues may 
be used to treat damaged hearts. Stem cell-based therapy therefore holds a great 
potential as a very attractive alternative to heart transplant for treating heart failure and 
other cardiovascular diseases. A major obstacle to the realisation of stem cell-based 
therapy is the lack of donor cells and this in turn is due to the fact that, currently, the 
molecular mechanisms or the regulatory signal transduction mechanisms that are 
responsible for mediating ES cell differentiation into cardiomyocytes are not well 
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understood. Overcoming this huge scientific challenge is absolutely necessary before  
the use of stem cell-derived cardiomyocytes to treat the damaged heart can become a 
reality.  
 
Therefore the aim of this thesis was to investigate the signal transduction pathways that 
are involved in the differentiation of stem cells into cardiomyocytes. The first objective 
was the establishment and use of cardiomyocyte differentiation models using H9c2 cells 
and P19 stem cells to accomplish the specific objectives of the thesis. The specific 
objectives of the thesis were, the  investigation  of the roles of (i) nitric oxide (ii) protein 
kinase C (PKC), (iii) p38 mitogen-activated protein kinase (p38 MAPK) (vi) 
phosphoinositide 3-kinase (PI3K) and (vi) nuclear factor-kappa B (NF-kB) signalling 
pathways in the differentiation of stem cells to cardiomyocytes and, more importantly, to 
identify where possible any points of convergence and potential cross-talk between 
pathways that may be critical for differentiation to occur. 
 
P19 cells were routinely cultured in alpha minimal essential medium (α-MEM) 
supplemented with 100 units/ml penicillin /100 µg/ml streptomycin and 10% foetal 
bovine serum (FBS).  P19 cell differentiation was initiated by culturing the cells in 
microbiological plates in medium containing 0.8 % DMSO to form embryoid bodies (EB). 
This was followed by transfer of EBs to cell culture grade dishes after four days.  
H9c2 cells were cultured in Dulbecco’s Modified Eagle’s medium (DMEM) 
supplemented with 10% FBS. Differentiation was initiated by incubating the cells in 
medium containing 1% FBS.  
iii 
 
In both models, when drugs were employed, they were added to cells for one hour prior 
to initiating differentiation. Cell monolayers were monitored daily over a period of 12 or 
14 days. H9c2 cells were monitored for morphological changes and P19 cells were 
monitored for beating cardiomyocytes. Lysates were generated in parallel for western 
blot analysis of changes in cardiac myosin heavy chain (MHC), ventricular myosin chain 
light chain 1(MLC-1v) or troponin I (cTnI) using specific monoclonal antibodies.  
H9c2 cells cultured in 1% serum underwent differentiation as shown by the time-
dependent formation of myotubes, accompanied by a parallel increase in expression of 
both MHC and MLC-1v. These changes were however not apparent until 4 to 6 days 
after growth arrest and increased with time, reaching a peak at day 12 to 14. P19 stem 
cells cultured in DMSO containing medium differentiated as shown by the time-
dependent appearance of beating cardiomyocytes and this was accompanied by the 
expression of cTnI.   
 
The differentiation of both P19 stem cells and H9c2 into cardiomyocytes was blocked by 
the PI3K inhibitor LY294002, PKC inhibitor BIM-I and the p38 MAPK inhibitor 
SB2035800.  However when LY294002, BIM-I or SB2035800 were added after the 
initiation of DMSO-induced P19 stem cell differentiation, each inhibitor failed to block 
the cell differentiation into beating cardiomyocytes. The NF-kB activation inhibitor, 
CAPE, blocked H9c2 cell differentiation into cardiomyocytes. Fast nitric oxide releasing 
donors (SIN-1 and NOC-5) markedly delayed the onset of differentiation of H9c2 cells 
into cardiomyocytes while slow  nitric oxide releasing donors (SNAP and NOC-18) were 
less effective in delaying the onset of differentiation or long term differentiation of H9c2 
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cells into cardiomyocytes.  Akt (protein kinase B) is the key downstream target of PI3K. 
Our cross-talk data also showed that PKC inhibition and p38 MAPK inhibition 
respectively enhanced and reduced the activation of Akt, as determined by the 
phosphorylation of Akt at serine residue 473. 
 
In conclusion, PKC, PI3K, p38 MAPK and NF-kB are relevant for the differentiation of 
stem cells into cardiomyocytes. Our data also show that the PKC, PI3K and p38 MAPK 
signalling pathways are activated as very early events during the differentiation of stem 
cells  into cardiomyocytes. Our data also suggest that PKC may negatively regulate Akt 
activation while p38 MAPK inhibition inhibits Akt activation.  Our fast NO releasing 
donor data suggest that nitric oxide may negatively regulate H9c2 cell differentiation.  
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1 INTRODUCTION 
 
1.1 Definition of stem cells 
 
A stem cell is an unspecialised or undifferentiated cell from the embryo (i.e. 
embryonic stem cell) or from adult or foetus tissue (i.e. adult stem cell). An 
embryonic stem cell has two important fundamental properties: unlimited  
ability  to divide and generate new stem cells (i.e. self-renewal) without going 
into senescence and under appropriate physiological or experimental 
conditions, can specialise or differentiate into other cell types (Evans and  
Kaufman, 1981; Martin, 1981; Thomson et al., 1998). Adult stem cells, like ES 
cells, are capable of self-renewal and can differentiate into various cell types. 
However, unlike ES cells, adult stem cells (at most) are only multipotent (i.e. 
are not pluripotent) and also have limited self-renewal ability. Self-renewal 
and pluripotency (multipotency for adult stem cells) allow stem cells to serve 
as building blocks in developmental processes in human and animals. In the 
adult human or animal, stem cells also maintain tissue homeostasis by 
providing a continuous supply of new cell types to replace highly differentiated 
cells that have become damaged or simply turn over as part of the normal 
physiology of organs or tissues regeneration.  Embryonic stem cells are the 
only non-transformed (i.e. stable diploid karyotype) mammalian cells that can 
be continuously propagated in vitro. 
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1.2 Potential benefits of stem cell research  
 
In the future, as our understanding of the essential properties and behaviour 
of stem cells increase, it may be possible to use them for cell-based therapies 
to treat human diseases (e.g. diabetes and heart diseases), to have more  
understanding of human development and  developmental-related diseases 
(such as birth defects), the aging process and aging-related diseases (e.g. 
Parkinson’s disease).  Stem cell research will also allow for the use of stem 
cell-derived specialised cell types for the screening of new drugs and other 
chemical compounds. Stem cell research therefore has huge scientific and 
medical importance. 
 
1.3 Classification of stem cells 
 
On the basis of their origin, human and animal stem cells can be classified 
into two categories: somatic or adult stem cells and embryonic stem cells. 
Three types of mammalian embryonic stem cells have been derived: 
embryonic stem (ES) cells (Evans and  Kaufman, 1981; Nagy et al., 1990; 
Brook and  Gardner, 1997; Thomson et al., 1998), embryonic carcinoma (EC) 
Cells (Martin, 1981; McBurney and  Rogers, 1982)  and embryonic germ (EG) 
cells (Shamblott et al., 1998; Turnpenny et al., 2003; Liu et al., 2004) (Figure 
1.10) On the basis of their developmental or differentiation potential ES cells 
can be further subdivided into the following types: totipotent, pluripotent, 
multipotent and unipotent stem cells. Totipotent stem cells (i.e. the zygote) 
can differentiate into all cell types of body.  The three types of embryonic stem 
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cells (ES, EC and EG) originate from the zygote (Figure 1.10). Pluripotent 
stem cells (i.e. cells of the inner cell mass at the blastocyst stage) can 
differentiate into any cell type of the three primary germ layers i.e. endoderm 
(e.g. pancreatic cells, thyroid cells and lung alveolar cells), mesoderm (e.g. 
cardiac muscle cells, skeletal muscle cells, kidney tubule cells) and the 
ectoderm (e.g. epidermal tissues, neuron and pigment cells). Multipotent stem 
cells (e.g. haematopoietic cell) can differentiate into several but not all cell 
types. Unipotent stem cells (e.g. spermatogenic stem cells) give rise to only 
one cell type. 
 
1.3.1 Embryonic stem (ES) cells 
 
Embryonic stem cells  are pluripotent cells derived from the inner cell mass of 
embryos at the blastocyst stage (3 to 5-day old embryo) (Evans and  
Kaufman, 1981; Martin, 1981; Doetschman et al., 1985; Nagy et al., 1990; 
Brook and  Gardner, 1997; Thomson et al., 1998) (Figure 1.10). When 
returned to the embryonic environment by transfer into a host blastocyst or 
aggregation with blastomere-stage embryos, cultivated ES cells reincorporate 
into normal embryonic development and have the full potential to develop into  
all lineages of the embryo proper (Bradley et al., 1984; Nagy et al., 1990).   
 
The blastocyst includes three structures: the trophoblast,  blastocoel and inner 
cell mass (ICM). The trophoblast is the layer of cells that surrounds the 
blastocyst. The blastocoel is the hollow cavity inside the blastocyst. The inner 
cell mass is a group of cells (approximately 30 cells) at one end of the 
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blastocoels (Figure 1.10). The ICM can be grown on mitotically arrested 
(mitomycin C treated or gamma irradiated) adherent mouse embryonic 
fibroblasts (MEF) or feeder layer as it is referred to.  Both mitomycin-C and 
gamma irradiation induce DNA damage and cause cell cycle. Mitomycin-C 
binds to DNA and causes DNA cross-linking (Rink et al., 1996; Volpato et al., 
2005; Nieto et al., 2007). This interferes with DNA replication, RNA 
transcription and protein synthesis. Gamma irradiation treatment induces DNA 
damage irradiation (Bishay et al., 2000; Ibuki et al., 2003). Therefore the 
treatment of cells with either mitomycin C or gamma arrests the cell growth or 
proliferation. The feeder layer cells provide a sticky surface for the ES cells 
and also release nutrients into the culture medium. In developing tissues, a 
stem cell from the blastocyst is capable of giving rise to the multiple 
specialised cell types. ES cells have  been differentiated into various cell 
types including cardiomyocytes (Doetschman et al., 1985; Kehat et al., 2001), 
skeletal and smooth muscle cells (Rohwedel et al., 1994; Drab et al., 1997),  
neuronal cells (Bain et al., 1995; Bruneau et al., 1999; Reubinoff et al., 2001; 
Zhang et al., 2001), β islet pancreatic cells  (Assady et al., 2001), dipocytes 
(Dani et al., 1997), endothelial cells  (Levenberg et al., 2002)  and several 
other tissue types. 
 
The other types of embryonic stem cells are embryonic (embryonal) 
carcinoma cells and embryonic germ (EG) cells. Embryonal carcinoma (EC), 
like ES, are  fully  pluripotent cells  derived from malignant teratocarcinomas 
rather than, directly from , the ICM (Martin, 1981; McBurney and  Rogers, 
1982) (Figure 1.10). Embryonic germ (EG) cells are also pluripotent and are 
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derived from primordial germ cells of foetal gonadal or genital ridges 
(Shamblott et al., 1998; Turnpenny et al., 2003; Liu et al., 2004) (Figure 1.10). 
 
Mouse EG cells, like the  ES cells, are cultured on MEF or in the presence of 
leukaemia inhibitory factor (LIF). Leukaemia inhibitory factor is a 
differentiation inhibitor that keeps stem cells in the undifferentiated state. In 
contrast to both ES and EG cells that require  culture on  embryonic fibroblast 
feeder  layer cells or in the presence of LIF, EC cells (e.g. P19 cell line) are 
embryonic fibroblast feeder-cell independent (Bradley et al., 1984). 
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Figure 1.10: Pluripotent embryonic cell lines from mammals: Embryonic 
carcinoma (EC) cells, embryonic stem (ES) cells and embryonic germ (EG) 
cells. The ES cells are derived from the ICM and epiblast. EC cells are 
derived from germ cell tumours or teratocarcinomas. EG cell lines are derived 
from primordial germ cells of  gondal or genital ridge  of  embryos. Taken from 
Boheler et al., 2002. 
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1.3.2 Adult Stem Cells 
 
Adult stem cells are undifferentiated cells found among differentiated cells in 
tissues. They can be isolated from foetal (after gastrulation) or adult tissues. 
Amniotic fluid stem cells are adult stem cells from foetal tissues (Perin et al., 
2008). Unlike ES cells which are pluripotent, adult stem cells are only 
multipotent and are generally believed to be programmed to differentiate into 
specialised cell types of the tissues or organs in which they reside. The 
primary role of adult stem cells in a living organism is to maintain tissue 
homeostasis and repair. They maintain homeostasis by generating new cells 
to replace terminally differentiated cells that are no longer functional. Adult 
stem cells have been isolated from a wide range of tissues or organs 
including the heart (Laugwitz et al., 2005; Moretti et al., 2007), bone marrow 
(Pittenger et al., 1999; Reyes et al., 2001), brain (Clarke et al., 2000),  liver 
(Yang et al., 2002), skin (Toma et al., 2001), adipose (Zuk et al., 2002),  
skeletal muscle (Jackson et al., 1999) and blood (Zhao et al., 2003). 
 
1.4 Stem cell niche 
 
The decision between stem cell self-renewal and differentiation is thought to 
be a highly regulated process under the control of molecular and cellular 
factors.  This in vivo regulatory microenvironment is known as a stem cell 
niche. Stem cell number, cell division, self-renewal and differentiation are 
likely to be controlled by both extrinsic factors and intrinsic factors. Extrinsic 
factors, including Wnt (Lam et al., 2006; Aicher et al., 2008; Fleming et al., 
2008), BMP (Kosinski et al., 2007), Notch (Alexson et al., 2006; Song et al., 
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2007) and intrinsic factors, including upstream controllers such as the 
unpaired (upd) gene (Kiger et al., 2001; Tulina and  Matunis, 2001; Boyle et 
al., 2007) and transcription factors, such as Early Growth Response 1(EGR1) 
(Min et al., 2008), Pharynx and Intestine in Excess (PIE-1) (Mello et al., 1996; 
Seydoux et al., 1996) play roles in stem cell niche. Stem cell niches have 
been proposed to exist in several adult tissues, including the haematopoietic 
system (Calvi et al., 2003; Zhang et al., 2003b; Arai et al., 2004), neural 
tissues (Shen et al., 2004) and in epithelial tissues including the  gut 
epithelium (He et al., 2004) and the skin  (Tumbar et al., 2004). In vivo, the 
stem cell niche favours the maintenance of the stem cells in the 
undifferentiated state. The ultimate decision of a stem cell to remain in the 
undifferentiated state or to differentiate into specific cell types may depend 
upon the expression of several regulatory molecules, including transcription 
factors within the niche. The expression of these regulatory molecules may be 
induced either by intrinsic or extrinsic events or by both. A clear understanding 
of how the decision between stem cell self-renewal and differentiation is made 
will make it easier to culture adult stem cells in the differentiated state and 
also to direct their differentiation into specific cell types using the appropriate 
conditions. This clear understanding may be part of the first steps in the 
direction toward the realisation of the huge therapeutic potentials of adult 
stem cells.  
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1.5 Bone marrow stem cells 
 
The bone marrow (BM) is a good source of adult stem cells. The bone marrow 
contains at least two kinds of stem cells: haematopoietic stem cells (HSC) and 
mesenchymal stem cells (MSC). The HSC give rise to all the blood cells: red 
blood cells, B lymphocytes, T lymphocytes, natural killer cells, neutrophils, 
basophils, eosinophils, monocytes, macrophages, and platelets (Spangrude 
et al., 1988; Okada et al., 1991; Bhatia et al., 1997; Yang et al., 2005). 
Mesenchymal stem cells have the potential to differentiate into multiple 
lineages but they are rare (i.e. 1 in 10,000 of nucleated BM cells). 
Mesenchymal stem cells express several markers but none of the markers 
expressed are specific to their identification. The identification of MSC is 
therefore based on a composite marker expression and a lack or absence of 
haematopoietic stem cell marker expression such as CD45 (Lu et al., 2005; 
Polisetty et al., 2008), CD34 (Conrad et al., 2002; Polisetty et al., 2008), CD14 
(Lu et al., 2005) or CD11 (Polisetty et al., 2008). Mesenchymal stem cells also 
do not express some co-stimulatory molecules  such as CD80 (Sun et al., 
2003; Lu et al., 2005), CD86 (Lu et al., 2005; Liu et al., 2006) or CD40 (Liu et 
al., 2006). Human MSC can however express CD105 (Barry et al., 1999; 
Conrad et al., 2002; Roura et al., 2006; Odabas et al., 2008), CD73 (Barry et 
al., 2001; Trivedi and  Hematti, 2007; Odabas et al., 2008), CD44 (Oswald et 
al., 2004; Yanada et al., 2006; Zhu et al., 2006), CD90 (Oswald et al., 2004; 
Wiesmann et al., 2006) and some adhesion molecules (e.g. CD106 (Polisetty 
et al., 2008), CD166 and CD29 (Oswald et al., 2004; Polisetty et al., 2008)). 
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Mesenchymal stem cells have the potential to contribute to the regeneration 
of various mesenchymal tissues including bone (osteocytes), cartilage cells 
(chondrocytes) (Worster et al., 2001; Bai et al., 2004), ligament, tendon, fat 
(adipocytes) (Scavo et al., 2004) and smooth muscles (Jeon et al., 2006; 
Wang et al., 2006). In addition to their differentiation into mesenchymal 
tissues, recent research suggests that MSC can also differentiate into 
cardiomyocytes (Hakuno et al., 2002; Li et al., 2006; Wang et al., 2006; 
Tomita et al., 2007; Muscari et al., 2008) and this can be achieved 
experimentally using  5-azacytidine (Fukuda, 2001; Xu et al., 2004b; 
Antonitsis et al., 2007).  5-azacytidine is a nucleoside analog of cytidine. 
Carbon 5 on the pyrimidine ring of 5-azacytidine is replaced by a nitrogen 
atom. Therefore when incorporated into DNA, 5-azacytidine cannot be 
methylated thus leaving the new synthesized genomic DNA largely in the 
unmethylated state (Jones and  Taylor, 1980; Taylor and  Jones, 1982). DNA 
methylation is one of the key mechanisms of gene regulation. The 
incorporation of 5-azacytidine into DNA can activate  gene expression and  
also alter the differentiation of some eukaryotic cells (Jones and  Taylor, 1980; 
Jones et al., 1983). The successful cardiac differentiation of the MSC was 
noted by expression of mRNA for Nkx2.5, GATA-4, TEF-1, and MEF2C 
(Myocyte Enhancer Factor 2 C) before and further expression of MEF2A and 
MEF2D after 5-azacytidine treatment. Cardiac proteins  including atrial 
natriuretic peptide (ANP) were also detected (Fukuda, 2001) . The analysis of 
their contractile protein, such as myosin and α-actin, indicated that their 
phenotype was similar to foetal ventricular cardiomyocytes  (Fukuda, 2001). 
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The differentiation of MSC into cardiomyocytes as determined by the 
expression of α-cardiac actin, β-myosin heavy chain and cardiac troponin-T by 
human MSC has also been demonstrated (Xu et al., 2004b; Antonitsis et al., 
2007). An important observation in these studies is that both 5-azacytidine-
treated cells and non-treated cells expressed cardiac specific genes (Fukuda, 
2001; Antonitsis et al., 2007).  It was further shown that cardiac specific genes 
were not expressed in undifferentiated MSC that were not being expanded in 
culture (Antonitsis et al., 2007). This suggests that while MSC can 
differentiate into cardiomyocytes, they do not do so randomly or 
spontaneously but only in the presence inducing factors (e.g. 5-azacytidine or 
conditions such as being expanded in culture).  While the physiological 
stimulus that drives MSC differentiation into cardiomyocytes is not yet known, 
these results raise a possibility that MSC (or cardiomyocytes derived from 
bone marrow sources) can potentially be valuable for the treatment of 
myocardial infarction. A better understanding of the MSC differentiation into 
cardiomyocytes may allow the use of MSC-derived cardiomyocytes to replace 
cardiomyocytes in the damaged heart. 
 
1.6 Potential advantages and disadvantages of ES and adult 
stem cells 
 
1.6.1 Embryonic stem cells 
 
Embryonic stem cells are obtained from embryos and can be expanded in 
culture for a very long time. Pluripotent ES cells can undergo flexible 
differentiation into many different cell types. However, the pluripotent nature of 
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ES cells means that they are difficult to differentiate into a uniform or 
homogeneous population of one cell type. Due to their pluripotent capacity, 
undifferentiated ES cells transplanted into target tissues may form teratomas. 
Apart from the risks of tumour formation, ES cell-derived target cell types may 
also cause an immune reaction in the recipient, thus, causing the rejection of 
transplanted cells. Apart from the above scientific issues with ES cells that 
have to be resolved, there is also an ethical dimension to human ES cell 
research and potential future use.  Currently available  stem cell technologies, 
for the derivation of pluripotent human ES cells, require the “destruction” of 
human embryos at the blastocyst stage (Thomson et al., 1998). Therefore for 
some people, ES cell research and potential use may pose ethical problems. 
However the creation of induced pluripotent stem cells (iPS) from adult human 
cells (Takahashi et al., 2007; Yu et al., 2007) may  offer a viable alternative to 
the human embryo as a source for  pluripotent stem cells. Octamer-binding 
protein (Oct-3/4), a transcription and  pluripotency marker,  is  expressed in 
embryonal carcinoma cells, embryonic stem cells and embryonic germ cells 
(Thomson et al., 1998; Hansis et al., 2000; Reubinoff et al., 2000). Human 
amniotic fluid stem cells have also been shown to express Oct-3/4. Human 
amniotic fluid stem cells can be obtained without the destruction of human 
embryos (Prusa et al., 2003; De Coppi et al., 2007; Perin et al., 2008; Zheng 
et al., 2008b). In the future iPS and adult stem cells, like amniotic fluid stem 
cells with higher pluripotency, may offer viable alternatives to the human 
embryo as a source for pluripotent stem cells. 
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1.6.2 Adult stem cells  
 
Adult stem cells are rare in mature tissues and methods for harvesting pure 
adult stem cells and growing them culture are difficult. Therefore adult stem 
cells unlike ES are relatively more difficult to obtain in large numbers.  
 
For research purposes, the need for a pure population of adult stem cells is a 
critical consideration because the reliability of experimental results from adult 
stem studies may be compromised by the presence of other cell type in the 
cell culture or stem cell preparation from adult tissues. The presence of non-
stem cell populations in isolated adult stem cell population can lead to the 
wrong  interpretation of results, especially if the contaminating cell type has or 
express the phenotypes of the final or target cell type for the differentiation 
studies.  
 
Adult stem cells exist in vivo and this means that they must be able to self-
renew in order to be able to participate in the maintenance of long term tissue 
homeostasis in human and animals, but isolated adult stem cells cannot 
undergo long-term self-renewal in vitro. The renewal capacity of adult stem is 
therefore less than that of ES cells hence adult stem cells may not live as long 
as ES cells in culture. For future stem cell therapies, the rarity of adult stem 
cells and their low self-renewal capacity are very important considerations, 
since a large number of cells may be needed on a routine basis for patient 
treatment. 
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Adult stem cells are programmed to differentiate into cell types of the tissues 
in which they are found. However emerging evidence suggest that under 
appropriate conditions, animal and human adult stem cells can differentiate 
into cell types of tissues other than that of their origin.  Human MSC have 
been differentiated into cardiomyocytes (Grauss et al., 2007), chondrocytes  
(Bai et al., 2004), adipocytes (Scavo et al., 2004)  and smooth muscle (Jeon 
et al., 2006). Mouse MSC have been differentiated into cardiomyocytes (Kudo 
et al., 2003) and neurons (Tropel et al., 2006). Rat  MSC have been 
differentiated into neurons (Lou, et al. 2003) and  smooth muscle (Wang et al., 
2006) and horse  MSC have been differentiated into chondrocytes (Worster et 
al., 2001). However, generally, adult stem cells have less differentiation 
potentials then ES cells and may, therefore, be more difficult to differentiate 
into cell of other tissue other than the tissue of origin. A key potential 
advantage of using adult stem cells is that if the patient's own cells are 
expanded in culture and then re-introduced into the patient, the risk of 
immune rejection of the transplanted cells may be avoided. In terms of ethical 
considerations, adult stem cell research and their therapeutic use may be 
more acceptable than ES cells, since adult stem cells can be isolated without 
any potential harm to the donors. 
 
1.7 Embryonic stem cell culture models 
 
Embryonic stem cells are cultured at low density on a mitotically inactivated 
embryonic fibroblast feeder layer or in the presence of LIF or both. Under 
these culture conditions, the stem cells are prevented from undergoing 
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undirected spontaneous differentiation processes thus maintaining their stem 
cell pluripotency  (Evans and  Kaufman, 1981; Martin, 1981; Smith et al., 
1988; Williams et al., 1988; Niwa et al., 1998).  
 
A huge amount of what we know about stem cell and stem differentiation 
comes from studies using mouse ES cell models. Experience with human ES 
cells is relatively new and limited, but comparison between human and mouse 
models using the limited data from human have revealed important 
differences between the two models. These differences include the cell 
culture requirements to keep the stem cells in the undifferentiated state, 
morphology, growth kinetics and antigenic phenotypes or stem cell specific 
molecular markers. 
 
1.8 Differences between human and mouse embryonic stem 
cells 
 
1.8.1 Differences in leukaemia inhibitory factor requirement  
 
The leukaemia inhibitory factor (LIF) (fully discussed below under LIF 
signalling) alone is sufficient, even in the absence of feeder layer cells, to 
maintain mouse stem cell cultures in the undifferentiated state. However LIF 
alone is not sufficient to prevent the differentiation of human (and other 
primates) ES cells (Schuringa et al., 2002). This means that human ES cells, 
unlike mouse ES cells, are maintained in an undifferentiated state through a 
signalling pathway(s) that may be independent of or in addition to LIF 
signalling.  
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1.8.2 Differences in cell morphologies and growth kinetics  
 
Mouse ES cells grow in tightly attached rounded masses while human ES 
cells form relatively flat compact colonies with high nuclear to cytoplasm ratio 
and prominent nucleoli (Thomson et al., 1998; Reubinoff et al., 2000; Park et 
al., 2004). Human colonies can be easily dissociated into single cells with 
conventional mechanical and enzymatic techniques. The population doubling 
time of human ES cells of approximately  36 hours (Hovatta et al., 2003; Park 
et al., 2004) is significantly longer than that of mouse ES cells (approximately 
10-16 hours) (Viswanathan et al., 2002; Berrill et al., 2004; Fok and  Zandstra, 
2005; Greenlee et al., 2005). 
 
1.8.3 Differences in stem cell specific markers 
 
In addition to morphological differences, human and mouse pluripotent stem 
cells differ in their expression of a number of antigenic phenotypes or stem 
cell specific molecular markers. Common stem cell markers that are used in 
characterisation of ES  cells include the glycolipid surface Stage Specific 
Embryonic Antigens (SSEA-1, SSEA-3, SSEA-4) and the keratan sulfate-
related antigens (TRA-1-60 and TRA-1-81)  (Solter and  Knowles, 1978; Gooi 
et al., 1981; Ozawa et al., 1985; Krupnick et al., 1994; Draper et al., 2002). 
The TRA antigens (or antibodies) were named after the Battle of Trafalgar.  
Undifferentiated primate (human and nonhuman primates) ES cells express 
the specific cell surface markers: SSEA-3, SSEA-4, TRA-l-60 and TRA-1-81 
(Draper et al., 2002; Henderson et al., 2002). They also express alkaline 
phosphatase. However differentiated primate  ES cells strongly expressed 
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SSEA-l (Krupnick et al., 1994; Thomson et al., 1995). Differences between 
mouse and human is shown by the fact that mouse inner cell mass cells, 
undifferentiated ES cells and EC cells  express SSEA-1 but do not express 
SSEA-3, SSEA-4, TRA-1-60, or TRA-1-81, in contrast to  undifferentiated 
primate ES cells. SSEA-1 appears during the late cleavage stages of mouse 
embryogenesis. SSEA-1 is strongly expressed by undifferentiated mouse ES 
cells  (Solter and  Knowles, 1978; Gooi et al., 1981; Ozawa et al., 1985; 
Krupnick et al., 1994). Differentiated murine ES cells are characterised by the 
loss of SSEA-1 expression (Cui et al., 2004). The loss of SSEA-1 expression 
may be accompanied in some instances by the appearance of SSEA-3 and 
SSEA-4. In contrast to undifferentiated mouse ES  cells, undifferentiated 
human ES cells are characterised by the expression of SSEA3, SSEA4, TRA-
1-60, and TRA-1-81, and by the lack of SSEA1 (Draper et al., 2002; 
Henderson et al., 2002). The differentiation of human ES and EC cells is 
characterised by down-regulation of SSEA-3 and SSEA-4 (Draper et al., 
2002). In contrast to the differential expression of the above stem cell 
markers, both mouse and human embryonic stem cell express octamer-
binding transcription factor-3/4 (Oct-3/4) (Thomson et al., 1998; Hansis et al., 
2000; Reubinoff et al., 2000), Nanog (see section 1.10.3)   (Chambers et al., 
2003; Mitsui et al., 2003; Hart et al., 2004; Sato et al., 2004) and have high 
telomerase activity (Thomson et al., 1998; Amit et al., 2000; Armstrong et al., 
2000; Yang et al., 2008). Stem cell markers are proteins found in stem cells 
(and rarely in other cells) and as such they have specific physiological 
functions. For example, Oct-3/4 is a transcription factor that is expressed in 
totipotent and pluripotent stem cells of the pregastrulation embryo and is 
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required to sustain stem cell self-renewal and pluripotency (Rosner et al., 
1990; Palmieri et al., 1994; Nichols, 1998; Niwa et al., 2000). While the 
physiological functions of many stem cell markers are not currently known, 
stem cell markers are important research tools for the identification of 
undifferentiated stem cells and the characterization of differentiated cell types. 
 
1.9 Stem cell self-renewal and pluripotent state 
 
While research effort has been directed toward clearly understanding the 
mechanisms that are involved in stem cell differentiation into various cell 
types, it is also equally important to understand the regulatory mechanisms 
that are responsible for ES cell self-renewal and pluripotency. A clear 
understanding of the key self-renewal/pluripotency regulatory mechanisms 
can lead to better differentiation protocols and this may lead to the realisation 
of ES cells full therapeutic potentials. While intracellular signalling events that 
are involved in the maintenance of ES cell self-renewal and pluripotency are 
complex and not yet fully understood, research data point to the involvement 
of various extrinsic factors (e.g. LIF, BMP, Wnt) and key ES cell specific 
factors (e.g. Nanog, Oct-4, Sox2). 
 
1.9.1 Leukaemia inhibitory factor signalling and stem cell self-renewal 
 
In  cell culture medium, pluripotent ES cells undergo spontaneous 
differentiation to generate the three germ layers: endoderm, mesoderm and 
ectoderm leading to a mixed population of cell lineages and cell types  (Amit 
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et al., 2000; Schuldiner et al., 2000). The presence of  leukaemia inhibitory 
factor (LIF) or closely related cytokines is required in culture, in order to 
prevent  this spontaneous differentiation (Smith and  Hooper, 1987; Smith et 
al., 1988; Williams et al., 1988; Niwa et al., 1998). LIF, a multifunctional 
cytokine of the interleukin-6 (IL-6) cytokine family, sustains ES cell self-
renewal and pluripotency by signalling mechanisms that are not yet fully 
understood. 
Leukaemia inhibitory factor acts on a cell surface receptor complex that is 
composed of two chains [(i.e.  an 80-kDa  LIF-binding α-chain and  a 130-kDa 
signal transducer β-chain (gp130)].The gp130 chain is a common receptor 
subunit that is shared by receptors for other cytokines of the IL-6 family, 
including IL-6,  IL-11,  cardiotrophin-1, oncostatin M, and ciliary neurotrophic 
factor (Hibi et al., 1990; Gearing et al., 1991; Gearing and  Bruce, 1992; Ip et 
al., 1992; Davis et al., 1993; Murakami et al., 1993). Interleukin-6 can 
substitute for LIF in mouse ES cells. Mouse ES cells can  be maintained in the 
undifferentiated state using a combination of interleukin-6 and soluble 
interleukin-6 receptor (IL-6/sIL-6R) (Nichols et al., 1994; Yoshida et al., 1994; 
Yoshida et al., 1996) 
 
The binding of LIF induces the dimerisation of the receptor chains to  form a 
high affinity heterodimer complex (Davis et al., 1993; Murakami et al., 1993). 
The high affinity receptor complex formation leads to the recruitment and 
activation of cytosolic tyrosine kinases  of the Janus kinase (JAK) family (i.e. 
JAK-1, JAK-2, JAK-3 and Tyk2). The activated JAK cross phosphorylate 
themselves (Narazaki et al., 1994; Stahl et al., 1994) and then phosphorylate  
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the tyrosine residues on the intracellular domain of gp130 (Stahl et al., 1994; 
Nakamura et al., 1998).  This phosphorylation by JAKs creates binding or  
docking sites (i.e. the phosphorylated tyrosine residues) on the receptor  for 
the binding of proteins containing the Src-homology 2 (SH2) domain. The 
creation of docking sites on the gp130 receptor, is followed by the activation 
of two major signalling cascades:  JAK-STAT which promotes ES cell self-
renewal (Boeuf et al., 1997; Niwa et al., 1998; Matsuda et al., 1999; Raz et 
al., 1999) and SHP2-Ras/Raf/ERK/MAPK which promotes ES cell 
differentiation (Burdon et al., 1999). This means that the balance between the 
JAK-STAT cascade and the SHP-2-ERK cascade may be crucial in 
determining whether ES cells differentiate or remain the differentiate state. 
 
1.9.2 Leukaemia inhibitory factor signalling: STAT cascade 
 
Docking sites on gp130 are required for LIF/STAT signalling to maintain ES 
cell self-renewal (Niwa et al., 1998). The STAT (signal transducer and 
activator of transcription) protein family include STAT1, 2, 3, 4, 5A, 5B and 6. 
Non-phosphorylated latent STAT proteins are activated to become active 
transcription factors by phosphorylation. STAT3 is the major or critical 
mediator of LIF signalling that maintain ES cells in the differentiated state. 
Over-expression of STAT3F (dominant negative mutant form of STAT3 with 
tyrosine 705 changed to phenylalanine)  in ES cells growing in the presence 
of LIF can cause  loss of  pluripotency and enhanced cell differentiation  
(Boeuf et al., 1997; Niwa et al., 1998). STAT3 activation is required and 
sufficient to maintain mouse ES cells in the undifferentiated state (Matsuda et 
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al., 1999; Raz et al., 1999). It has been shown that the inhibition of STAT3 
activation blocked ES cell self-renewal and promoted differentiation (Niwa et 
al., 1998). 
 
When STAT3 docks on the cytosolic domain of the receptor via SH-2-
phosphotyrosine interactions, it (i.e. STAT3) is phosphorylated by receptor-
bound JAKs (or other nonreceptor tyrosine kinases). STAT3 phosphorylation 
at Tyr705 is required for dimerisation and nuclear translocation because over-
expression of STAT3F has  been shown to block the activation of endogenous 
STAT3  in myeloid leukemia Ml cells (Minami et al., 1996; Nakajima et al., 
1996). The activated STAT factors dissociate from the receptor complex, 
undergo homodimerisation or heterodimerisation and then translocate into the 
nucleus where they bind to elements in the promoters of STAT responsive or 
target genes to control their transcription (Figure 1.11) 
 
1.9.3 Leukaemia inhibitory factor signalling: ERK/MAPK cascade 
 
The SHP-2-ERK cascade is activated by docking of growth factor receptor-
bound protein 2 (Grb2) on phosphorylated SHP2 on the activated gp130 
receptor. Grb2 and   the son of sevenless (SOS) form a complex. The 
complex formation leads to the activation of Ras which in turn activates Raf. 
Many other pathways also use Ras signalling to achieve various outputs or 
functions. It is not yet fully understood how specificity is generated. Specificity 
of Ras action may be determined by cell type or the presence (or absence) of 
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specific signal-activated and tissue-restricted signalling molecules (e.g. 
transcription factors). 
 
Ras-activated Raf activates mitogen-activated protein kinase kinase (MEK) 
which in turn finally activates ERK (Figure 1.11). Activated SHP-2-ERK 
cascade antagonises the STAT3 cascade to promote stem cell differentiation. 
ERK1 and ERK2 play a role in mediating mitogenic responses of cells to 
growth factors (Pages et al., 1993; Cowley et al., 1994; Weber et al., 1997).  
SHP-2-ERK activation is also not unique to controlling the balance between 
ES cell renewal and differentiation. However, SHP-2-ERK activation has been 
linked to the regulation of mouse ES cell self-renewal. SHP-2-ERK signalling 
can repress the expression of Nanog in mouse ES cells (Hamazaki et al., 
2006). A dominant-negative mutant of Ras has been found to suppress the 
expression of GATA-4, GATA-6 and other markers of extraembryonic 
endoderm differentiation.  It has also been reported that a constitutively active 
Ras promoted ES cell differentiation and this promoted ES cell differentiation 
was inhibited by the application of a MEK inhibitor (U0126) (Yoshida-Koide et 
al., 2004). Similarly it has been shown that the inhibition  of ERK signalling 
promotes self-renewal of mouse ES cells (Burdon et al., 1999). 
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Figure 1.11: LIF signalling and stem cell self-renewal. This diagram shows 
a simplified view of LIF-induced signalling events. LIF binding to the receptor 
leads to recruitment of JAK and the activation of STAT. STAT dimerise, 
translocate to the nucleus and switch on the expressions of cytokine (e.g., 
LIF) target genes. In the case of LIF binding to the receptor, in stem cells, 
genes that keep the stem cells in the undifferentiated state are activated. 
Abbreviations: JAK (Janus kinase); MEK (MAPK kinase); P (Phosphate 
group); SOS (Son of sevenless) and STAT (Signal transducers and activators 
of transcription); Sh-2-Containing Tyrosine Phosphatase (SHP2),  
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1.9.3.1 Negative regulation of LIF signalling by SHP-2 and SOCS 
 
The gp130-dependent signalling pathway is regulated by action of Src-
homology tyrosine phosphatases 2 (SHP-2) and suppressor of cytokine 
signalling (SOCS) proteins (Figure 1.12). SHP-2 recruited to the 
phosphorylated gp130 receptor, in addition to their activation of ERK cascade, 
also negatively regulate gp130-induced STAT3 activation by 
dephosphorylation of phosphotyrosines  (Anhuf et al., 2000; Ohtani et al., 
2000). In SHP2 signal–deficient mice, gp130-induced STAT3 activation 
showed prolonged gp130-induced STAT3 activation (Ohtani et al., 2000). 
Suppression of SHP-2 signalling promotes mouse ES cell self-renewal 
(Burdon et al., 1999).   
 
The eight SOCS proteins (SOCS1-SOSC7 and CIS) are characterised by a 
conserved C-terminal SOCS box, a central SH2 domain and a variable N-
terminal (Hilton et al., 1998). It has been shown that over-expression of  
SOCS3 can completely suppress LIF-induced signalling events (Yasukawa et 
al., 2001). Over-expression of SOCS3 in a trophoblast stem cell line (Rcho-1) 
also suppressed the cell differentiation while SOCS3-deficient Rcho-1 cells 
were found to rapidly differentiate thus demonstrating that SOCS3 negatively 
regulates the ES cell differentiation (Takahashi et al., 2003). 
 
The mechanism by which SOCS inhibit gp130 receptor signalling is not yet 
entirely clear. SOCS proteins can be recruited to specific phosphotyrosine 
residues in activated gp130 receptor or can bind to receptor bound-JAKs and 
inhibit LIF signalling. For example it  has been shown that SOCS1 can inhibit 
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the activities of JAK1, JAK2 and  JAK3 by direct  interaction (Endo et al., 
1997; Nicholson et al., 1999). In contrast SOCS3 inhibitory   activity may 
depend on its direct interaction with  the phosphorylated gp130 receptor 
(Nicholson et al., 2000). The gp130 receptor activation is known to induce 
rapid and transient up-regulation of the expression of SOCS proteins. The 
SOCS proteins then inhibit the signalling pathways that initially led to their 
production in  a negative feedback loop (Krebs and  Hilton, 2001).   
 
The importance of the negative regulatory role of the SOCS proteins may be 
the reason why LIF can keep mouse ES cells but not human (including other 
primates) ES cells in the undifferentiated state. It has been shown that human 
but not mouse ES cells are rich in SOCS proteins (e.g. SOCS-1) (Schuringa 
et al., 2002; Sato et al., 2003).The negative regulation by SOCS proteins and 
SHP-2 ensure that LIF/STAT signalling has the appropriate magnitude and 
the durations. 
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Figure 1.12: Negative regulation of LIF signalling by socs proteins. 
Cytokine binding to the receptor activates the JAK-STAT pathway, leading to 
the induction of SOCS protein. The induced SOCS proteins act in a negative 
feedback loop to inhibit LIF signalling either by interacting with JAK or with the 
phosphorylated gp130 receptor. Redrawn from  (Krebs and  Hilton, 2001) with 
modifications. Abbreviations: JAK (Janus kinase); STAT (Signal transducers 
and activators of transcription); SOCS (suppressor of cytokine signalling) 
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1.10 Regulation of stem cell self-renewal and pluripotency 
 
1.10.1 LIF signalling and pluripotent transcription factors 
 
LIF signalling post STAT3 is poorly understood. Effectors downstream of 
STAT3 are poorly understood.  Whether LIF signalling has any effect on key 
transcription factors that are responsible for ES cell self-renewal and 
pluripotency, is not yet clearly established. Evidence of direct connection 
between LIF/STAT signalling (i.e. post STAT3 activation)  and ES cell self-
renewal associated  transcription factors (such as Nanog, Sox2 and Oct-4)  is 
still missing. Information linking LIF/STAT signalling to these transcription 
factors can lead to the better understanding of LIF effects on ES  cells and 
may also lead to the development of efficient stem cell culture and 
differentiation protocols. 
 
LIF/STAT3 signalling has been given a prominent role in the maintenance of 
ES self-renewal and pluripotency in  many studies (Niwa et al., 1998). 
However LIF signalling pathway is not essential for the maintenance of ICM 
and human ES cell self-renewal and pluripotency. For example Nanog is 
capable of maintaining ES cell self-renewal independently of LIF/STAT3 
signalling (Chambers et al., 2003; Mitsui et al., 2003).  LIF is also not specific 
to ES cells because it can act on a wide range of cell types. LIF can mediate 
growth arrest and apoptosis in myeloid leukemia Ml cells (Minami et al., 
1996). Moreover LIF also does not exert a consistent effect on all cells. LIF 
can inhibit differentiation (i.e. promotes cell self-renewal) or LIF can induce 
differentiation (i.e. inhibit cell self-renewal). Both of these two mutually 
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exclusive   processes (differentiation and self-renewal) require the activation 
of LIF signalling so the presence (or absence) of a set of genes (which may or 
may not be unique to the target cell type) with which LIF can interact,  may 
ultimately determine whether LIF will promote self-renewal or induce of 
differentiation. In fact, ES cell pluripotency is thought to be maintained by a 
few key transcription factors including Oct-4, Nanog, Sox2 and other. These 
factors bind to regulatory sequences in the promoters   of self-renewal and 
pluripotency specific genes and control their expression, thus, regulating ES 
cells self-renewal and pluripotency. 
 
1.10.2 Octamer-binding protein -3/4   
 
Octamer-binding protein -3/4 (Oct-3/4) belongs to POU (PIT/OCT/UNC) family 
of transcription factors. It binds to octameric sequence AGTCAAAT in target 
genes.  Oct-4 is expressed in totipotent and pluripotent stem cells of the 
pregastrulation embryo and the germ cell lineage (Okamoto et al., 1990; 
Rosner et al., 1990; Yeom et al., 1996; Nichols, 1998).  When  the embryo 
differentiates into the endoderm and mesoderm, Oct-4 expression is down-
regulated (Rosner et al., 1990). Oct-4 is  expressed in the ICM but not in the 
trophectoderm (Palmieri et al., 1994).  Oct4-deficient embryos develop 
normally to the blastocyst stage, but their ICM  cells are not pluripotent 
(Nichols, 1998).  The trophectoderm (TE) is the first differentiated cell lineage 
or tissue of the mammalian blastocyst. The TE surrounds the ICM. Forced 
repression of Oct-4 has been shown to induce the  loss of pluripotency in ES 
cells  causing their  differentiation into the TE lineage (Niwa et al., 2000).  The 
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above study results strong evidence in support of the requirement of Oct-4 for 
ES cell pluripotency. 
 
The precise levels of Oct-4 are critical for proper maintenance of ES self-
renewal and pluripotency. Repression of Oct-4 (~50% of normal level) induces 
differentiation toward the trophectoderm formation (i.e. differentiation) while 
over-expression of Oct-4 (~150% of normal level) induces differentiation 
mainly toward  extraembryonic endoderm (Niwa et al., 2000).  It is generally 
accepted that Oct-4 expression is unique to ES cells. However this view is 
been increasingly challenged  by several studies that reported the expression 
of  Oct-4 in the MSC of human  (D'Ippolito et al., 2004; Izadpanah et al., 
2006), rhesus monkey (Izadpanah et al., 2006) and mouse  (Pallante et al., 
2007). MSC  “pluripotency”  was demonstrated by the expression of Oct-4 and 
also by MSC ability  to differentiate into beating cardiomyocytes and also 
expressed cardiac specific protein cardiac genes including Nkx2.5, cTnT,  α-
cardiac actin, MLC-2v, Cx43, and Cx40 (Pallante et al., 2007).  These results 
suggest that Oct-4 critical roles in pluripotency may not be unique for ES cells 
but may also apply to adult stem cells. 
 
1.10.3 Nanog  
 
Nanog was named after Tir nan Og, a mythical celtic land of the ever young, 
by Chamber et al., 2003, in recognition of its ability to maintain ES cell self-
renewal and Pluripotent state.  Nanog is both necessary and sufficient for self-
renewal and pluripotency of mouse epiblast and ES cells (Chambers et al., 
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2003; Mitsui et al., 2003). It has been found that Nanog-deficient ICM can not  
generate epiblast and also that  nanog-deficient ES cells can not maintain 
pluripotency (Mitsui et al., 2003). Over-expression of  Nanog is sufficient  to 
maintain  ES cell self-renewal independently of LIF signalling (Chambers et 
al., 2003; Mitsui et al., 2003). These studies demonstrate that Nanog is 
required for the maintenance of pluripotency in both ICM and ES cells. 
 
1.10.4 Sox2 
 
Sox2, like Oct4, is expressed in the ICM, epiblast, and germ cells (Avilion et 
al., 2003). Sox2  and Oct-4 synergistically bind  in the enhancers of several 
genes (Yuan et al., 1995; Ambrosetti et al., 1997; Okuda et al., 1998; 
Nishimoto et al., 1999; Ambrosetti et al., 2000; Boyer et al., 2005; Tan et al., 
2007). Octamer-Sox enhancers can regulate the expression of pluripotent 
stem cell-specific genes, including Nanog, Oct-4 and Sox2 itself. It has been 
shown that forced expression of Oct-4 can  rescue the pluripotency of Sox2-
null ES cells (Masui et al., 2007). These results suggest that Sox2 is 
dispensable for the activation of Oct–Sox enhancers but is essential for 
maintaining the correct levels of Oct-4  in order to  stabilise ES cells in a 
proper pluripotent state (Masui et al., 2007) 
 
1.10.5 Cooperative Interaction of Oct-4, Sox2 and Nanog  
 
The cooperative interaction of Oct-4, Sox2 and Nanog  is required in early 
development and  also for the maintenance of the   pluripotent and 
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undifferentiated states.  Cooperation of Oct-4 and Sox2 has been detected in 
the  enhancers of several genes including  fibroblast growth factor (fgf)-4 
(Yuan et al., 1995; Ambrosetti et al., 1997; Ambrosetti et al., 2000), 
undifferentiated embryonic cell transcription factor 1 (UTF1)(Nishimoto et al., 
1999; Boyer et al., 2005), Fbox15 (Tokuzawa et al., 2003) and Nanog (Kuroda 
et al., 2005; Rodda et al., 2005).  
 
UTF1 is expressed in human and mouse ES cells and the ICM (Okuda et al., 
1998; Boyer et al., 2005; Tan et al., 2007) but  its transcription stops at the 
onset of differentiation (Okuda et al., 1998). Similarly the expressions of Oct-
4, Sox-2 and UTF1 are down-regulated following the induction of 
differentiation in ES cells (Nishimoto et al., 1999; Boyer et al., 2005)..  The 
simultaneous down-regulation of Oct-4, Sox-2 and UTF1 suggest that UTF1 
expression may be controlled by synergistic binding of Oct-4 and Sox-2 to an 
Oct–Sox regulatory sequence  in UTF1 (Nishimoto et al., 1999; Boyer et al., 
2005). Like UTF1, fgf-4 gene expressions in the ICM and in EC cells requires 
the cooperative activity of Sox-2 and Oct-4 (Yuan et al., 1995; Ambrosetti et 
al., 1997; Ambrosetti et al., 2000). The cooperative activity of Sox-2 and Oct-4 
may also be required for the   transcription of Nanog.  It has been shown that 
specific knockdown of Oct4 and Sox2 mRNA by RNA interference  inhibited  
the expression of Nanog  (Rodda et al., 2005).  
 
The above data suggest that the combinatorial regulatory actions of Oct-4 and 
Sox2 may be a general mechanism by which Sox-2 and Oct-4 can control the 
expression of several genes, especially those that are involved in the 
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maintenance of ES cell self-renewal and pluripotent state. Oct4, Sox2, Nanog 
and possibly other factors may be part of a very complex auto-regulatory 
network that is required to balance ES cell decisions between self-renewal 
and differentiation.  
 
1.11 Embryonic stem cell differentiation protocols 
 
1.11.1 Embryoid body formation 
 
The most common method used for in vitro differentiation is to culture ES cells 
in non-treated dishes (e.g. Petri dishes) and in absence of a feeder layer or 
LIF. Standard non-treated culture plates (e.g. microbiological plates) are 
usually sufficient for this purpose.  ES cells that are cultured under these 
conditions  form multicellular aggregates called embryoid bodies (EBs) and 
spontaneously and irreversibly differentiate into cell types of the three 
embryonic germ layers (ectoderm, mesoderm and endoderm)  (Evans and  
Kaufman, 1981; Martin, 1981; Doetschman et al., 1985; Smith et al., 1988; 
Williams et al., 1988; Niwa et al., 1998). The three-dimensional structure of 
EBs is thought to initiate signalling that induces the differentiation of ES cells 
into cell types of embryonic germ layers (Keller, 1995; Itskovitz-Eldor et al., 
2000). The differentiation of ES cells into specific subsets of cells may be 
induced by treatment with specific factors (e.g. growth factors). 
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1.11.2 Formation of EB by the Hanging Drops Method 
 
Different protocols have been used in mouse ES cell culture for initiating the 
formation of EBs. One of the widely used methods is the "hanging drops" 
technique. In this technique, a definite number of mouse ES cells (usually 
400) are cultivated in hanging drops (droplet of medium on the inside of a 
culture dish for a short period (e.g. 2 days). The EBs are then collected and 
further cultured for an additional period (e.g. 4-5 days) in suspension and then 
plated on gelatin-coated culture dishes for further differentiation.  A simpler 
method than the “hanging drop method” is the liquid suspension culture. In the 
method, a definite number of stem cells are seeded in bacterial-grade dishes 
in an appropriate growth medium and left to form EBs. After the EB formation, 
they are then transferred   to cell culture-grade dishes. 
 
1.11.3 Embryonic stem cell differentiation into cardiomyocytes 
 
The fundamental question of whether stem cells can actually differentiate into 
functional cardiomyocytes has been scientifically and convincingly answered. 
Under the appropriate experimental conditions, mouse and human ES cells 
can be differentiated into cardiomyocytes  (Wobus et al., 1991; Xu et al., 
1998; Kehat et al., 2001; He et al., 2003; Mummery et al., 2003). The 
differentiation of ES cells into cardiomyocytes can be monitored by  
expression of several cardiac specific structural proteins including 
tropomyosin (Moore et al., 2004), α-actinin (Denning et al., 2006), cardiac 
troponin I (cTnI) (Kehat et al., 2001), cardiac troponin T (cTnT) (Kehat et al., 
2001), atrial natriuretic peptide (ANP) (Denning et al., 2006), cardiac myosin 
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light chain isoforms (MLC-2v and  MLC-2a) (Kehat et al., 2001; Moore et al., 
2004), MLC-1v & MLC-1a and cardiac myosin heavy chain isoforms (α-MHC  
and β-MHC) (Kehat et al., 2001; Denning et al., 2006; Anderson et al., 2007). 
ES cell  differentiation into cardiomyocytes can be also be tracked by the 
expression of several cardiac specific transcription factors including Nkx2.5, 
GATA-4 (Kehat et al., 2001; Nakamura et al., 2003; Anderson et al., 2007), 
and myocyte enhancer factor (MEF2C) (Denning et al., 2006; Anderson et al., 
2007).  
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1.12 Cardiac transcription factors and stem cell differentiation 
into cardiomyocytes 
 
 
Cardiac development requires the interactions of many cardiac transcription 
factors. Cardiac transcription factors regulate cardiac specification and 
differentiation of cardiac cell types by controlling the expression of various 
cardiac genes that code for structural proteins or regulatory proteins.  From 
Drosophila to man, cardiac specification and differentiation is guided by a 
complex transcriptional regulatory network that include the GATA family of 
transcription factors, cardiac-specific homeobox transcription factor 
(Csx/Nkx2.5), MEF2 transcription factors and the T-box transcription factors. 
The roles of GATA and the Nkx2.5 transcription factors are discussed below 
as examples of the complex roles of transcription factors in cardiomyocyte 
differentiation 
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1.13 GATA TRANSCRIPTION FACTORS 
 
GATA transcription factors belong to a family of proteins that contain either 
one or two highly conserved zinc finger DNA-binding domains. The family 
name “GATA” is based on the a recognition of the consensus DNA sequence 
(T/A)GATA(A/G) (Orkin, 1992; Lowry and  Atchley, 2000). Within the 
promoters and enhancers of target genes, the GATA family  members bind 
this consensus  sequence with high efficiency and specificity (Orkin, 1992). 
The zinc finger motif in the GATA DNA binding domain is in  the form Cys-X2-
Cys-X17-20-Cys-X2-Cys followed by a basic region (Patient and  McGhee, 
2002). In animals, where GATA factors have been shown to play critical roles 
in development, differentiation and control of cell proliferation, the GATA DNA 
binding domain adopts the form Cys-X2-Cys-X17-Cys-X2-Cys  (Patient and  
McGhee, 2002).  The C-terminal zinc finger  and the  adjacent basic domain 
are required for DNA consensus sequence recognition and binding to the 
DNA (Tsai et al., 1989; Lee et al., 1991; Morrisey et al., 1996) (Figure 1.13). 
 
Six members of the GATA family of  transcription factors (GATA-1 to -6)  have 
been  identified in  vertebrates and a wide  range of other eukaryotic 
organisms  including plants (Reyes et al., 2004), insects, and echinoderms 
(Lowry and  Atchley, 2000) and  fungi (Maxon and  Herskowitz, 2001). Based 
on sequence homology and expression pattern, GATA transcription factors 
have been divided into two subgroups. The first subgroup of GATA proteins 
(GATA-1, -2 and -3) plays important roles mainly in haematopoiesis. GATA-2 
is indispensable for  development of definitive haematopoiesis  (Mouthon et 
al., 1993; Labbaye et al., 1995; Orlic et al., 1995; Tsai and  Orkin, 1997; 
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Shimizu and  Yamamoto, 2005).  The second subgroup includes GATA-4, -5 
and -6. These are found predominantly in the heart, digestive system and the 
extraembryonic endoderm. GATA-4, -5 and -6 bind to similar consensus 
sequences in cardiac genes (Charron et al., 1999). There are confirmed 
phosphorylation sites in GATA -4 ( but not in GATA -5 or -6) (Grepin et al., 
1994; Ip et al., 1994; Jiang and  Evans, 1996) (Figure 5). 
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Figure 1.13: Structural similarity among the GATA transcription factors. 
Domains and the putative phosphorylation sites with their respective kinases 
are shown. The * denotes a confirmed MAPK phosphorylation site. The 
percentage shown represents the degree of homology for each protein in 
comparison to GATA-4.  ZF = zinc finger; TAD = transactivation domain; DBD 
=DNA binding domain; NLS = nuclear localisation signal, FOG = Friend of 
GATA) and MADS is an acronym that refers to the genes in which the 
sequence element was first identified: MCM1 (minichromosomal maintenance 
protein 1) in Saccharomyces cerevisiae, Agamous from Arabidopsis thaliana, 
Deficiens from the snapdragon Antirrhinum majus and SRF from human. 
Taken from Temsah et  al. (Temsah et al., 2005) 
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1.13.1 Roles of GATA transcription factors in cardiogenesis 
 
In the developing embryo, the expression of GATA-4, -5 and -6 is detected 
and persists later in the developing heart. GATA-6 gene expression is 
restricted to the precardiac mesoderm, the embryonic heart tube and the 
primitive gut (Morrisey et al., 1996). GATA-4 and GATA-6 transcript 
localisation overlap throughout the developing cardiogenic region (Jiang and  
Evans, 1996). GATA-5 is also expressed in cardiac crescent prior to formation 
of the primordial heart tube. After the tube heart, the expression of GATA-5 is 
then seen in both endocardium and myocardium (Laverriere et al., 1994). 
GATA-4 is a potent transcriptional regulator of the  promoters of several 
cardiac specific genes including ANP, BNP (Grepin et al., 1994; Charron et 
al., 1999; McBride and  Nemer, 2001), α-MHC, cTnI (Molkentin et al., 1997; 
Murphy et al., 1997; Di Lisi et al., 1998; Charron et al., 1999), and cTnC (Ip et 
al., 1994)and MLC (McGrew et al., 1996).  All the above are strong evidence 
to suggest that these transcription factors play key roles in cardiogenesis.  
 
1.13.2 Role of GATA-4 in cardiogenesis 
 
Homozygous GATA4 null (GATA-4-/-) mice arrested and died between 7.0 and 
10.5 days post coitum (dpc) because of severe developmental abnormalities 
including ventral foregut closure and cardiac bifida (Kuo et al., 1997; 
Molkentin et al., 1997; Xin et al., 2006). The GATA-4-/- embryos showed 
severe defects in the “rostral-to-caudal” and “lateral-to-ventral folding” (Kuo et 
al., 1997). The embryos of these GATA-4-/- mice developed splanchnic 
mesoderm that differentiated into primitive cardiomyocytes that expressed 
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contractile proteins (Kuo et al., 1997; Molkentin et al., 1997). However the 
GATA-4 null embryos lacked primitive heart tubes because the 
procardiomyocytes failed to migrate to the ventral midline to form a linear 
heart. The GATA-4-/- cardiomyocytes and endocardial cells were still able to 
populate the hearts of GATA-4-/--C57BL/6 chimeric mice(Kuo et al., 1997).  
The two bilaterally symmetric promyocardial primordia in the mutants did not 
migrate ventrally but remained lateral and formed two independent heart 
tubes containing  differentiated cardiomyocytes (Molkentin et al., 1997).These 
results suggest a role for GATA-4 in cardiac morphogenesis but not in 
cardiomyocyte lineage specification.  
 
Small interfering RNAs (siRNA)  that  specifically target  GATA-4 in cardiac 
mesodermal cells suppressed  the expression of N-cadherin mRNA   without 
affecting the expression of the other cardiac marker mRNAs however it 
caused cardia bifida in chick embryos (Zhang et al., 2003a). The selective 
suppression of N-cadherin, one of the genes essential for the single heart 
formation, with the lack of effect on cardiac specific markers by GATA-4 
siRNA also suggests that GATA-4 may not be essential for cardiomyocyte 
commitment during cardiogenesis. 
 
Similarly, the inhibition of GATA-4 using GATA-4 antisense transcripts 
blocked P19 stem cell cardiac differentiation at the premyocardial 
(cardioblast) stage but brachyury T was also found to be expressed. 
Brachyury T   is a T-box transcription factor (Kispert et al., 1995) and is 
necessary for the establishment of  the mesoderm in vertebrates (Schulte-
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Merker et al., 1992). Mesodermal lineage gives rise to cardiomyocytes. The 
expression of brachyury T  suggests  that mesodermal  lineage commitment  
occur in the absence of GATA-4 (Grepin et al., 1997)   (Grepin et al., 1997).  
The expression of brachyury T in absence of GATA-4 is further strong 
supporting evidence that GATA-4 is not essential for the initiation of cardiac 
lineage commitment.  
 
Zebrafish embryos depleted of GATA-5 and GATA-6 have no heart. In 
contrast, embryos depleted of GATA-4 in the presence of either functional 
GATA-5 or GATA-6 develop defective heart tubes (Holtzinger and  Evans, 
2007) rather than total blockage of cardiomyocyte specification. These results 
also support an essential role for GATA-4 in cardiac morphogenesis but not in 
cardiomyocyte lineage specification. 
 
All the above data when considered together, suggest that GATA-4 may be 
required for the events that control normal cardiac morphogenesis after the 
early stages of cardiomyocyte commitment but may not be essential for 
cardiomyocyte commitment during the early stages of cardiogenesis. The lack 
of normal cardiac morphogenesis in the absence of functional GATA-4 but in 
the presence of intact GATA-5 and GATA-6 also suggest that there may not 
be functional redundancy between GATA-4 and GATA-5 or between GATA-4 
and GATA-6. 
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1.13.3 Role of GATA-5 and GATA-6 in cardiogenesis 
 
GATA-6 is expressed at the blastocyst stage in part of the inner cell mass and 
in the trophectoderm (Koutsourakis et al., 1999). This suggests that GATA-6 
may have a role to play in the very early events of heart development. 
Inactivation of GATA-6 gene in mice is lethal at gastrulation, with 
differentiation defects in the ectoderm and part of the visceral endoderm 
(Koutsourakis et al., 1999). GATA-6 is expressed in cardiac mesoderm before 
gastrulation (Peterkin et al., 2003). In both Xenopus and zebrafish embryos, 
the injection of anti-sense oligonucleotides to specifically block the translation 
of GATA-6 protein severely   reduced the expression of cardiac proteins in  
embryos (Peterkin et al., 2003).  
 
The fact that zebrafish embryos lacking  GATA-5 and GATA-6 did not develop 
hearts (i.e. lack of cardiomyocyte specification) (Holtzinger and  Evans, 2007) 
but those lacking only GATA-4 in the presence of a functional GATA-5 or 
GATA-4 can developed defective tubular hearts (i.e. cardiomyocyte 
specification) suggest that GATA-5 or GATA-6 may be essential and also 
perform redundant functions during cardiomyocyte specification. Similarly, the 
ablation of both GATA-5 and GATA-6   resulted in complete lack of the 
expression  of Nkx2.5, vMHC and MLC-2  in zebrafish embryos  (Peterkin et 
al., 2007), thus also suggesting  important  roles  for either GATA-5 or GATA-
6  or both. Embryos null for both GATA-4 and GATA-6 ( GATA4-/-GATA6-/- ) 
completely lack hearts (Zhao et al., 2008).These studies point to non-
essential roles for GATA-4 but possible essential roles for GATA-5 or GATA-
6. It is beginning to emerge that, in contrast to the more prominent roles that 
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are attributed to GATA-4 in literature, GATA-5 or GATA-6 rather than GATA-4 
may have essential roles to play in the induction of cardiomyocyte 
differentiation. 
 
1.13.4 Cooperative Interaction between GATA-4 and GATA-6  
 
No single GATA transcription factor has been found to be both necessary and 
sufficient for cardiogenesis or cardiomyocyte specification. This along with 
their co-expression and localisation, developmental regulation during 
cardiogenesis and their structural similarities had led to the suggestion of 
possible functional redundancy among cardiogenic GATA factors. However 
instead of a possible redundancy of GATA-4 and GATA-6 function, several 
studies (as discussed above) point to a possible cooperative interaction 
between GATA-4 and GATA-6. GATA-4  and -6 have similar potency in 
activating  cardiac genes including ANP, BNP (Charron et al., 1999) and 
troponin C (Morrisey et al., 1996). Furthermore the down-regulation of either 
GATA-4 or GATA-6 proteins in primary cardiomyocytes resulted in reduced 
mRNA expression of several cardiac genes  including BNP, α-MHC, β-MHC 
and  cTnI (Charron et al., 1999). Mice that are heterozygous for either a 
GATA4 or GATA6 null allele are normal but compound heterozygosity of 
GATA4 and GATA6 is lethal by E13.5 (Xin et al., 2006). These results 
suggest a possible cooperative interaction between GATA-4 and GATA-6 the 
regulation of cardiac specific gene expression. 
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1.13.5 Partners or Targets for GATA-4 
 
GATA-4 interacts with Nkx2.5, a key cardiac transcription factor. ANP gene is 
a direct downstream target for Nkx2.5 and DNA binding sites for this 
transcription factor are found in the ANP promoter (Durocher et al., 1996). 
GATA-4 physically associates with Nkx2.5 to cooperatively activate the 
transcription of cardiac-restricted genes  including ANP (Durocher et al., 1996; 
Durocher et al., 1997; Durocher and  Nemer, 1998; Lee et al., 1998; 
Sepulveda et al., 1998). BMP activation of cardiac-specific proteins appears 
to be mediated by the transcription factors GATA-4 and Nkx-2.5. Application 
of BMP-2 in vivo induced ectopic expression of Nkx2.5 and GATA-4, 5 and 6 
(Merika and  Orkin, 1993; Zhu et al., 1997; Svensson et al., 1999).  
 
More supporting  evidence for crosstalk between GATA-4  and  Nkx2.5 comes 
from experimental data which showed that simultaneous over-expression of 
Nkx2.5 and GATA-4 in P19Cl6[noggin] cells induced cardiac differentiation 
while differentiation was not observed when  either Nkx2.5 or GATA-4 alone 
was  over-expressed in P19Cl6noggin cells (Monzen et al., 1999).   
P19Cl6noggin over-express the noggin gene. The noggin gene codes for a 
family of secreted proteins that bind to BMP and   inhibit their interaction with 
their receptor thus blocking their signalling roles (Zimmerman et al., 1996). 
 
Besides Nkx2.5, GATA-4 also associates with other transcription factors  
including NFAT( Nuclear Factor of Activated T cells) (Suzuki et al., 1999; 
Diedrichs et al., 2004; Jiang et al., 2007), SRF (Belaguli et al., 2000; Moore et 
al., 2001), p300 (Slepak et al., 2001; Yanazume et al., 2003), MEF2 (Morin et 
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al., 2000) and Friend of GATA-2 (FOG-2) (Svensson et al., 1999). GATA-4 
association with these other transcription factors that are targets of several 
signalling pathways underlies the complex mechanisms by which GATA 
proteins can regulate many important processes during cardiogenesis.  
 
1.13.6 GATA-4 and Upstream Protein Kinases 
 
Phosphorylation is a key regulatory mechanism in many biological systems.  
The location of numerous  phosphorylation sites in GATA-4  protein (Figure 
1.13) suggests that it is a direct downstream target for several kinases, 
including the MAP Kinases ERK  (Liang et al., 2001). It has been shown that 
RhoA potentiates the transcriptional activity of GATA-4 via a p38 MAPK-
dependent pathway that phosphorylates GATA-4 activation domains. It was 
also shown that GATA binding sites mediate RhoA activation of target cardiac 
promoters (Charron et al., 2001).  Over-expression of  TAK1 [a mitogen-
activated protein kinase kinase kinase (MAPKKK)] can restore the ability of 
P19CL6noggin cells to differentiate into cardiomyocytes (Monzen et al., 
1999). The over-expression of the dominant negative form of TAK1 in parental 
P19CL6 cells blocked cardiomyocyte differentiation. While the over-
expression of Nkx2.5 or GATA-4 alone  can not  restore  the ability of 
P19CL6noggin cells to differentiate into cardiomyocytes, the over-expression 
of both GATA-4 and Nkx2.5 can rescue P19CL6noggin ability to differentiate  
into cardiomyocytes (Monzen et al., 1999). These results suggest that TAK1, 
Nkx-2.5 and GATA-4 may cooperatively interact in BMP induced cardiogenic 
signalling. 
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1.13.7 Summary for GATA transcription factors 
 
GATA transcription factors are key regulator molecules in animal 
development. GATA-1, 2 and 3 are relevant in the haematopoietic system 
while GATA-4, 5 and 6 have roles to play in cardiogenesis. The promoters of 
many cardiac specific proteins including ANF, BNF, cTnI, α-MHC, MLC 
contain consensus sequence for GATA-4 in their genes. GATA-4 also 
interacts with the specific cardiac transaction factor Nkx2.5 and other 
transcription factors including  p300, FOG-2 and NFAT.  Great prominence is 
attributed to the role of GATA-4 in cardiomyocyte commitment but emerging 
evidence suggests that GATA-4 may not be essential for cardiomyocyte 
commitment. GATA-4 may play an important role in the events that control 
normal cardiac morphogenesis after the early stages of cardiomyocyte 
commitment or cardiogenesis. Increasingly important roles for GATA-5 or 
GATA-6 or both are also emerging. Finally, all the research data or evidence 
about the roles of GATA transcription factors in cardiogenesis in vertebrates 
(e.g. mouse, Xenopus and Zebrafish Chicken) strongly supports the existence 
of critical roles for GATA-4, 5 and 6 during normal cardiogenesis. 
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1.14 CARDIAC HOMEOBOX TRANSCRIPTION FACTOR  
 
The discovery of the tinman gene in Drosophila contributed enormously to our 
understanding of some of the molecular events that are involved in the 
vertebrate heart development. Tinman expression is essential for the 
specification of cardiac cells and the formation of Drosophila heart (Kim and  
Nirenberg, 1989; Azpiazu and  Frasch, 1993; Bodmer, 1993; Zaffran and  
Frasch, 2005).  
 
Csx/Nkx2.5 [i.e. Cardiac-Specific homeobox  (Csx) or  the fifth vertebrate 
gene identified in the NK2 homeobox gene family (Nkx2.5)] is a member of 
the NK homeobox gene family that is conserved in evolution. The gene 
products act as  DNA-binding transcriptional activators (Kim and  Nirenberg, 
1989). Each NK2 protein consists of a highly conserved structure that is 
composed of an N-terminal TN domain, the homeodomain and the NK-2-
specific domain (NK2-SD). Four NK genes (i.e. NK1, NK2, NK3, and NK4) 
were originally identified in Drosophila. The equivalent of Drosophila tinman 
gene  in mammal is Csx/Nkx2.5 (i.e. Nkx2.5) (Komuro and  Izumo, 1993; Lints 
et al., 1993). Nkx2.5 is a universal marker for early heart development and its 
homeodomain has a helix-turn-helix motif that binds to DNA sequences. The 
specific consensus DNA sequence is 5′ T(C/T) AAGTG 3′. Nkx2.5 is 
expressed in a wide  range of species including  XNkx2.3 and XNkx2.9 in 
Xenopus (Tonissen et al., 1994; Evans et al., 1995; Cleaver et al., 1996; 
Newman and  Krieg, 1998), cNkx2.3 and cNkx2.8 in chicken (Buchberger et 
al., 1996; Boettger et al., 1997; Brand et al., 1997; Reecy et al., 1997), nkx2.3 
and nkx2.7 in zebrafish (Lee et al., 1996) and Nkx2.6 in mouse (Biben and  
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Harvey, 1997; Nikolova et al., 1997).  Nkx2.5 is expressed in the human heart 
(Kasahara et al., 2000; Inga et al., 2005; Zheng et al., 2008a). The loss of function of 
human NKX2.5 (due to mutations) is associated with congenital heart 
diseases (Kasahara et al., 2000; Inga et al., 2005). 
 
1.14.1 Role of the transcription factor Nkx2.5 in cardiogenesis 
 
Nkx2.5 is one of the earliest markers of heart field mesoderm in Drosophila 
and vertebrates. In the mouse, the expression of Nkx2.5 starts early (about 
7.5 dpc) in the precardiac mesoderm. This early expression of Nkx2.5 in the 
heart progenitor cells in the first heart field (FHF) and the second hearts field 
(SHF) continues at a high level in the heart through adulthood (Komuro and  
Izumo, 1993; Lints et al., 1993; Lee et al., 2004). The specification of 
cardiogenic cells and the development of the Drosophila dorsal vessel (the 
insect equivalent of the mammalian heart) requires tinman (Kim and  
Nirenberg, 1989; Azpiazu and  Frasch, 1993; Bodmer, 1993). Drosophila with 
mutated tinman are unable to express myosin  and the precardiac markers, 
zfh-1 and eve in the heart (Azpiazu and  Frasch, 1993; Bodmer, 1993). Wild-
type tinman expression can partially rescue the mutant phenotype, but 
widespread expression of tinman does not result in ectopic expression of 
cardiac markers (Bodmer, 1993). This suggests that tinman alone is not 
sufficient to initiate the regulatory pathway leading to heart formation. Tinman 
may require the cooperation of additional regulatory proteins. Indeed as 
already mentioned above Nkx2.5 needs cooperative interaction with other 
factors such as GATA-4. Cell culture studies suggest that the Nkx2.5 protein 
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may act together with other transcription factors to regulate the expression of 
cardiac genes. For example, the ability of Nkx2.5 to activate transcription from 
the cardiac α-actin promoter is strongly increased by the presence of the 
MADS domain protein, serum response factor (SRF) (Chen and  Schwartz, 
1996). Even higher levels of transcriptional activation are achieved from this 
promoter when Nkx2.5, SRF, and the zinc finger protein GATA-4 are all 
present in the same cell (Sepulveda et al., 1998). 
 
The over-expression of either XNkx2.5 or XNkx2.3 in Xenopus (Cleaver et al., 
1996) or zebrafish (Chen and  Fishman, 1996) embryos caused enlarged 
hearts   which were  perfectly normal in all other features. The enlarged heart 
was due to the  thickening of the myocardium caused by an increase in the 
overall number of myocardial cells (hyperplasia) (Cleaver et al., 1996). On the 
other hand the  expression of inhibitory or dominant negative mutants of either 
XNkx2.3 or XNkx2.5 in the Xenopus embryos resulted in complete lack of 
cardiac gene expression and  complete absence of heart formation (Fu et al., 
1998; Grow and  Krieg, 1998). This inhibition can be rescued by expression of 
wild-type Nkx2.5 (i.e. tinman) sequences (Grow and  Krieg, 1998) thus 
underlining the importance of the role of Nkx2.5 in cardiogenesis. The gain-of-
function results by Nkx2.5 over-expression and the inhibitory effects of 
dominant negative Nkx2.5 suggest that Nkx2.5 has an important role in 
cardiogenesis. 
 
Nkx2.5 knockout mice die in utero shortly after looping morphogenesis. Heart 
tube formation was normal in mutant embryos, but looping morphogenesis, a 
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critical determinant of heart formation was not initiated at the linear heart tube 
stage (8.25-8.5 days p.c.) (Lyons et al., 1995).  It has also been found that 
hearts of homozygous null embryos underwent looping but showed arrest of 
cardiac development and poor development of blood vessels (Tanaka et al., 
1999). Commitment to the cardiac muscle lineage was not compromised 
(Lyons et al., 1995).  The ventricular specific marker, MLC-2v was not 
expressed in mutant hearts or in mutant ES cell-derived cardiomyocytes, but 
β-MHC, another ventricular specific marker was expressed in the mutant 
mouse hearts. Cardiac development is multi-step process. The arrest of 
cardiac development in the Nkx2.5 knockout mice suggests that Nkx2.5 may 
be required for the expression of several essential factors in the early stages 
of the developing heart. However the expression of β-MHC in the mutant 
hearts indicated that not all ventricular-specific genes depend on Nkx2.5 for 
their expression (Lyons et al., 1995). But the data however demonstrate that 
Nkx2.5 is required for cardiogenesis.  In addition, many studies  have shown 
that the lack of Nkx2.5 compromised or reduces the expression of several 
cardiac specific genes including the  transcription factors  eHAND (Biben et 
al., 1997), Msx2, MEF2C, N-Myc (Tanaka et al., 1999), CARP (Zou et al., 
1997) and Irx4 (Bruneau et al., 2000) and many other  cardiac genes 
including ANF, BNP, MLC-2v (Lyons et al., 1995; Tanaka et al., 1999). 
Cardiac transcription factors are critical players in cardiogenesis and the fact 
that many may be under the control of Nkx2.5 is an indication of the 
importance of Nkx2.5 in this process.  
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1.14.2 Nkx2.5 role in stem cell differentiation into cardiomyocytes 
 
P19 stem cells differentiate into cardiomyocytes in 1% DMSO (McBurney et 
al., 1982; Habara-Ohkubo, 1996; Angello et al., 2006). The expression of a 
dominant-negative mutant of Nkx2.5 blocked  this differentiation  (Jamali et 
al., 2001). The inability of the cells to form cardiomyocytes was accompanied 
by the loss of endogenous expression of cardiac genes including GATA-4 and 
MEF2C. This indicated that the function of Nkx2.5, as well as being critical for 
cardiogenesis in vivo, is also critical for stem cell differentiation into 
cardiomyocytes.  
 
1.14.3 Summary for the Roles of the Homeobox Nkx2.5 
 
Research data from Drosophila, mouse, Xenopus and zebrafish support 
important regulatory roles for Nkx2.5 in cardiogenesis and the functions of the 
normal heart. Nkx2.5 interacts with other transcription factors including GATA 
transcription factors (as discussed earlier) and T-box factors (discussed 
below) and serum response factor. Nkx2.5 is also involved in the roles of 
cardiogenic extracellular signalling proteins including BMPs and Wnts 
(discussed below). Results from both loss and gain of function experiments 
have established Nkx2.5 as a very important cardiac transcription factor and 
support a transcriptional regulatory role of Nkx2.5 over a cascade of other 
cardiac transcription factors and cardiac specific genes. 
 
 
 
 54
1.15 T-BOX TRANSCRIPTION FACTORS 
 
The T-box proteins are mainly of importance during the specification of the 
chamber myocardium after the linear tube heart has been formed. Their roles 
come into play after cardiac lineage commitment. They are therefore 
discussed very briefly in this introduction. 
 
The T-box proteins belong to a family of transcription factors that are essential 
for early cardiac lineage determination, chamber specification and 
valvuloseptal development. This protein family is characterised by the 
presence of a highly conserved DNA-binding domain (i.e. the T-box). 
Seventeen T-box proteins been described in vertebrates (Naiche et al., 2005). 
Tbx1, Tbx2, Tbx3, Tbx5, Tbx18 and Tbx20 are expressed in vertebrate 
embryonic hearts and play specific roles in the heart development.  
 
1.15.1 Role of T-box transcription factors in cardiogenesis  
 
The T-box proteins are conserved regulators of heart development from 
Drosophila to human and other vertebrates. Drosophila Dorsocross complex 
(Doc), the three linked T-box genes (equivalent to mammalian 
Tbx4/Tbx5/Tbx6) are critical for Drosophila cardiac specification. Doc is 
required for the Drosophila cardiac specification (Reim and  Frasch, 2005). 
Drosophila T-box genes  midline and H15 pannier (i.e. equivalent to 
mammalian Tbx20)  participate in cardiac specification in determining 
cardioblast differentiation, polarity and patterning (Miskolczi-McCallum et al., 
2005; Reim et al., 2005). Midline represses Doc in a subset of cardioblasts, 
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and this is crucial for establishing the morphological and functional 
characteristics of the distinct classes of muscle cells, one functioning in the 
propulsion of haemolymph and another acting as valves (Reim et al., 2005). 
 
1.15.2 Mechanisms of action of T-Box transcription factors 
 
T-box proteins perform their functions by combinatorial and cooperative 
interaction with other transcription factors. Tbx1 and Tbx2  (Bruneau et al., 
2001; Habets et al., 2002; Xu et al., 2004a) and   Tbx5  (Hiroi et al., 2001) can 
cooperatively interact with Nkx2.5. Tbx5 can also cooperatively interact with 
GATA-4 (Garg et al., 2003). In the developing hearts, Tbx20 directly interacts 
with Nkx2.5, GATA-4 and GATA-5 in regulation of gene expression in the 
developing heart (Stennard et al., 2003). Drosophila Doc, like the mammalian 
T-box proteins, also functions in association with two Drosophila transcription 
factors, tinman (i.e.  equivalent to  mammalian Nkx2.5) and pannier (i.e. 
equivalent to mammalian GATA-4), during  cardiac specification (Reim and  
Frasch, 2005).  
 
1.15.3 Roles of Tbx2 and Tbx5 in heart chamber development  
 
Mouse Tbx5 is expressed in the cardiac crescent, indicating its involvement in 
the earliest stages of cardiac induction, then in a graded fashion along the 
heart tube with the highest levels in the sinoatrial region (Bruneau et al., 
1999). In Tbx5 null embryos, the left ventricular and sinoatrial regions are 
severely hypoplastic   (Bruneau et al., 2001) . However the formation of the 
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linear heart tube suggests that Tbx5 may be essential for regulation of 
chamber-specific gene expression and morphogenesis of the early heart but 
is not essential for cardiac lineage specification. 
 
Tbx2 functions as a transcriptional repressor in non-chamber myocardium 
zones (i.e. outflow tract, inflow tract and AVC) of the tube heart in order to 
restrict chamber myocardium formation. Tbx2 cooperatively interacts with 
Nkx2.5. Their combinatorial interaction represses the expression of chamber 
myocardium specific genes in non-chamber myocardium zones (i.e. outflow 
tract, inflow tract and AVC) of the tube heart. ANF gene (first marker for 
chamber formation ) is specifically repressed by Tbx2/Nkx2.5 interaction 
(Charron et al., 1992; Habets et al., 2002; Harrelson et al., 2004; Cai et al., 
2005).   
 
In contrast to Tbx2, Tbx5 combinatorial interaction with Nkx2.5 activates the 
expression of chamber myocardium specific genes in chamber myocardium 
zones (i.e. left ventricle and left atrium) of the tube heart (Bruneau et al., 
2001; Habets et al., 2002). ANF gene is specifically induced by Tbx5/Nkx2.5 
interaction in chamber myocardium forming zones (left ventricle and left 
atrium)  of the tube heart  (Bruneau et al., 2001). The  opposing actions of 
Tbx2 and Tbx5 are required at various cardiac developmental stages for the 
correct formation of the heart. 
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EXTRACELLULAR SIGNALLING PROTEINS AND 
STEM DIFFERENTIATION INTO 
CARDIOMYOCYTES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 58
1.16 ROLES OF EXTRACELLULAR SIGNALLING PROTEINS IN 
STEM DIFFERENTIATION INTO CARDIOMYOCYTES 
 
Extracellular signalling factors are central for stem cell differentiation or for 
remaining in the undifferentiated state. Stem cell cardiomyocyte lineage 
commitment involves complex networks of extracellular signalling molecules 
that activate various signalling pathways. These activated signal transduction 
pathways in turn exert complex positive or negative controls on this process.  
 
Well known peptide growth factors or extracellular signalling molecules that 
have been identified as essential regulators during the development of 
vertebrate heart are also involved in stem cell differentiation into 
cardiomyocytes. These include the bone morphogenetic proteins (BMP) 
(Zhang and  Bradley, 1996; Schlange et al., 2000), sonic hedgehog (SHH) 
(Yamagishi et al., 2003; Hu et al., 2004),  fibroblast growth factor (FGF) (Kelly 
et al., 2001; Vitelli et al., 2002), Wnt (Ku and  Melton, 1993; Schneider and  
Mercola, 2001; Garriock et al., 2005) and Notch proteins  (Loomes et al., 
2002; Timmerman et al., 2004). The role of BMP and Wnts in cardiogenesis 
and stem cell differentiation into cardiomyocytes  are discussed as examples 
of the essential roles of these extracellular signalling factors in cardiomyocyte 
lineage commitment  
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1.17 BONE MORPHOGENETIC PROTEINS 
 
Bone morphogenetic proteins (BMPs) belong to the transforming growth 
factor-β (TGF-β) superfamily of structurally related secreted proteins that are 
expressed in lateral endoderm and ectoderm and play central roles in the 
induction of heart formation in vertebrate embryos. The other members of  this   
superfamily are  TGF-β, activins, nodal, anti-Mullerian hormone (AMH) and 
myostatins. BMPs were originally identified as proteins that induce ectopic 
bone and cartilage formation in vivo (Wozney et al., 1988). BMP and its family 
members play crucial roles during embryonic development, cell division or 
proliferation, differentiation, organisation migration, adhesion, extracellular 
matrix production and apoptosis. 
 
BMPs exert their biological effects by binding to heteromeric complexes of two 
types of receptors (types I and II receptors) with intrinsic serine/threonine 
kinase activity and activation of specific downstream intracellular effectors 
known as  Smad proteins (Wrana et al., 1994). Smads relay the signal from 
the cell membrane to the nucleus, where they affect the transcription of target 
genes.   
 
BMP type II and I receptors are cell surface receptors. BMP type II receptors 
are single transmembrane proteins with glycosylated cysteine-rich 
extracellular ligand binding domains and cytoplasmic domains with intrinsic 
serine/threonine kinase activity(Lin et al., 1992). Type I receptors share a 
glycine/serine residue-rich stretch (GS-domain) in the juxtamembrane region, 
which is essential for type I receptor activation (Wrana et al., 1994). BMP bind 
 60
weakly to type I or type II receptors alone. BMPs bind to heteromeric type 
I/type II receptor complex with high affinity (ten Dijke et al., 1994; Liu et al., 
1995; Rosenzweig et al., 1995). BMP signalling occurs via at least two 
pathways:  MAPK and  Smad pathways. 
 
1.17.1 BMP receptor Intracellular signalling and Smad proteins 
 
The Smad (Similar To Mothers Against Decapentaplegic) transcription factors 
are the major intracellular signalling molecules or effectors  of BMP-induced 
signalling pathway (Canalis et al 2003; Shi and Massague 2003; Kawabata et 
al 1998). BMP, TGF-β and other family members induce their membrane 
receptors to directly activate the Smads which then form transcriptional 
complexes to control the expression of target genes. Eight different Smad 
proteins (Smads 1 through 8) have been identified in mammals.  Five of the 
mammalian Smads (Smad 1, 2, 3, 5 and 8) act as substrates for the TGF-β 
receptor family. These five Smads are known as receptor-regulated Smads 
(R-Smads). R-Smads 1, 5 and 8 serve mainly as specific substrates for 
activated BMP and Muellerian  type I receptors while R-Smads 2 and 3 serves 
as specific substrates for activated TGF-β, activin, and Nodal type I receptors.  
Smad 4 serves as a type I receptors common mediator or common partner 
Smad (Co-Smad) for all R-Smads. R-Smads activation by BMP receptors 
leads to their heterodimerization with the Co-Smad (i.e. Smad 4). Smad 6 and 
7 are inhibitory Smads (I-Smad) that serve as decoys interfering with Smad–
receptor or Smad–Smad interactions.  In addition to this intracellular 
regulation by I-Smads, BMP signally is also regulated at the receptor level by 
 61
extracellular proteins (e.g. Noggin) that directly bind BMP molecules and 
inhibit their interaction with the BMP receptors.  
 
Upon BMP-induced heteromeric complex formation, the constitutively active 
serine/threonine kinase of type II receptor phosphorylates type I receptor in its 
intracellular domain. Phosphorylation activate the kinase activity of type I 
receptor. The activated type I receptor phosphorylates  and activates target 
proteins of the R-Smads (Wrana et al., 1994; Chen and  Weinberg, 1995). 
The phosphorylation of R-Smad causes a conformational change, which 
promotes heterodimerization with Smad4. The R-Smad/Smad4 complex 
translocates to the nucleus. Within the nucleus R-Smad/Smad4 bind to 
specific sequences in the promoters of BMP target genes and control their 
expression in a cell-type specific manner (Figure 1.14). 
 
 
 
 
 
 
 
 
 
 
 
 
 62
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.14: BMP signalling pathway. BMP bind and form a heteromeric 
complex with type I and type II BMP receptors.  The type II receptor 
phosphorylates the type I receptor. This leads to the phosphorylation of  
receptor-regulated smads (SMAD1,5 or 8). The phosphorylated SMAD forms 
a complex with the common mediator or common partner Smad (SMAD4). 
This complex is then  and is transported into the nucleus leading to the 
activation of target genes. The intracellular inhibitor of BMP signal 
transduction is SMAD6. BMP= bone morphogenetic protein, R-Smads= 
receptor-regulated Smads, Co-SMAD = common mediator or common partner 
Smad, I-SMAD = inhibitory Smads and P= phosphate group. 
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1.17.2 Role of BMPs in stem cell differentiation into  cardiomyocytes 
 
As already stated, BMPs are expressed in lateral endoderm and ectoderm of 
vertebrate embryos. Stimulatory factors from the anterior endoderm in 
combination with BMP signals in the anterior lateral mesoderm promote heart 
formation (Schultheiss et al., 1997; Andrée et al., 1998; Schlange et al., 2000; 
Tzahor and  Lassar, 2001).  It has been shown that BMP-2 soaked beads can 
induce the  ectopic expression of Nkx2.5 and GATA-4 in chick embryos 
(Schultheiss et al., 1997). BMP-2 can  induce the expression of cardiac 
specific proteins in chick embryos  and the addition of Noggin to explants 
resulted in loss of the expression of Nkx2.5, GATA-4, eHAND, MEF2A and 
MHC expression (Schlange et al., 2000). This suggests that BMP-2 is 
upstream of Nkx2.5 and GATA-4, and as already mentioned, eHAND, MEF2A 
and MHC are under the control of GATA-4 and Nkx2.5. 
 
DMSO induces the cardiac differentiation of P19CL6 (a derivative of P19 stem 
cells). Over-expression of noggin (a natural inhibitor of BMP) in P19CL6 cells 
(P19CL6 [noggin] cells) prevented DMSO-induced differentiation of P19 cells 
into cardiomyocytes (Monzen et al., 1999). Spontaneously beating cells did 
not result and cardiac transcription factor and contractile proteins were not 
present in P19Cl6[noggin] cells. This cardiac differentiation arrest could be 
rescued by over-expression of BMP-2 or by directly adding BMP proteins to 
the culture medium  (Monzen et al., 1999). The data provide strong evidence 
for the involvement of BMPs in stem cell differentiation into cardiomyocytes.  
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1.17.3 Role of BMP and MAPK signalling in cardiomyocyte differentiation 
 
In addition to the Smad pathways discussed above, BMP signalling also 
occurs via MAPK signalling pathways. The MAPK TGF-β-activated kinase 1 
(TAK1) is expressed in P19CL6 cells and therefore could be involved in the 
DMSO-induced differentiation of these cells into cardiomyocytes. Over-
expression of dominant negative TAK1 led to an inhibition P19CL6 cell 
differentiation into cardiomyocytes  while over-expression of wild-type TAK1 
or constitutively active TAK1 rescued cardiac differentiation in 
P19CL6[noggin] cells (Monzen et al., 1999). The above data suggests that 
BMP-induce activation MAPK signalling can lead to cardiac lineage 
specification in ES cells. 
 
1.17.4 Role of BMP and Smad Signalling in Cardiomyocyte 
Differentiation 
 
P19CL6noggin cells, which constitutively over-express the BMP antagonist 
noggin,   do not differentiate into cardiomyocytes when treated with DMSO. 
Over-expression of both Smad1 and Smad4 has been found to be sufficient to 
rescue cardiac differentiation in DMSO-treated P19Cl6[noggin] cells (Monzen 
et al., 2001). The same studies demonstrated that over-expression of  the 
inhibitory Smad6 completely blocked differentiation of P19CL6 (Monzen et al., 
2001), thus suggesting that like the BMP-mediated activation of the MAPK 
signalling pathway, the BMP-activated  Smad pathway is also necessary for 
ES cell differentiation into cardiomyocytes  
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1.17.5 Crosstalk between Smad and MAPK signalling  
 
Experimental evidence suggests that ATF-2 (activating transcription factor 2) 
may be a common target  for both Smad and TAK1 pathways in TGF-β 
signalling (Makino et al., 1999).  ATF-2  activity is enhanced after 
phosphorylation by stress-activated protein kinases such as c-Jun N-terminal 
kinase and p38. ATF-2 has also been found to be bound by Smad3 and 
Smad4 upon TGF-β stimulation (Makino et al., 1999). It has also been found 
that the over-expression of dominant negative forms of ATF-2 inhibited the 
P19CL6 cell differentiation into cardiomyocytes, while wild type ATF-2 
enhanced the ability of Smad 1&4 and TAK1  to rescue cardiac differentiation 
in P19CL6noggin cells (Monzen et al., 2001).  
 
ATF-2 was also  found to stimulate β-MHC promoter activity in a synergistic 
manner with Smad1&4 and TAK1 and promoted terminal cardiomyocyte 
differentiation of P19CL6noggin, whereas over-expression of the dominant 
negative form of ATF-2 reduced the promoter activities of several cardiac-
specific genes including GATA-4, MEF2C, MLC2v β-MHC, ANP and BNP and 
inhibited differentiation of P19CL6 (Monzen et al., 2001).  These results 
suggest that Smads, TAK1, and their common target ATF-2 cooperatively 
play a critical role  during the differentiation of  stem cells into cardiomyocytes. 
1.17.6 Summary of bone morphogenetic proteins 
 
BMP have important roles in both in vivo cardiogenesis and the differentiation  
of stem cells into  cardiomyocytes. BMP are expressed very early in the 
endoderm and ectoderm and play central roles in the induction of heart 
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formation in vertebrate embryos. In addition to the Smad pathways BMP 
signalling also occurs via MAPK signalling pathways.  This is very important 
since phosphorylation is a key post-transcriptional mode of gene control. The 
MAPK signalling when activated could control many other targets including 
transcription factors and other kinases. 
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1.18 Wnt Proteins 
 
Wnt proteins belong to a  family of cysteine-rich  and lipid-modified signalling 
proteins (Willert et al., 2003). The Wnt signalling pathways are  highly 
regulated  and play major roles in embryological development, tissue 
morphogenesis, homeostasis and regeneration,  cell proliferation (van de 
Wetering et al., 2002)  and differentiation, cell fate decisions, apoptosis, axial 
polarity and axonal guidance. 
 
Wnt signalling cascade is initiated by Wnt binding to the cysteine-rich, extra-
cellular domain of a frizzled (Fz)   receptor.  For the effective Wnt binding, in 
addition to the Fz receptor, the presence of  single-pass transmembrane 
molecule of the low density  lipoprotein receptor-related proteins (LRP)  (also 
known as the arrow  protein in Drosophila) (Wehrli et al., 2000) or  LRP5/6 
(i.e. vertebrate equivalent of Drosophila arrow protein) (Pinson et al., 2000; 
Tamai et al., 2000) is required.  The LRPs are co-receptors to the Fz 
receptors. The Fz receptors, like the LRPs, are also transmembrane proteins 
with a long N-terminal extension called a cysteine-rich domain (CRD). Wnt 
proteins bind directly to the CRD region (Bhanot et al., 1996; Hsieh et al., 
1999; Dann et al., 2001).  
 
1.18.1 Wnt Signalling pathways 
 
Wnt binding to Fz receptors can result in the activation of one of three 
different Wnt regulated pathways: Wnt/β-catenin (canonical signalling 
 68
pathway) and two non-canonical Wnt signalling pathways (i.e. the Wnt/planar 
cell polarity (Wnt/PCP) and Wnt/calcium (Wnt/Ca2+) pathway) 
 
1.18.1.1 Wnt canonical  (Wnt/β-catenin)  pathway 
 
In the absence of Wnt/receptor interactions, the level of β-catenin is kept low 
by degradation induced by β-catenin association with a large multiprotein β-
catenin destruction complex that includes two scaffolding proteins (i.e. axin 
and adenomatous polyposis coli (APC)), two serine/threonine kinases β (i.e. 
glycogen synthase k inase 3β (GSK3β) and casein kinase 1 (CK1) (Giles et 
al., 2003; Logan and  Nusse, 2004). In this complex, β-catenin is 
phosphorylated by CK1 and GSK3β. This phosphorylation triggers the 
ubiquitination of β-catenin resulting in its subsequent degradation in the 
proteosome.  
 
Wnt binding to Fz and LRP receptor complex induces the phosphorylation of 
LRP (Tamai et al., 2004; Davidson et al., 2005). A cytoplasmic protein known 
as Dishevelled (Dsh/Dv1) is also phosphorylated and activated (Figure 1.15). 
The activation of Dsh leads to the recruitment of Axin to the membrane, where 
it interacts with the cytoslic tail of LRP.  Axin recruitment to the membrane 
from the multiprotein β-catenin destruction complex (i.e. 
Axin/APC/CK1/GSK3β) leads to the subsequent disruption or inhibition of the 
destruction complex. GSK3β is therefore not able to phosphorylate β-catenin. 
The net effect of GSK3β inhibition is the stabilisation and the accumulation of 
the non-phosphorylated form of β-catenin in  the cytosol.  The non-
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phosphorylated  cytosolic β-catenin then  translocates into the nucleus, where 
it competes with members of the groucho family of co-factors for interactions 
with the T-cell factor/lymphoid-enhancing factor 1 (TCF/LEF) family of 
transcription factors   (Molenaar et al., 1996; van de Wetering et al., 1997; 
Cavallo et al., 1998; Eastman and  Grosschedl, 1999) . Once an active 
(LEF/TCF)-β-catenin complex is formed  the transcription of Wnt target genes 
is activated (Yamaguchi et al., 1999; Ai et al., 2000). TCF/LEFs bind to a 
conserved DNA sequence known as the Wnt-response element (WRE) (i.e. 
C/T-C-T-T-T-G-A/T-A/T) via their HMG domain (van de Wetering et al., 1997). 
In the absence  of Wnt, TCF  form a complex   with Groucho. This complex  
acts  as transcriptional repressor of  Wnt responsive genes (Cavallo et al., 
1998; Eastman and  Grosschedl, 1999).  
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Figure 1.15:  Activation of canonical (Wnt/ β-catenin)  pathway. (A) In the 
absence of Wnt   β-catenin associates with the Axin-APC- GSK3β complex.  
β-catenin is phosphorylated  !and   then targeted for degradation. At the same 
time, Wnt target genes are repressed by the association of TCF with Groucho. 
(B)  Wnt binding to the Frizzled and LRP receptors induces phosphorylation of 
LRP and recruitment of Axin. Dsh is also phosphorylated, and the 
Axin·APC·GSK-3 complex is inhibited, leading to accumulation of cytosolic β-
catenin and its subsequent translocation into the nucleus. In the nucleus β-
catenin replaces Groucho from the T-cell factor/lymphoid-enhancing factor 1 
(TCF/LEF) and then activates target genes. 
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1.18.1.2 Non-canonical Wnt/Ca2+ signalling pathway 
 
In addition to the canonical pathway described above, a non-canonical 
pathway known as the Wnt/Ca2+ signalling pathway can also be activated by 
binding of Wnt proteins  to Fz receptors. However unlike canonical pathway, 
the downstream pathways activated by this binding do not involve GSK-3β or 
β-catenin. The activation of the Wnt/Ca2+ signalling pathway is thought to 
involved that  activation of  G-proteins and phospholipase C (PLC) leading to 
the release of intracellular Ca2+ ions, The increased intracellular calcium 
levels in turn activate key enzymes such protein kinase C (PKC) and 
Ca2+/calmodulin-dependent protein kinase II (CaMKII) (Sheldahl et al., 1999; 
Pandur et al., 2002; Sheldahl et al., 2003) (Figure 1.16). It has been shown in  
zebrafish blastulae, that the over-expression of Wnt5a or rat Fz2 (i.e. Frizzled 
receptor) stimulates the frequency of calcium fluxes in the enveloping layer 
(EVL) cells  (Slusarski et al., 1997). Similarly in Xenopus embryos, over-
expression of Wnt5a or Wnt1 activated calcium-sensitive kinase protein 
kinase C (Sheldahl et al., 1999) and calcium/calmodulin-dependent kinase II 
(CamKII) (Kuhl et al., 2000). In contrast blocking the over-expressed Wnt 
signalling using  antibodies to Frizzled-5 (wnt5a the receptor) was found to 
inhibit PKC activity (Weeraratna et al., 2002). 
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Figure 1.16: Activation of Wnt/ca2+ non-canonical pathway. Wnt binding to 
the receptor stimulates G-proteins which in turn activate phospholipase C. 
This leads to the release of calcium ions and  the activation of protein kinase 
C and Ca2+/calmodulin-dependent protein kinase II (CaMKII). Signalling 
events downstream from this stage may lead to the inhibition of the canonical 
wnt signalling pathway. 
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1.18.1.3 Non-canonical Wnt/PCP signalling pathway 
 
The second non-canonical signalling is the Wnt/PCP pathway. The Wnt/PCP 
signalling pathway regulates the generation of planar cell polarity (PCP). Like 
in the other Wnt pathways, in this non-canonical pathway, Wnt binding to the 
Fz receptor activates Dsh but in this case, Dsh activation does not lead to 
either a stabilisation of β-catenin or to an influx or release of intracellular 
calcium ions. Instead Dsh is localised to the cell membrane where it mediates 
the activation of small GTPases (RhoA and Rac) which then activate Rho 
kinase and c-Jun N-terminal kinase (JNK) (Endo et al., 2008) (Figure 1.17). 
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Figure 1.17: Activation of Wnt/PCP  non-canonical pathway. Wnt binding 
to the receptor stimulates Dsh protein which in turn RhoA and Rac. RhoA and 
Rac respective activation of Rho kinase and JNK is thought to control cell 
migration and polarity and the cytoskeleton. 
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1.18.2 Classes of Wnt proteins 
 
Based on the preference or ability to signal through the canonical or non-
canonical pathway, Wnt proteins are divided into two groups: Wnt1 group 
(e.g. Wnt1, Wnt3a, and Wnt8) and wnt5a group (e.g. Wnt4, Wnt5a, and 
Wnt11).  Wnt1 group are thought to signal exclusively via the canonical 
Wnt/β-catenin pathway while the Wnt5a group normally signal through the 
non-canonical Wnt signalling (Tada and  Smith, 2000; Pandur et al., 2002; 
Maurus et al., 2005). The signals generated  by the Wnt5a group can 
suppress β-catenin-mediated signalling (Torres et al., 1996; Topol et al., 
2003; Westfall et al., 2003; Maye et al., 2004). This suggests that wnt5a group 
of Wnt proteins function as negative regulators   of Wnt1 class proteins. 
 
1.18.3 Wnt inhibitors 
 
1.18.3.1 Endogenous Wnt inhibitors: secreted frizzled-related proteins 
 
Secreted frizzled-related proteins (sFRP) are distinct but related to the Fz cell 
membrane receptor proteins (Rattner et al., 1997). The Wnt binding domain is 
conserved among sFRP and Fz proteins. The sFRP exert their biological 
activity acting as competitive inhibitor for Wnts binding to their cell membrane 
receptors  (Bafico et al., 1999; Golan et al., 2004; Roman-Roman et al., 
2004).  
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1.18.3.2 Endogenous Wnt inhibitors: Dickkopf (Dkk) proteins 
 
Dickkopf (Dkk) like the sFRP also   inhibit the canonical Wnt signalling  
(Glinka et al., 1998). However, unlike the sFRP which bind to Fz receptors, 
the Dkk exert their inhibitory activities on  canonical Wnt by competitively 
binding to the extracellular domains of the co-receptors (LRP5 and LRP6) 
(Mao et al., 2001; Semenov et al., 2001).  Beside their competitive inhibition 
of the canonical pathway at the LRP5/6 receptor level, Dkk signalling may 
also  regulate  the activity of canonical Wnt proteins  (Bafico et al., 2001; 
Davidson et al., 2002; Mao et al., 2002). 
 
1.18.4 Frizzled receptor family in the mesoderm 
 
In addition to the enormous number of Wnt ligands, many different Wnt 
receptors of the Frizzled family have been detected in the mesoderm of the 
heart-forming fields, cardiac neural crest cells or the adult heart, including Fz-
4 (DeRossi et al., 2000), Fz-7 and  Fz-8 (Wheeler and  Hoppler, 1999; Saitoh 
et al., 2001), Fz-10a and -10b (Moriwaki et al., 2000), Fz-1 and Fz-2 (van Gijn 
et al., 2001) and Fz-9 (Sagara et al., 1998; Wang et al., 1999). The  sFRP-1 is 
expressed in the heart and in the visceral yolk sac during mouse 
development, and that sFRP-1 and mWnt-8 display overlapping expression 
patterns during heart morphogenesis  (Jaspard et al., 2000). The extensive 
expression of different Wnt proteins and receptors  in the developing hearts is 
strong indication that Wnt proteins  have a role to play in the  different stages 
of cardiogenesis. 
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1.18.5 Roles of Wnt roles in cardiogenesis  
 
Vertebrate heart development starts with specification of myocardial precursor 
cells within the mesodermal germ layer of the early embryo. Several Wnt 
ligands and Frizzled receptors have been shown to be expressed in a special 
and temporal manner regulated during early heart development. Wnt-11 
expression is found in the  heart-forming fields in chicken, mouse and 
Xenopus (Ku and  Melton, 1993). It has also been shown that Wnt11-R, a 
protein closely related to mammalian Wnt11, is required for heart 
morphogenesis in Xenopus (Garriock et al., 2005). It has  also be shown that   
Wnt (Wnt-11) gene is expressed by newly gastrulated mesoderm cells within 
chicken embryos in a pattern which  suggests that it may be involved in 
formation of the cardiogenic fields  (Eisenberg et al., 1997).  In mouse 
embryos, by 7.5-8.5 dpc , the expression of Wnt2 in the early heart field 
overlaps with that of Wnt-11 before it becomes restricted to the pericardium 
(Monkley et al., 1996). 
 
1.18.6 Roles of the canonical Wnt/β-catenin signalling in ES cell 
differentiation into cardiomyocyte 
 
 
The current model of the role  of Wnt in development of the  heart is that 
inhibition of canonical Wnt/β-catenin signalling pathway is essential for the 
induction cardiac lineage commitment (Marvin et al., 2001; Schneider and  
Mercola, 2001; Tzahor and  Lassar, 2001; Pandur et al., 2002).  However this 
model is not universally supported by published data. Data from some studies 
suggest that canonical Wnt/β-catenin signalling inhibits cardiogenesis while   
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data from other studies support positive regulation of ES cell differentiation 
into cardiomyocytes by the Wnt/β-catenin signalling (Nakamura et al., 2003; 
Naito et al., 2006; Kwon et al., 2007; Liu et al., 2007).  
 
It  has been shown in Xenopus laevis that the administration of Dkk-1 and 
Crescent (Wnt inhibitors) and also the ectopic expression of GSK-3β can 
initiate cardiogenesis in ventral marginal zone mesoderm  (Schneider and  
Mercola, 2001). Similarly in chick embryos  Crescent and Dkk-1 were found to 
induce heart muscle formation in the posterior lateral plate mesoderm (Marvin 
et al., 2001). These studies suggest that the Wnt/β-catenin signalling 
negatively regulates cardiogenesis and the activation of pathways that inhibit 
Wnt/β-catenin signalling is required for the induction of cardiogenesis. 
 
In contrast to the inhibitory roles suggested by the above studies, data from 
other studies suggest that Wnt/β-catenin signalling positively regulates ES cell 
cardiac differentiation during the early stages.  Using mouse embryos,  it was 
found that Wnt8a  was also specifically expressed in heart precursors at E8.5 
and also expressed initially throughout the developing heart tube  (Kwon et 
al., 2007). It was also found that the expression of the early cardiac genes 
Nkx2.5 and Tbx5 in EBs was up-regulated by Wnt3a and down-regulated by 
Dkk-1.The  addition  of  Wnt3a to EBs before the induction of early cardiac 
genes increased the number of beating EBs to more than 50% while the 
addition of Fz8/Fc or Dkk-1 and Fz8/Fc, at this stage resulted in a complete 
absence of beating EBs (Naito et al., 2006; Kwon et al., 2007). The second 
heart (SHF) field marker, Islet1 was similarly affected by Wnt3a and Dkk-1  
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(Kwon et al., 2007).  Constitutively active GSK-3β (i.e. degradation of  β-
catenin) also completely blocked Tbx5 (a mesoderm marker) and GATA4 
(Nakamura et al., 2003; Kwon et al., 2007) and also inhibited the expression 
of BMP2, BMP4, and FGF8 (Nakamura et al., 2003). In contrast,  LiCl (a 
GSK-3β inhibitor) significantly increased the expression of Nkx2.5, GATA4, 
Tbx5, BMP2, and BMP4 (Nakamura et al., 2003). These results strongly 
suggest a positive rather than a negative regulation of the stem cell 
differentiation into cardiomyocytes. 
 
In addition to functional data mentioned above, the wide expression of 
canonical Wnts in the developing heart may suggest positive roles for 
canonical Wnts during the myocardial fate specification. For example 
canonical Wnts  including Wnt2 (Monkley et al., 1996; Karasawa et al., 2002), 
Wnt9a (Karasawa et al., 2002; Person et al., 2005) and Wnt6 (Rodriguez-
Niedenfuhr et al., 2003) are also expressed in the developing heart.  
 
In addition to a positive role for Wnt/β-catenin signalling  during ES cell 
cardiac differentiation, it was shown that this pathway  exhibited biphasic 
effects. While Wnt/β-catenin signalling positively regulated ES cell 
differentiation into cardiomyocytes during the early phases, it negatively 
regulated ES cell cardiac differentiation during the late stages of 
cardiomyocyte differentiation (Nakamura et al., 2003; Naito et al., 2006; Kwon 
et al., 2007).  In support of a negative role of Wnt/β-catenin signalling during 
the  late stage cardiomyocyte differentiation, it was shown that the  treatment 
of EBs with Dkk-1 and Fz8/Fc, by day 5 (i.e. late cardiomyocyte differentiation 
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stage  in those experiments) increased the number of cardiomyocytes (Naito 
et al., 2006; Kwon et al., 2007)  thus suggesting a negative role of Wnt at this 
stage.  
 
Support of  a positive role for Wnt during the early phase of cardiogenesis 
comes from the high expression of Wnt3 and Wnt8a in the pre-streak and 
early gastrula-stage embryo (Kemp et al., 2005). In ES cells, Wnt3 and Wnt8a 
are transiently   induced between day 2 and 3 of differentiation. It was also 
shown that Dkk-1 addition at day 0, 1 or 1.5, completely inhibited the 
generation of cells expressing Flk1 (a lateral mesoderm early marker). 
Lineage commitment was reduced by 80%. In contrast Dkk1 added at day 2 
and later had negligible effects (Lindsley et al., 2006). 
 
All the above data when considered together, suggest that Wnt/β-catenin 
signalling is required for commitment of mesodermal cells into cardiomyocytes 
during the early phase of the of ES differentiation into cardiomyocytes. The 
down-regulation of of cardiac gene expression by Dkk-1, Fz8/Fc and 
constitutively active GSK-3β suggest that Wnt/β-catenin signalling played 
positive roles during the  early phases of ES cell cardiac differentiation.  The 
inhibition of the expression of Nkx2.5, GATA-4, Tbx5, BMP2, and BMP4 by 
constitutively active GSK-3β and the induction of these genes by LiCl (a GSK-
3β inhibitor) also suggest that Wnt/β-catenin signalling is required for 
commitment of mesodermal cells into a cardiomyocyte lineage and the 
differentiation of the committed cells into cardiomyocytes. The inhibition of the 
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expression of BMP2, BMP4, and FGF8 also suggest that  Wnt pathway is 
upstream of the BMP and FGF signalling pathways. 
 
1.18.7 Summary of Wnt Proteins 
 
There is extensive expression of different Wnt proteins and their receptors in 
the developing hearts. Wnt and their receptors are expressed in the heart 
forming fields, cardiac crest and also in the adult heart.   Wnt signalling is very 
complex. Some Wnts activate the canonical pathway, which signals through 
stabilisation of β-catenin.  Wnts in Wnt1 group signal  mainly through β-
catenin. Some Wnts in wnt5a group signal through Wnt/PCP pathway leading 
to the regulation of cell migration and polarity and the cytoskeleton. Other 
Wnts in wnt5a group signal through activation of phospholipase C leading to 
of Ca2+ ion release, the activation of protein kinase C and Ca2+/calmodulin-
dependent protein kinase II (CaMKII) and this has been suggested to cause to 
the inhibition of the canonical Wnt/β-catenin signalling. 
 
While data from previous studies suggest that the Wnt/β-catenin signalling 
inhibit cardiogenesis, more recent data suggest that the canonical Wnt/β-
catenin signalling play positive role during the early phases  of cell lineage 
specification in vivo and in ES cell cardiac differentiation.  The fact that data 
from some reports support a positive role for the Wnt/β-catenin signalling in 
the  commitment of mesodermal cells into a cardiomyocyte lineage and the 
differentiation of the committed cells into cardiomyocytes, while data from 
other reports suggest a negative role, may be a reflection of the existence  
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large number of Wnts  and also our lack of clear understanding of the roles of 
these proteins  in cardiomyocyte differentiation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 83
1.19 Overview of extracellular signalling molecules and 
transcription factors in cardiogenesis and stem cell 
differentiation into cardiomyocytes 
 
 
 
There is no doubt that stem cells offer many important potential benefits for 
treating many diseases including cardiovascular diseases. The key problem is 
how to derive a particular cell type from stem cells. There are data on the 
process of stem cell differentiation into cardiomyocytes. Many signal 
molecules and signal transduction pathways have been implicated in stem cell 
differentiation but there is no complete account of the mechanisms that keep 
stem cells in the undifferentiated state. Equally, there is no comprehensive 
account of the mechanisms that can drive stem cell differentiation into a 
particular cell type. 
 
Investigations of the molecular mechanisms of many transcription factors 
including Nkx2.5, and GATA transcription factors have helped clarify 
understanding of this area but these studies are still at an early stage and  
exact details of their modes of action are not fully understood.  As it has been 
seen in other systems, it is more likely that it is the actual interactions (or 
combinatorial actions) rather than the role of each factor alone that may hold 
the keys to our understanding of their roles in cardiogenesis. 
 
At the receptor level many molecules including Wnt, BMP have been shown 
to play important roles in stem cell and stem cell differentiation (Figure 1.18). 
Signalling downstream of various classical signalling pathways  including 
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PI3K, PKC, MAPK and others have been implicated to have roles to play in 
stem cell differentiation into cardiomyocytes but the exact molecular 
mechanisms by which these may mediate the stem cell cardiomyocyte 
lineage commitment  and differentiation is  currently not fully understood. 
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Figure 1.18: Extracellular signalling molecules and transcription factor 
position in cardiogenesis. In response external conditions or factors signal 
molecules including, BMP, wnts and other molecules are released.  A range 
of specific signalling pathways are activated. Downstream proteins including 
kinases are activated. Cardiac specific transcription factors are expressed and 
these factors then initiate cardiac differentiation or cardiac lineage 
commitment. BMP= bone morphogenetic proteins, Oct-4= Octamer-binding 
protein-4, SHH= sonic hedgehog, FgF= fibroblast growth factor, TGF-β = 
transforming growth factor-β and DMSO= dimethylsulfoxide 
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1.20 Mechanisms of heart development 
 
A clear understanding of the basic molecular mechanisms of heart 
development and the signalling pathways of several transcription factors that 
promote cardiac differentiation is relevant for stem cell differentiation into 
cardiomyocytes. Identification of soluble growth factors, transcription factors 
and signalling cascades capable of priming cardiogenesis is a crucial issue for 
the in vitro development of cardiomyocytes from ES cells. Many key 
transcription factors including, GATA factor, Nkx2.5 and T-box factors are 
expressed in the developing heart. In addition to these key transcription 
factors, many extracellular molecules including BMP and Wnt proteins that 
are upstream of these transcriptions factors are also expressed in the 
developing heart.  
 
Early development of the heart is composed of two major stages: cardiac 
myocyte specification/differentiation and heart morphogenesis (i.e. the 
organisation of tissue into the specific anatomical structure). A great deal of 
research information about heart morphogenesis has been collected using in 
vivo and in vitro genetic manipulation, biochemical, and structural analyses. 
On the other hand there is less research information about the factors or 
mechanisms that regulate the cardiomyocyte differentiation.  
 
The vertebrate heart formation involves cell commitment to cardiac lineage, 
proliferation, differentiation, migration and integrated multicellular 
morphogenesis. This complex process is regulated by various signalling 
molecules, including transcription factors. Vertebrate heart formation is highly 
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susceptible to errors that can result to congenital heart diseases (CHD).  
Congenital heart diseases with incidence of nearly 1% of live birth,  are the 
most common forms of genetic diseases (Hoffman and  Kaplan, 2002; Garg, 
2006; Thom et al., 2006).  
 
1.20.1 Origin of cardiac progenitor cells 
 
1.20.1.1 First heart field (FHF) 
 
The heart is the first embryonic organ to become functional in the developing 
embryos. Heart formation is a process that is based on a series of progressive 
lineage restrictions. The whole heart is likely to be derived from a single 
mesodermal cardiac progenitor cell (Meilhac et al., 2004).  
 
However, an early lineage restriction that occurs prior to heart formation 
creates two profoundly distinct pools of cardiac progenitor cells.  The 
myocytes of vertebrate heart are derived from (at least) these progenitor cell 
populations. The  cardiogenic committed progenitor cells found in two 
bilaterally symmetrical regions of anterior lateral mesoderm constitute the first 
lineage known as the  first heart field (FHF) (Buckingham et al., 2005). The 
FHF forms the  cardiac crescent (Meilhac et al., 2004). The FHF cells begin 
differentiation at the crescent stage at approximately embryonic day 7.5 to 8.0 
(E7.5-8.0) in the mouse embryo (corresponds to week 2-3 of human 
gestation).  The two lateral halves of this cell population migrate, fuse at the 
anterior midline undergo early differentiation at the cardiac crescent stage. 
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These cell then form a simple linear heart tube  (Franco et al., 1998; 
Buckingham et al., 2005). 
 
From the very beginning this tubular heart exhibits slow autonomous 
peristaltic contractions (Garg, 2006; Srivastava, 2006) and consists of an 
interior layer of endocardial cells and an exterior layer of myocardial cells. The  
linear heart tube consists of cardiac progenitors for parts  of the ventricles 
(Buckingham et al., 2005). The other parts or compartments are formed by 
the addition of cells to its cranial and caudal poles (De La Cruz et al., 1977; 
Noden, 1991; Redkar et al., 2001). Subsequently, the linear heart tube 
undergoes rightward looping and is remodelled into a mature four-chambered 
heart i.e. ventricular and atrial chambers with inflow and outflow regions and 
valves to control the flow of blood.  In mammals and also in birds, the four-
chambered heart is separated into two ventricles and two atria by a septum 
that separates oxygenated blood from deoxygenated blood. 
 
1.20.1.2 Second heart field (SHF)  
 
A progenitor cell lineage occupies a position caudally and medially to the first 
lineage at the cardiac crescent stage. This is the second heart field (SHF).  
The SHF is a population of undifferentiated multipotent cardiac progenitor 
cells that contribute to the heart tube growth at both inflow and outflow poles. 
A small number of myocytes in  left ventricle (LV) and atria  are  derived from 
SHF. However The SHF provides the majority of myocytes in the right 
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ventricle (RV) and outflow tract (OFT) (Kelly et al., 2001; Mjaatvedt et al., 
2001; Cai et al., 2003).  
 
The FHF and SHF comprises the ventral and dorsal-medial aspect of the 
cardiogenic plate  respectively (Cai et al., 2003). The FHF differentiates at the 
cardiac crescent stage while the SHF differentiates relatively late as the 
second lineage migrates in to join the already differentiated cells of the first 
lineage. Both lineages appear to be regulated by complex positive and 
negative signalling networks involving members of the bone morphogenetic 
protein (BMP), sonic hedgehog (SHH), fibroblast growth factor (FGF), Wnt, 
and Notch proteins. 
 
1.20.2 Parallel between heart formation and ES cell differentiation into 
cardiomyocytes 
 
Cardiogenesis is very complex process that involves many signalling 
molecules and signal transduction pathways. This process is regulated by 
various extracellular signalling molecules and transcription factors. A clear 
understanding of the basic molecular mechanisms of heart development is 
essential for the selective differentiation of ES cells to generate pure cardiac 
cell lineages. Some examples of the parallel between ES differentiation into 
cardiomyocytes and the vertebrate heart formation mechanisms are 
discussed to highlight the similarities between in vivo and in vitro 
cardiomyogenesis.  
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Mesodermal lineage in the FHF gives rise to cardiomyocytes. P19 stem cells 
differentiating into cardiomyocytes express brachyury T  (mesodermal  
lineage commitment marker) (Grepin et al., 1997). Brachyury T   is a T-box 
transcription factor (Kispert et al., 1995) and is necessary for the 
establishment of  the mesoderm in vertebrates (Schulte-Merker et al., 1992).  
ES cells undergoing cardiac differentiation brachyury T and cardiac specific 
transcription  factors and structural proteins including Nkx2.5, GATA-4, MLC-
2a MLC-2v, ANF, MHC and troponin T (Schwanke et al., 2006). This suggests 
that vertebrate stem cells in culture follow the same cardiac differentiation 
programme as in vivo. 
 
Nkx2.5 is one of the early markers during  stem cell differentiation into 
cardiomyocytes (Nakamura et al., 2003; Naito et al., 2006; Kwon et al., 2007). 
Nkx2.5 is also one of the earliest markers of heart field mesoderm. In the 
mouse, the expression of Nkx2.5 starts early in heart progenitor cells in the 
FHF and SHF continues at a high level in the heart through adulthood 
(Komuro and  Izumo, 1993; Lints et al., 1993; Lee et al., 2004).  
 
In Xenopus embryos, the expression of inhibitory or dominant negative 
mutants forms of Nkx2.5 (Nkx2.3 or XNkx2.5) resulted to complete lack of 
cardiac gene expression and  complete absence of heart formation (Fu et al., 
1998; Grow and  Krieg, 1998). Similarly in  P19 stem cells the expression of a 
dominant-negative mutant of Nkx2.5 blocked  the cell differentiation into 
cardiomyocytes (Jamali et al., 2001).  
 92
GATA-6 is expressed in cardiac mesoderm before gastrulation (Peterkin et 
al., 2003). In both Xenopus and zebrafish embryos, the inhibition of the 
GATA-6 mRNA translation into protein by anti-sense oligonucleotides led to 
markedly  reduced levels of  cardiac proteins in  the embryos (Peterkin et al., 
2003).   Zebrafish embryos depleted of both GATA-5 and GATA-6 can  not 
develop hearts (Holtzinger and  Evans, 2007). Mouse embryos null for both 
GATA-4 and GATA-6  had no hearts (Zhao et al., 2008). Similarly, the 
inhibition of GATA-4 using GATA-4 antisense transcripts blocked P19 stem 
cell cardiac differentiation at the premyocardial (cardioblast) (Kispert et al., 
1995). 
 
BMPs are expressed in lateral endoderm and ectoderm of vertebrate 
embryos. BMP signals in the anterior lateral mesoderm promote heart 
formation (Schultheiss et al., 1997; Andrée et al., 1998; Schlange et al., 2000; 
Tzahor and  Lassar, 2001).  It has been shown that BMP soaked beads can 
induce the  ectopic expression of Nkx2.5 and GATA-4 in chick embryos 
(Schultheiss et al., 1997). Over-expression of noggin (a natural inhibitor of 
BMP) in P19 stem cells prevent their differentiation into cardiomyocytes  while 
the  over-expression of BMP-2 or  direct addition of  BMP proteins to the 
culture medium rescued the cell cardiac differentiation (Monzen et al., 1999).  
 
Wnt proteins, Wnts receptors, Wnt receptor antagonists and Wnt antagonists 
are important for the signalling events that control the development of the 
heart. These proteins have been detected in the mesoderm of the heart-
 93
forming fields in vertebrates (DeRossi et al., 2000) (Wang et al., 1999; 
Wheeler and  Hoppler, 1999; van Gijn et al., 2001). 
 
In ES cells differentiating into cardiomyocytes it was found that the  addition  
of  Wnt3a to EBs increased th expression of  cardiac genes and differentiation  
into beating cardiomyocytes while the addition of Fz8/Fc or Dkk-1 and Fz8/Fc 
(wnt antagonists) resulted in a complete absence of beating EBs (Naito et al., 
2006; Kwon et al., 2007).The SHF marker, Islet1 was similarly affected by 
Wnt3a and Dkk-1  (Kwon et al., 2007).   
 
1.20.3 Summary of mechanisms of heart development 
 
In summary the few selected examples discussed above, show the 
remarkable similarities between heart formation in the vertebrates and ES cell 
differentiation. This similarities show the importance or the relevance of 
understanding the basic mechanisms of heart development to the 
differentiation of ES cells into cardiomyocytes. 
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1.21 Stem cell research and cardiovascular diseases 
 
Cardiovascular diseases (e.g. heart failure) are among the leading causes of 
mortality and morbidity worldwide (Murray and  Lopez, 1997) and particularly  
in the developed world (Rosamond et al., 1998). The high incidence of 
cardiovascular diseases is a combination of non-modifiable (non-preventable) 
and modifiable (preventable) risk factors. The non-modifiable risk factors 
include increasing age (Jousilahti et al., 1999; 
Asia_Pacific_Cohort_Studies_Collaboration, 2006), gender (being male)  
(Jousilahti et al., 1999; Lloyd-Jones et al., 1999) and heredity. The modifiable 
risk factors include tobacco smoke (Kawachi et al., 1993; Raftopoulos et al., 
1999; Van Berkel et al., 1999; Kaprio et al., 2000), high blood total cholesterol 
and LDL (Manolio et al., 1992; Stamler et al., 1993; Woodward et al., 2008), 
high systolic blood pressure (Rutan et al., 1989; Navas-Nacher et al., 2001; 
Sundaram et al., 2005; Prugger et al., 2008) and  physical inactivity (Kaprio et 
al., 2000; Kruger et al., 2003; Sundaram et al., 2005; Jenum et al., 2006), 
obesity (Hubert et al., 1983; Li et al., 2002; Sundaram et al., 2005) and  
diabetes mellitus (Sundaram et al., 2005; Prugger et al., 2008). The high 
incidence of cardiovascular diseases makes the search for new therapeutic 
approaches for improving the functions of the damaged heart is a critical 
endeavour. Myocardial infarction is associated with irreversible loss of 
cardiomyocytes. Cardiomyocytes undergo apoptosis during the acute and 
chronic phases of myocardial infarction. This has been shown  in human  (Itoh 
et al., 1995; Saraste et al., 1997; Baldi et al., 2002; Akasaka et al., 2006),  rat   
(Fliss and  Gattinger, 1996; Palojoki et al., 2001; Chandrashekhar, 2005; 
Louhelainen et al., 2007) and the mouse (Bialik et al., 1997; Engel et al., 
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2004). Studies have shown  that the inhibition of cardiomyocyte apoptosis can 
slow down post-infarction cardiac remodelling and also  improve cardiac 
function in the mouse (Diwan, 2007), rat (Chandrashekhar, 2005; Chen et al., 
2007) and rabbit (Qin et al., 2007).  
 
Myocardial infarction can lead to heart failure. The loss of cardiomyocytes 
poses a major difficulty or challenge in the treatment of the damaged heart 
since cardiomyocytes have very limited regeneration potential.  This means 
that, currently, the only effective treatment for severe heart failure is heart 
transplantation (Anyanwu et al., 2002; Hertz et al., 2002). The worldwide heart 
transplant data  from the International Society for Heart and  Lung 
Transplantation (ISHLT) shows that transplant half-life (i.e. the time at which 
50% of those transplanted remain alive) for heart transplant patients is 10 
years (Taylor et al., 2007). This represents a good extension to life, especially 
for elderly patients (e.g. those aged 60 years and above). 
 
Despite the good survival rates of heart transplant patients, heart 
transplantation is not a viable treatment option and has not delivered or met 
the high expectation that it generated among patients with heart diseases, 
when it was first introduced. This is due to the increasing number of patients 
on the heart transplant waiting list as the result of the continuous decrease in 
the availability of hearts for transplant. Heart transplantation as a treatment for 
heart failure is limited by the acute shortage of donor hearts (Anyanwu et al., 
2002). The ISHLT  data showed that the number of annual reported heart 
transplants since 1982 peaked at 4428 in 1994 (Trulock et al., 2003; Taylor et 
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al., 2007). This peak  was then followed by a gradual  but steady decline as 
the results of decreased number  of heart transplant procedures in many 
countries (Taylor et al., 2006; Taylor et al., 2007). The latest annual figure for 
heart transplants worldwide stands at 3095 in 2005 (Taylor et al., 2007). The 
worldwide number of patients on the waiting list far exceeds the number of 
hearts available for transplant.   In the United Kingdom alone, there were 379 
patients on the cardiothoracic waiting list  in 2006-2007 while in the same 
period only 292 cardiothoracic  transplants were carried out (UK Transplant, 
2007). The high incidence of heart diseases and the acute scarcity of donor 
hearts underline the urgent need to find alternative therapeutic approaches to 
heart transplantation.  
 
Stem cell research may lead to a viable alternative to heart transplant for the 
treatment of heart disease.  Several animal and human studies have 
demonstrated that transplantation of cardiomyocytes (or cardiac progenitor 
cells) may be an alternative treatment to whole heart transplant for patients 
with severe heart failure. ES cells therefore represent a potential alternative 
source of functionally intact cardiomyocytes for the treatment of 
cardiovascular diseases. Research evidence on the regenerative potential of 
stem cell-derived cardiomyocytes and progenitor cells for the prevention or 
treatment of heart failure has created intense interests in stem cell-based 
therapy for heart failure.  In a rat model of myocardial infarction (created by 
the ligation of the left anterior descending coronary artery) it has been shown 
that implantation of cardiac progenitor cells rescued scarred infarcted 
myocardium and improved cardiac function in rats (Bonaros et al., 2006; 
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Gonzalez et al., 2008; Rota et al., 2008).  Similarly, in a mouse myocardial 
infarction (also created by the ligation of the left anterior descending coronary 
artery), transplantation of human ES cell-derived cardiomyocytes improved 
left ventricular function (Cao et al., 2008). The above data show that 
differentiation of stem cells into functional cardiomyocytes or cardiac 
progenitor cells  follows by their engraftment into the damaged heart  to  
regenerate healthy myocardial tissues to replace the damaged tissues may be 
used to slow the deterioration of the acutely or chronically damaged heart 
after myocardial infraction. This means that stem cell-based therapy holds a 
great potential as a very attractive alternative to heart transplant for the 
treating heart failure and other cardiovascular diseases. 
 
1.21.1 Stem cell therapy for infarcted hearts 
 
One of the key issues still to be resolved is whether undifferentiated ES cells 
transplanted into normal or infarcted heart can be guided by the local 
environment in the heart to differentiate and contribute to cardiac functions. It 
has been shown that undifferentiated hES are not directed to specifically 
differentiate into cardiomyocytes in normal or infarcted heart of the nude 
mouse (Leor et al., 2007). Undifferentiated ES cells transplanted into normal 
or infarcted heart undergo non-specific lineage   differentiation (Leor et al., 
2007; Nussbaum et al., 2007).  In contrast to the above other groups have 
shown that transplantation of undifferentiated ES cells into infracted 
myocardium can induce the cardiac differentiation of the transplanted ES and 
improved cardiac functions. This has been shown in the rat  (Behfar et al., 
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2002; Hodgson et al., 2004) and in the mouse (Nelson et al., 2006; Singla et 
al., 2006). Being pluripotent, ES cells may be difficult to differentiate into 
cardiac specific cells, if undifferentiated ES cells are directly transplanted into 
infarcted hearts.   
 
As already mentioned in vitro differentiation of ES cells into functional 
cardiomyocytes has been achieved. Under appropriate experimental 
conditions, ES cells can faithfully follow the same  course of cardiomyocyte 
differentiation as in vivo (Wobus et al., 1991; Xu et al., 1998; Kehat et al., 
2001; He et al., 2003; Mummery et al., 2003) There is also extensive 
evidence in the scientific literature that adult stem cells (e.g. MSC)  can 
differentiate into cardiomyocytes (Makino et al., 1999; Fukuda, 2001; Toma et 
al., 2002; Xu et al., 2004b; Antonitsis et al., 2007; Bartunek et al., 2007). 
These adult stem cell-derived cardiomyocytes, like ES cell-derived 
cardiomyocytes, express cardiac specific transcriptions factors  (including 
GATA-4, and Nkx2.5, TEF1, MEF2C, MEF2A and MEF2D) during the course 
of their differentiation (Makino et al., 1999; Fukuda, 2001). These 
cardiomyocytes also express β-MHC, desmin, and cardiac α-actin and cardiac 
troponin T (Xu et al., 2004b).  
Beyond the fundamental question of whether of ES cells can differentiate into 
functional cardiomyocytes, the next question is: can ES cell-derived 
cardiomyocytes successfully engraft into adult animal hearts and improve post 
MI heart? Functional cardiomyocytes have been derived from cultures of 
human H1, H7, H9, and H14 embryonic stem cells (He et al., 2003). These 
ES cells  were originally derived from human blastocysts (Thomson et al., 
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1998; Lavon and  Benvenisty, 2003).  Cardiomyocytes derived from these ES 
cells displayed expected cardiomyocyte morphology such Z bands and 
intercalated disks and they express numerous cardiac myocyte specific  
proteins  including α-cardiac actin, atrial myosin light chain, ventricular myosin 
light chain, α-myosin heavy chain, atrial natriuretic peptide, and cardiac 
troponin T and I (He et al., 2003). They also showed rhythmic contractions 
and  long duration of action potentials (He et al., 2003). Interestingly, similar 
results have been report with cardiomyocytes derived from MSC (Makino et 
al., 1999; Fukuda, 2001; Toma et al., 2002; Antonitsis et al., 2007). 
 
Despite the close similarities between stem cell-derived cardiomyocytes and 
normal cardiomyocytes, the long-term effects of cardiac cell transplantation on 
cardiac functions are unknown at the moment. However several animal 
studies demonstrate that successful engraftment of stem-cell derived 
cardiomyocytes into the adult heart is possible.  ES-derived cardiomyocytes 
can successfully engraft into adult animal hearts and improve post myocardial 
infarction heart  This has been shown in pig complete atrioventricular block model 
[created by ablating the His bundle (the major electrical conduction pathway, connecting 
the atria with the ventricles)] (Kehat et al., 2004) and  rat myocardial infarction 
model (created by the ligation of the left anterior descending coronary artery) 
(Etzion et al., 2001; Behfar et al., 2002; Muller-Ehmsen et al., 2002; Laflamme 
et al., 2005; Caspi et al., 2007b; Leor et al., 2007). In the rat model of 
myocardial infarction, cardiomyocytes differentiated from human ES  cells 
showed in vivo functional integration in the animal infarcted hearts (Laflamme 
et al., 2007). The transplanted cardiomyocytes thickened the wall of the left 
 101
ventricle and enhanced ejection fraction and reduced paradoxical systolic 
bulging of the infarct in post myocardial infarction rats (Müller-Ehmsen et al., 
2002; Caspi et al., 2007a). Interestingly results similar to those reported with 
ES cells have also been obtained using MSC. It has been shown, in the 
mouse (Kudo et al., 2003; Grauss et al., 2007) and the rat (Hahn et al., 2008; 
Pasha et al., 2008) models of myocardial infarction (both created by the 
ligation of the left anterior descending coronary artery), that transplantation of 
MSC led to reduction in infarct size, improved LV function and survival.  The 
rat myocardial infarction model also showed that  the transplanted MSC 
promoted neovascularisation and myogenesis  (Pasha et al., 2008) and a 
regain of  80−90% of the lost myocardial volume and completely normalised 
systolic and diastolic cardiac functions (Mangi et al., 2003).  
 
Like the need for prior differentiation of ES cells into cardiomyocytes before 
transplantation into infarcted hearts, MSC may need specific pre-treatment 
before transplantation. For example it  was also shown that mice transplanted 
with MSC that were  pre-treated with  growth factors (i.e. BMP-2, FGF-2, IGF-
1) before transplantation had fewer apoptotic cells in infarcted hearts, smaller 
infarct size and better cardiac function than mice transplanted with untreated 
MSC (Hahn et al., 2008).  Almost identical results were obtained with dogs 
that were treated MSC that were induce to differentiate by BMP-2, FGF-2 and  
IGF-1) (Bartunek et al., 2007). The treated MSC expressed muscle-specific 
(MEF2) and cardiac-specific (GATA-4 and Nkx-2.5) transcription factors  
(Bartunek et al., 2007), a strong evidence  for their differentiation along the 
cardiac lineage. Myocardial injection of these cardiomyocytes differentiated 
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from autologous MSC into dogs with chronic myocardial infarction resulted in 
cardiac regeneration of the chronically infarcted myocardium (Bartunek et al., 
2007).    
 
The role of cardiac endothelial cells in the use of stem cells to treat an 
infarcted heart is also important. It has also been demonstrated that 
transplantation of human MSC (Grauss et al., 2007) or mouse MSC (Kudo et 
al., 2003) into ischemic hearts of mice caused the transplanted MSC to  
differentiate into myocytes and endothelial cells  and contribute to reduced 
infarct size, reduced fibrosis, significant preservation of LV ejection fraction, 
increased vascularity of the infarct scar and  a marked reduction in the 
thinning of the infarcted wall in the mice (Kudo et al., 2003; Grauss et al., 
2007). While it was not determined whether the cardiac improvements 
reported in these studies were the results of cell fusion (Terada et al., 2002) 
or MSC actually differentiating  into cardiac cells, these results suggest that 
both cardiomyocytes and cardiac endothelial cells are important for cardiac 
regeneration in infarcted hearts.  
 
Collectively, the all the above studies with both ES cell-derived and adult stem 
cell-derived cardiomyocytes have demonstrated that stem cell based therapy 
can be used to improve the function of the damaged heart and also improve 
survival after myocardial injury. They also show that stem cell therapy may 
become an alternative therapeutic approach to the current use of human heart 
transplants for the treatment of heart failure in patients. However there are still 
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many critical hurdles that must be overcome before the therapeutic potential 
of stem cells can be realised. 
1.21.2 Challenges facing stem cell-based therapy 
 
The potentials and challenges of stem therapy for treating human 
cardiovascular diseases are presented below. The challenges are by no 
means limited to cardiovascular diseases but are equally the concerns of 
stem cell-based therapies that may be targeting other human diseases. 
Progress has been made in the identification, isolation characterization, and 
maintenance of stem cells in culture (Evans and  Kaufman, 1981; Martin, 
1981; Shamblott et al., 1998; Thomson et al., 1998) but the specific 
differentiation of  ES cell into  cardiomyocytes (or any other particular cell 
type)   remains a problem. 
 
1.21.2.1 Challenge of cardiac-specific differentiation of stem cells  
 
Cardiac-specific differentiation of stem cells or the selection of lineages 
consisting of pure embryonic cardiomyocytes is essential and represents a 
scientific challenge. The search for growth factors and signalling molecules 
that are involved in cardiac-specific differentiation is therefore an active area 
of research.  There is need for the design and establishment of suitable and 
reliable differentiation techniques that can overcome the problem of inefficient 
and also spontaneous stem cell differentiation. The homogeneous 
differentiation of stem cells into cardiomyocytes with sufficient yield is a critical 
requirement for the clinical use of stem cells in cardiovascular medicine. A 
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serious limiting factor of stem cell therapy for the treatment of cardiovascular 
diseases is the current difficulty in generation sufficient number of stem-cell 
derived cardiac cells. Across many laboratories, differentiation methods are 
not only inefficient but sometime difficult to reproduce. The problems of 
variable reproducibility may be due to the variations in the conditions under 
which ES cells are routinely maintained and cultured or could be due to 
variation in differentiation conditions or both. There is a need for common 
stem cell culture conditions for the maintenance and for differentiation. This 
will not only simplify maintenance of multiple lines in single research but may 
help to improve the poor reproducibility of specific differentiation protocols 
among various research teams. Using two independently  derived human 
embryonic stem cell lines (BG01 and HUES-7), it has been demonstrated in  
principle that it is possible to develop  protocols  that can be applied to 
multiple stem cell lines (Denning et al., 2006). Reproducible differentiation 
methods at the research levels may eventually develop into technologies that 
lead to generation of a large number of   homogeneous stem-cell derived cell 
types. Such future technologies may in turn lead to easy availability of needed 
stem-cell-derived cell types, which can be applied in sufficient doses in order 
to achieve the maximum desired therapeutic benefits. 
 
1.21.2.2 Challenge of post-transplantation tumour formation 
 
Indefinite self-renewal capacity and pluripotency are the key attractive 
features of stem cells. However these features also carry the potential risks 
for tumour formation after transplants. Undifferentiated or partially 
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differentiated ES cells can subsequently form post-transplantation teratomas 
(i.e. germline tumours consisting of various cell types).  Therefore the 
development of robust and reproducible methods to derive a homogeneous 
population of cardiomyocytes from ES cells is essential for therapeutic 
application of ES cells.  A  homogeneous cell type not only ensures that a 
sufficient numbers of the desired cell type for a  maximum therapeutic benefit 
are applied but most importantly  it ensures the removal of unwanted cell 
types that could lead to harmful  side effects.   
 
Tumorigenesis following transplantation of undifferentiated ES cells or cell 
types differentiated from ES has been described in many reports (Thomson et 
al., 1998; Swijnenburg et al., 2005; Caspi et al., 2007a; Nussbaum et al., 
2007).  A test of five different human embryonic cell lines found that all 
produced teratomas after injection into severe combined immunodeficient 
(SCID)-beige mice (Thomson et al., 1998). Mostly important was the finding 
that each injected mouse formed teratomas that included cell types of the 
three germ layers -  i.e. gut epithelium (endoderm), cartilage, striated muscle, 
bone, and smooth muscle and (mesoderm); and neural epithelium, embryonic 
ganglia and stratified squamous epithelium (ectoderm) (Thomson et al., 
1998). The generation of all cell types from the three germ layers is an 
indication that uncontrolled differentiation occurred.  Efforts to remove 
undifferentiated ES cell or enrich differentiated cell types is therefore an active 
area of research. It is also possible, in principle, to deplete undifferentiated 
cells from a heterogeneous cell population using molecular methods. A 
heterogeneous cell population (obtained from the differentiation of stem cells) 
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can be treated with a vector that puts an effector gene under control of a gene 
element that allows the specific and higher expression of transgene in the 
undifferentiated subpopulation. The transgene product can then be used to 
separate the undifferentiated cell population from the differentiated cells using 
specific antibodies. This has the potential to produce a cell population that is 
relatively enriched for differentiated cell types. For example, it has been 
shown that cardiomyocytes differentiated from ES cells that were transfected 
with a fusion gene consisting of  alpha-cardiac myosin heavy chain promoter 
driving the aminoglycoside phosphotransferase (neomycin resistance gene) 
led to higher harvest of cardiomyocytes with  undetectable levels of Oct-4 
(Zandstra et al., 2003). The undetectable level of Oct-4 suggests that 
undifferentiated ES cells were depleted from the ES cell-derived 
cardiomyocyte population. Similarly, it  has been shown that, when a 
construct of  murine α-MHC promoter driving the neomycin-resistance gene, 
was  introduced into hES3 cells, a differentiated cell population  with more 
than 99% cardiomyocytes resulted, after cardiac differentiation  that was 
followed by G418 selection (Xu et al., 2008). These studies demonstrated not 
only that ES cell-derived cardiomyocytes can be enriched but also that the 
elimination of undifferentiated cells is possible. Another  potential  procedure 
to remove undifferentiated ES cells is by selection against undifferentiated ES 
cells using monoclonal antibodies against well-characterised human ES cell  
surface antigens (e.g.SSEA-4) (Shibata et al., 2006). Flow-cytometric cell 
sorting (i.e. fluorescence-activated cell sorting; FACS) and monoclonal 
antibodies can also be used to enrich differentiated cell types from 
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undifferentiated stem using antibodies against the specific marker of the 
differentiated cell types (Fukuda et al., 2006). 
 
1.21.2.3 Summary of Stem cell research and cardiovascular diseases 
 
The search for new therapeutic approaches for improving the function of the 
damaged heart is urgent.  Cardiomyocytes have very limited regeneration 
potential so their loss, one of the underlying causes of myocardial infarction 
and eventual heart failure, is a major problem for treating heart failure. 
Currently, heart transplantation is the only cure for heart failure but this is not 
a viable treatment option due to the acute shortage of donor hearts. 
 
There is sufficient evidence to conclude that the therapeutic application of 
stem cell-derived cardiomyocytes can be a realised. Various animal models 
have shown that stem cell-derived cardiomyocytes can successfully engraft 
into adult hearts and can also improve the function of infarcted hearts. 
However, realisation of the full potential of stem cells for the treatment of 
various heart diseases will be possible only after the resolution of key issues 
including the limited availability of homogenous stem-cell derived 
cardiomyocytes, potential immune rejection, post transplant teratoma 
formation and others.  While there have been advances in the differentiation 
of stem cells into cardiomyocytes and better understanding of potential post 
transplantation risks (e.g. teratoma formation), a fully understanding about the 
above problems and how to avoid them is needed. The various reports of 
post-transplantation tumour formation in various models of stem cell-based 
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cell therapy and the various attempts to resolve this issue is a reflection of the 
seriousness of all the critical hurdles that must be overcome before stem cell 
therapy can become a clinical reality.  
 
1.22 Aim of the PhD project  
 
As already discussed above, ES cell-derived cardiomyocytes are potential or 
promising alternative to heart transplant in the treatment of heart diseases for 
cardiac repair.  The realisation of stem cell therapy is been currently 
hampered by the critical lack of reliable, selective and readily reproducible 
differentiation methods. This difficulty is in turn due to the lack of a clear 
understanding of mechanisms of signal transduction pathways that mediate 
stem cell differentiation into cardiomyocytes. Without a clear understanding of 
the mechanism of stem cell cardiac lineage commitment and differentiation 
into cardiomyocytes, it would be difficult to obtain homogenous and sufficient 
number of cardiomyocytes for use in stem cell base therapy. The specific, 
efficient and selective differentiation of stem cells into cardiomyocytes is 
absolutely necessary for realisation of stem cell therapy for treating the 
damaged heart and this remains a tough scientific challenge.  
 
The aim of this PhD thesis is therefore to investigate the cell signalling 
pathways that are responsible for mediating the differentiation of stem cells 
into cardiomyocytes. This PhD project, besides being a scientific challenge for 
the reason stated above, it has another challenging dimension, in that, it is the 
first of its kind in the host laboratory. The project is the first attempt by our 
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laboratory to direct our strong   background in cell signalling research to the 
studies of stem cell differentiation into cardiomyocytes.  
 
The project specific aims/objectives are as follows:  
 
1. The first objective is to establish cardiomyocyte differentiation models 
using H9c2 and P19 stem cells and the use of these models to 
accomplish the other specific objectives, which are, to: 
 
2. Investigate the role of nitric oxide (NO) in the differentiation of stem 
cells  into cardiomyocytes 
 
3. Investigate the role of phosphoinositide 3-kinase (PI3K) signalling 
pathway in the differentiation of stem cells  into cardiomyocytes 
 
4. Investigate the role of protein kinase C (PKC) signalling pathway in the 
differentiation of stem cells  into cardiomyocytes 
 
5. Investigate the role of nuclear factor-kappa B (NF-kB) signalling 
pathway in the differentiation of stem cells  into cardiomyocytes 
 
6. Investigate the role of p38 mitogen-activated protein kinase (p38 
MAPK) signalling pathway in the differentiation of stem cells  into 
cardiomyocytes 
 
Possible alternative research approaches, to the above that we took, include 
investigating the roles of traditional molecules  (e.g. BMP, TGF-β, Fgf, Wnt 
and growth factors) that have been implicated in stem cell differentiation into 
cardiomyocytes The signal transduction pathways that we investigated may 
be downstream of these molecules. Therefore an understanding of the roles 
of these downstream signal transduction pathways, in the differentiation of 
stem cells into cardiomyocytes, may give us a better insights or understanding 
of the roles of these traditional molecules mentioned above. This project is 
using two relevant cardiomyocyte differentiation models (H9c2 cell and P19 
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stem cell models) to investigate the roles of the signalling pathways (listed 
above) in stem cell differentiation into cardiomyocytes. 
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2 Materials and Methods 
 
2.1 Resuscitation and culture of H9c2 cells from frozen stock  
 
The H9c2 (2-1) line (H9c2 cells), at passage 8, was purchased from the 
European Collection of Cell Cultures [ECACC (No: 88092904), Salisbury, 
Wiltshire, UK]. On day 1, a 1ml vial of frozen H9c2 stem cells was quickly 
thawed in a water bath at 37oC (Katayama et al., 1997). The cells were then 
resuspended in 9ml of fresh complete culture medium (i.e. Dulbecco's 
Modified Eagle's Medium (DMEM) supplemented with 10% foetal bovine 
serum (FBS), 100units/ml penicillin/100µg/ml     streptomycin) in a 15ml 
centrifuge tube. All the components of the full medium were purchased from 
Invitrogen, UK. The tube was spun in a centrifuge at 1000 RPM at 4oC for 5 
minutes. The medium was then aspirated and the pellet was kept. Next, 5 ml 
of new fresh complete medium was added to the tube and the clumped cells 
were dissociated by trituration (i.e. pipetting up and down). The dissociated 
cells were transferred into a new T25 (25 cm2 of cell growth area) culture flask 
in a total volume of 5ml of fresh culture medium and cultured in a cell culture 
incubator at 37oC, 95% air and 5% CO2.  
 
On day 2, the cells in the T25 flask were observed under a microscope to 
ensure that they were growing and also healthy. The spent medium was 
removed at day 3 and replaced with fresh complete growth medium. The cells 
were subsequently trypsinised and subcultured on day 4, as described below 
(Section 2.4), when they were approximately 60-70 % confluent. The cell 
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suspension was then placed in a T75 (75 cm2 of cell growth area) flask and 
placed back into the incubator at 37oC, 95% air and 5% CO2. The cells were 
left to become 60-70 % confluent and then brought into suspension again. 
The cell suspension was split into five parts (1:5 splitting). One part (1ml) of 
the cell suspension was subcultured in a new T75 flask. The cells from this 
flask were used to generate more cells for routine cell culture (i.e. cell 
generation for experiments and storage). The rest of the cell suspension (i.e. 
4 parts or 4ml) were frozen and stored in liquid nitrogen for future use as 
described below (Section 2.5).  
 
2.2 Resuscitation and culture of P19 stem cell from frozen 
stock  
 
P19 embryonal carcinoma stem cell (P19 stem cells) (passage 18) were 
purchased from the European Collection of Cell Cultures [ECACC (No: 
95102107), Salisbury, Wiltshire, UK]. The resuscitation and culture of P19 
stem cell from frozen stock was carried out as already described above for 
H9c2 cells (Section 2.1). The only modification made to the above was that 
the frozen vial of P19 stem cells was directly cultured  in a T75 flask (i.e. 
without the initial culture in T25 as was the case with H9c2 cells). P19 stem 
cells do not need the initial culture in a small growth area (i.e. T25 flask) as 
they have high growth rates. The frozen vial of P19 stem cells was 
resuspended in fresh complete culture medium (i.e. alpha Minimum Essential 
Medium (α-MEM) supplemented with 10% FBS and 100units/ml 
penicillin/100µg/ml streptomycin) in a 15 ml centrifuge tube. All the 
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components for the full medium were purchased from Invitrogen, UK. The 
cells were processed exactly as detailed for H9c2 cells. 
 
2.3 Routine cell culture 
 
2.3.1 Routine cell culture of H9c2 cells 
 
H9c2 cells were routinely cultured in full culture medium (i.e. DMEM 
supplemented with 10% FBS, 100units/ml penicillin/100µg/ml streptomycin).  
The cells were maintained in a tissue culture incubator at 37oC, 95% air and 
5% CO2. Cells were routinely subcultured when 60-70% confluence.  This 
precaution was to prevent the loss of differentiation potential should the cells 
reach confluency.  
 
2.3.2 Routine cell culture of P19 stem cells  
 
P19 stem cells were routinely cultured in full culture medium (i.e. α-MEM 
supplemented with 10% FBS, 100units/ml penicillin/100µg/ml streptomycin). 
The cells were maintained in a tissue culture incubator at 37oC, 95% air and 
5% CO2. The cells were routinely subcultured when 60-70% confluent.  This 
precaution of not allowing the cells to become confluent was to prevent their 
spontaneous or non-directed differentiation.  
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2.4 Subculture of cells 
 
P19 stem cells or H9c2 cells were subcultured when 60-70 % confluent. This 
was carried out by removing the culture medium from the flask, washing cells 
3 times with warm (37oC) phosphate buffered saline (PBS) (Invitrogen, UK)  
and then  adding 3ml of warm (37oC) 0.05% trypsin/EDTA solution 
(Invitrogen, UK) cells in T75 flasks (i.e. 120µl trypsin/cm2). Flasks were then 
placed in an incubator at 37oC, 95% air and 5% CO2 for 3-5 minutes. The 
trypsin was subsequently inactivated when all the cells had detached by 
adding 7ml of full growth medium. The serum in the full growth medium 
contains inhibitors that inhibit or neutralise the trpypsin.  If the cells were not 
required for studies, the cell suspension was placed in a T75 flask and 
cultured to 60-70% confluent. If required, the cells were used for experiments. 
 
2.5 Cryopreservation of cells 
 
Excess cells or cells not required for immediate experimentation, were 
routinely cryopreserved and stored for later use. To freeze the cells, they were 
brought into suspension as before. The cell suspension was transferred into a 
15ml centrifuge tube and spun at 1000 RPM for 5 minutes at 4oC. The 
medium was then aspirated and the pellet was kept. The H9c2 cell pellet was 
re-suspended in freezing medium (i.e. 90% FBS and 10% dimethylsulfoxide 
(DMSO) (Invitrogen, UK)). The P19 stem cell pellet was re-suspended in 
freezing medium (i.e. 90% FBS and 10% DMSO or 10% glycerol (Invitrogen, 
UK)). The cell suspension was gently but thoroughly triturated to  break apart 
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any cell clumps. The cell suspension was then aliquoted in 1ml volumes in 
cryovials and placed in a Thermo Scientific NALGENE® Mr. Frosty (i.e. a 
controlled rate freezing container) (Fisher Scientific, UK) for freezing at -80oC 
overnight before transferring into liquid nitrogen for long term storage. 
Normally one T75 flask of cells was frozen into two cryovials, each containing 
1ml of resuspended cells (i.e. splitting ratio of 1:2) 
 
2.6 Quantification of cells 
 
In order to plate cells at the required densities, the total number of cells from 
each flask was determined using the Trypan Blue exclusion assay. The flask 
of cells was first trypsinised as described (Section 2.4). The cell suspension 
was transferred into a 15ml centrifuge tube and spun at 1000 RPM for 5 
minutes at 4oC. The medium was then aspirated and the pellet was kept.  The 
pellet resuspension was carried out in a small known volume (usually, 1-2 ml) 
of complete cell culture medium for each T75 flask of cells. Then 100µl of the 
cell suspension was mixed with an equal volume of 0.4% w/v) Trypan blue in 
an eppendorff tube. A moistened cover-slip was slipped over the chamber of a 
clean Neubauer haemocytometer. A 10µl aliquot of the cell/Trypan blue 
suspension was then added to each chamber on the haemocytometer and 
viewed under a light microscope using a 10X magnification on the eyepiece 
lens and a 20X objective lens.  
 
Cells were counted in the two chambers of haemocytometer. All the cells in 
the 1mm center square (E) and four 1mm corner squares (A, B, C and D) 
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were counted in the first chamber (Figure 2.10). Separate counts of viable 
(seen as translucent with no blue staining) and non-viable (stained blue) cells 
were recorded. This procedure was repeated for the second chamber. In total, 
the cells in ten squares (five from each chamber) were counted.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10: A schematic diagram (cartoon) of a haemocytometer a. 
Diagram shows a chamber of a haemocytometer and the areas (A, B, C, D 
and E) from which the cells were counted. 
 
 
 
 
 
 
 
E
1 mm  
corner square
1 mm  
center square
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The cell concentration in the cell suspension was determined as follows:  
 
 
 
 
 
 
 
 
 
 
 
 
Concentration of viable cells (cells/ml) = A x C x D 
 
Where: 
 
A is the mean number of viable cells counted i.e. 
 
 
C is the dilution factor and  
 
D is the correction factor (x104) 
 
 
Total number of viable cells per flask =                  
suspension cell of  volumeX cells  viableofion concentrat
 
used squares ofNumber 
 counted cells  viableofnumber  Total
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2.7 Cell viability (MTT) assay  
 
 In order to eliminate any non selective cytotoxic actions of the drug used, cell 
viability was determined after each treatment by monitoring the cellular 
metabolism of (3-[4, 5-dimethylthiazol-2-yl] 2, 5-diphenyl-tetrazolium bromide 
(MTT) to formazan. This is a widely used cytotoxicity assay in which the  
water soluble tetrazolium salt is converted into an insoluble purple compound, 
formazan, by cleavage of  the tetrazolium ring by mitochondrial 
dehydrogenases in viable cells (Mosmann, 1983). This assay is therefore 
largely a measure of mitochondrial activity. The MTT can be used to 
determine cytotoxicity of compounds. The water insoluble formazan dissolves 
in acidic isopropanol. The absorbance of formazan in the solution is 
proportional to the concentration of MTT metabolised and is believed to be a 
good indicator of cell viability. Toxic concentrations of a compound would lead 
to a reduction in the mitochondrial dehydrogenase ability to metabolise (MTT) 
to formazan. Toxic concentrations of a compound would therefore produce a 
reduced absorbance in the MTT assay.  In contrast to the MTT assay, the 
Trypan Blue exclusion assay used to determine the number of cells for 
experiments, is based on the ability of viable (live) cells to exclude Trypan 
Blue and appear translucent (with no blue staining) under the microscope. 
Dead (non-viable) cells, on the other hand, cannot exclude Trypan Blue and 
are therefore stained blue, as the result of Trypan blue uptake, and appear 
blue under the microscope.  
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H9c2 cells (2x103 cells/cm2) were seeded in p60 dishes or 6-well plates in full 
culture medium and allowed to grow to 60-70% confluence.  The full growth 
medium was removed and the cells were washed twice with warm (37oC) 
PBS. The differentiation medium (i.e. DMEM supplemented with 1% FBS and 
100units/ml penicillin/100µg/ml streptomycin) containing the appropriate 
concentration of the selected drug was added to the cells. The cells were 
incubated at 37oC, 95% air and 5% CO2 for defined time periods. Control cells 
were incubated in the differentiation medium without the selected drug.  
 
At the end of the incubation period, 200µl of MTT (Sigma, UK) stock (5mg/ml, 
made in PBS) was added to 2ml of culture medium in each p60 dish, giving a 
final concentration of 0.5mg/ml. The cells were incubated at 37°C, 95% air 
and 5% CO2 for one hour. At the end of the incubation period, the cells were 
removed from the incubator and the culture medium was removed. The  cells 
were incubated for 10 minutes with 1ml of acidic isopropanol (0.04M HCl in 
absolute isopropanol) to dissolve the formazan crystals.  The resulting 
formazan solution was thoroughly vortexed to dissolve precipitates and the 
absorbance was measured at 540 nm using a microplate reader (Labsystems 
Multiskan Ascent, UK).  
 
 The cell viability in the control cells (untreated cells)  was considered as 
100%. The drug concentration-dependent (or time-dependent) viability in the 
treated cells was calculated a  percentage of control viability. The cell viability 
at each drug concentration (or time point) was calculated as a percentage of 
control viability at that drug concentration (or time point). The viability values 
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were calculated using the formula shown below and reported as percentage 
of control cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
%100x
 CellsControl A
 Cells TreatedDrugAViabilityCell%
540
540
=
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2.8 Differentiation of H9c2 cells into cardiomyocytes  
 
2.8.1 Initiation of H9c2 Cell differentiation into cardiomyocytes  
 
H9c2 cells (2x103 cells/cm2) (passage number not more than 25) were seeded 
in p60 dishes or 6-well plates and allowed to become 60-70% confluent in full 
culture medium. The monolayers of cells were washed twice with warm (37oC) 
PBS and re-incubated in differentiation medium (DMEM supplemented with 
1% FBS, 100units/ml penicillin/100µg/ml streptomycin) to initiate 
differentiation (Kageyama et al., 2002; Pagano et al., 2004; Hunter et al., 
2007).  The total proteins in a parallel dish were extracted and used as the 
zero time point when analysing changes in expression of targeted cell 
differentiation markers. Other dishes were incubated in the differentiation 
medium for defined time periods. Changes in cell morphology were recorded 
for up to 12 or 14 days by taking photos every two days, using a standard 
microscope and a digital eyepiece. Cell lysates were generated in parallel at 
the end of each time point and stored at -20oC until analysed by western 
blotting, using specific monoclonal antibodies against cardiac myosin heavy 
chain (MHC), cardiac troponin I (cTnI) or cardiac ventricular myosin light chain 
(MLC-1v), as described below  (Section 2.14) 
 
 
 
 
123 
 
2.8.2 Effects of drugs (signalling pathway inhibitors) on the 
differentiation of H9c2 cells into cardiomyocytes  
 
To determine whether the activation of a particular signalling pathway is 
required during the differentiation of H9c2 cells into cardiomyocytes, a drug 
(i.e. selective and specific inhibitor of that signalling pathway) was used to 
block the pathway. The effects of the pathway inhibition were then observed 
or measured. For the determination  of the effects of drugs on the 
differentiation of H9c2 cells into cardiomyocytes, both the designated control 
cells and the cells to be treated with the selected drug (i.e. drug treated cells) 
were separately seeded in p60 dishes or 6-well plates at a density of 2x103 
cells/cm2. The cells were placed in the incubator at 37oC, 95 % air and 5% 
CO2 and allowed to become 60-70% confluent in full culture medium in the 
absence of the selected drug. The culture medium was removed and the 
monolayers of cells were washed twice with warm (37oC) PBS. The control 
cells were re-incubated in fresh full growth medium. The drug treated cells 
were re-incubated in the fresh full growth medium supplemented with the 
appropriate concentration of the selected drug. After one hour of incubation 
the culture medium was removed from  both the control and the treated cells. 
The monolayers of cells were washed twice with warm (37oC) PBS.  The 
control cells were re-incubated in fresh differentiation medium (i.e. DMEM 
supplemented with 1% FBS, 100 units/ml penicillin/100 µg/ml streptomycin) to 
initiate differentiation. The fresh differentiation medium added to the control 
H9c2 cells did not contain any drug. The drug treated cells were re-incubated 
in the fresh differentiation medium supplemented with the appropriate 
concentration of the selected drug.  The total proteins in a parallel dish were 
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extracted and used as the zero time point when analysing changes in 
expression of targeted cell differentiation markers. Other dishes were 
incubated in the differentiation medium in the presence or absence of 
selected drug as appropriate for defined time periods.  Changes in cell 
morphology were recorded for up to 12 or 14 days by taking photos every two 
days, using a standard microscope and a digital eyepiece. Cell lysates were 
generated in parallel at the end of each time point and stored at -20oC until 
analysed by western blotting, using specific monoclonal antibodies against 
cardiac myosin heavy chain (MHC)  or ventricular cardiac myosin light chain 
1(MLC-1v) as described below  (Section 2.14). 
 
2.9 Differentiation of P19 Stem cells into beating 
cardiomyocytes  
 
2.9.1 Initiation of P19 cell differentiation into cardiomyocytes 
 
To initiate differentiation, P19 stem cells (1x106 cells) (passage not more than 
30) were seeded in P100 Petri (i.e. microbiological) dishes in the 
differentiation medium (i.e. α-MEM supplemented with 10% FBS, 100 units/ml 
penicillin/100 µg/ml streptomycin and 0.8% DMSO). P19 cells grown in Petri 
dishes (i.e. non-adherent conditions) do not attach but instead form cell 
aggregates known as embryoid bodies (EB) which subsequently differentiate 
into  cardiomyocytes (McBurney et al., 1982; Habara-Ohkubo, 1996; Brewer 
et al., 2005). Embryoid bodies were allowed to form over a period of 4 days 
before transferring these into cell culture grade p60 dishes containing 4ml of 
full growth medium without DMSO. The day on which the embryoid bodies 
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were transferred to cell  culture grade  dishes was labelled or designated as 
day 0. According to this labelling system, day 2 and day 4, for example, refer 
to the sixth and eighth day respectively since the P19 stem cell differentiation 
experiment was started with the setup of embryoid bodies. The growth 
medium was changed every other day and the cell monolayers were 
monitored daily for up to 12 or 14 days for the appearance of beating 
cardiomyocytes. Photographs were taken and where beating cardiomyocytes 
were present, videos were also recorded. Cell lysates were generated in 
parallel for western blot analysis using specific monoclonal antibody against 
cardiac troponin I (TnI) as described below (Section 2.14).  
 
2.9.2 Effects of drugs (signalling pathway inhibitors) on P19 stem cell 
differentiation into cardiomyocytes 
 
To determine whether the activation of a particular signalling pathway is 
required during the differentiation of P19 stem cells into cardiomyocytes, a 
selective and specific inhibitor of that signalling pathway was used to block 
the pathway. The effects of the pathway inhibition were then observed or 
measured. For the determination of the effects of drugs on the differentiation 
of P19 stem cells into cardiomyocytes, both control and drug-treated P19 
stem cells (1x106 cells) were separately seeded in p100 Petri dishes. Control 
P19 stem cells were seeded in differentiation medium (i.e. α-MEM 
supplemented with 10% FBS, 100units/ml penicillin/100µg/ml streptomycin 
and 0.8% DMSO). The drug-treated cells were initially seeded in culture 
medium as above but in the absence DMSO. The cells were placed in the 
incubator at 37oC, 95% air and 5% CO2. After one hour of incubation, the cell 
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suspensions in the Petri dishes of the drug-treated cells were supplemented 
with 0.8% DMSO and the cells were returned to the incubator. The control 
cells were left as before. 
 
Four days after DMSO treatment, the EBs were transferred to cell culture 
grade p60 dishes or 6-well plates in full growth medium (i.e.  without DMSO). 
Hereafter, the growth medium was changed every other day. The cell 
monolayers were monitored daily for up to 12 or 14 days for the appearance 
of beating cardiomyocytes. Cell photographs  were taken and where beating 
cardiomyocytes were present, videos were also recorded. Cell lysates were 
generated in parallel for western blot analysis using appropriate selective 
antibodies as described below (Section 2.14). 
 
2.9.3 Effects of delayed inhibition of signalling pathways on P19 stem 
cell differentiation into beating cardiomyocytes 
 
The activation of a signalling pathway may be required only at a particular 
stage of a biological process. To determine the stage at which a particular 
signalling pathway is activated or required during the differentiation of P19 
stem cells into cardiomyocytes, a selective and specific inhibitor of that 
signalling pathway was separately added to one batch of cells during DMSO-
induced differentiation at the EB formation stage. The inhibitor was also 
separately added to another batch of cells four days after DMSO-initiated 
differentiation (i.e. inhibitor was only added after the formation of EB in 
DMSO). EB formation can be carried out over several days but a four day 
period is commonly used. We therefore decided to test the effects of the 
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addition of inhibitor after four days of DMSO-induced differentiation of P19 
stem cells. 
 
The control P19 cells were treated with differentiation medium (i.e. α-MEM 
supplemented with 10% FBS, 100units/ml penicillin/100µg/ml streptomycin 
and 0.8% DMSO) containing an appropriate concentration of the selected 
inhibitor on the day the EBs were set up in Petri dishes. Control cells were 
exposed to the inhibitor only during the EB formation stage (i.e. no inhibitor 
exposure after the EB formation stage). 
 
The delay-inhibition P19 cells were not initially treated with the inhibitor on the 
day the EBs were setup and were also not treated with the inhibitor 
throughout the EB formation stage, in Petri dishes. The delay-inhibition P19 
cells were initially treated with differentiation medium (as above) in the 
absence of the selected inhibitor on the day the EBs were set up in Petri 
dishes. The delay-inhibition P19 stem cells were only treated with the 
differentiation medium containing the inhibitor  from  the day the EBs were 
transferred from Petri dishes to cell culture dishes (i.e. only after the four-day 
EB formation stage). 
 
For differentiation experiments, both control P19 cells and delay-inhibition P19 
cells (1x106 cells) were separately seeded in p100 Petri dishes. Control P19 
cells were seeded in DMSO-free medium containing the appropriate 
concentration of the selected inhibitor. The delay-inhibition P19 cells were in 
seeded in differentiation medium (i.e. α-MEM supplemented with 10% FBS, 
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100units/ml penicillin/100µg/ml streptomycin and 0.8% DMSO) in the absence 
of the selected inhibitor. All the cells were placed in the incubator at 37oC, 95 
% air and 5% CO2. After one hour of incubation, the cell suspensions in the 
Petri dishes of the control P19 cells were supplemented with 0.8% DMSO (i.e. 
became differentiation medium plus drug) and the cells were returned to the 
incubator. The delay-inhibition P19 cells were left as initially set (i.e. 
differentiation medium only). 
 
Four days after DMSO treatment, the EB of the control P19 cells were 
transferred to cell culture grade p60 dishes or 6-well plates in full growth 
medium (i.e.  without DMSO). For the EB of the delay-inhibition P19 cells, 
after EB transfer to cell culture grade p60 dishes or 6-well plates, the 
differentiation medium was supplemented with the appropriate concentration 
of the selected inhibitor (i.e. became differentiation medium plus drug) for upto 
day 12. 
 
The monolayers of both groups of cells were monitored daily for up to 12 days 
for the appearance of beating cardiomyocytes. Cell photos were taken and 
where beating cardiomyocytes were present, videos were also recorded. Cell 
lysates were generated in parallel for western blot analysis using a specific 
monoclonal antibody against cardiac troponin I as described below (Section 
2.14). 
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2.10 Cross-talks between PI3K signalling pathway and other 
signalling pathways (PKC and p38 MAPK) 
 
2.10.1 Time course of Akt phosphorylation at serine 473 residue in H9c2 
cells differentiating into cardiomyocytes 
 
To examine possible crosstalk(s) between the PI3K signalling pathway and 
the other signalling pathways (PKC and p38 MAPK), cross talk studies were 
carried out.  For determination of the time course of Akt phosphorylation at 
serine 473 residue, H9c2 cells were seeded in p60 dishes at a density of 
2x103 cells/cm2 in full growth medium (i.e. DMEM supplemented with 10% 
FBS and 100units/ml penicillin/100µg/ml streptomycin). The cells were placed 
in the incubator at 37oC, 95 % air and 5% CO2 and allowed to become 60-
70% confluent. The culture medium was removed and the monolayers of cells 
were washed twice with warm (37oC) PBS. All the cells were incubated in 
fresh serum-free culture medium (i.e. DMEM supplemented with 100units/ml 
penicillin/100µg/ml streptomycin but no FBS) for 24 hours. After this period, 
the serum-free culture medium was removed and the monolayers of cells 
were washed twice with warm (37oC) PBS. Control cells were re-incubated in 
fresh serum-free medium and 1% FBS-treated H9c2 cells (i.e. cells treated 
with low serum or e differentiation medium) were re-incubated in fresh 
differentiation medium (i.e. DMEM supplemented with 1% FBS and 
100units/ml penicillin/100µg/ml streptomycin). All the cells were placed in the 
incubator at 37oC, 95 % air and 5% CO2 and left for 0, 5, 10, 20, 30 minutes, 
1, 2, 4, 6, 48 and 72 hours. Cell lysates were generated at the end of each 
time point and stored at -20oC until analysed by western blotting, using a 
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specific monoclonal antibody against phospho-Akt (Ser473) (Cell Signaling 
Technology via New England Biolabs, UK) as described below (Section 2.14). 
 
2.10.2 Effects of drugs (signalling pathway inhibitors) on Akt 
phosphorylation at serine 473 residue in H9c2 cells differentiating 
into cardiomyocytes 
 
To examine the effects of drugs (i.e. selective and specific inhibitors of 
signalling pathways) on Akt phosphorylation at serine 473 residue, H9c2 cells 
were seeded in p60 dishes at a density of 2x103 cells/cm2 in full growth 
medium (i.e. DMEM supplemented with 10% FBS and 100units/ml 
penicillin/100µg/ml streptomycin). The cells were placed in the incubator at 
37oC, 95 % air and 5% CO2 and allowed to become 60-70% confluent. The 
culture medium was removed and the monolayers of cells were washed twice 
with warm (37oC) PBS. The cells were incubated in fresh serum-free culture 
medium (i.e. DMEM supplemented with 100units/ml penicillin/100µg/ml 
streptomycin but no FBS) for 24 hours. After this period, the serum-free 
culture medium was removed from the dishes and the monolayers of cells 
were washed twice with warm (37oC) PBS and the following cell treatment 
were carried out. Three experimental groups were then designated according 
how each particular group of cells was treated. 
 
Control H9c2 cells: Control H9c2 cells (labelled as control) were treated with 
only serum-free medium throughout the Akt phosphorylation procedure 
(including the initial 24 hour treatment with serum-free medium). These cells 
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were not treated with any inhibitor or drug and were also not exposed to   1% 
FBS medium.  
 
1 % FBS-treated H9c2 cells: 1 % FBS-treated H9c2 cells (labelled as 1% 
FBS) were treated only with differentiation medium (i.e. DMEM supplemented 
with 1% FBS and 100units/ml penicillin/100µg/ml streptomycin) (i.e. after the 
initial 24 hour treatment with serum-free medium). These cells were also not 
treated with any inhibitor or drug.  
 
Inhibitor-treated H9c2 cells were labelled with the name of the inhibitor.  
After the initial 24 hour treatment with serum-free medium, the Inhibitor-
treated H9c2 cells were first treated in the appropriate concentration of the 
selected drug in fresh serum-free medium. After one hour incubation at  37oC, 
95 % air and 5% CO2, the serum-free medium, containing the drug, was 
removed and the differentiation medium (i.e. DMEM supplemented with only 
with 1% FBS and 100units/ml penicillin/100µg/ml streptomycin) containing a 
fresh preparation  the appropriate concentration of the selected drug was 
added to the cells.  
 
 After the appropriate treatment, cells were placed in the incubator at 37oC, 95 
% air and 5% CO2 and left for 15 minute incubation. After this period, cell 
lysates were generated and stored at -20oC until analysed by western blotting, 
using specific monoclonal antibodies against Akt phosphorylated at serine 
473 residue (phospho-Akt-Ser473) as described below (Section 2.14). 
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2.11 Total protein extraction for western blotting  
 
When required, lysates were generated from cells using a lysis buffer 
consisting of 20mM Tris-HCl, pH7.4, 1% SDS and 150mM NaCl.   Cells were 
washed twice with ice-cold PBS and up to 500µl of hot (heated to 95oC) lysis 
buffer was added to cells in wells or dishes.  The plates/dishes were 
immediately placed on ice and then 2.5µl of 200mM PMSF (i.e. 1mM PMSF 
final concentration) was added to cells in the dish. The cells were scraped off 
the dishes. The dishes with the scraped cells were left on ice for 15 minutes. 
During this time the cell lyates were regularly agitated by gentle trituration to 
obtain a homogenous lysate. The cell lysate or extract was transferred into a 
microcentrifuge tube and heated at 95oC for 5 minutes. The sample was then 
sonicated at 5-10 second interval for 1 minute. The homogenate or clear cell 
extract was transferred into a microcentrifuge tube and centrifuged at 1400 
RPM at 4oC for 30 minutes to pellet insoluble materials. The pellet was 
discarded. The supernatant was transferred to a new microcentrifuge tube. 
The total proteins in the lysates were determined (see Section 2.12).  The cell 
lysates or protein samples were prepared for loading onto gels as described 
below (section 2.13.1). Western blotting was usually carried out immediately 
or samples were stored at -20oC for later western blot analysis (Section 2.14). 
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2.12 Total protein determination in cell lysates using the BCA 
assay  
 
The Pierce bicinchoninic acid (BCA) protein assay (Perbio Science, UK Ltd) 
was used to determine the total protein concentration in the cell lysates. This 
is a detergent-compatible formulation for the colorimetric detection and 
quantitation of total proteins. This method is a combination of the  reduction of 
cupric ions [Cu (II)] to cuprous ions [Cu (I)] by proteins in an alkaline medium 
(i.e.  biuret reaction) and a selective and  sensitive colorimetric detection of 
the cuprous ions. The purple-colour reaction product of BCA assay is formed 
by the chelating of one Cu (I) ion by two molecules of BCA (Smith et al., 1985; 
Wiechelman et al., 1988).  The purple complex formed has a maximum 
absorbance at 562nm. The absorbance is directly proportional to protein 
concentration (Smith et al., 1985). 
 
The colour produced from this reaction is stable and increases in a 
proportional manner over a broad range of increasing protein concentrations 
(Smith et al., 1985).  This colour complex exhibits a strong absorbance at 562 
nm. The BCA method is not a true end-point method (i.e. colour development 
does not stop at the time of absorbance measurement). However, following 
incubation, the rate of continued colour development is sufficiently 
insignificant to allow large numbers of samples to be assayed together.  
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2.12.1 Preparation of bovine serum albumin (BSA) standards for the 
BCA assay 
 
The microplate version of the BCA assay was carried out on the cell lysates 
using bovine serum albumin (BSA) (Sigma, UK) standard concentrations (0.0 
to 0.5µg/µl). The microplate version of the BCA is linear between 0.02 to 
2µg/µl of BSA or proteins. The BSA standard concentrations were prepared 
as shown in Table 1 from a 1mg/ml stock solution of BSA. All dilutions were 
carried out in the same lysis buffer used to lyse cells. 
 
Table 1: Preparation of Diluted Albumin (BSA) Standards 
Volume (µl)  of 
1mg/ml solution 
Volume (µl)  of 
lysis buffer 
Final BSA 
concentration (µg/µl) 
0 1000 0 
25 975 0.025 
50 950 0.050 
100 900 0.100 
200 800 0.200 
300 700 0.300 
400 600 0.400 
500 500 0.500 
 
 
2.12.2 Procedure of the BCA assay 
 
Pierce BCA assay reagent A contains sodium carbonate, sodium bicarbonate, 
bicinchoninic acid and sodium tartrate in 0.1M sodium hydroxide. Reagent B 
contains 4 % (w/v) Copper (II) sulfate pentahydrate (CuSO4 • 5H2O).  A 1:50 
dilution of reagent B in reagent A  was prepared.  A 10 µl aliquot of either 
standards or cell lysate was added in triplicate to a 96-well plate. To each well 
containing standards or cell samples, 100µl of the BCA reagent was added. 
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The lid or cover was put on the plate. The plate was incubated for 45-60 
minutes at room temperature and  the absorbance measured at 620nm on a 
multiscan plate reader (Labsystems Multiskan Ascent, UK). The average 
absorbance  measured for the blanks (i.e. lysate buffer alone)  was subtracted 
from the absorbance measurements of all other  values. A protein standard 
curve was generated by plotting the average corrected absorbance (i.e. 
measured absorbance – blank absorbance) for each BSA standard against its 
concentration in µg/µl, using Microsoft Excel 2003 software. The equation for 
the best fit of  standard curve was used to determine the protein concentration 
of each unknown sample. Alternative to the standard curve generation, using 
Microsoft Excel, the linear regression routine in GraphPad Prism software 
(version 4) was used to work out the protein concentration in  lysates. In 
Microsoft Excel and GraphPad Prism software, only standard curves with r2 
value (a measure of linearity of BSA standard concentrations) of 97% or 
better were used. A dilution factor of 11 was applied to the calculations to 
determine the protein concentration in the cell lysates. A representative BCA 
protein standard curve is shown in Figure 2.11. 
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Figure 2.11: A Representative BCA Standard Curve. The protein standard 
curve was set up as described above. The average absorbance measurement 
of the blank was subtracted from the absorbance values of each standard 
used. The mean of triplicate readings was then taken and plotted against the 
BSA concentration used. This standard curve is representative of several 
BCA assays carried out during the course of the studies.  
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Using the equation generated from the standard curve (Figure 2.11), for a 
sample with an absorbance of 0.039 at 620nm; the corresponding protein 
concentration was calculated as follows: 
 
 
 
 
 
 
Applying a dilution factor of 11 (10µl of sample in 110µl total volume) gave: 
 
 
 
 
 
Volume of sample containing the selected amount of total protein was 
calculated and this was used to load gels for western blotting as required.   
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2.13 Western blot analysis 
 
The Western blotting  procedure carried out consisted  of the following steps: 
cell lysate preparation,  separation or resolution of the proteins in the lysate by 
gel electrophoresis, transfer of  the resolved proteins from the gel to a 
membrane, immunoblotting (i.e. incubation antibody of the transferred 
proteins on the membrane with antibodies), detection of the proteins bands 
that have been recognised or  bound by the antibodies  on x-ray films and 
analysis of  the bands captured on the films. 
 
2.13.1 Sample preparation for western blot analysis 
 
A volume of protein extract containing an appropriate amount (e.g. 40, 60 or 
80µg) of  total proteins was added to an equal volume of 2X concentrated 
sample buffer containing Tris-HCl, pH6.8  (120mM), SDS (4%), glycerol 
(10%), β-mercaptoethanol (2%) and bromophenol blue 0.006%). 
 
2.13.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS PAGE) 
 
A resolving and stacking gel were prepared on a Bio-Rad Mini-PROTEAN II 
casting stand (Bio-Rad, UK). For the casting of 5ml of an 8.0% resolving gel 
(enough for one mini blot), the following components were added in the order 
listed: double distilled water (2.34ml), 30% acrylamide/bisacrylamide 37.5:1 
(1.30ml), 1.5M Tris-HCl, pH8.8 (1.25ml), 10% sodium dodecyl sulphate (SDS) 
(0.050ml), 10% ammonium persulfate (APS)  (0.025ml) and N,N,N′,N′-
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tetramethylethylenediamine (TEMED) (0.005ml). For a 10% resolving gel, the 
water and acrylamide/bisacrylamide volumes were adjusted to 2.0ml and 
1.67ml respectively and everything else stayed the same. Similarly for a  12% 
resolving gel, the water and acrylamide/bisacrylamide volumes were adjusted 
to 2.0ml and 1.67ml respectively and everything else stayed the same. 
 
After polymerisation of gels was complete, 5% stacking gel was prepared by 
adding the following components: water (2.84ml), 30% 
acrylamide/bisacrylamide 37.5:1 (0.83ml), 0.5M Tris-HCl pH6.8 (1.25ml), 10% 
SDS (0.050ml), 10% APS (0.025ml) and TEMED (0.005ml). The stacking gel 
was layered on top of the resolving gel and allowed to polymerise. 
 
The gel was transferred to a Bio-Rad Mini-PROTEAN II (Bio-Rad, UK) 
electrophoresis tank.  A 1x electrophoresis tank buffer was prepared from a  
10X stock consisting of:  30.28 g/L of Tris base (0.25M, pH 8.3), 144.0 g/L of 
glycine (1.92M), 100ml of 10% SDS (1%). Enough 1x diluted electrophoresis 
buffer to cover the top of the gel, was added to the gel tank. The prepared 
lysates along with a biotinylated protein ladder (Cell Signaling Technology via 
NEB, UK) were heated at 95°C for 5 minutes prior to loading onto the gel.  
The gel was run at a constant voltage of 100V for 40-60 minutes or until the 
bromophenol blue front   had migrated to the  bottom of the gel. 
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2.13.3 Transfer of proteins from gel to PVDF Membrane 
 
The semi-dry transfer with a single buffer system was used to transfer the 
protein proteins from the gel to a 0.45µm pore size polyvinylidene fluoride 
(PVDF) membrane (Amersham, UK). Following SDS-PAGE, a  10X transfer 
buffer (1litre) was prepared using the following:  58.2 g/L of Tris base (0.48M, 
pH 8.3), 29.3 g/L of glycine (0.39M), 3.75ml of 10% SDS (0.038%).  This was 
then stored at 40C and diluted 1:10 in double distilled water to give a 1x 
working solution containing 20% methanol.  The PVDF membrane was cut to 
the same size as the gel, soaked in methanol for 1 minute, rinsed in excess 
distilled water for 1 minute and then equilibrated in the transfer buffer for at 
least 5 minutes.   
 
Six filter papers, each cut to the same size as the gel, were soaked in the 
diluted transfer buffer. When available, two pieces of   extra thick blot papers 
(Bio-Rad, UK) (each used in place of three filter papers)  were used. Three of 
the six buffer-soaked filters were placed on the electroblotter (semi-dry 
transfer systems) (Bio-Rad, UK).  The PVDF membrane was then placed on 
top of the stacked soaked filter papers on the electroblotter.  A reference of 
the protein side on the PVDF membrane was made by cutting a small notch in 
one corner of the membrane. The gel was removed from the gel cast and 
placed on top of the PVDF membrane (Figure 2.12). The other three buffer-
soaked filter papers were positioned over the gel and air bubbles between the 
gel and the filter papers were removed by gently rolling a clean 25ml pipette 
over the top filter or blot paper.  A constant current of 0.8mA/cm2 was applied 
to the gel and the protein transfer was carried out for 2-3 hours. 
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Figure 2.12: Semi-dry transfer of protein from gel to PVDF. This 
schematic diagram illustrates the arrangement of components in the semi-dry 
transfer assembly. 
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2.13.4 Blocking of the membrane  
 
The membranes were blocked to prevent non-specific binding of antibodies to 
charged and other molecules on the membrane, thus preventing or reducing 
background noise. One litre of  10X Tris-buffered saline (TBS) solution 
containing 24.2g/L of Tris base (20mM; pH 7.5), 87.7g/L of NaCl (150mM) 
was prepared and normally stored at 4oC.  The 10x TBS was used to prepare 
a 100ml of blocking buffer as follows: 10ml of 10x TBS, 5g (5% w/v) dry 
virtually fat-free milk (Marvel Brand) and 100µl  (0.1% v/v) of Tween 20 
(Sigma, UK) in double distilled water. The membrane was incubated in the 
blocking buffer for 1 hour at room temperature or overnight at 4oC.  
 
2.13.5 Western blot antibody staining 
 
After blocking, the membrane was incubated, using gentle agitation on a 
shaker, with the primary antibody in a sealed plastic bag. The incubation was 
carried out at room temperature for one hour. The primary antibody used to 
probe the blots was mouse monoclonal antibody to cardiac myosin heavy 
chain (1:2500) or mouse monoclonal antibody to cardiac troponin I (1:2500) or 
mouse monoclonal antibody to cardiac ventricular myosin light 1 (MLC-1v) 
(1:2500) or mouse monoclonal antibody to troponin I (1:1000) in blocking 
buffer.  These primary antibodies were purchased from Abcam (Cambridge, 
UK). For the lysates generated  from cross-talk studies, the primary antibody 
used in the blocking buffer to probe the blot, was the mouse monoclonal 
antibody to phospho-Akt (Ser473) (i.e. Akt phosphorylated at serine 473) 
(1:1000) (Cell Signaling Technology via New England Biolabs (NEB), UK).  
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After incubation with the primary antibody, the blot was washed three times 
(each wash lasting for 5- 10 minutes on a shaker) in wash buffer  made up 
with 1x TBS containing 0.1% Tween 20. The incubation reactions and post 
incubation washes as described for the primary antibodies were repeated 
using goat anti-mouse IgG conjugated to horseradish peroxidase (1:5000) 
(Cell Signaling Technology via NEB, UK) as the secondary antibody. An anti-
biotin antibody (1:2000) (Cell Signaling Technology via NEB, UK) also 
conjugated to horseradish peroxidase was added in order to detect the protein 
ladder. Anti-β-actin antibody (1:10000) (Sigma, UK) conjugated to horseradish 
peroxidase was added in order to detect β-actin which was used as a loading 
control.  
 
2.13.6 Detection of Protein Bands Using ECL Reagents 
 
Detection or visualization of targeted protein bands (i.e. bound antibodies) 
was carried out in a dark room  using enhanced chemiluminescence (ECL). 
The ECL reagent was prepared following the manufacturer’s instructions by 
mixing equal volumes of reagent 1 and 2 supplied in the ECL Western Blotting 
Detection kit (Amersham, UK). The solution was immediately added to the 
membrane and incubated for 1 minute at room temperature.  Excess 
detection reagent was drained from the membrane using a tissue paper. The 
blot was covered with cling film, ensuring there were no trapped air bubbles 
on the membrane. A sheet of autoradiography film, Hyperfilm ECL 
(Amersham, UK) was placed on top of the wrapped membrane in a  film 
cassette  and  exposed for 5 minutes. The membrane was then developed, 
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fixed, rinsed under running tap water and then dried in air at room 
temperature.  
 
2.13.7 Quantification of protein bands  
 
The developed protein bands on the film were scanned using Epson 
(Perfection 2480 Photo)  Scanner and the intensities of the protein bands on 
the scanned image were measured using densitometery software, Syngene 
Gene Tools (version 3.00). 
 
2.14 Data Analysis  
 
Data obtained from at least 3 independent experiments, (performed in single 
or duplicates, where possible), were used for statistical analysis. The one-way 
analysis of variance (ANOVA) test, followed by post-hoc Bonferroni's multiple 
comparison test or Dunnett's multiple comparison test, was carried out using 
GraphPad Prism version 4.  A difference between the treatments was 
considered significant when P< 0.05. Data presented are means ± SD from at 
least 3 independent experiments.  
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CHAPTER 3.0 
ESTABLISHMENT OF CARDIAC DIFFERENTIATION MODELS 
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3.1 INTRODUCTION 
 
In order to be able to conduct the studies described in this thesis, it was 
essential to develop an in vitro model of cardiomyocyte differentiation. This 
was achieved by exploiting the ability of H9c2 cells to differentiate into  
cardiomyocytes  when  cultured in growth medium containing a reduced 
concentration of serum (Hescheler et al., 1991) and also by  using  the mouse 
pluripotent  P19 embryonal carcinoma stem cell line which can be maintained 
and differentiated into cardiomyocytes  under standard  cell culture  conditions 
(e.g. 10% FBS and without the need for  LIF or feeder cells) (McBurney et al., 
1982; Wobus et al., 1991; Angello et al., 2006). 
 
3.1.1 H9c2 cell line model of cardiomyocyte differentiation  
 
The H9c2 cell line is a well established cardiomyocyte differentiation model.  
These cells were established from embryonic rat ventricles by Kimes and 
Brandt  (1976) and are now widely used by researchers as an in vitro model 
for generating cardiomyocytes (Kim et al., 1999; Menard et al., 1999; Hong et 
al., 2001; Kageyama et al., 2002; Giusti et al., 2004; Pagano et al., 2004).  
 
In addition to differentiation studies, H9c2 cells have been used as a simple 
and relevant model to study various mechanisms in cardiomyocytes including 
apoptosis (Ekhterae et al., 1999; Chae et al., 2001; Hong et al., 2001; 
Kageyama et al., 2002; Bonavita et al., 2003; Kim et al., 2005; Pesant et al., 
2006; Qin et al., 2006), glucose transport (Armoni et al., 2005), opioid-induced 
 147 
acute cardioprotection (Gross et al., 2006) and reactive oxygen species 
(ROS)-induced cardiotoxicity in cardiomyocytes (Salvatorelli et al., 2006). 
 
The differentiation of these cells into cardiomyocytes  is a highly ordered and 
regulated  multi-step process that is initiated in response to a number of 
environmental signals including exposure to low serum content  (Tamai et al., 
2000). The differentiation is initiated by mononucleated cell alignment, 
elongation and fusion leading to the formation of multinucleated myotubes. 
This process is accompanied by an increase in the expression of muscle 
specific proteins (Ludolph and  Konieczny, 1995). Manipulations such the 
effect of drugs (e.g. inhibitors of signalling pathways) can be easily monitored 
during the cardiac differentiation of these cells. The H9c2 cell line is therefore 
a good model for investigating the signalling events that control 
cardiomyocyte differentiation.  
 
3.1.2 P19 cell line model of cardiomyocyte differentiation  
 
The P19 embryonal carcinoma stem cell line (P19 stem cells) is pluripotent  
and has been used as an in vitro model of stem cell differentiation into  
cardiomyocytes (Wobus et al., 1991; Angello et al., 2006). The cardiomyocyte 
differentiation of P19 stem cells is  initiated  in the presence of DMSO 
(McBurney et al., 1982). The cardiac specific transcription factors, GATA-4 
and Nkx2-5, are expressed in during the differentiation of P19 cells into 
cardiomyocytes (Skerjanc et al., 1998). 
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Using these two cell types, we have developed systems which generate 
cardiomyocytes and thus provide models which we could exploit to investigate 
the mechanisms that regulate the differentiation of stem cells into 
cardiomyocytes 
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3.2 MATERIALS AND METHODS 
 
3.2.1 Culture and differentiation of H9c2 Cells  
 
The routine culture of H9c2 cells was carried out as described in section 2.3.1 
(Chapter 2). H9c2 cells were trypsinised and the appropriate cell density for 
the differentiation experiments was calculated as described in section 2.6 
(Chapter 2). H9c2 cells (2x103 cells/cm2) were seeded in p60 dishes or 6-well 
plates in full culture medium (i.e. DMEM supplemented with 10% FBS, 
100units/ml penicillin/100µg/ml streptomycin), placed in a  tissue culture 
incubator at 37oC, 95% air and  5% CO2 and allowed to become 60-70% 
confluent. The differentiation of H9c2 cells into cardiomyocytes was carried 
out in 1% serum as described in section 2.8.1 (Chapter 2).  
 
3.2.2 Culture and differentiation of P19 stem cells  
 
The routine culture of P19 stem cells was carried out as described in section 
2.3.2 (Chapter 2).  To initiate differentiation, P19 stem cells (1x106 cells) were 
seeded in P100 Petri (i.e. microbiological) dishes in the differentiation medium 
(i.e. α-MEM supplemented with 10% FBS, 100 units/ml penicillin/100 µg/ml 
streptomycin and 0.8% DMSO) and the differentiation of P19 stem cells into 
beating cardiomyocytes  was carried out as described in section 2.9.1 
(Chapter 2).  
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3.2.3 Western blot analysis  
 
In order to perform the western blot analysis, the following procedures were 
carried out as described in Chapter 2 under the sections indicated in 
parenthesis: cell lysate generation (section 2.11), preparation of BSA 
standards (section 2.12.1) and BCA assay (section 2.12.2). The western 
blotting was carried out as described in section 2.13. 
 
3.2.4 Data analysis  
 
Data obtained from independent experiments were used for statistical 
analysis as described in section 2.14 (Chapter 2). 
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3.3 RESULTS 
 
3.3.1 Establishment and characterization of H9c2 Cell differentiation 
model 
 
Freshly cultured undifferentiated H9c2 cells in full growth medium containing 
10 % FBS initially were rounded but subsequently attached and grew as a 
monolayer.  These undifferentiated H9c2 cells grew as single cells with clearly 
defined boundaries and looked almost spindly-shaped in morphology (Figure 
3.10). This morphology is maintained throughout culture if the cells are not 
induced to undergo differentiation. The cells became highly confluent but 
failed to initiate cell alignment, elongation and fusion to form myotubes (Figure 
3.11). In agreement with the lack of morphological changes in H9c2 cultured in full 
growth medium cardiac myosin heavy chain (alpha or beta isoform) (α/β-MHC) was 
not expressed as determined by western blotting (Figure 3.12). 
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Figure 3.10: Morphology of H9c2 cells (undifferentiated) in routine culture. 
H9c2 cells cultured in full growth medium consisting of DMEM supplemented with 
10% FBS and 100 units/ml penicillin/ 100 µg/ml streptomycin grew as single 
elongated cells (white arrows). The photograph at day 4 was taken under 200X 
magnification and is representative of several microscope fields from several cultured 
flasks. 
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Figure 3.11: Morphology of undifferentiated H9c2 cells in full culture medium 
H9c2 cells cultured in full growth medium consisting of DMEM supplemented with 
10% FBS and 100 units/ml penicillin/100 µg/ml streptomycin grew as single 
elongated cells becoming very tightly packed and undefined after 10-14 days in 
culture. The photographs (200X) are representative microscope fields for the 
indicated days. 
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Figure 3.12: Expression of myosin heavy chain in undifferentiated H9c2 cells. 
In agreement with the lack of morphological changes in H9c2 cultured in  full growth 
medium (i.e. DMEM supplemented with 10% FBS and 100 units/ml penicillin/100 
µg/ml streptomycin), cardiac myosin heavy chain (MHC) was not expressed as 
determined by western blotting using a monoclonal antibody specific for the α and β 
isoforms of the protein. A blot of lysates from H9c2 cells cultured in full medium is 
shown and is representative of three independent experiments. 
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3.3.2 Differentiation of H9c2 cells into cardiomyocytes 
 
In contrast to the growth pattern of H9c2 cells observed in the full growth 
medium, when these cells were cultured in 1% serum, they initially grew as 
flat, elongated mononucleated myoblasts similar to the morphology seen in 
the 10% FBS culture medium. However after four days in low serum culture, 
neighbouring cells began to fuse with complete differentiation becoming 
evident at day 12 to day 14. The differentiated cells acquired a myotube-like 
morphology (Figure 3.13). Spontaneous contraction, a distinguishing feature 
of cardiomyocytes, was however not observed in these cells. 
 
The morphological changes seen in H9c2 cells undergoing differentiation into 
cardiomyocytes were accompanied by parallel increases in the expression of 
cardiac specific markers, including myosin heavy chain (MHC) (Figure 3.14)  
and ventricular myosin light chain (MLC-1v) (Figure 3.15). The expression of 
MHC was not detected in differentiated cells between days 0 to 2 in cells 
induced to differentiate. Myosin heavy chain expression was however evident 
at day 4 and continued to increase up to day 10, reaching a peak from day 12 
to day 14. By comparison, MLC-1v expression, although absent in lysates 
from cells at day 0, was quite evident from day 2, reaching a peak between 
day 10 to 12. 
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Figure 3.13: Morphology of differentiated H9c2 cells in culture. H9c2 cells 
cultured in differentiation medium consisting of DMEM supplemented with 1% FBS 
and 100 units/ml penicillin/100 µg/ml streptomycin grew initially grew as single 
elongated cells (white arrows on day 0 and day 2) which by day 4 began to fuse, 
forming myotubes that were more evident at days 12 to 14 (black arrows on day 4 to 
14). The photographs were taken under 200X magnification are representative 
microscope fields for the indicated days. 
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Figure 3.14: Changes in the expression of myosin heavy chain in differentiated 
H9c2 cells. H9c2 cells were cultured in differentiation medium consisting of DMEM 
supplemented with 1% FBS and 100 units/ml penicillin/100 µg/ml streptomycin. Cell 
lysates were prepared at the end of each time point specified on the graph and 
subjected to western blotting using a specific monoclonal anti-MHC antibody. A blot 
of lysates from cells cultured in is shown (Panel A). The bar graph is the 
densitometric data (mean ± SD) from three independent experiments (Panel B). 
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Figure 3.15: Changes in the expression of ventricular myosin light chain in 
differentiated H9c2 cells. H9c2 cells were cultured in differentiation medium 
consisting of DMEM supplemented with 1% foetal bovine serum (FBS) and 100 
units/ml penicillin/100 µg/ml streptomycin. Cell lysates were prepared at the end of 
each time point specified on the graph and subjected to western blotting using a 
specific monoclonal anti-MLC-1v antibody. A blot of lysates from cells cultured in is 
shown (Panel A). The bar graph is the densitometric data (mean ± SD) from three 
independent experiments (Panel B). 
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3.3.3 Establishment and characterization of P19 stem cell differentiation 
model 
 
P19 embryonal carcinoma stem cells cultured in normal cell culture grade 
dishes in complete culture medium did not form embryoid bodies and did not 
differentiate into cardiomyocytes. Instead, they grew as a single cell 
monolayer but in clusters (Figure 3.16).  In contrast, P19 cells cultured in 
microbiological Petri dishes in complete cell culture medium resulted in the 
cells aggregating and growing in suspension as embryoid bodies (EBs). This 
occurred within a few hours with the aggregates growing in size over time. 
The sizes and shapes of the formed EBs were however highly variable. The 
EBs increased in size over time (Figure 3.17).  
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Figure 3.16: Normal growth pattern of P19 embryonal carcinoma stem cells in 
culture. P19 cells were seeded into standard cell culture dishes and allowed to grow 
in complete culture medium (α-MEM supplemented with 10%. The cells grew as 
clusters (white arrows) in a monolayer FBS and 100 units/ml penicillin/100 µg/ml 
streptomycin) did not form embryoid bodies. The photograph was taken under 200X 
magnification and is representative of several microscope fields from more than three 
cultured flasks. 
 
 
 
 
 
 
 
 
 
Adherent P19 Stem Cells 
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Figure 3.17: Formation of embryoid bodies from P19 embryonal carcinoma 
stem cells in culture. P19 cells were seeded into Petri dishes and allowed to grow 
in complete culture medium (α-MEM supplemented with 10% FBS and 100 units/ml 
penicillin/100 µg/ml streptomycin) and 0.8% DMSO to form embryoid bodies (white 
arrows). The photograph of the developing embryoid body at 24 hour was taken 
under 200X magnification and it is representative of several microscope fields from 
three independent experiments. 
 
 
 
 
 
 
 
 
 
P19 stem cell Embryoid Bodies at Day 1 
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3.3.4 Differentiation of P19 stem cells into beating cardiomyocytes 
 
The transfer of EB from Petri dishes to standard tissue culture dishes resulted 
in cell adhesion. The cell growth pattern changed from the three dimensional 
EB to a two dimensional monolayer (Figure 3.18).  Twenty fours later, EB 
adhesion was followed by cell migration and proliferation. A rapid cell growth 
was observed in these early stages with monolayers becoming confluent by 
day 4. The first beating clusters of cardiomyocytes were routinely detected by 
day 6 or 7. When present, the size and number of beating clusters of 
cardiomyocytes usually increased up to day 14. There was a high degree of 
variability both in term of the clusters of beating cells and in the frequency at 
which they appeared to beat. Sometimes, isolated clusters of beating cells 
within monolayers (day 6 and day 14) were seen. At other times, uniform 
beating monolayers (day 8, day 10 and day 12) were seen. Some colonies 
demonstrated a much more rhythmic and rapid rate of contraction (day 8, day 
10 and day 12) while others showed an intermediate or much slower 
contraction rates or uncoordinated contractions (day 6, and day 14). The slow 
or uncoordinated contractions appeared to occur more in isolated clusters of 
cells within monolayers while the much more rhythmic and rapid rate of 
contraction was evident in uniform monolayers.   
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Figure 3.18: DMSO-induced differentiation of P19 stem cells into beating 
cardiomyocytes. P19 stem cell EBs were formed in differentiation medium 
consisting of α-MEM supplemented with 10% FBS, 100 units/ml penicillin/100 µg/ml 
streptomycin and 0.8% DMSO for four days and then transferred into standard cell 
culture dishes in DMSO-free medium. DMSO caused the differentiation of P19 stem 
cells into beating cardiomyocytes. The beating areas of cardiomyocytes are indicated 
by the dotted white circles. The beating focus of each beating area is shown by a 
black arrow. Photographs and movie clips of beating cells were taken under 200X 
magnification on the days indicated and  are representative of microscope fields (for 
their respective days) from at least three  independent differentiation experiments. 
NBC = no beating cardiomyocytes. 
D0:NBC D2:NBC
D4: NBC D6
D8 D10
D12 D14
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3.4 DISCUSSION 
 
This project is the first of its kind in the laboratory in which it was carried out. 
The host laboratory has strong background in the research field of cell 
signalling in cardiovascular biology but had carried out no research work on 
stem cell differentiation at the beginning of this project. This project is 
therefore a new direction in the research activity in our laboratory.  
 
As discussed in the background to this project, cardiomyocyte lineage 
specification during cardiogenesis is a complex event. Therefore in the design 
of a study to explore cardiomyocyte differentiation in vitro the choice of a 
model has to be given careful consideration. Thus the first challenge was to 
find a model to investigate the cell signalling events that mediates 
cardiomyocyte differentiation. It was decided to use a model that is not only 
relevant but also simple so that it can be easily manipulated to address key 
questions about signalling events during cardiomyocyte differentiation. The 
P19 stem cell and H9c2 cell models meet this condition. Therefore given that 
this is the  first stem cell project in our laboratory, the P19 stem and H9c2 cell 
lines were  attractive models  to seek key answers or cues to signalling 
pathway that mediate  cardiac differentiation.  
 
The H9c2 cell line was chosen due to its relevance in cardiac regeneration, 
simplicity of use as well as the fact that this cell line has been extensively 
used by other researchers as a cardiomyocyte differentiation model   and also 
for the investigation of  other molecular or biological process in 
cardiomyocytes  (Kim et al., 1999; Menard et al., 1999; Hong et al., 2001; 
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Kageyama et al., 2002; Giusti et al., 2004; Pagano et al., 2004). In addition to 
the differentiation studies, H9c2 cells have been used as a simple and 
relevant model to study various mechanisms in cardiac muscle cells including 
apoptosis (Ekhterae et al., 1999; Chae et al., 2001; Hong et al., 2001; 
Kageyama et al., 2002; Bonavita et al., 2003; Pesant et al., 2006; Qin et al., 
2006), glucose transport (Armoni et al., 2005), opioid-induced acute 
cardioprotection (Gross et al., 2006) and reactive oxygen species (ROS) 
cardiotoxicity  (Salvatorelli et al., 2006). Differentiated H9c2 cells preserve the 
receptor systems, signalling pathways and cardiac proteins (e.g. cardiac L-
type Ca2+ channels) found in primary cardiomyocytes (Hescheler et al., 1991; 
Sipido and  Marban, 1991). The H9c2 cell line is therefore an appropriate 
model for our studies aimed at investigating the signalling mechanisms that 
regulate differentiation into cardiomyocytes.   
 
Freshly cultured H9c2 cells in a suspension of complete growth medium 
looked rounded. Once attached, the undifferentiated cells grew as spindle-
shaped mononucleated cells and did not express cardiac specific markers. 
The cells maintained this morphology throughout their period in culture (14 
days).  On the other hand, differentiated cells looked elongated and often fuse 
to form multinucleated myotubes. The expression of both MHC and MLC-1v 
was also evident in the cells differentiated in culture medium containing low 
serum (1% FBS).  
 
The mechanism by which low serum induces the differentiation of H9c2 cells 
into cardiomyocytes is not clear; however there are possible and/or plausible 
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explanations. A critical event in the activation of the canonical Wnt/β-catenin 
pathway is level of cytosolic β-catenin. The phosphorylation of β-catenin by 
Glycogen synthase kinase 3β (GSK-3β) mediates the ubiquitination of β-
catenin resulting in the subsequent degradation of β-catenin by proteosomes 
(Giles et al., 2003; Logan and  Nusse, 2004). While phosphorylated β-catenin 
is targeted for degradation, the non-phosphorylated form of β-catenin is 
degradation-resistant. A decreased in phosphorylation of β-catenin causes an 
increase in the levels of β-catenin in the cytoplasm and this leads to its 
subsequent translocation into the nucleus. In the nucleus,  β-catenin, in a 
complex with LEF/TCF, activates the transcription of Wnt target genes  
(Yamaguchi et al., 1999; Ai et al., 2000).  
 
Lithium (a GSK-3β inhibitor) treatment mimics the activation of the canonical 
Wnt/β-catenin signalling  pathway by inducing the stabilization and nuclear 
translocation  of β-catenin via  inhibition of β-catenin phosphorylation  by 
GSK-3β  (Klein and  Melton, 1996; Hedgepeth et al., 1997; Rao et al., 2005).  
Our data showed that H9c2 cells in 10% serum do not differentiate into 
cardiomyocytes but do so in low serum medium.  It has also been shown that 
the treatment of H9c2 cells with lithium can cause  H9c2 cell to differentiate  
into cardiomyocytes (Kashour et al., 2003). This suggests that lithium 
treatment mimics low serum condition and also that low serum, like lithium, 
may activate some elements of  the canonical Wnt/β-catenin signalling  
pathway which may play roles  in the initiation of H9c2 cell differentiation  into 
cardiomyocytes.  Whether low serum, like lithium, can induce the activation of 
the canonical Wnt/β-catenin signaling pathway warrants further investigation.  
 167 
H9c2 cells generally grow very slowly. The splitting ratio or cell density is 
therefore a critical consideration and once determined for optimal growth, the 
ratio should be adhered to in order to avoid inconsistent growth rates which, 
from our observations, can influence differentiation. Another factor worth 
mentioning is the fact that when brought from long term storage (in liquid 
nitrogen) the cells should first be cultured at high density in a smaller culture 
flask than that in which   they were originally frozen from.  This was found to 
be critical in helping the cells to regain their growth potential after a long stay 
in the liquid nitrogen.   Where this is not carried out, the cells will either not 
recover from the freezing or  may show sluggish growth and may never fully 
recover in future passages.  Routine splitting ratios of 1:3-1:5 of 60-70% 
confluent H9c2 were found to be appropriate for maintaining the cells in a 
viable healthy state.   
 
While H9c2 cells are easy to manipulate and differentiate into cardiomyocytes 
under standard laboratory conditions, the myoblast population in the cell line 
can easily be lost if proper care is not taken during routine cell culture. 
Therefore when H9c2 cells are used for cardiac differentiation experiments, 
the prevention of the depletion of the myoblast population is essential. 
Prolonged or continual culture of H9c2 cells without subculturing, during 
routine cell culture, will lead to a rapid depletion of the myoblast population in 
the cell line. This was avoided in our studies by making sure that at all times 
while in culture  the cells were not allowed to become more than 60-70 % 
confluent. If  the cells became fully confluent for any reason they were 
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discarded and a new batch was resuscitated from the liquid nitrogen cell 
stock.  
 
The H9c2 cardiac differentiation model, like most models, is not a perfect 
substitute for the in vivo processes. Despite the many attractive features of 
working with these cells, one of the serious limitations of the H9c2 model for 
cardiac differentiation is that the cell line was derived from an embryonic 
heart. This means the cardiac lineage commitment may have already taken 
place. However cardiac specific genes such as those which code for cardiac 
specific myosin light chain and ventricular myosin light chain-1 are not 
constitutively expressed in undifferentiated H9c2 cells but are strongly 
expressed when  the cells are induced to differentiate into cardiomyocytes.  
This makes these cells relevant for exploring the signalling transduction 
events that drives their differentiation into cardiomyocytes.  
The use of P19 stem cell line as a model for stem cell differentiation into 
cardiomyocytes was also developed in parallel with the H9c2 cell model. The 
P19 stem cell line, like H9c2 cells, is relatively simple and can be easily   
manipulated in experiments. With proper care for the cells during routine cell 
culture and also during differentiation experiments, P19 stem cell 
differentiation into cardiomyocytes can be highly regulated and reproducible. 
An essential element in ensuring differentiation of ES cells is the formation of 
three-dimensional (3D) aggregates known as embryoid bodies (EB). P19 cells 
when cultured in the suspension form EB.  The EB consists of ectodermal, 
mesodermal and endodermal cell types  and the 3D environment in the EB 
helps in the recapitulation of the early stages of embryonic development thus 
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initiating the cell differentiation into cell types of all the three germ layers 
including cardiomyocytes (Wobus et al., 1991; Maltsev et al., 1993; Denning et 
al., 2006), endothelial cells (Zhang et al., 2005), neuronal cells (Bain et al., 1995), 
adipocytes (Dani et al., 1997) and blood  cell precursors  (Schmitt et al., 1991).  
In P19 stem cells, EB formation in the presence of DMSO induces the cells to 
specifically differentiate into cardiomyocytes. 
 
Between 6 to 8 days after EB transfer into cell culture grade dishes, beating 
cardiomyocytes were regularly observed in DMSO-induced P19 stem cells.  
While beating cardiomyocytes can be readily obtained, the population is 
highly heterogeneous. The beating rates from one cluster to another varied 
considerably even within the same culture dish. Where the main research 
focus is the unravelling of the signalling pathways that are mediating the 
differentiation of P19 stem cells into cardiomyocytes, this lack of homogenous 
P19 stem-derived beating cardiomyocytes may not be a major problem.  
 
P19 stem cells have several good features. The cells are pluripotent and can 
be maintained continuously in serum-supplemented growth medium without 
the need for LIF or mitotically inactive feeder cells to keep them in the 
undifferentiated state.  The fact that these cells can be maintained under 
standard cell culture conditions means that key experiments can be 
performed at relatively very low cost in comparison to the same experiments  
being performed using other ES cells that may need special conditions such 
as knockout serum,  LIF or  feeder cells.  Another strong point for the use of 
P19 stem cells is that the cell line is a well-established model of 
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cardiomyocyte differentiation (Wobus et al., 1994; Zhang et al 2005; Angello 
et al., 2006). Moreover P19 cells can be induced to differentiate into 
cardiomyocytes fairly readily following exposure to  DMSO (McBurney et al., 
1982; Monzen et al., 1999; Naito et al., 2003; Brown et al., 2004; Brewer et 
al., 2005).  
 
In culture medium containing DMSO, P19 cells differentiating into 
cardiomyocytes recapitulate the principal biological features or stages of 
embryonic cardiogenesis. The expression of cardiac transcription factors 
including Nkx-2.5  (Skerjanc et al., 1998; Monzen et al., 1999; Wen et al., 
2007) GATA-4 (Monzen et al., 1999; Uchida et al., 2007; Wen et al., 2007) 
and MEF2C  (Skerjanc et al., 1998; Wen et al., 2007) have been well 
documented in  P19 stem cells differentiating into cardiomyocytes. Cardiac 
specific proteins, including MHC (Habara-Ohkubo, 1996) and MLC (Habara-
Ohkubo, 1996; Moore et al., 2004), are expressed by cardiomyocytes derived 
from P19 stem cells. This means that P19 stem cells differentiating into 
cardiomyocytes follow the same mechanisms as normal embryonic stem 
cells.  
 
It is not entirely clear how DMSO induces P19 stem cells to differentiate along 
the cardiac lineage.  DMSO actions are not specific for P19 stem cells and 
neither are its actions limited to induction of cell differentiation. Beside the 
induction of cell  differentiation, many other biological effects including 
membrane transport, vasodilation, muscle relaxation and antagonism of  
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platelet aggregation,  have been attributed to DMSO (Jacob and  Herschler, 
1986).  
 
Some available evidence suggests a possible role of DMSO in the Wnt/β-
catenin signalling pathway for the commitment of P19 stem cell to differentiate 
into cardiomyocytes. Evidence for a regulatory role of DMSO on canonical 
Wnt/β-catenin signalling was shown by the ability of DMSO to induce a 
decrease in levels of phosphorylated β-catenin and the elevation of the non-
phosphorylated form of β-catenin in the cytoplasm  (Nakamura et al., 2003). It 
was also shown that the levels of Wnt3a and Wnt8a were up-regulated by 
DMSO before the expression of cardiac specific  transcription factors such as 
Nkx2.5, GATA-4 and Tbx5 (Nakamura et al., 2003). Wnt3a and Wnt8a are 
believed to  signal exclusively via the canonical Wnt/β-catenin pathway (Tada 
and  Smith, 2000; Pandur et al., 2002; Maurus et al., 2005). The DMSO 
induced elevation of cytoplasmic  β-catenin levels was suppressed  by 
Frizzled-8/Fc (Fz-8/Fc) (Nakamura et al., 2003),  a protein that belongs to the 
secreted frizzled-related proteins. Secreted frizzled-related proteins are in vivo  
Wnt  antagonists  (Rattner et al., 1997; Bafico et al., 1999; Pera and  De 
Robertis, 2000; Shibata et al., 2000; Marvin et al., 2001). The treatment of 
P19 stem cells with Fz-8/Fc also inhibited the  DMSO-induced expression of 
cardiac transcription factors, cardiogenic growth factors (i.e BMP2, BMP4 and 
FGF8)   and cardiac α-MHC  (Nakamura et al., 2003). This is  a strong 
evidence that  DMSO activates or  modulates  the  the Wnt/β-catenin 
signalling pathway.  
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Glycogen synthase kinase 3β, as mentioned above, is responsible for keeping 
the canonical Wnt/β-catenin pathway in the “off” or inactive state through the 
phosphorylation of β-catenin canonical wnt/β-catenin signalling. Constitutively 
active GSK-3β  blocks DMSO-induced  differentiation of P19 stem cells  while 
lithium and Wnt3A-conditioned medium up-regulated early cardiac markers 
and the proportion of differentiated P19 stem cells in the presence of DMSO 
(Nakamura et al., 2003). The inhibition of DMSO-induced cardiac 
differentiation of P19 stem cells by constitutively active GSK-3β also suggests 
that DMSO may act through the Wnt/β-catenin signaling pathway. All the 
above data when taken together form a strong evidence to suggest that 
Wnt/β-catenin signalling is activated during the initiation of cardiac 
differentiation of P19 stem cell and that DMSO mode of actions may be the 
activation or modulation of the canonical wnt/β-catenin signalling pathway.  
 
DMSO is not an endogenous signalling molecule but a clear understanding of 
The mode of action of DMSO  in the induction of P19 stem cell differentiation 
into cardiomyocytes may increase our understanding of stem cell 
differentiation into cardiomyocytes. For example the suppression of DMSO-
induced cardiac specific  transcription factors (such as Nkx2.5 and  GATA-4) 
in P19 cells  by Wnt antagonists and GSK-3β  inhibitors (Nakamura et al., 
2003) is also seen in other  stem cell cardiac  differentiation  models (e.g. 
AB2.2 ES cells) where DMSO is not the cardiac inducing agent (Liu et al., 
2007). Thus a clearer understanding of DMSO roles in P19 stem cell 
differentiation into cardiomyocytes may lead to improved protocols for the 
differentiation of stem cells into cardiomyocytes. 
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There are several potential cardiac markers for monitoring the differentiation 
of stem cells into cardiomyocytes. These include Nkx2.5, GATA-4 (Kehat et 
al., 2001; Nakamura et al., 2003; Anderson et al., 2007), myocyte enhancer 
factor (MEF2C) (Denning et al., 2006; Anderson et al., 2007), tropomyosin 
(Moore et al., 2004), α-actinin (Denning et al., 2006), cardiac troponin I (cTnI) 
(Kehat et al., 2001), cardiac troponin T (cTnT) (Kehat et al., 2001), atrial 
natriuretic peptide (ANP) (Denning et al., 2006), cardiac myosin light chain 
isoforms (MLC-2v and  MLC-2a) (Kehat et al., 2001; Moore et al., 2004), 
MLC-1v & MLC-1a and cardiac myosin heavy chain isoforms (α-MHC  and β-
MHC) (Kehat et al., 2001; Denning et al., 2006; Anderson et al., 2007).  For 
this project we monitored cardiac differentiation by the expression of cardiac 
α-MHC/β-MHC, MLC-1v (in H9c2 cells)  and cTnI (in P19stem cells).  
Ventricular myosin light chain 1 (MLC-1v) along with MLC-2v is  present in 
both ventricles of the heart (Chuva de Sousa Lopes et al., 2006).  
 
3.5 Summary 
 
Freshly cultured undifferentiated H9c2 cells in full growth medium containing 
10 % FBS attached and grew as a monolayer with spindly-shaped 
morphology. In agreement with the lack of morphological changes, undifferentiated 
cells did not expressed cardiac myosin heavy chain  as determined by western 
blotting. In contrast to their growth pattern in full medium, when H9c2 cells 
were cultured in 1% serum, the cells became aligned, elongated, fused  and 
formed myotubes. The morphological changes seen in H9c2 cells undergoing 
differentiation into cardiomyocytes were accompanied by parallel increases in 
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the expression of cardiac specific markers, including cardiac myosin heavy 
chain (MHC) and cardiac ventricular myosin light chain (MLC-1v).  
 
P19 embryonal carcinoma stem cells cultured in normal cell culture grade 
dishes in complete culture medium (with or without 0.8% DMSO) did not form 
embryoid bodies (EB) but grew as clusters, in a single cell monolayer, which 
did not differentiate into cardiomyocytes. In contrast, P19 cells cultured in 
microbiological Petri dishes in complete culture medium, supplemented with 
0.8% DMSO, formed EBs. The transfer of EB from Petri dishes to standard 
tissue culture dishes resulted in cell adhesion, the formation of a two-
dimensional monolayer, cell migration and proliferation. The first beating 
clusters of cardiomyocytes were routinely detected by day 6 or 7. The size 
and number of beating clusters of cardiomyocytes usually increased up to day 
14. There was a high degree of variability both in term of the clusters of 
beating cells and in the frequency at which they appeared to beat. 
 
In conclusion, models of cardiomyocyte differentiation using P19 cells and 
H9c2 cells were successfully established in this project. These models were 
subsequently used in further studies exploring the mechanisms that may 
regulate stem cell differentiation into cardiomyocytes. Both P19 stem cells and 
H9c2 cells are relevant models for cardiomyocyte differentiation studies. 
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CHAPTER 4.0 
ROLE OF NITRIC OXIDE IN CARDIOMYOCYTE 
DIFFERENTIATION 
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4.1 INTRODUCTION 
 
4.1.1 Physiological functions of nitric oxide 
 
Nitric oxide (NO) is a gas that plays many important roles as signalling 
molecule in the cardiovascular system. A key feature of this molecule is its 
high but time limited reactivity. The roles of nitric oxide in the cardiovascular 
system include the maintenance  of vascular integrity through the inhibition of 
platelet aggregation (Freedman et al., 1999), leukocyte–endothelium 
adhesion (Kubes et al., 1991; Lefer et al., 1999) and the  regulation of cardiac 
smooth muscle contraction (Skarsgard et al., 2000) to cause vasodilatation.  
NO relaxes the smooth muscles to cause vasodilation. Nitric oxide also 
functions as neurotransmitter in the nervous system. 
 
4.1.2 Biosynthesis of nitric oxide 
 
The generation of nitric oxide is controlled by nitric oxide synthases (NOS) of 
which three isoforms exist: cytokine-inducible NOS (iNOS), endothelial NOS 
(eNOS) and neuronal NOS (nNOS). These enzymes display tissue-specific 
expression and their activation is also related to the cell status and specific 
stages during development.  Neuronal NOS is predominantly expressed in 
certain neurons and in skeletal muscle, eNOS is predominantly expressed in 
endothelial cells and iNOS is expressed by macrophages and monocytes. 
Monocytes are phagocytes circulating in the blood. When a monocyte leaves 
the blood and enters into tissues, it undergoes a series of cellular changes to 
become a macrophage. 
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4.1.3 Molecular or physiological targets of nitric oxide 
 
Nitric oxide mediates its second messenger or signalling roles through soluble 
guanylate cyclase (sGC), its  main physiological target (Gold et al., 1990; 
Trigo-Rocha et al., 1993; Phung et al., 1999). Nitric oxide activates guanylate 
cyclase by binding to the heme group. The activation of sGC by NO results in 
increased levels of cGMP.  Nitric oxide, through cGMP, regulates various 
downstream protein kinases (e.g. cGMP-dependent kinase) (Archer et al., 
1994; Pineda et al., 1996), ion channels (i.e.  cGMP-dependent ion channels) 
(D'Ascenzo et al., 2002) and cGMP-dependent phosphodiesterases  (Wexler 
et al., 1998; Zima et al., 2000). In the vasculature NO relaxation of vascular 
smooth muscle is also mediated through cGMP. The role of nitric oxide as a 
neurotransmitter in the nervous system is also mediated by increase in cGMP 
level.  
 
In contrast to the beneficial cGMP-dependent signalling roles of NO, cGMP-
independent actions may be toxic to the cells and tissues.  For example, NO 
reactions with superoxide anion to form peroxynitrite anion(Brealey et al., 
2002), the inhibition of  mitochondrial complexes I and IV (Takehara et al., 
1995; Okada et al., 1996; Brealey et al., 2002) and the activation of poly-ADP 
ribose polymerase (PARP) (Endres et al., 1998) leading to depletion of NAD+  
(a key glycolytic substrate) and the eventual depletion of cellular energy 
stores are all general mechanisms that underlie some of the toxic effects  of 
NO. 
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4.1.4 Nitric oxide and stem cell differentiation 
 
Some available data suggest that NO may have positive roles during stem cell 
commitment to cardiac lineage. On the hand, there are other reports with data 
to suggest that NO may negatively regulate stem cell differentiation into 
cardiomyocytes. Therefore currently the exact role of NO during stem cell 
commitment to cardiac lineage is not clear. 
 
Reports that  NO may be involved in stem differentiation into cardiomyocytes 
have been published (Kanno et al., 2004). NO treatment  of ES D3 cells using 
NO donors and also iNOS transfected in the ES cell  were  found to increase 
the number and the size of beating foci in EB outgrowths (Kanno et al., 2004). 
It has also been demonstrated that incubation of EBs with the NOS inhibitor N 
(G)-methyl-L-arginine acetate (L-NMMA) markedly attenuates their 
differentiation into cardiomyocytes with the  inhibition being reversed by the 
application of the NO-donor spermine-NONOate (Bloch et al., 1999). Taken 
together, these findings indicate a positive role for NO in the differentiation of 
stem cells into cardiomyocytes. In addition to stem cells, NO may also 
regulate differentiation of numerous other cell types. For example, NO has 
been reported to promote the differentiation of mouse bone marrow clonal 
stromal cells (ST2 cells)  to osteoblast-like cells (Hikiji et al., 1997; Koyama et 
al., 2000), human neuroblastoma cells (Obregon et al., 1997; Ghigo et al., 
1998), human trophoblast (Lyall et al., 1998; Sanyal et al., 2000), as well as 
regulate differentiation of NG108-15  (Cote et al., 1998) and PC12 cells 
(Phung et al., 1999; Nakagawa et al., 2000) into neurones.  
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The role of NOS and NO in heart muscle during embryonic development has 
been extensively investigated. On day 7.5, no NOS isoform was detected in 
mouse and rat embryos (Bloch et al., 1999). However from E9.5 both rat and 
mouse embryos displayed prominent expression of iNOS and eNOS, which 
correlated with high expression of soluble guanylate cyclase (sGC) and also 
with elevated levels of cyclic guanosine monophosphate (cGMP) (Bloch et al., 
1999).  
 
It was found that after E14.5, the expression of both iNOS and eNOS was 
down-regulated and also shortly after birth, eNOS expression was detectable 
while that of iNOS  was barely detectable (Bloch et al., 1999). In ES D3 cells, 
the NOS expression pattern in seen in vivo was also seen in  these cells 
(Bloch et al., 1999). Similarly, the expression of eNOS and nNOS but not 
iNOS in undifferentiated ES cells was also reported in another study  
(Krumenacker et al., 2006). The expression of  all three NOS  isoforms were 
detected  at different phases after the initiation of  differentiation of ES cells 
into cardiomyocytes (Krumenacker et al., 2006). In these studies, nNOS 
expression decreased within one day while iNOS mRNA became detectable 
after several days, and eNOS increased after 7-10 days (Krumenacker et al., 
2006). The differential expression of the various NOS isoforms suggest that 
NO may be involved in early stages of cardiogenesis and also that there may 
be change in NO requirement as differentiation progresses.  
 
Similarly it was shown that oxytocin-induced differentiation of P19 stem cells 
into cardiomyocytes was inhibited by the NOS inhibitor N (G)-nitro-L- arginine 
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methyl ester (L-NAME). The NO donor SNAP was able to reverse L-NAME  
mediated inhibition of P19 cell differentiation into cardiomyocytes (Danalache 
et al., 2007). These studies clearly indicate a role for NO and the NOS 
enzymes in stem cell differentiation but what is evident is that this may be a 
complex process. This complexity is highlighted by the fact that suppression 
of NOS activity by L-NAME has also been shown to increase the number of 
stem and progenitor cells in the bone marrow of irradiated mice (Michurina et 
al., 2004), indicating  a negative regulatory role for NO in the generation of, at 
least, bone marrow derived stem and progenitor cells. The role of NO 
therefore clearly warrants further investigation, especially in determining the 
precise role of the different NOS isoforms in the differentiation process and 
indeed the levels and profile of NO release that may be required for promoting 
or regulating differentiation.  
 
The aim of these studies was therefore to confirm the role of NO in the 
generation of stem cell derived cardiomyocytes and to further investigate the 
potential mechanisms that may mediate the process. To achieve these aims 
NO donors with varying profiles of NO release were used in these 
investigations. The following nitric oxide donors were used:  
NOC-5 (3-[2-Hydroxy-1-(1-methylethyl)-2-nitrosohydrazino]-1-propanamine) is 
a stable NO donor that can spontaneously release two equivalents of nitric 
oxide in solution under physiological conditions without any cofactor. NOC-5 
is fast releasing NO donor with a half-life of 93 minutes. SIN-1 (i.e. 3-
Morpholinosydnonimine) is also a fast releasing NO donor with a half-life of 40 
minutes (Lomonosova et al., 1998).  It spontaneously decomposes to yield 
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nitric oxide and superoxide anion radicals. NOC-18 (i.e. 2, 2′-
(Hydroxynitrosohydrazino)bis-ethanamine) is a slow releasing NO donor half-
life with a half-life of 20 hours (Shami et al., 1998). SNAP (i.e. (±)-S-Nitroso-N-
acetylpenicillamine) is also a slow releasing NO donor with a half-life of 37 
hours (Ferrero et al., 1999). 
 
In further studies examining the role of NO in cardiac differentiation, 
guanosine 8-Bromo-,3′,5′-cyclic monophosphate (8-Bromo-cGMP) was also 
used to determine whether NO may act through the cGMP pathway as 
indicated indirectly in other studies. 8-Bromo-cGMP is a cell-permeable cGMP 
analog that referentially activates protein kinase G. It is more resistant than 
cGMP to cleavage by phosphodiesterases.  
 
The rationale for taking this approach is because NO generally acts by 
elevating cGMP levels within vascular cells in exerting its actions. Thus if NO 
was activating the guanylate cyclase pathway and enhancing cGMP levels in 
H9c2 cells then we would anticipate that treatment of cells with 8-Bromo-
cGMP would mimic the effects seen with the NO donors. These studies were 
carried out using the H9c2 cells initially and it was hoped that the studies will 
be extended to the P19 stem cell line. The latter was however not used 
because of the negative data obtained with the H9c2 cells and time 
constraints.  
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4.2 MATERIALS AND METHODS 
 
4.2.1 Culture and differentiation of H9c2 Cells  
 
The routine culture of H9c2 cells was carried out as described in section 2.3.1 
(Chapter 2). H9c2 cells were trypsinised and the appropriate cell density for 
the differentiation experiments was calculated as described in section 2.6 
(Chapter 2). H9c2 cells (2x103 cells/cm2) were seeded in p60 dishes or 6-well 
plates in full culture medium (i.e. DMEM supplemented with 10% FBS, 
100units/ml penicillin/100µg/ml streptomycin), placed in a  tissue culture 
incubator at 37oC, 95% air and  5% CO2 and allowed to become 60-70% 
confluent. The differentiation of H9c2 cells into cardiomyocytes was carried 
out in 1% serum as described in section 2.8.1 (Chapter 2). The effects of the 
nitric oxide donors (NOC-5, NOC-18, SIN-1 or SNAP, each at a concentration 
of 100µM) on the differentiation of H9c2 cells into cardiomyocytes were 
investigated as described in section 2.8.2 (Chapter 2). The role of 8-Bromo-
cGMP (100µM) on the differentiation of H9c2 cells into cardiomyocytes was 
also investigated as described in section 2.8.2 (Chapter 2). The 
concentrations of NOC-5, NOC-18, SIN-1, SNAP and 8-Bromo-cGMP, used in 
experiments, were prepared by diluting the stock concentrations. The 
preparation of stock concentration, for each of the above compounds, was 
carried out as explained (Appendix III). 
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4.2.2 Cell viability assay  
 
To examine the effects of various NO donors on H9c2 cell viability, the MTT 
assay was carried out as described in section 2.7 (Chapter 2). 
 
4.2.3 Western blot analysis  
 
In order to perform the western blot analysis, the following procedures were 
carried out as described in the Chapter 2 under the sections indicated in 
parenthesis: cell lysate generation (section 2.11), preparation of BSA 
standards (section 2.12.1) and BCA assay (section 2.12.2). The western 
blotting was carried out as described in section 2.13. 
 
4.2.4 Data analysis  
 
Data obtained from independent experiments were used for statistical 
analysis as described in section 2.14 (Chapter 2). 
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4.3 RESULTS 
 
4.3.1 Effects of the NO donor NOC-5 on H9c2 cell differentiation into 
cardiomyocytes   
 
Differentiation of H9c2 cells into cardiomyocytes, as determined by elongation 
and cell fusion, was significantly delayed in cells treated with NOC-5 when 
compared to controls. By day 4, differentiation was visible in control H9c2 
cells. In contrast, NOC-5 treated cells maintained their normal single cell and 
spindle shaped morphology. However, by day 8, both controls and NOC-5 
treated cells appear differentiated and this was clearly evident at day 12 
(Figure 4.10). Thus although NOC-5 did not inhibit the long term differentiation 
of H9c2 cells into cardiomyocytes, it appeared to delay the onset of the 
process.  
 
In parallel with the morphological changes, exposure to NOC-5 also caused a 
significant reduction in the expression of MLC-1v in treated cells.  This was 
more evident at day 4 where MLC-1v expression was less than 50% of the 
levels seen in the control cells (p < 0.01) (Figure 4.11). Although MLC-1v 
levels increased at day 8 (p > 0.05) and at day 12 (p >0.05), the levels 
detected were still only about 80% of those detected in control cells. 
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Figure 4.10: Effects of the NO donor NOC-5 on H9c2 cell differentiation 
into cardiomyocytes: morphological changes. Control H9c2 cells were 
cultured in differentiation medium consisting of DMEM supplemented with 1% 
FBS and 100 units/ml penicillin/100 µg/ml streptomycin. The differentiation 
medium of treated cells was further supplemented with 100µM of the nitric 
oxide donor, NOC-5. Cell alignment, elongation and myotube formation in 
H9c2 cells treated with 100µM of NOC-5 was slow in onset when compared to 
the control cells.  While the control cells showed visible differentiation by day 
4 (shown by black arrows), NOC-5 treated cells appeared to maintain their 
normal single cell and spindle shaped morphology. Morphologically, both 
control and NOC-5 treated H9c2 cells appeared to show marked 
differentiation by day 12 (shown by black arrows). Both control cells and 
NOC-5-treated cells showed the normal single cell morphology (shown by 
white arrows) at day 0. The photographs were taken under 200X 
magnification and are representative of at least three differentiation 
experiments. 
 
 
 
 
 
Day 0 Day 4 Day 8 Day 12
Co
n
tr
o
l
N
O
C-
5
50 µm 50 µm 50 µm 50 µm
 186 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11: Effects of the NO donor NOC-5 on H9c2 cell differentiation 
into cardiomyocytes: cardiac ventricular myosin light chain 1 
expression. Western blot analysis of MLC-1v revealed that expression of this 
protein was suppressed by NOC-5 in comparison to the control expression. 
The blot is representative of at least three differentiation experiments (panel 
A). The densitometric data (mean ± SD), from three independent experiments, 
show the time dependent changes in MLC-1v expression in NOC-5 treated 
H9c2 cells (panel B). 
 
 
 
 
 
 
 
A 
0 4 8 120 4 8 12
23 kDa
Control NOC-5
MLC-1v
Day 0 Day 4 Day 8 Day 12
0
25
50
75
100
p  < 0.01
p > 0.05p > 0.05
Ch
a
n
g 
in
 
M
LC
-
1v
 
Ex
pr
e
s
s
io
n
(%
 
Co
n
tro
l)
B
 
 187 
4.3.2 Effects of the NO donor SIN-1 on H9c2 cell differentiation into 
cardiomyocytes   
 
SIN-1, like NOC-5, inhibited the early phase (day 4) of H9c2 cell differentiation 
into cardiomyocytes but NOC-5 appeared to have more effect at this stage. 
Cell elongation and cell fusion was slow in the H9c2 cells that were treated 
with SIN-1 in comparison to the control cells. By day 4, the usual 
differentiation was visible in the control H9c2 cells but not in the SIN-1 treated 
H9c2 cells. SIN-1 treated cells maintained their normal single cell and spindle 
shaped morphology (Figure 4.12). H9c2 cells in both control medium and SIN-
1 supplemented medium showed differentiation at day 8 and day 12. 
Differentiation in both control and SIN-1 treated H9c2 cells was extensive by 
day 12. 
 
The expression of MLC-1v in SIN-1 treated H9c2 cells was reduced at day 4, 
8 and 12 in comparison to control cells (p > 0.05). MLC-1v levels in SIN-1 
treated were just a little above 50% the control levels by day 4 (p > 0.05)  
(Figure 4.13).  By day 8 MLC-1v levels in treated cells had recovered to more 
than 75% of control levels (p > 0.05). But by day 12, MLC-1v levels had only 
recovered to a little over 90% of MLC-1v levels in the control cells. MLC-1v in 
levels SIN-1 treated H9c2 cells never reached the levels seen in the control 
cells (p > 0.05). MLC-1v levels in both control and SIN-1 treated H9c2 cells 
were in agreement with the differentiation or morphological changes observed 
in these cells (Figure 4.13). 
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Figure 4.12: Effects of the NO donor SIN-1 on H9c2 cell Differentiation 
into Cardiomyocytes: Morphological changes. Control H9c2 cells were 
cultured in differentiation medium consisting of DMEM supplemented with 1% 
1% FBS and 100 units/ml penicillin/100 µg/ml streptomycin. The differentiation 
medium of treated cells was further supplemented with 100µM of the NO 
donor, SIN-1. Cell alignment, elongation and myotube formation in H9c2 cells 
treated with 100µM of the SIN-1 was slow in onset when compared to the 
control cells. Control cells showed visible differentiation by day 4, but NOC-5 
treated cells appeared to maintain their normal single cell and spindle shaped 
morphology (shown by black arrows). Morphologically, both control and SIN-1 
treated H9c2 cells appeared to show marked differentiation by day 12. Both 
control cells and SIN-1-treated cells showed the normal single cell 
morphology (shown by white arrows) at day 0. The photographs were taken 
under 200X magnification and are representative of at least three 
differentiation experiments. 
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Figure 4.13: Effects of the NO donor SIN-1 on H9c2 cell Differentiation 
into Cardiomyocytes: cardiac ventricular myosin light chain 1 
expression. Western blot analysis of MLC-1v revealed that expression of this 
protein was slightly suppressed by SIN-1 in comparison to the control 
expression. The blot is representative of at least three independent 
differentiation experiments (panel A). The densitometric data (mean ± SD), 
from three independent experiments, show the time dependent changes in 
MLC-1v expression in SIN-1 treated H9c2 cells (panel B). 
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4.3.3 Effects of the NO donor NOC-18 on H9c2 cell differentiation into 
cardiomyocytes 
 
Treatment of H9c2 cells with NOC-18 delayed their differentiation into 
cardiomyocytes as determined by the lack of differentiation associated 
morphological changes. By day 4, the usual differentiation was visible in the 
control H9c2 cells but not in the NOC-18 treated H9c2 cells. Like the SIN-1 
treated cells, cell elongation and fusion was slow in the H9c2 cells that were 
treated with NOC-18 in comparison to the control cells. NOC-18 treated cells 
maintained their normal single cell and spindle shaped morphology (Figure 
4.14). Both control and NOC-18 treated cells showed increased differentiation 
from day 8 to day 12. Differentiation or morphological changes in both control 
and NOC-18 treated H9c2 cells were extensive by day 12. 
 
By day 4, MLC-1v levels in NOC-18 treated H9c2 cells were lower than the 
levels determined in the control cells (p > 0.05).  The delay in MLC-1v 
expression, although not statistically significant, was in agreement with the 
lack morphological changes seen in these cells. By day 8, MLC-1v levels in 
NOC-18 cells had recovered to more than 95% of control levels  p > 
0.05)(Figure 4.15).  By day 12, MLC-1v   levels in NOC-18 treated slightly fell 
to about 80% of control levels p > 0.05).  The levels of MLC-1v determined in 
the NOC-18 treated H9c2 cells never reached the levels seen in the control 
cells. In both control cells and NOC-18 treated H9c2 cells the levels of MLC-
1v determined were in agreement with the differentiation or morphological 
changes observed in these cells. 
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Figure 4.14: Effects of the NO donor NOC-18 on H9c2 cell Differentiation 
into Cardiomyocytes: Morphological changes. Control H9c2 cells were 
cultured in differentiation medium consisting of DMEM supplemented with 1% 
1% FBS and 100 units/ml penicillin and 100 µg/ml streptomycin. The 
differentiation medium of treated cells was further supplemented with 100µM 
of the nitric oxide donor, NOC-18. Differentiation (i.e. cell alignment, 
elongation and myotube formation) in H9c2 cells treated with NOC-18 was 
slow in onset when compared to the control cells. By day 4, differentiation 
(shown by black arrows) was visible in the control cells but not in NOC-18 
treated cells which appear to maintain their normal single cell and spindle 
shaped morphology (shown by black arrows). Morphologically, both control 
and NOC-18 treated H9c2 cells appeared to show marked differentiation by 
day 12. Both control cells and NOC-18-treated cells showed the normal single 
cell morphology (shown by white arrows) at day 0. The photographs were 
taken under 200X magnification and are representative of at least three 
differentiation experiments. 
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Figure 4.15: Effects of the NO donor NOC-18 on H9c2 cell Differentiation 
into Cardiomyocytes: cardiac ventricular myosin light chain expression. 
Western blot analysis of MLC-1v revealed that expression of this protein was 
slightly suppressed by NOC-18 in comparison to the control expression. The 
blot is representative of at least three differentiation experiments (panel A). 
The densitometric data (mean ± SD), from three independent experiments, 
show the time dependent changes in MLC-1v expression in NOC-18 treated 
H9c2 cells (panel B). 
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4.3.4 Effects of the NO donor SNAP on H9c2 cell differentiation into 
cardiomyocytes  
 
H9c2 cells treated with SNAP appeared to have differentiated to the same 
extent as the control cells. By day 4, the usual differentiation was visible in 
both control and SNAP treated H9c2 cells. The degree of cell elongation and 
fusion in both H9c2 and SNAP treated H9c2 cells were very similar.  
Morphological changes in both control and SNAP treated H9c2 cells 
increased from day 4 and by day 12, these changes were extensive as usual 
(Figure 4.16). 
 
In agreement with the morphological seen in the control cells and SNAP 
treated cells, MLC-1v levels in SNAP treated H9c2 cells were almost equal to 
those seen in the control cells. SNAP treatment slightly reduced the 
expression of MLC-1v (p > 0.05) (Figure 4.17).  By day 8, SNAP treatment 
increased the expression of MLC-1v by more than 100% of control levels 
(Figure 4.17).  However the SNAP mediated increase in MLC-1v levels was 
not statistically significant (p > 0.05). By day 12, both control and SNAP 
treated cells had similar levels of MLC-1v (p > 0.05). MLC-1v levels in both 
control and SNAP-treated H9c2 cells were in agreement with the 
differentiation or morphological changes observed in these cells. 
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Figure 4.16: Effects of the NO donor SNAP on H9c2 cell Differentiation 
into Cardiomyocytes: Morphological changes. Control H9c2 cells were 
cultured in differentiation medium consisting of DMEM supplemented with 1% 
1% FBS and 100 units/ml penicillin and 100 µg/ml streptomycin. The 
differentiation medium of treated cells was further supplemented with 100µM 
of the nitric oxide donor, SNAP. The differentiation (i.e. cell alignment, 
elongation and myotube formation) (shown by black arrows) of H9c2 cells 
treated with SNAP was almost as much as the control cells. The degrees of 
cell elongation and fusion in both H9c2 and SNAP treated H9c2 cells were 
very similar.  Morphological changes in both control and SNAP treated H9c2 
cells increased from day 4 and by day 12, these changes were extensive as 
usual. Both control cells and SNAP-treated cells showed the normal single 
cell morphology (shown by white arrows) at day 0. The photographs were 
taken under 200X magnification and are representative of at least three 
independent experiments. 
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Figure 4.17: Effects of the NO donor SNAP on H9c2 cell Differentiation 
into Cardiomyocytes: cardiac ventricular myosin light chain 1 
expression. MLC-1v levels in control and SNAP treated H9c2 cells were 
almost equal. SNAP treatment did not inhibit the expression of MLC-1v in 
H9c2 cells differentiating into cardiomyocytes.  SNAP treatment increased 
MLC-1v levels in comparison to the control cells. The blot is representative of 
at least three independent experiments (panel A). The densitometric data 
(mean ± SD), from three independent experiments, show the time dependent 
changes in MLC-1v expression in SNAP treated H9c2 cells (panel B). 
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4.3.5 Effects of 8-Bromo-cGMP on H9c2 cell differentiation into 
cardiomyocytes 
 
To further explore the actions of NO in regulating the differentiation of H9c2 
cell into cardiomyocytes, we examined whether 8-Bromo-cGMP, an analogue 
of the second messenger cGMP would mimic the effects seen with the NO 
donors. As shown in Figure 4.18, H9c2 cells treated with 8-Bromo-cGMP 
appeared to have differentiated almost as much as the control cells.  Similar 
to the NO donor treated cells, the degree of cell elongation and fusion in both 
controls and 8-Bromo-cGMP treated H9c2 cells appeared at day 8  and  at 
day 12. In parallel, the expression of MLC-1v in 8-Bromo-cGMP-treated H9c2 
cells was reduced at day 4 (p > 0.05) but indistinguishable from the levels 
detected in the control cells at day 8 (p > 0.05) and at day 12 (p > 0.05) 
(Figure 4.19). Thus, like the NO donors, 8-Bromo-cGMP regulated H9c2 cell 
differentiation into cardiomyocytes by delaying the induction of this process. 
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Figure 4.18: Effects of 8-Bromo-cGMP on H9c2 cell Differentiation into 
Cardiomyocytes: morphological changes. Control H9c2 cells were cultured 
in differentiation medium consisting of DMEM supplemented with 1% FBS and 
100 units/ml penicillin and 100 µg/ml streptomycin. The differentiation medium 
of treated cells was further supplemented with 100µM of 8-Bromo-cGMP. The 
differentiation (i.e. cell alignment, elongation and myotube formation) (shown 
by black arrows) of H9c2 cells treated with 8-Bromo-cGMP appeared to be 
almost as much as the control cells. The degrees of cell elongation and fusion 
in both H9c2 and 8-Bromo-cGMP treated H9c2 cells were very similar.  
Morphological changes in both control and 8-Bromo-cGMP treated H9c2 cells 
were extensive by day 12. Both control cells and SNAP-treated cells showed 
the normal single cell morphology (shown by white arrows) at day 0. The 
photographs were taken under 200X magnification and are representative of 
at least three independent experiments. 
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Figure 4.19: Effects of 8-Bromo-cGMP on H9c2 cell Differentiation into 
Cardiomyocytes: ventricular myosin light 1 (MLC-1v) expression. 
Western blot analysis of MLC-1v revealed that expression of this protein was 
initially delayed in 8-Bromo-cGMP treated H9c2 cells in comparison to the 
control expression (A). Thereafter MLC-1v levels increased to more than 
those seen in the control cells. The blot is representative of at least three 
independent experiments. The densitometric data (mean ± SD), from three 
independent experiments, show the time dependent changes in MLC-1v 
expression in 8-Bromo-cGMP treated H9c2 cells (B). 
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4.3.6 Viability of H9c2 cells in various concentration of NOC-5 
 
There was no difference between the viability of control H9c2 cells and cells 
treated with NOC-5 at concentrations ranging from 3µM to 30µM (p>0.05) 
(Figure 4.20). There was however a significant difference between the viability 
of control H9c2 cells and those cell treated NOC-5 concentrations above 
30µM (p<0.01). At these high concentrations, NOC-5 reduced cell viability to 
66% at 100µM and 9.5 % at 1000µM. As a result 100µM was selected for 
investigating the effects of NOC-5 on H9c2 cell differentiation into 
cardiomyocytes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20: Viability of H9c2 cells in the presence of various 
concentration of NOC-5. H9c2 cells were seeded in 6-well plates and 
treated with NOC-5 as described in the methods section above   (Section 
4.3.1). The MTT assay was carried out at the end of the treatment. The data 
were analysed by one-way analysis of variance (ANOVA) test. The control 
viability was compared to the viability at each concentration using post-hoc 
Dunnett's multiple comparison test. There was no significant difference in cell 
viability between the control and each NOC-5 concentrations from 3 to 30µM 
(p>0.05). There was a significant difference in cell viability between the control 
and each NOC-5 concentrations form 100 to 1000µM (p<0.01). The data 
presented in the graph are the mean ± SD from three independent 
experiments.  
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4.3.7 H9c2 Cell Viability in Various concentration of SIN-1 
 
As seen with NOC-5, SIN-1 had no significant effect on cell viability at 
concentrations of 3µM to 30 (Figure 4.21; p>0.05). There was a significant 
difference between the viability of control H9c2 cells and the viability of the 
H9c2 cells that were treated with each SIN-1 concentration above 30µM 
(p<0.01). At 100uM SIN-1 reduced viability to 71.7%  while the viability at with 
1000µM SIN-1 was 10% that of control cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.21: Viability of H9c2 cells in the presence of various 
concentration of SIN-1. H9c2 cells were seeded in 6-well plates and treated 
with SIN-1 as described in the methods section above (Section 4.3.1). The 
MTT assay was carried out at the end of the treatment. The data were 
analysed by one-way analysis of variance (ANOVA) test. The control viability 
was compared to the viability at each concentration using post-hoc Dunnett's 
multiple comparison test.  There was no significant difference in cell viability 
between the control and each SIN-1 concentrations from 3 to 30µM (p>0.05). 
There was a significant difference in cell viability between the control and 
each SIN-1 concentrations from 100 to 1000µM (p<0.01). The data presented 
in the graph are the mean ± SD from three independent   experiments.  
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4.3.8 H9c2 Cell Viability in Various concentration of NOC-18 
 
Consistent with the other NO donors, NOC-18 did not cause any distinct 
cytotoxicity when used at concentrations of up 30µM (Figure 4.22; p>0.05). 
Concentrations of 100µM and above however caused marked cytotoxicity of 
the same magnitude seen with the other compounds. At 100µM NOC-5 the 
cell  viability was reduced to  67.5% while the viability of H9c2 cells treated 
with 1000µM NOC-18  was only 9.8% of control cell viability. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.22: Viability of H9c2 cells in the presence of various 
concentration of NOC-18. H9c2 cells were seeded in 6-well plates and 
treated with NOC-18 as described in the methods section above (Section 
4.3.1). The MTT assay was carried out at the end of the treatment. The data 
were analysed by one-way analysis of variance (ANOVA) test. The control 
viability was compared to the viability at each concentration using post-hoc 
Dunnett's multiple comparison test. There was no significant difference in cell 
viability between the control and each NOC-18 concentrations from 3 to 30µM 
(p>0.05). There was a significant difference in cell viability between the control 
and each NOC-18 concentrations from 100 to 1000µM (p<0.01). The data 
presented in the graph are the mean ± SD from three independent 
experiments.  
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4.3.9 H9c2 Cell Viability in Various concentration of SNAP 
 
Of all the NO donors used, SNAP appears to be the least toxic and best 
tolerated since incubation of cells with this compound produced only marginal 
toxicity at concentrations of up to  200µM (Figure 4.23; p>0.05). SNAP at 
concentration at 300µM reduced viability to 63 % that of control H9c2 cells. 
SNAP concentration of 100µM, with cell viability of 92% was selected for 
investigating the effects of SNAP on H9c2 cell differentiation into 
cardiomyocytes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.23: Viability of H9c2 cells in the presence of various 
concentration of SNAP. H9c2 cells were seeded in 6-well plates and treated 
with SNAP as described in the methods section above (Section 4.3.1). The 
MTT assay was carried out at the end of the treatment. The data were 
analysed by one-way analysis of variance (ANOVA) test. The control viability 
was compared to the viability at each concentration using post-hoc Dunnett's 
multiple comparison test. There was no significant difference in cell viability 
between the control and each SNAP concentrations from 10 to 200µM 
(p>0.05). There was a significant difference in cell viability between the control 
H9c2 cells an H9c2 cell treated with 300µM SNAP (p<0.05). The data 
presented in the graph are the mean ± SD from three independent 
experiments.  
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4.4 DISCUSSION 
 
Nitric oxide has been suggested to play a role in stem cell differentiation into 
different lineages including cardiomyocytes. In this regard, NO has been 
reported to facilitate mouse embryonic stem cell differentiation into 
cardiomyocytes (Kanno et al., 2004). In NO donor (SNAP, PAPA/NO and 
DEA/NO)  treated ES D3 cells and also  in ES cells transfected with iNOS, the 
number of EBs with beating foci and the size of beating foci in the EB 
outgrowths was increased. In support of  the cardiac differentiation of these  
cells being mediated by NO, the number of EBs with beating foci  and also the 
size of the foci were decreased by L-NAME (Kanno et al., 2004). In similar 
study in ES D3 stem cells, it was shown that exposure of cells to arginine 
vasopressin (AVP) increased the number of beating embryoid bodies and also 
caused an increase in the expression of GATA-4.  These AVP effects on the 
cells were also found to be antagonised by L-NAME (Gassanov et al., 2007) 
thus again suggesting a positive role for nitric oxide in stem cell differentiation 
into cardiomyocytes. As already highlighted,  expression of eNOS, iNOS  and 
nNOS have also been found in undifferentiated ES cells (Bloch et al., 1999; 
Krumenacker et al., 2006)  with the profile of expression  changing during  the 
differentiation process (Krumenacker et al., 2006). The above mentioned data 
suggest a positive role of NO in the differentiation of stem cells into 
cardiomyocytes. 
 
In addition to  reported positive role  of NO in the differentiation of stem cells 
into cardiomyocytes, NO has been reported to play positive role in the 
differentiation of other cell types, For example, over-expression of nNOS or 
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exogenous nitric oxide has also been shown to increase neuronal 
differentiation of neuroblastoma cells (Ciani et al., 2004).  A similar report has 
also shown that nNOS and nitric oxide are required for neuronal differentiation 
of PC12 cells.  In the latter, transfection of PC12 cells  with a nNOS dominant 
negative mutant block  nerve cell growth factor-induced  neuronal 
differentiation (Phung et al., 1999), thus suggesting that nitric oxide  has a 
positive role to play in PC12 cell  neuronal differentiation. NO has also been 
shown  to increased differentiation  of cultured rat preadipocytes into  
adipocytes (Yan et al., 2002).   
 
In contrast to  the positive roles of nitric oxide in cell differentiation, it  has 
recently been  reported that  the differentiation  of preadipocytes (3T3-L1  
cells)  into  adipocytes  is suppressed by NO (Kawachi et al., 2007).  In 
addition, inhibition of NO synthesis using L-NAME   increased the number of 
stem and progenitor cells in the bone marrow of irradiated mice (Michurina et 
al., 2004). Thus, it is evident that the actions of NO in regulating stem cell 
production and/or differentiation may be a complex process that requires 
further investigation. The conflicting reports about the role of NO in cell 
differentiation may reflect the variable nature of NO in cell differentiation or 
variation in experimental procedures used by different laboratories. Nitric 
oxide is a molecule with a transient half-life and a diverse array of biological 
functions in humans. Thus when examining the actions of NO, the 
experimental conditions may be critical in dictating the results obtained. 
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We investigated the role of NO in the differentiation of H9c2 cells into 
cardiomyocytes using both fast NO releasing donors, NOC-5 and SIN-1 with 
respective half-lives of 40 and 93 minutes and the slow NO releasing donors 
NOC-18 and SNAP with respective half-lives of 20 and 37 hours. Our data 
showed that NO donors with different profiles of NO release can have 
different effects on H9c2 cell differentiation into cardiomyocytes. Both SIN-1 
and NOC-5 delayed the onset of differentiation of H9c2 cells into 
cardiomyocytes. However SNAP and NOC-18 were not as effective in 
delaying the onset of differentiation or long term differentiation of H9c2 cells 
into cardiomyocytes. By day 8, H9c2 cell differentiation, as determined by 
MLC-1v western blot, in the presence of SNAP or NOC-18 had recovered to 
levels that were almost the same as those seen in the control cells. In fact by 
day 8, the expression of MLC-1v in SNAP treated was greater than that seen 
in the control cells.  The delayed effects of fast-releasing NO donors on the 
onset of H9c2 cell differentiation can be interpreted as evidence that NO (at 
least from that fast-releasing NO donors) negatively regulates H9c2 cell 
differentiation into cardiomyocytes. However it should be noted, that fast-
releasing NO donors release large amounts  of their NO content in a matter of 
minutes and this may be detrimental to cells independent of  direct  and 
specific negative effects on the signalling  events mediating the H9c2 cells 
differentiation into cardiomyocytes.    
 
NO produced in small or regulated amount (as produced by constitutively 
expressed nNOS and eNOS), is involved in cell signalling leading to the 
regulation of many downstream targets.  Soluble guanylyl cyclase, an enzyme  
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that  generates cGMP, is the main physiological target for NO (Gold et al., 
1990; Trigo-Rocha et al., 1993; Phung et al., 1999). Nitric oxide, by regulating 
the production of cGMP, also  regulates various downstream protein kinases 
(e.g. cGMP-dependent kinase) (Archer et al., 1994; Pineda et al., 1996), ion 
channels (i.e.  cGMP-dependent ion channels) (D'Ascenzo et al., 2002) and 
cGMP-dependent phosphodiesterases  (NO can cause stimulation or  
inhibition) (Wexler et al., 1998; Zima et al., 2000).   However, excessive 
formation of NO may be detrimental to the cells and tissues. This is evident 
from several reports that implicate NO in the pathogenesis of many diseases 
including  stroke  (Archer et al., 1994; Iadecola et al., 1994; Ai et al., 2000; Li 
and  Forstermann, 2000) and  sepsis (Brealey et al., 2002).  Excessive NO 
can disrupt cellular functions by binding to the heme group in cytochrome c 
oxidase and inhibit the enzyme leading to increased production of superoxide 
in the mitochondrial electron transport chain. The increased superoxide can 
further react with NO to yield peroxynitrite  which can directly damage the  
enzymes in the mitochondrial  electron  transport  chain (Brealey et al., 2002).  
This can cause major disturbances in the cells ability to produce ATP that is 
required for the maintenance of many vital cellular functions. Peroxynitrite is 
also an unstable compound which can breakdown into hydroxyl (OH.) and 
nitrite (NO2˙) radicals. The hydroxyl radical causes the most damage to cells 
and tissues and may be responsible for many cellular damages that are 
attributed to excess production of NO. The nitrite radical can covalently modify 
proteins by nitration and this can also lead to detrimental effects on cells.  
Apoptosis is a vital biological process but abnormal apoptosis (i.e. too little or 
excessive apoptosis) as the results of breakdown of the balance between 
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anti-apoptotic and pro-apoptotic cellular signals, is detrimental to cells. Nitric 
oxide can mediate either apoptosis or cell survival. For example, it has been 
shown that over-expression of nNOS  or the slow-releasing NO donor, DETA 
NONOate (i.e. NOC-18) protects human neuroblastoma SK-N-BE cells from 
serum withdrawal-induced apoptosis (Ciani et al., 2002b). Normal levels  of 
NO can prevent apoptosis by inhibiting the activities of caspases including 
caspase-3, caspase-8 and 9 (Kim et al., 1997; Li et al., 1999; Zhou et al., 
2005). Nitric oxide may also prevents  apoptosis by regulating signalling  from 
the  fas receptor, another  apoptotic mechanism (Hebestreit et al., 1998). On 
the other hand higher levels of NO may overcome the cell protective 
mechanisms against oxidative stress leading to apoptosis or other cytotoxic 
effects. The expression of key pro-apoptotic proteins, such as bax and 
caspases have been shown to be repressed by endogenous NO while the  
inhibition of NO production induces the expression of these pro-apoptotic 
proteins (Thippeswamy et al., 2001). Similarly the inhibition of NO production 
has also been shown to decrease the mRNA and protein levels of   Bcl-2, an 
anti-apoptotic gene (Ciani et al., 2002a).  It has been shown that inhibition of 
NO production by L-NAME, resulted in progressive apoptosis   in cochlear 
ganglion cells (CGC)  cells while slow-releasing NO donors or a cGMP 
analogue rescued the L-NAME induces apoptosis (Ciani et al., 2002a). From 
the above it can be appreciated that normal levels of NO can promote cell 
survival while excess NO can contribute to cell damage and death. Our MTT 
data, with all the NO donors used, showed that NO is toxic at high 
concentrations. Therefore, the balance between the transient but very high 
NO concentrations and the sustained production of NO at low concentrations 
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may determine whether NO plays a beneficial or detrimental role in a 
biological process. In cells undergoing differentiation, shifting this balance in 
favour of cell survival may play  critical or  positive roles, since cell 
differentiation is a very stressful process and this means that normal level of 
NO as generated by nNOS and eNOS or control released by slow-releasing 
NO donor may have positive effects on stem cell  differentiation into 
cardiomyocytes. The fact that our data showed that fast NO releasing donors 
markedly delayed the onset of differentiation of H9c2 cells into 
cardiomyocytes while slow NO releasing donors  were not as effective in 
delaying the onset of differentiation or long term differentiation of H9c2 cells 
into cardiomyocytes  shows the need for a fine balance between the transient 
but very high NO concentrations and the sustained production of NO at low 
levels or concentrations. 
 
To further explore the role of NO on the differentiation process, the effects of 
8-Bromo-cGMP on H9c2 cell differentiation was investigated. As already 
mentioned, NO exerts most of its physiological actions via activation of 
soluble guanylate cyclase, which leads to an increase in intracellular 
concentration of the second messenger, cGMP (Gold et al., 1990; Trigo-
Rocha et al., 1993; Phung et al., 1999). The analog of cGMP, 8-Bromo-
cGMP, is more resistant to phosphodiesterases than endogenous cGMP.   
 
Our 8-Bromo-cGMP data are in agreement with the data obtained with some 
of the NO donors used in that treatment of cells with 8-Bromo-cGMP also 
delayed the onset of differentiation and reduced the expression of MLC-1v 
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significantly at the earlier stages of differentiation. However after prolonged 
incubations, MLC-1v expression was virtually indistinguishable in both 
controls and drug treated cells. What is not clear is whether this recovery is 
due to a loss in the actions of NO and/or 8-Bromo-cGMP over time. In our 
experiments, cells were exposed to the compounds for one hour prior to and 
then 48 hours after initiation of differentiation. After this period, cells were 
cultured in differentiation medium alone and it is possible that as a 
consequence of omitting the compounds from the incubation medium, their 
actions gradually diminished over time. What is clear however is the fact that 
NO (at least NO from fast-releasing NO donors) and indeed 8-Bromo-cGMP 
may inhibit rather than enhance the differentiation process, at least over the 
initial stages of the process. This is clearly contradictory to the other studies 
highlighted above which show a positive regulatory role of NO in the 
differentiation of stem cells not only into cardiomyocytes but also into other 
lineages.  Our studies, as they stand, give little indication as to conflicting 
findings and further experiments are clearly needed especially in real stem 
cells or stem cell lines. These studies although planned were not carried out 
because of time constraints but are clearly needed. It would also be very 
useful in future studies to use NOS inhibitors and also combine NO donors 
with cGMP analogs (e.g. Br-cGMP) to complement the findings with the NO 
donors. 
 
One possible but perhaps less convincing reason as to why the NO donors 
suppressed differentiation in our studies may be because of their ability to 
suppress cellular metabolic activity as indicated by the decreases in MTT 
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metabolism observed in the cytotoxicity assays carried out. Even if this did not 
result in cell death the reduction in metabolic activity within cells could 
regulate various cellular processes, including differentiation. The 
concentrations of the different compounds used were however well within the 
ranges used in several other studies. In fact NOC-5 has been used at 
concentrations ranging from 0.1-3000µM (Hotta et al., 1999; Okuyama et al., 
2000; Kim et al., 2005) while NOC-18 and SNAP have both been used in 
other studies at concentrations of up to 500µM (Palmer et al., 2000; Sasaki et 
al., 2000; Bal-Price and  Brown, 2001; Niedbala et al., 2002; Kim et al., 2005). 
SIN-1 has been used at up to 2000µM (Mistry and  Garland, 1998; Mathy-
Hartert et al., 2000; Eligini et al., 2001; Kim et al., 2005). These are all much 
higher than the 100µM used in our studies. The 100µM concentration was 
chosen because the cells appeared to recover, without adversely detrimental 
effects, after the NO donors compound were removed from the incubation 
medium.  In the future research, dose-response studies to clearly establish 
effective and non-toxic concentrations of these compounds, would very useful  
 
4.5 Summary 
 
NOC-5 and SIN-1 appeared to delay the onset of H9c2 cell differentiation into 
cardiomyocytes, as determined by cell elongation and fusion to form 
myotubes.  In parallel with the morphological changes, NOC-5  and SIN-1 
also caused a reduction in the expression of MLC-1v in differentiating H9c2 
cells. NOC-18 also delayed the onset of H9c2 cell differentiation into 
cardiomyocytes but to a lesser extent than NOC-5 and SIN-1. Differentiation 
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associated morphological changes in both control and SNAP-treated H9c2 
cells were similar.  In agreement with the morphological seen in the control 
cells and SNAP treated cells, MLC-1v levels in SNAP-treated  and control 
H9c2 cells were almost equal. 8-Bromo-cGMP, an analogue of cGMP, 
appeared to delay the onset of H9c2 cell differentiation into cardiomyocytes. 
However, like NOC-5 and SIN-1, 8-Bromo-cGMP failed to block the long term 
differentiation of H9c2 cells into cardiomyocytes. In parallel, expression of 
MLC-1v was reduced at day 4 but thereafter MLC-1v expression in controls 
and 8-Bromo-cGMP-treated cells were indistinguishable. 
 
In conclusion, our data suggest that generation of cardiomyocytes from H9c2 
cells may be negatively regulated by NO and this may occur through 
generation of cGMP. Our data are however preliminary and further studies are 
needed to confirm these findings. Moreover, a detailed study of the full 
signalling pathway activated by NO may prove important in understanding 
how this molecule regulates differentiation. 
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CHAPTER 5.0 
ROLE OF PROTEIN KINASE C IN CARDIOMYOCYTE 
DIFFERENTIATION 
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5.1 INTRODUCTION 
 
5.1.1 Structural features of protein kinase C isoforms 
 
Protein kinases Cs (PKC) are members of the serine–threonine second 
messenger-dependent protein kinase family. They play pivotal roles in 
mediating cellular responses to extracellular stimuli that regulate cell 
proliferation, differentiation and apoptosis. PKC isoforms are single 
polypeptides with an N-terminal regulatory region and a C-terminal catalytic 
region. A key regulatory and structural feature of the PKC isoforms is the 
presence of four conserved  domains (i.e. C1, C2, C3 and C4) (Coussens et 
al., 1986) (Figure 5.10).  
 
The C1 domain contains a cysteine-rich motif (Parker et al., 1986)  that forms 
the 1, 2-diacyglycerol (DAG) (endogenous ligand) binding site. Diacylglycerol 
and phorbol esters (PKC activators) are hydrophobic anchors that recruit PKC 
enzyme to cell membranes (Orr et al., 1992; Mosior and  Epand, 1993). 
Phorbol esters, which are non-hydrolysable analogues of DAG, also bind to 
the C1 domain (Johnson et al., 2000). The C1 domain also contains the auto-
inhibitory pseudosubstrate sequence upstream of the cysteine-rich motif 
(House and  Kemp, 1987; House and  Kemp, 1990). The C2 domain contains 
the recognition site for acidic lipids and in conventional PKC isoforms. It also 
contains the Ca2+ ion binding site. The C3 domains form the ATP binding site 
and the C4 domain form the substrate binding site.  
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Figure 5.10: A schematic diagram showing the structure of 
conventional, novel and atypical PKCs. The pseudosubstrate domain 
(gold), C1 domain motifs (blue), C2 domain (green), C3 the ATP-binding lobe 
(pink) and C4 the substrate-binding lobe (gray) are shown.  The C2 domain 
(i.e. novel C2) of novel nPKCs lacks Ca2+ binding capacity. The C1 (atypical 
C1) of atypical protein kinase Cs have only one Cys-rich motif which does not 
bind DAG or phorbol ester. PSS = pseudosubstrate, PHS = phosphatidyl-L-
serine, PBE = phorbol esters and ATP= adenosine triphosphate 
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5.1.2 Generation of PKC second messengers 
 
Stimulus (e.g. growth factor) mediated activation of membrane bound 
phospholipase C (PLC) plays a central role in the activation of both 
conventional PKCs and novel PKCs. The stimulation of many G-protein 
coupled receptors can lead to the activation of PLC. Activated PLC converts 
phosphatidylinositol (1, 4) bisphosphate (PIP2) into inositol (1, 4, 5) 
trisphosphate (IP3) and DAG. 
 
5.1.3 Differential requirement of second messengers by PKC isoforms  
 
All PKC isoforms via their C1 domains bind phosphatidyl-L-serine 
(phosphatidylserine) (Hurley et al., 1997), a membrane acidic phospholipids 
that is located only on the cytoplasmic side of cell membranes. 
Phosphatidylserine binding is necessary for the high-affinity interaction of 
PKC  with DAG containing membranes (Orr and  Newton, 1994). The ten PKC 
isoforms are classified into three subgroups (conventional novel, and atypical 
PKCs) based on the composition of their regulatory domains moiety 
(Nishizuka, 1995; Musashi, 2000; Newton, 2003) (Figure 5.10). The particular 
configuration or domains in the regulatory region of each isoform determines 
the cofactor requirement of that  isoform 
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5.1.3.1 Conventional PKC (cPKC) isoforms 
 
The conventional PKC alpha, beta1, beta2 and gamma isoforms (α, βI, βII, γ) 
contain functional C1 and C2 domains (Figure 5.10). They therefore require 
DAG and Ca2+ ions for their full activities and functions.  
5.1.3.2 Novel PKC (nPKC) isoforms 
 
The novel PKC delta, epsilon, eta and theta isoforms (δ, ε, η, θ) contain a 
functional C1 domain and a non-ligand-binding (i.e. non-Ca2+/membrane-
binding) novel C2 domain (Figure 5.10). They are therefore Ca2+ independent 
but require DAG for their full activation and functions. The C1 domain of  
novel PKCs has an intrinsic affinity for DAG-containing membranes that is 2 
fold higher than that of the C1 domain of conventional PKCs (Giorgione et al., 
2006). This allows the novel PKCs to respond to agonists that cause the 
production of DAG but not Ca2+ ion release. In contrast, cPKCs have to be 
targeted to membranes by their Ca2+-binding C2 domain, in response to 
elevated of cytosolic Ca2+ ons, before they can to respond to DAG (Nalefski 
and  Newton, 2001).  
 
5.1.3.3 Atypical PKC (aPKC)  isoforms 
 
Atypical PKC zeta and tau/lamda isoforms (ζ, ί/λ) contain a single non-DAG-
binding ("atypical") C1 domain but no C2 domain (Figure 5.10). Therefore they 
do not respond to Ca2+ ion or DAG or phorbol esters.  
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5.1.4 PKC activation by phosphorylation, 
 
All PKC isoyzmes have to be primed by a series of ordered phosphorylations 
before they can become structurally competent for catalysis. These kinases 
share three conserved phosphorylation motifs which must be primed by 
phosphorylations at critical residues or else kinases will remain catalytically 
inactive (Newton, 2003).  
 
The processing of conventional PKCβII serves a model for the processing of 
PKC isoforms. The first phosphorylation  of  cPKCβII  is catalyzed on a critical 
threonine residue (threonine 500), in the  activation loop, by PDK-1 (i.e. the 
same kinase that activates Akt at threonine 308 in Akt activation loop). The 
importance of this phosphorylation event was demonstrated when it was 
found that mutation of the critical threonine residue to a neutral (i.e. non-
phosphorylatable residue) inhibited PKC activity (Cazaubon et al., 1994).  
PDK-1 is responsible for the phosphorylation-driven priming of all PKC 
isoforms.  PDK-1 phosphorylates conventional PKCs (Dutil et al., 1998), novel 
PKCs (Le Good et al., 1998; Cenni et al., 2002) and atypical PKCs (Chou et 
al., 1998; Le Good et al., 1998) at the critical threonine residues. In ES cells 
lacking PDK1 (PDK-1-/- cells), the intracellular levels of PKCα, PKCβI, PKCγ, 
PKCδ and  PKCε,  were markedly   reduced (Balendran et al., 2000). While 
PDK-1 activity directed at Akt  is phosphoinositide-dependent (i.e. PIP3 must 
be bound to Akt PH domain), PDK-1-driven phosphorylation of PKCs is PIP3 
independent (Sonnenburg et al., 2001). This PDK-1-driven phosphorylation in 
the activation loop is followed by  two further intramolecular 
autophosphorylations on two conserved residues; one on threonine 450 in the 
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turn motif in the C-terminal region and another on serine 660 in the 
hydrophobic motif (Newton, 2003). These phosphorylation events produce a 
mature (i.e. fully phosphorylated) PKC that is catalytically competent but not 
activated.  
 
5.1.5 PKC activation by second messengers 
 
The mature PKCs are localized to the cytosol and maintained in an inactive 
conformation by an auto-inhibitory pseudosubstrate sequence that blocks the 
active site. This auto-inhibition is relieved by allosteric interactions with 
second messengers. Diacylglycerol binds both cPKC and nPKC. 
Diacylglycerol binding recruits the enzymes to the membranes through their 
C1 and C2 domains. This induces a conformational change in the enzyme 
leading to the exposure of the auto-inhibitory pseudosubstrate domain and the 
removal of the pseudosubstrate from the substrate binding site thus allowing 
the  substrate to bind and be phosphorylated (Orr et al., 1992; Orr and  
Newton, 1994; Sakai et al., 1997; Oancea and  Meyer, 1998). In addition, IP3 
mediates the release of Ca2+ ions from intracellular stores and the Ca2+ ions in 
turn potentiate the activation of cPKC. The activity of fully activated PKC 
activity is terminated by metabolism of DAG.  As  atypical PKCs do not 
respond to  DAG or  Ca2+, the only clear regulation is their requirement   for  
PDK-1 for the phosphorylation step  that primes  these isoforms (Chou et al., 
1998; Le Good et al., 1998). These PKC isoforms have a pseudosubstrate 
sequence that allosterically regulates the enzyme. Their activation may also 
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depend on PI3K and increase in PIP3 (Standaert et al., 2001) but  the exact 
mechanism of this is not clear.  
 
5.1.6 PKC isoforms and cell differentiation  
 
PKC isoforms have  been implicated in the differentiation of various cell types  
(Balazovich et al., 1987; Melloni et al., 1987; Kanakaraj et al., 1998; Kim et 
al., 2005; Marchisio et al., 2005a). Differential regulation of PKC isoforms has 
been shown during the differentiation of various cell types. For example, PKC 
α, ζ, and δ are strongly and preferentially expressed and activated by 
phosphorylation during DMSO-induced erythroid differentiation of Friend 
erythroleukemia cells (Marchisio et al., 2005a). Similarly it has also been 
shown that enhanced protein levels and activities of  PKC βI and βII isoforms 
are required for the monocytic differentiation of HL-60 cells (Kim et al., 2005).  
It has also been reported that the expressions of PKC α and ζ did not change 
significantly during the differentiation of immature mononuclear satellite cells 
to polynuclear myotubes (Boczan et al., 2000). In contrast, the expression of 
PKC γ and η increased with differentiation while PKC θ showed high 
expression during the early phases of differentiation, but a decreased 
expression in the differentiated myotubes (Boczan et al., 2000). 
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5.1.7 PKC isoforms and stem cell differentiation  
 
Like other cell types, differential regulation of PKC isoforms has also been 
shown during the differentiation of stem cells. Studies have shown that the 
expression of specific PKC isoforms changed significantly as ES cells 
differentiate into cardiomyocytes.  It has been shown that the differentiation of 
ES cells into beating cardiomyocytes requires the  down-regulation of PKC β 
and ζ in conjunction with the up-regulation of PKC ε(Zhou et al., 2003).  
 
From the above, it can be seen that while PKC isoforms have been implicated 
in the differentiation of stem cells and other cell types, their exact roles are 
currently poorly understood. Therefore the aim of this study is to investigate 
the role of the PKC pathway in the cardiac differentiation of H9c2 cell and P19 
stem cells. H9c2 and P19 stem cells are different cell types but both can 
differentiate in cardiomyocytes. Investigation of the  role of PKC in the cardiac 
differentiation of these cells may yield information about the cell specific 
effects  or  possible cell-type independent effects of  PKC during  cardiac 
differentiation. To achieve the aim a PKC inhibitor, bisindolylmaleimide I (BIM-
I) (Appendix VI (a)) was used for this study. BIM-I is a potent inhibitor for PKC 
(IC50=10nM) (Toullec et al., 1991). It is highly selective for α (IC50=20nM), βI 
(IC50=17nM) βII, (IC50=16nM), γ (IC50=20nM) (Toullec et al., 1991).  BIM-I 
also inhibit novel PKCδ (IC50=210nM), PKCε (IC50=132nM) and atypical 
PKCζ (IC50=5800nM)(Martiny-Baron et al., 1993). BIM-I is a  PKC competitive 
inhibitor and competes for the ATP-binding site of PKC (Toullec et al., 1991). 
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5.2 MATERIALS AND METHODS 
 
5.2.1 Culture and differentiation of H9c2 Cells  
 
The routine culture of H9c2 cells was carried out as described in section 2.3.1 
(Chapter 2). H9c2 cells were trypsinised and the appropriate cell density for 
the differentiation experiments was calculated as described in section 2.6 
(Chapter 2). H9c2 cells (2x103 cells/cm2) were seeded in p60 dishes or 6-well 
plates in full culture medium (i.e. DMEM supplemented with 10% FBS, 
100units/ml penicillin/100µg/ml streptomycin), placed in a  tissue culture 
incubator at 37oC, 95% air and  5% CO2 and allowed to become 60-70% 
confluent. The differentiation of H9c2 cells into cardiomyocytes was carried 
out in 1% serum as described in section 2.8.1 (Chapter 2). The role of PKC 
signalling pathway in the differentiation of H9c2 cells into cardiomyocytes was 
investigated. The effects of the inhibition of the PKC signalling pathway were 
investigated using 10µM of BIM-I as described in section 2.8.2 (Chapter 2).  
 
 A BIM-I stock (10 mM solution) was prepared by dissolving 1mg of BIM-I in 
242µl of DMSO. The stock solution was distributed into 10 or 20µl aliquots 
and stored in the freezer at -20oC. The aliquots were protected from light 
during storage and use.  The differentiation medium was used to dilute 
(1:1000) the frozen stock BIM-I solutions (10mM) to the BIM-I concentration 
(10µM) used in the differentiation experiments. The preparation of stock BIM-I 
concentration was carried out as explained in appendix VIII.  More details 
about BIM-I are located in appendix VI (a). 
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5.2.2 Culture and differentiation of P19 stem cells  
 
The routine culture of P19 stem cells was carried out as described in section 
2.3.2 (Chapter 2).  To initiate differentiation, P19 stem cells (1x106 cells) were 
seeded in P100 Petri (i.e. microbiological) dishes in the differentiation medium 
(i.e. α-MEM supplemented with 10% FBS, 100 units/ml penicillin/100 µg/ml 
streptomycin and 0.8% DMSO) and the differentiation of P19 stem cells into 
beating cardiomyocytes  carried out as described in section 2.9.1 (Chapter 2). 
The role of PKC signalling pathway in the DMSO-induced differentiation of 
P19 stem cells into beating cardiomyocytes was investigated. The effect of 
the inhibition of PKC signalling pathway by 10µM of BIM-I on the DMSO-
induced P19 stem cell differentiation into beating cardiomyocytes was 
investigated as described in section 2.9.2 (Chapter 2). Furthermore the effects 
of delayed inhibition of PKC on P19 stem cell differentiation into 
cardiomyocytes were also investigated as described in section 2.9.3 (Chapter 
2). 
 
5.2.3 Cell viability assay  
 
To examine the effects of the PKC inhibition on H9c2 cell viability, the MTT 
assay was carried out as described in section 2.7 (Chapter 2). 
 
5.2.4 Western blot analysis  
 
In order to perform the western blot analysis, the following procedures were 
carried out as described in the Chapter 2 under the sections indicated in 
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parenthesis: cell lysate generation (section 2.11), preparation of BSA 
standards (section 2.12.1) and BCA assay (section 2.12.2). The western 
blotting was carried out as described in section 2.13. 
 
5.2.5 Data analysis  
 
Data obtained from independent experiments were used for statistical 
analysis as described in section 2.14 (Chapter 3). 
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5.3 RESULTS 
 
5.3.1 Effects of protein kinase C inhibition on H9c2 cell differentiation 
into cardiomyocytes 
 
The inhibition of the PKC signalling pathway, using BIM-I (10µM, caused 
marked inhibition of cell elongation, fusion and myotube formations that 
usually accompany H9c2 cell differentiation into cardiomyocytes.  Control 
H9c2 cells cultured in the absence of BIM-I underwent differentiation and 
formed myotubes as seen previously. In contrast, cells exposed to BIM-I 
(10µM) maintained their undifferentiated single cell and spindle shaped 
morphology at day 4 and 8. By day 12 there were only marginal signs of cell 
elongation, fusion and myotube formation in the in  BIM-I treated cells (Figure 
5.11). 
 
In agreement with the lack of morphological change observed in BIM-I treated 
H9c2 cells, the expression of MLC-1v protein in these cells was completely 
blocked up to day 4. Expression of MLC-1v in BIM-I treated cells was however 
detectable at day 8, increasing marginally by day 12. MLC-1v levels in BIM-I 
treated cells, by day 12, were just slightly above 50% of the levels seen in the 
control cells (p<0.001) (Figure 5.12). 
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Figure 5.11: Effects of the protein kinase C inhibition on H9c2 cell 
differentiation into cardiomyocytes: morphological changes. Control 
H9c2 cells were cultured in differentiation medium consisting of DMEM 
supplemented with 1% FBS and 100units/ml penicillin/100µg/ml streptomycin. 
The above differentiation medium was further supplemented with 10µM of 
BIM-I for the treated cells. BIM-I caused significant inhibition of H9c2 cell 
differentiation (i.e. cell alignment, elongation and myotube formation). Cells 
cultured in the absence of this compound followed the normal differentiation 
pattern (shown by black arrows in day 4 to day12 control cells). In contrast, 
cells exposed to BIM-I maintained their normal single cell and spindle shaped 
morphology (shown by black arrows in day 4 to day12 BIM-treated cells).  
Morphologically at day 4, 8 and 12 there were only marginal signs of 
differentiation in BIM-I treated H9c2 cells. Both control cells and BIM-I-treated 
cells showed the normal single cell morphology (shown by white arrows) at 
day 0. The photographs were taken under 200X magnification and are 
representative of at least three independent differentiation experiments. 
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Figure 5.12:  Effects of the protein kinase C inhibition on H9c2 cell 
differentiation into cardiomyocytes: cardiac ventricular myosin light 
1(MLC-1v)  expression.  Western blot analysis of MLC-1v revealed that the 
expression of this protein in H9c2 cells was blocked by treating the cells with 
10µM of BIM-I. . A a marginal  expression started at  day 8  and by day 12, 
MLC-1v levels in BIM-I treated cells were just slightly above 50% of the levels 
seen in the control cells. At day 4, day 8 and day 12, there was significant 
difference between control cells and BIM-treated cells (p<0.001). This is 
indicated by a horizontal line (drawn from day 4 to day 12) with the indicated 
p-value.  The blot is representative of at least three differentiation experiments 
(panel A). The densitometric data (mean ± SD), from three independent 
differentiation experiments, show the time dependent changes in MLC-1v 
expression in BIM-I treated H9c2 cells (panel B). 
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5.3.2 Viability of H9c2 cells in 10µM of the protein kinase C inhibitor, 
BIM-I 
 
The widely used concentration of 10µM for the PKC inhibitor BIM-I was 
selected for use in the experiments designed to investigate the effects of PKC 
inhibition on H9c2 differentiation into cardiomyocytes. BIM-I at the 
concentration of 10µM, like the other widely used concentrations of the other 
inhibitors used in this project, was not overtly toxic to the cells (Figure 5.13). 
The average viability was about 73% of the viability determined in the control 
cells. The control viability was significantly different than that in the treated 
cells at 6, 12, 24 and 48 hours (p< 0.01). At 48 hours (longest time that the 
cells were in the drug), the viability of treated cells was about 75% of the 
control viability and this was comparable or similar to the viability seen in the 
cells treated with other drugs. 
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Figure 5.13: Viability of H9c2 Cells in the presence of BIM-I.  H9c2 cells 
were seeded in 6-well plates and treated with 10µM BIM-I as described in the 
methods section above (section 5.3.1). The MTT assay was carried out at the 
end of each time point after the treatment. BIM-I at the concentration of 10µM 
was not toxic to the cells. The average viability was about 73% of the viability 
determined in the control cells. The control viability (control bar in the graph) 
was significantly different than the viability, calculated in BIM-I treated cells, at 
6, 12, 24 and 48 hours (p< 0.01). At 48 hours (longest time that the cells were 
in the drug), the viability of treated cells was about 75% of the control viability 
and this was comparable or similar to the viability seen in the cells treated 
with other drugs. The MTT data presented in the graph are the mean ± SD 
from three independent experiments 
 
 
 
 
 
 
Control 6hr 12hr 24hr 48hr
0
20
40
60
80
100 p < 0.01
H9
c2
 
Ce
ll 
Vi
ab
ili
ty
 
in
 
BI
M
-
I (%
 
Co
n
tr
o
l A
54
0)
 229 
5.3.3 Effects of the protein kinase C inhibition on P19 stem cell 
differentiation into beating cardiomyocytes 
 
The control and BIM-treated P19 cell embryoid bodies followed their normal 
pattern of growth as already described in the establishment of the P19 
cardiomyocyte differentiation model (Chapter 3). Upto day 5, beating 
cardiomyocytes were not usually observed in control or treated cells. Between 
day 6 and 7, P19 stem cells treated with DMSO in the absence of BIM-I 
usually began to show signs of beating cardiomyocytes (Figure 5.15). When 
present, the number of beating clusters of cardiomyocytes usually continued 
to increase up to day 14. In contrast, P19 stem cells treated with DMSO in the 
presence of 10µM BIM-I did not show any signs of beating cardiomyocytes 
during the same period. No beating cardiomyocytes were observed in any of 
the dishes containing BIM-I treated P19 stem cells over the whole course of 
the experiment (Figure 5.14).   
 
P19 stem cell-derived cardiomyocytes were highly variable.  Beating rates 
amongst the clusters of cardiomyocytes were highly variable. The patterns of 
cardiomyocyte beating clusters (including number and beating rates), from 
P19 stem cells treated with DMSO in the absence of BIM-I (i.e. no inhibition of 
PKC signalling pathway), were as already described in Chapter 3 (see Figure 
5.15). 
 
In agreement with the lack of appearance of beating cardiomyocytes in BIM-I 
treated P19 stem cells, the long term expression of cardiac restricted protein 
troponin I was inhibited at day 8 and day 12. (Figure 5.16)   
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Figure 5.14: A schematic diagram of the effects of protein kinase C 
Inhibition on DMSO-induced differentiation of P19 stem cells into 
cardiomyocytes. PKC inhibition with BIM-I (10µM) blocked the differentiation 
of P19 stem cells into beating cardiomyocytes, when the inhibitors was added 
to the cells during the EB formation stage in the absence of BIM-I beating 
cardiomycytes were seen from day 6 to day 14 after the EB were transferred 
to cell culture dishes. 
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Figure 5.15: Effects of protein kinase C Inhibition on DMSO-induced 
differentiation of P19 stem cells into cardiomyocytes. Control P19 stem 
cell EBs were formed in differentiation medium consisting of α-MEM 
supplemented with 10% FBS and 100 units/ml penicillin/100 µg/ml 
streptomycin and 0.8% DMSO. The above differentiation medium was 
supplemented with 10µM of BIM-I for the treated P19 stem cells. DMSO-
induced differentiation of P19 stem cells into beating cardiomyocytes was 
inhibited by BIM-I. The areas of  beating cardiomyocytes are shown within the 
closed figures drawn with white dotted lines. The beating focus of each beating area 
is shown by a black arrow.  Photographs and movie clips of beating cells were 
taken under 200X magnification on the days  indicated and  are 
representative of microscope fields (for their respective days) from at least 
three independent differentiation experiments. D10 to D14 = day 10 to day 14. 
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Figure 5.16: Effects of the protein kinase C inhibition on P19 stem cell 
differentiation into cardiomyocytes: Troponin I expression. Control P19 
stem cells were cultured in differentiation medium consisting of α-MEM 
supplemented with 10%  FBS, 100 units/ml penicillin and 100µg/ml 
streptomycin as described in section 5.3.2. The above differentiation medium 
was further supplemented with 10µM of BIM-I for the treated cells. In BIM-
treated P19 stem cell, the long term expression of cardiac restricted protein 
troponin I was inhibited at day 8 and day 12. While beating cardiomyocytes 
were observed in some dishes of the control cells, beating cardiomyocytes 
were not seen in any of the BIM-I treated P19 stem cells. The blot is 
representative of 3 differentiation experiments.  
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5.3.4 Effects of delayed inhibition of protein kinase C on P19 stem cell 
differentiation into beating cardiomyocytes 
 
To determine the stage at which PKC may regulate the differentiation of P19 
stem cells into cardiomyocytes, BIM-I was added to cell culture four days after 
exposure to DMSO (Figure 5.17). Control P19 stem cells were treated with 
DMSO and BIM-I at the EB formation stage and for comparison, parallel 
dishes of P19 cells (delay-inhibition P19 cells) were treated with DMSO only 
at EB formation stage and then only treated with BIM-I after the EB were 
transferred to culture dishes (section 5.3.2). 
 
Twenty four hours after the setup of cells in Petri dishes, cell aggregates 
(EBs) were observed in the control cells and also in the delay-inhibition P19 
cells.  The EBs in both groups of cells underwent normal adhesion followed by 
proliferation and migration and both control and experimental cells were 
confluent by day 4. As already described, no beating cardiomyocytes were 
observed in both control and delay-treatment cells before day 6. By day 6 or 
7, the first beating appeared in the delay-inhibition P19 cells (Figure 5.18). As 
expected, DMSO failed to induce P19 stem cell differentiation into beating 
cardiomyocytes, when 10µM of BIM-I was added at the EB formation stage.  
 
However when DMSO was allowed to initiate P19 stem cell differentiation 
before the inhibition of the PKC signalling pathway (using 10µM of BIM-I), 
BIM-I failed to block the DMSO-induced differentiation of P19 stem cells into 
beating cardiomyocytes (Figure 5.17). The patterns of beating cardiomyocyte 
clusters (including number and beating rates)  from P19 stem cells, in which 
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DMSO was allowed to initiate their differentiation before the inhibition of the 
PKC signalling pathway, were as already described in Chapter 3 (see Figure 
5.18). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.17: Effects of delayed inhibition of protein kinase C on P19 
stem cell differentiation into beating cardiomyocytes. In P19 stem treated 
with BIM-I (10µM) four days after the initiation of DMSO-induced cardiac 
differentiation, BIM-I failed to block the cell differentiation into beating 
cardiomyocytes. 
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Figure 5.18: Effects of delayed inhibition of protein kinase C on P19 
stem cell differentiation into beating cardiomyocytes. Control EBs were 
formed in differentiation medium consisting of α-MEM supplemented with 10% 
FBS, 100units/ml penicillin/100µg/ml streptomycin, 0.8% DMSO and 10µM of 
BIM-I. For the delay inhibition of PKC, BIM-I was added four days after 
DMSO. Delayed addition of BIM-I has no effects on DMSO-induced 
differentiation of P19 stem cells into beating cardiomyocytes.  The beating 
areas of cardiomyocytes are indicated by the dotted white circles. The beating focus 
of each beating area is shown by a black arrow.  Photographs and movie clips of 
beating cells were taken under 200X magnification on the days  indicated and  
are representative of microscope fields (for their respective days) from at least 
three independent differentiation experiments. D10 to D14 = day 10 to day 14. 
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5.4 DISCUSSION 
 
At both morphological and biochemical levels, the data showed that the 
inhibition of PKC by BIM-I markedly inhibited H9c2 cell differentiation into 
cardiomyocytes. Control cells cultured in the absence of BIM-I underwent the 
usual differentiation associated morphological changes (i.e. cell alignment, 
elongation and fusion to form myotues). In contrast BIM-treated H9c2 cells 
maintained their normal single cell and spindle shaped morphology with only 
marginal signs of morphological changes.  This strongly suggests that the 
activation of PKC signalling may have key roles to play in the events that are 
responsible for causing these morphological changes during H9c2 cardiac 
differentiation.  In agreement with the lack of morphological changes observed 
in BIM-I treated H9c2 cells, the BIM-I suppression of the expression of MLC-
1v also suggest roles for PKC activation during H9c2 cell differentiation into 
cardiomyocytes. 
 
In agreement with the PKC pathway having a role to play during H9c2 cell 
differentiation into beating cardiomyocytes, PKC inhibition also blocked the 
differentiation of P19 stem cells into cardiomyocytes. Control P19 stem cells 
differentiated into beating cardiomyocytes and expressed cardiac specific 
troponin I while BIM-I treated cells failed to differentiate into beating 
cardiomyocytes. Furthermore P19 stem cell cardiac differentiation as 
determined by the expression of cardiac specific troponin I was also inhibited. 
Our data are significant in that, it is suggestive of a need for PKC activation in 
both H9c2 and P19 stem cells. H9c2 and P19 stem cells are different cell 
types but both can differentiate into cardiomyocytes. The need for PKC 
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activation for the differentiation of both cell types (i.e. H9c2 and P19 cells) 
therefore suggests that the activation of PKC signalling pathway may be a 
fundamental or an essential signalling event during the differentiation of stem 
cells into cardiomyocytes. 
 
The human embryonal carcinoma cell line NT2/D1 can differentiate into 
neuronal cells in the presence of retinoic acid. An increased PKC activity has 
been shown to accompany neuronal differentiation of these  cells (McCarthy 
et al., 1995). All-transretinoic acid (ATRA) can induce the differentiation of the 
human promyelocytic leukaemia cell line (HL-60) into mature granulocyte-like 
cells. It has also been found that the activation of PKC is necessary for ATRA-
induced differentiation of HL-60 cells (Kanakaraj et al., 1998; Kim et al., 
2005).   
 
PKC translocation from the cytoplasm to the plasma membrane is a central 
mechanism for the activation and activity of PKC isoforms, however selective 
nuclear accumulation of PKC ζ have been reported in HL-60 cells induced to 
differentiate along the granulocytic lineage by ATRA (Zauli et al., 1996; 
Bertolaso et al., 1998; Neri et al., 1999). PKC ζ also accumulated in the nuclei 
of U937 cells (human promonocytic leukemia cells)  that have undergone 
monocyte differentiation(Kiley and  Parker, 1995). More importantly, it has 
been reported that PKC ζ nuclear accumulation, was blocked by the inhibition 
of PI3K using Wortmannin (Neri et al., 1999).The inhibition of PKC ζ nuclear 
translocation, by wortmannin , has also been reported during ischemia in rat 
hearts (Mizukami et al., 1997). Increased expression and phosphorylation of 
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PKC α, ε, ζ and δ has been shown following DMSO-induced differentiation in 
Friend erythroleukemia cells also suggest a possible role of this PKC in the 
differentiation of these cells (Marchisio et al., 2005b). All the above results 
suggest that PKC may be involved in cell differentiation. These studies also 
suggest that the localisation of PKC isoforms to different subcellular 
compartments may be a mode of regulation or an indication of unique 
functions for individual PKC isoforms.  
 
In agreement with suggestions from the previous studies that PKC isoforms 
have role to play in cell differentiation, our data suggest that PKC have may a 
role in the differentiation of both P19 stem cells and H9c2 cells. BIM-I blocked 
the differentiation of both cells into cardiomyocytes.  While previous data 
suggest important roles for PKC during cell differentiation and our data 
specifically suggest a role for PKC in the differentiation of stem cells into 
cardiomyocytes, the exact mechanism by which PKC can mediate its positive 
effects on cell differentiation is not clearly defined.  PKC isoforms are second 
messenger dependent kinases. PKC activation depends on either DAG or 
Ca2+ or both depending on the isoform. The increase in intracellular DAG or 
Ca2+ is mediated by phospholipase C (PLC).  The elevation of intracellular 
Ca2+ ions is essential for the activation of conventional PKC isoforms. It is 
therefore very  interesting to note that that some members of the Wnt-5a 
group  that signal through the non-canonical Wnt/Ca2+ signalling pathway  
caused a PLC mediated increased in  intracellular Ca2+ ion levels (Sheldahl et 
al., 1999; Pandur et al., 2002; Sheldahl et al., 2003) that go on to activate 
PKC.  It is/was generally thought that signalling events downstream of Wnts 
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belonging to Wnt-5a group, via the Wnt/Ca2+ signalling pathway, cause  the 
inhibition   of the canonical Wnt/β-catenin signalling pathway (Torres et al., 
1996; Topol et al., 2003; Westfall et al., 2003; Maye et al., 2004). However it 
is becoming clear that the assigned sole function of the non-canonical 
Wnt/Ca2+ signalling as an inhibitor of the canonical Wnt/β-catenin signalling 
pathway may not be   as simple as reported.  
 
As discussed in Chapter 3, the available evidence suggests that DMSO-
induced differentiation of P19 stem cells into cardiomyocytes may occur 
through the Wnt/β-catenin signalling pathway.  Calcium ion release from the 
Wnt/Ca2+ signalling would be expected to activate PKCs. If the Wnt/Ca2+ 
signalling pathway function is the inhibition of the  Wnt/β-catenin signalling 
pathway,  then PKC  (at least the conventional PKC isoforms) would be 
expected to play negative roles in the differentiation of P19 stem cell into 
cardiomyocytes. Clearly our data are in direct contrast to that expectation. Our 
data showed that inhibition of PKC led to the inhibition of the cardiac 
differentiation of P19 stem cells and H9c2 cells. 
 
The activation of the Wnt/Ca2+ signalling pathway has been shown to cause 
calcium ion  influx and the activation of PKC (Sheldahl et al., 2003). 
Interestingly it has also been shown that the activation PKC inactivated GSK-
3β and increased the accumulation of cytosolic β-catenin (Garrido et al., 
2002). In the same study, it was also found that the inhibition of Ca2+-
dependent PKC isoforms activated GSK-3β. Wnt-3a and lithium mimicked 
PKC activation (Garrido et al., 2002; Sanai et al., 2004). Clearly the 
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inactivation of GSK-3β by PKC and the accumulation of cytosolic β-catenin 
will enhance rather than inhibit the Wnt/β-catenin signalling pathway.  
Whether PKC in our experimental system can phosphorylate and inactivate 
GSK-3β remains to be examined.  Whether PKC in our experimental system 
was activated by Ca2+ ions from the Wnt/Ca2+ signalling pathway also remains 
to be examined.  It is possible that the PKC in our experimental system may 
be activated in a mechanism that is entirely independent of the Wnt/Ca2+ 
signalling pathway.  However if PKC in our system was activated by Wnt/Ca2+ 
signalling pathway then our data suggest that Wnt/Ca2+ signalling pathway 
may also contribute to  Wnt/β-catenin mediated differentiation of stem cells in  
cardiomyocytes in contrast to the inhibitory role assigned to  this pathway 
during cardiogenesis.  
 
5.5 Summary 
 
The inhibition of the PKC signalling pathway, using BIM-I (10µM), caused 
marked inhibition of cell elongation, fusion and myotube formation that usually 
accompany H9c2 cell differentiation into cardiomyocytes. Control H9c2 cells 
cultured in the absence of BIM-I underwent differentiation and formed 
myotubes.  In agreement with the lack of morphological change observed in 
BIM-I-treated H9c2 cells, the expression of MLC-1v protein in these cells was 
completely blocked up to day 4 and then significantly inhibited thereafter. 
 
P19 stem cells cultured in 0.8% DMSO in the absence of BIM-I differentiated 
into beating cardiomyocytes. In contrast, P19 stem cells treated with 0.8% 
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DMSO in the presence BIM-I (10µM) did not differentiate into beating 
cardiomyocytes. However when DMSO was allowed to initiate P19 stem cell 
differentiation before the addition of BIM-I, the cells differentidate into beating 
cardiomyocytes (i.e. BIM-I failed to block their DMSO-induced cardiac 
differentiation). In agreement with the lack of appearance of beating 
cardiomyocytes in BIM-I treated P19 stem cells, the long term expression of 
cardiac restricted protein troponin I (TnI) was inhibited. 
 
In conclusion, our data therefore suggest that the activation of PKC signalling 
pathway may be required for the differentiation of H9c2 cell and P19 stem cell 
differentiation into cardiomyocytes. The data also suggest that the activation 
of PKC signalling pathway may be required during the early stages of P19 
stem cell differentiation into cardiomyocytes. 
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CHAPTER 6.0 
ROLE OF p38 MAP KINASE IN H9C2 AND P19 STEM 
CELL DIFFERENTIATION INTO CARDIOMYOCYTES 
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6.1 INTRODUCTION 
 
6.1.1 Mitogen-activated protein kinase  
 
The p38 kinases are serine/threonine kinases that belong to a very large 
protein kinase family known as the mitogen-activated protein kinases 
(MAPKs). The MAPKs control several  cell functions including gene 
expression (Wu et al., 2004; Lawrence et al., 2007; Mochizuki et al., 2007), 
differentiation (Zetser et al., 1999; Jadlowiec et al., 2004; Bokui et al., 2008; 
Kook et al., 2008), proliferation (Souza et al., 2004; Erlich et al., 2007; Jia et 
al., 2008), migration (Goetze et al., 1999; Rousseau et al., 2006; Jia et al., 
2008) and cell survival or apoptosis (Chuang et al., 2000; Pan et al., 2002; 
Chen et al., 2008; Cho et al., 2008). They are activated by a range of  
extracellular stimuli (mitogens) including growth factors (Moriuchi et al., 2001; 
McFarland and  Pesall, 2008), hypotonic stress (Niisato et al., 2007) and 
oxidative stress (Kurata, 2000; Gaitanaki et al., 2003; Kim et al., 2004; Frossi 
et al., 2007).  The effects of antioxidant on various MAPKs may depend on 
the MAPK and/or the activating stimulus. For example the antioxidants, 
ascorbic acid, catalase and superoxide dismutase, have been reported to 
suppress p38-MAPK signalling pathway in the perfused frog hearts (Gaitanaki 
et al., 2006) . On the other hand, in cultured rat aortic smooth muscle cells, 
diphenyleneiodonium chloride (DPI), ascorbic acid, N-acetyl cysteine (NAC), 
diethyldithiocarbamic acid (DETC) and 6-Hydroxy-2,5,7,8-
tetramethylchromane-2-carboxylic acid (Trolox C)  have no effects on 
angiotensin II-induced activation of ERK 1/2 activation (Kyaw et al., 2001). In 
contrast, angiotensin II-induced activation of p38 MAPK was inhibited by DPI 
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and ascorbic acid, NAC (at high concentration) but not DETC or Trolox C 
(Kyaw et al., 2001). 
 
The MAPK signalling pathway architecture consists of an arrangement of 
three sequentially acting protein kinases (Figure 6.10). The pathway is 
activated by a small guanosine 5’-triphosphate (GTP)-binding protein (GTP) 
protein (of the Ras or Rho family) or by an adaptor protein. The adaptor 
protein transmits the signal directly to MAP kinase kinase kinase (MAPKKK) 
(i.e. the kinase at the top of this architecture). Alternatively, the adaptor 
protein can also transmit the signal through a mediator kinase (i.e. MAP 
kinase kinase kinase kinase (MAPKKKK)) which phosphorylates and activates 
MAPKKK. In the second step, the activated MAPKKK phosphorylate and 
activate MAP kinase kinase (MAPKK) which in turn activates MAPK. Activated 
MAPK then phosphorylate a wide range of substrates.  
 
Specificity is achieved among this complex arrangement of competing MAPK 
pathways because the kinase activities at each sequential phosphorylation 
step are directed toward specific downstream kinases by specific protein- 
protein interactions. Specific scaffold proteins  that interact with substrates 
and their corresponding kinases along with the presence of specific docking 
sites or sequences in the MAPKs ensure specific recognition and activation by 
appropriate upstream kinases (Bardwell et al., 2003; Tatebayashi et al., 2003; 
Sharma and  Mondal, 2006). Termination of MAPK activation (i.e. inactivation) 
is regulated by dephosphorylation that is carried out by MAPK  
phosphatases (MKPs) (Bardwell et al., 2003; Noordman et al., 2006).  
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Figure 6.10: MAPK signalling pathway architecture. A schematic diagram 
showing the three sequential levels for the activation of downstream MAPKs 
by upstream MAPKs in the architecture of the MAPK signalling pathways. 
Some examples of targets for  terminal kinases (i.e. p38, ERK  and c-
jun/SAPK)  and downstream biological effects are shown  in the diagram. 
NFAT = Nuclear Factor of Activated T cells, STAT= Signal Transducers And 
Activators Of Transcription, MEF2C = Myocyte Enhancer Factor 2 C, ATF2= 
Activating  Transcription factor 2, MSK= MAPK/SAPK-activated kinase, MNK1= 
MAPK signal-activating kinase 1, Elk-1 = E26-like protein 1, Transforming 
growth factor-β-activated kinase (TAK), Mixed lineage kinase 3, MEKK1/4 = 
Mitogen ERK kinase kinase, 1/4, ASK= apoptosis stimulating kinase, DLK= 
dual leucine zipper bearing kinase, ERK= extracellular signal-regulated kinase 
JNK= c-Jun N-terminal kinase, SAPK= stress-activated protein kinase, 
MAPKKK=MAP kinase kinase kinase, MAPKK=MAP kinase kinase, MAPK = 
Mitogen activated protein kinase, MEK = Mitogen-activated Protein/Extracellular 
Signal-regulated Kinase Kinase (MEK). 
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6.1.2 Mitogen-activated protein kinase family  
 
The MAPK family consists of three subgroups: p38 MAPK, extracellular 
signal-regulated kinase (ERK) and c-Jun N-terminal kinase/stress-activated 
protein kinase (JNK/SAPK). 
 
6.1.2.1 P38 MAPK Pathway 
 
Of the four p38 isoforms (p38α p38β, 38γ and p38δ), p38α is expressed in all 
tissues. The p38 MAPK pathway is activated by serum (Beier and  LuValle, 
1999), osmotic stress (Bell et al., 2000; Volonte et al., 2001), UV radiation 
(Bulavin et al., 1999; Bodero et al., 2003; Sethi and  Sodhi, 2004)  and  heat 
shock (Dorion et al., 2002; Zhou et al., 2005; Venkatakrishnan et al., 2006). 
The p38 MAPK pathway is also activated by proinflammatory cytokines (Nick 
et al., 1999; Suzuki et al., 2001). The p38 MAPK pathway is involved in 
apoptosis (Chuang et al., 2000; Cho et al., 2008), stress (Frossi et al., 2007; 
Niisato et al., 2007), proliferation (Souza et al., 2004), cell differentiation 
(Morooka and  Nishida, 1998; Cuenda and  Cohen, 1999; Zetser et al., 1999; 
Davidson and  Morange, 2000; Kook et al., 2008) and cell survival. In the p38 
pathway, stimulus-activated G proteins activate MAPKKKs. The MAPKKKs in 
turn phosphorylate and activate the MAPKKs (e.g. MKK3 and MKK6). These 
MAPKK then activate p38. The substrates for activated p38 kinases include 
cytosolic phospholipase A2 (Kramer et al., 1996; Hazan-Halevy and  Levy, 
2000; Degousee et al., 2001; You et al., 2005), the microtubule-associated 
protein Tau (Zhu et al., 2000; Li et al., 2003), transcription factors (MEF2C 
 247
(Yang et al., 1999; Zhao et al., 1999; de Angelis et al., 2005)) and other 
protein kinases. 
 
6.1.2.2 Extracellular signal-regulated kinase (ERK) 
 
The ERK  are activated by a wide range of extracellular stimuli including 
growth factors (Bottazzi et al., 1999; Ouwens et al., 2002; Bobick et al., 2007), 
serum (Frost et al., 1994; Beier and  LuValle, 1999), phorbol esters, cytokines 
and osmotic stress (Chiri et al., 2004). These stimuli activate the small GTP-
binding protein Ras. Activated Ras recruit Raf to the cell membrane where it 
becomes activated. The activated Raf (i.e. the MAPKKK) then phosphorylates 
and activates the MAPKK (MEK1 and 2) which in turn phosphorylate ERK1/2. 
The substrates for activated ERK1/2  include other  downstream kinases such 
as  ribosomal S6 kinases (RSKs) (Smith et al., 1999), MAPK/SAPK-activated 
kinase (MSK) (Deak et al., 1998) and MAPK signal-activating kinase 1 
(MNK1) (Fukunaga and  Hunter, 1997; Waskiewicz et al., 1997). Activated 
ERK1/2   also phosphorylate transcription factors  such as NF-AT (Ali et al., 
2000; Sanna et al., 2005), Elk-1(Muller et al., 1997; Vanhoutte et al., 1999; 
Thiels et al., 2002), c-Fos (Vanhoutte et al., 1999; Monje et al., 2003; Burch et 
al., 2004; Pellegrino and  Stork, 2006), c-Myc, (Pintus et al., 2002; Ramljak et 
al., 2003; Serra et al., 2008), STAT3 (Kanai et al., 2003) and apoptosis-
related proteins (Jan et al., 1999; Scheid et al., 1999; Ellert-Miklaszewska et 
al., 2005; Sawatzky et al., 2006; Caraglia et al., 2007). The ERK1/2 signaling 
pathway is involved in cell proliferation (Souza et al., 2004), differentiation 
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(Kim et al., 2005), transformation and apoptosis (Jan et al., 1999; Chuang et 
al., 2000; Ellert-Miklaszewska et al., 2005; Caraglia et al., 2007). 
 
6.1.2.3 C-Jun N-terminal kinase/stress-activated protein kinase  
 
The c-Jun N-terminal kinase/stress-activated protein kinases (JNK/SAPK) 
pathway are activated by growth factors, cytokines and stress related 
responses (e.g. UV radiation and  heat). JNK/SAPK signalling pathway is 
mainly involved in responses to stress. Like ERK, JNK/SAPK are also 
involved in cell proliferation (Sabapathy et al., 2001; Zhang et al., 2005; Ding 
et al., 2007), differentiation (Cuenda and  Cohen, 1999; Lemonnier et al., 
2004) and apoptosis (Chuang et al., 2000; Cho et al., 2008). 
 
In the JNK/SAPK pathway, activated G proteins (Cdc42, Rac, or Ras) activate 
several MAPKKK (e.g. apoptosis stimulating kinase (ASK) and other 
molecules including transforming growth factor-β-activated kinase (TAK)). 
These MAPKKKs, in turn, activate the MAPKKs (e.g. MKK4 and MKK7). The 
activated MAPKKs in turn directly phosphorylate and activate JNK/SAPK. The 
substrate for activated JNK/SAPK includes several  transcription factors such  
as c-jun (Hatzoglou et al., 2000; Zhong et al., 2007), ATF2 (Hayakawa et al., 
2003; Bailey and  Europe-Finner, 2005), STAT3 (Turkson et al., 1999) and 
Elk-1 (Hatzoglou et al., 2000; Zhang et al., 2007; Zhong et al., 2007). 
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6.1.2.4 MAPK and stem cell differentiation 
 
The MAPK have been implicated in the differentiation of various cells 
including the differentiation of stem cells  into cardiomyocytes  and other cell 
types (Zhang and  Bradley, 1996; Schlange et al., 2000). However the exact 
mechanism by which MAPK can regulate cell differentiation is not currently 
clear. There is evidence that GATA-4 actions may require the activation of 
MAPK (i.e.  p38) dependent pathway (Charron et al., 2001; Liang et al., 
2001).  Given their implication in the differentiation of various cells and the 
lack of clear understanding of their role in differentiation, the MAPK are 
therefore good candidates for studies aimed at understanding the cell 
signalling pathways that are responsible for mediating stem cell differentiation 
into cardiomyocytes.  P38 MAPK is downstream of PI3K and our data have 
already suggested that when PI3K is inhibited, the differentiation of H9c2 and 
P19 stem cell differentiation into cardiomyocytes, is also inhibited. We 
therefore extended our studies to determine whether the signalling events that 
control differentiation of these cells into cardiomyocytes are linked to the 
activation of the p38 MAPK.  
 
The aim of this study was to investigate the role of the p38 MAPK pathway in 
the cardiac differentiation of H9c2 and P19 stem cells.  Like p38 MAPK, ERK 
and JNK have also been implicated in differentiation of various cell types.  We 
initially started by examining the role of p38 MAPK in the hope that the study 
could be extended to examination of the roles of ERK and JNK.  The roles of 
JNK and ERK cardiac differentiation were not examined in this project due to 
time constraints and to other factors. The design of this study focused on the 
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use of a specific competitive inhibitor of p38 MAP kinase known as SB203580 
(4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole) 
(IC50=0.6µM) (Cuenda et al., 1995).  SB203580 (100µM) (i.e. ten times the 
widely used concentration  of 10µM), does not inhibit JNK/SAP kinase or  p42 
MAP kinase (Cuenda et al., 1995). SB20380 competes for enzyme ATP 
binding site of p38 MAPK (Cuenda et al., 1995; Young et al., 1997; Gum et 
al., 1998).  
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6.2 MATERIALS AND METHODS 
 
6.2.1 Culture and differentiation of H9c2 Cells  
 
The routine culture of H9c2 cells was carried out as described in section 2.3.1 
(Chapter 2). H9c2 cells were trypsinised and the appropriate cell density for 
the differentiation experiments was calculated as described in section 2.6 
(Chapter 2). H9c2 cells (2x103 cells/cm2) were seeded into p60 dishes or 6-
well plates in full culture medium (i.e. DMEM supplemented with 10% FBS, 
100units/ml penicillin/100µg/ml streptomycin), placed in a  tissue culture 
incubator at 37oC, 95% air and  5% CO2 and allowed to become 60-70% 
confluent. The differentiation of H9c2 cells into cardiomyocytes was carried 
out in 1% serum as described in section 2.8.1 (Chapter 2). Role of the p38 
MAPK signalling pathway in the differentiation of H9c2 cells into 
cardiomyocytes was investigated using SB203580 (10µM) as described in 
section 2.8.2 (Chapter 2). 
 
6.2.2 Culture and differentiation of P19 stem cells  
 
The routine culture of P19 stem cells was carried out as described in section 
2.3.2 (Chapter 2).  To initiate differentiation, P19 stem cells (1x106 cells) were 
seeded in P100 Petri (i.e. microbiological) dishes in the differentiation medium 
(i.e. α-MEM supplemented with 10% FBS, 100 units/ml penicillin/100 µg/ml 
streptomycin and 0.8% DMSO) and the differentiation of P19 stem cells into 
beating cardiomyocytes  carried out as described in section 2.9.1 (Chapter 2). 
The role of p38 MAPK signalling pathway in the DMSO-induced differentiation 
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of P19 stem cells into beating cardiomyocytes was investigated using 
SB203580 (10µM) as described in section 2.9.2 (Chapter 2). An SB203580 
stock (10 mM solution) was prepared by dissolving 1mg of SB203580 in 
264.97µl of DMSO. The stock solution was distributed into 10 or 20µl aliquots 
and stored in the freezer at -20oC. The aliquots were protected from light 
during storage and use.  The differentiation medium was used to dilute 
(1:1000) the frozen stock SB203580 solutions (10mM) to the SB203580 
concentration (10µM) used in the differentiation experiments.  The preparation 
of stock SB203580 concentration was carried out as explained in appendix 
VIII.  More details about SB203580 are located in appendix VI (c). 
Furthermore the effects of delayed inhibition of p38 MAPK on P19 stem cell 
differentiation into cardiomyocytes were also investigated as described in 
section 2.9.3 (Chapter 2). 
 
6.2.3 Cell viability assay  
 
To examine the effects of the inhibition of p38 MAPK, with SB203580, on 
H9c2 cell viability, the MTT assay was carried out as described in section 2.7 
(Chapter 2). 
 
6.2.4 Western blot analysis  
 
In order to perform the western blot analysis, the following procedures were 
carried out as described in the Chapter 2 under the sections indicated in 
parenthesis: cell lysate generation (section 2.11), preparation of BSA 
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standards (section 2.12.1) and BCA assay (section 2.12.2). The western 
blotting was carried out as described in section 2.13. 
 
6.2.5 Data analysis  
 
Data obtained from three independent experiments were used for statistical 
analysis as described in section 2.14 (Chapter 2). 
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6.3 RESULTS 
 
6.3.1 Effects of the p38 MAPK inhibition on H9c2 cell differentiation into 
cardiomyocytes 
 
As described in previous Chapters, morphological changes and marker 
expression were observed or determined during the course of the 
differentiation experiments. Morphologically, treatment of H9c2 cells with 
SB203580 (10µM) caused little or no inhibition of their differentiation into 
cardiomyocytes. In both control cell and cells treated with SB203580, cell 
elongation was visible from day 4. By day 8 to day 12, cell fusion and 
myotube formation were extensive and to the same degree in both groups 
(Figure 6.11). 
 
In contrast to the apparent lack of inhibition of the usual morphological 
changes that accompanied  H9c2 cell differentiation into cardiomyocytes, 
SB203580 treated cells decreased the expression of MLC-1v by day 4 
(p<0.05) (Figure 6.12). However, MLC-1v l expression in SB203580 treated 
cell had reached the same level seen in the control cells by day 8 (p>0.05). By 
day 12, MLC-1v expression in SB203580 treated cells fell back to nearly the 
levels seen in these cells at day 4 (p<0.05) (Figure 6.12).  
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Figure 6.11: Effects of p38 MAPK inhibition on H9c2 cell differentiation 
into Cardiomyocytes: Morphological changes. Control H9c2 cells were 
cultured in differentiation medium consisting of DMEM supplemented with 1% 
FBS and 100 units/ml penicillin and 100 µg/ml streptomycin. The 
differentiation medium of treated cells was further supplemented with 10µM of 
SB203580. Morphologically, SB203580 treatment of H9c2 cells shows very 
little signs of inhibition of their differentiation (i.e. cell alignment, elongation 
and myotube formation) into cardiomyocytes inhibited. Both control and 
SB203580 treated cells differentiated (shown by black arrows in day 4 to 
day12 control and SB20350-treated cells) to almost the same degree. By day 
8 to day 12, cell fusion and myotube formation were extensive and to the 
same degree in both groups. Both control cells and SB20359-treated cells 
showed the normal single cell morphology (shown by white arrows) at day 0. 
The photographs were taken under 200X magnification and are 
representative of at least three independent differentiation experiments. 
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Figure 6.12: Effects of p38 MAPK inhibition  on H9c2 cell differentiation 
into Cardiomyocytes: cardiac ventricular myosin light 1 expression. 
Western blot analysis of MLC-1v revealed that expression of this protein was 
initially delayed cells (by day 4, p<0.05) in comparison to the control 
expression (panel A).  By day 8, MLC-1v expression in treated cell reached 
levels seen in control cells (p>0.05) but  by day 12, MLC-1v level fell back to 
nearly the  levels seen at day 4 (p<0.05). The blot is representative of at least 
three independent experiments. The densitometric data (mean ± SD), from 
three independent differentiation experiments, show the time dependent 
changes in MLC-1v expression in SB203580 treated H9c2 cells (panel B). 
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6.3.2 Viability of H9c2 cells in 10µM of the p38 MAPK inhibitor, SB203580 
 
The widely reported concentration of 10µM for the p38 MPAK inhibitor 
SB203580 was selected for use in the experiments designed to investigate 
the effects of p38 MAPK inhibition on H9c2 differentiation into 
cardiomyocytes. The MTT cell viability test was carried out to determine if this 
concentration was toxic to the cells over the period that the cells were 
exposed to the  drug.  SB203580 at the concentration of 10µM was not toxic 
to the cells at any of the incubation time points.  The average viability was 
about 89% of the viability determined in the control cells. There was a slight 
reduction in SB203580 treated cells at 12 and 24 hours (p < 0.05) but  at 48 
hours, the cell viability recovered  to a value that was not significantly different   
from the control viability ( p > 0.05) (Figure 6.12). At 48 hours the viability was 
about 91% of the viability determined in the control cells (Figure 6.13). 
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Figure 6.13: Viability of H9c2 Cells in the presence of the p38 MAPK 
inhibitor, SB203580. H9c2 cells were seeded in 6-well plates and treated 
with 10µM SB203580 as described in the methods section above (Section 
6.3.3). The MTT assay was carried out at the end of the treatment. At 48 
hours  the viability of SB203580-treated cels  was not significantly different   
from the control viability ( p > 0.05). The data presented in the graph are the 
mean ± SD from three independent experiments. 
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6.3.3 Effects of p38 MAPK inhibition on P19 stem cell differentiation into 
cardiomyocytes 
 
Given the lack of effects of the p38 MAPK inhibitor on H9c2 cell differentiation 
into cardiomyocytes, we next investigated how p38 MAPK inhibition may 
affect P19 cell differentiation into cardiomyocytes. In contrast to the lack of 
inhibition H9c2 cell differentiation into cardiomyocytes, SB203580 markedly 
inhibited P19 Stem cells differentiation into cardiomyocytes as determined by 
the expression of the cardiac restricted protein troponin (TnI). (Figure 6.16) 
Control P19 stem showed a small level of TnI expression at the time of EB 
transfer  from  Petri dishes to cell culture plates. In control P19 cells, there 
was a marked increase on day 4 and this was followed further increased on 
day 8. The levels of TnI in SB203580 treated P19 stem cells were markedly 
reduced at every time point of the differentiation experiment as determined by 
western blot for TnI. The inhibited or low levels of TnI detected in SB203580 
treated cells are in agreement with the lack of appearance of beating 
cardiomyocyte clusters in these cells. While beating cardiomyocytes were 
observed in the control cells as usual, no beating cardiomyocytes were seen 
in the SB203580 treated P19 stem cells. As was observed in the cases of 
PKC inhibition (Chapter 5) and PI3K inhibition (Chapter 7), it was also 
observed that P19 stem treated with SB203580 four days after the initiation of 
DMSO-induced differentiation of P19 stem cells failed to block the cell 
differentiation into beating cardiomyocytes (Figure 6.15). However, SB203580 
blocked P19 stem cell differentiation into beating cardiomyocytes, when 
added to the cells during the EB formation stage (Figure 6.14). 
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Figure 6.14; A schematic diagram of the effects of p38 MAPK inhibition 
on P19 stem cell differentiation into cardiomyocytes P38 MAPK inhibition 
with SB203580 (10µM) blocked the differentiation of P19 stem cells into 
beating cardiomyocytes, when the inhibitors was added to the cells during the 
EB formation stage in the absence of SB203580  beating cardiomycytes were 
seen from day 6 to day 14 after the EB were transferred to cell culture dishes. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.15; A schematic diagram of the effects of delayed inhibition of 
p38 MAPK on P19 stem cell differentiation into cardiomyocytes. In P19 
stem treated with SB203580 (10µM) four days after the initiation of DMSO-
induced cardiac differentiation, SB2093580 failed to block the cell 
differentiation into beating cardiomyocytes. 
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Figure 6.16: Effects of p38 MAPK inhibition on P19 stem cell 
differentiation into cardiomyocytes: troponin I expression. Control P19 
stem cells were cultured in differentiation medium consisting of α-MEM 
supplemented with 10% FBS, 100 units/ml penicillin and 100µg/ml 
streptomycin as described in section 6.3.2. The above differentiation medium 
was further supplemented with 10µM of SB203580 for the treated cells. 
SB203580 treatment markedly inhibited P19 Stem cells differentiation into 
cardiomyocytes as determined by the expression of cardiac restricted troponin 
I (TnI). While beating cardiomyocytes were observed in the some dishes of 
the control cells, beating cardiomyocytes were not seen in any of the 
SB203580 treated P19 stem cells. The blot is representative of three 
independent differentiation experiments.  
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6.4 DISCUSSION 
 
The MAPKs are among the signalling pathways that have been well studied. 
The MAPKs are involved in the control  of gene expression (Wu et al., 2004; 
Lawrence et al., 2007; Mochizuki et al., 2007), proliferation (Souza et al., 
2004; Erlich et al., 2007; Jia et al., 2008), migration (Goetze et al., 1999; 
Rousseau et al., 2006; Jia et al., 2008) and cell survival or apoptosis (Chuang 
et al., 2000; Pan et al., 2002; Chen et al., 2008; Cho et al., 2008).  
 
The activation of the p38 MAPK signalling has been implicated in the 
differentiation of   various cell types  (Gallea et al., 2001; Tuli et al., 2003; 
Chang et al., 2007). including stem cell differentiation into cardiomyocytes 
(Monzen et al., 1999; Davidson and  Morange, 2000; Aouadi et al., 2006). The 
precise role of these kinases and how they relate to the complex network of 
signaling events that lead to differentiation is still not clearly understood.  
 
One of the key MAPKs, the p38 MAPK, is downstream of PI3K (Salh et al., 
2002). However, the p38 MAPK pathways can also be activated through PI3K-
independent mechanisms. As our data have already implicated PI3K in stem 
cell differentiation into cardiomyocyte (see Chapter 7) we therefore extended 
our studies to determine whether the signalling events that control H9c2 
and/or P19 stem differentiation cells into cardiomyocytes are linked to the 
activation of the p38 MAPK. A specific inhibitor of the p38 MAPK signalling 
pathway, SB203580 (Cuenda et al., 1995; Young et al., 1997; Gum et al., 
1998) was  used in this study.  The 10µM of SB203580 used in this study has 
been reported in other studies (Nick et al., 1999; Barancik et al., 2001; 
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Kwiecinska et al., 2005). Our data also showed that this concentration is not 
toxic to H9c2 cells. The effect of SB203580 on stem cell differentiation into 
cardiomyocytes reported here may therefore be due to the specific 
pharmacological inhibition of the p38 MAPK signalling pathway by this 
compound. 
 
Our data suggest that p38 MAPK signalling may have a role in the 
differentiation of P19 stem cells and H9c2 cells into cardiomyocytes. 
SB203580 (10µM) completely blocked the differentiation of P19 stem cells 
into beating cardiomyocytes. SB203580 also markedly reduced the 
expression of cardiac restricted troponin I in P19 stem cells.  Similarly, during 
the differentiation of H9c2 cells into cardiomyocytes, SB203580 delayed the 
expression of MLC-1v.  The expression of MLC-1v subsequently recovered as 
time progressed during the 14 day incubation period. Perhaps of interest is 
the fact that SB203580 did not significantly alter the morphological changes 
(i.e. cell elongation, cell fusion and formation of myotubes) that accompany 
the initiation of H9c2 differentiation into cardiomyocytes. This may however be 
due to the fact that the morphological changes generally become more 
apparent at the later stages of differentiation by which time the cells have 
started to recover from the inhibition caused by SB203580. Whether  the lack 
of a significant effect, by SB203580, on the  morphological changes that 
accompanied H9c2 differentiation into cardiomyocytes, is due to p38 MAPK  
having a lesser role in these changes (than in the regulation of MLC-1v 
expression) was not investigated. This may need further investigation in future 
studies. As our data stand, it would appear that the role of the p38 MAPK in 
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stem cell differentiation is more prominent in P19 when compared to the H9c2 
cells.  A role for the p38 MAPKs in stem cell differentiation indicated in our 
studies would be consistent with reports in other systems (Gallea et al., 2001; 
Tuli et al., 2003; Chang et al., 2007); (Monzen et al., 1999; Davidson and  
Morange, 2000; Aouadi et al., 2006).  
 
Our data have further suggested that the p38 MAPK mediated mechanisms or 
events that control P19 stem cells differentiation into cardiomyocytes are 
switched on very early following DMSO treatment. Since SB203580 (10µM) 
was able to block P19 stem differentiation into beating cardiomyocytes only 
when added at the time of initiation of P19 cell differentiation (i.e. at the EB 
formation stage). Addition of SB203580 to P19 cells at the EB formation stage 
completely blocked cell differentiation into beating cardiomyocytes. However 
when exposed to cells four day after DMSO treatment, SB203580 had no 
effect on the ability of the cells to differentiate into beating cardiomyocytes. 
This strongly suggests that activation of the p38 MAPK pathway occurs very 
early in the differentiation process. The data also suggest that the activation of 
p38 MAPK pathway may be transient since late application of SB2003580 
failed to inhibit the differentiation process. Whether p38 activation is indeed 
transient or whether it is sustained but become irreverent after the initiation of 
the differentiation process remains to be determined. 
 
Bone morphogenetic proteins  are well known extracellular signalling 
molecules that are involved in stem cell differentiation into cardiomyocytes  
(Zhang and  Bradley, 1996; Schultheiss et al., 1997; Schlange et al., 2000). 
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The core signalling mechanism of BMP is through the activation of SMAD 
proteins (Wrana et al., 1994; Monzen et al., 2001). However BMP signalling 
can also be channelled through MAPK via SMAD-independent mechanisms 
(Gallea et al., 2001). Also GATA-4, a key cardiac transcription factor may be a 
direct downstream target of several kinases  including the MAPK (Liang et al., 
2001) as there are  many potential  phosphorylation sites  within this 
transcription factor. It has been reported that GATA-4, is a nuclear mediator of 
RhoA signalling. The convergence of RhoA on GATA signalling was 
suggested by the finding that RhoA potentiates the activity of GATA-4 via a 
p38 MAPK-dependent pathway that phosphorylates GATA-4 activation 
domains. It was also found that GATA binding sites mediate RhoA activation 
of target cardiac promoters. Thus, it is possible that p38 MAPK may regulate 
stem cell differentiation through its activation by upstream signaling events 
associated with the Rho pathway and subsequent downstream regulation of  
the transcriptional activities of GATA-4 (Charron et al., 2001). Whether this is 
part of a sequence of events that also requires PKC and/or PI3K in our cell 
systems remain to be determined.  
  
Besides showing that p38 MAPK is required for cardiomyocyte differentiation, 
the project has gone further to investigate if the p38 MAPK affects cardiac 
differentiation in conjunction with other leading pathways that were 
investigated in this project. This is explained in more detail in Chapter 7 where 
the ‘cross-talk’ studies are discussed. 
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6.5 Summary 
 
The differentiation of H9c2 cells into cardiomyocytes was blocked by the 
inhibition of p38 MAPK signalling using SB203580 (10µM). However 
SB203580 had little or no effect on the differentiation associated 
morphological changes in H9c2 differentiating into cardiomyocytes. In both 
control cell and SB203580-treated cells, morphological changes were visible. 
In contrast to the apparent lack of inhibition of morphological changes in 
SB203580-treated H9c2 cells, the expression of MLC-1v was decreased in 
these cells.  
 
In contrast H9c2 cells, SB203580 markedly inhibited the expression of cardiac 
restricted protein troponin (TnI) and also blocked the cell differentiation into 
beating cardiomyocytes. The small expression of TnI seen in control P19 
stem cells, at the time of EB transfer to cell culture plates, increased upto day 
8. In comparison to control cells, TnI levels in SB203580-treated P19 stem 
cells were reduced. The inhibited or low levels of TnI detected in SB203580-
treated cells were in agreement with the lack of appearance of beating 
cardiomyocytes. It was also observed that SB203580 blocked P19 stem cell 
differentiation into beating cardiomyocytes, when added to the cells during the 
EB formation stage. In contrast, SB203580 failed to block the differentiation of 
P19 stem cells into beating cardiomyocytes, when the cells were treated, with 
this compound, four days after the initiation of DMSO-induced cardiac 
differentiation.  
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In conclusion, our data therefore suggest that the activation of p38 MAPK 
signalling pathway may be an essential signalling event during the 
differentiation of stem cells into cardiomyocytes.  The data also suggest that 
the p38 MAPK exerts its effects at the early stages of P19 stem cell 
differentiation into cardiomyocytes. 
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CHAPTER 7.0 
ROLE OF PHOSPHOINOSITIDE 3-KINASE IN H9c2 
AND P19 STEM CELL DIFFERENTIATION INTO 
CARDIOMYOCYTES 
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7.1 INTRODUCTION 
 
7.1.1 Phosphoinositide 3-kinases 
 
The phosphoinositide 3-kinase (PI3K) enzymes are present in all cell types 
and have been shown to be crucial regulators for many cell functions 
including cell cycle control (Rosenzweig et al., 1997), proliferation (Erlich et 
al., 2007; Nakao et al., 2007; Ramos-Nino et al., 2008; Rosseland et al., 
2008), survival (Li et al., 2001; Hambardzumyan et al., 2008; Lim et al., 2008) 
and migration (Nakao et al., 2007).  
 
Class I PI3K (IA and IB) are the most extensively studied isoforms. Class 1A 
PI3Ks are heterodimers of regulatory (p85) and a catalytic (p110) subunits. 
Class II PI3Ks are monomeric proteins that lack adapter subunits. The 
preferential substrates of class II PI3Ks  are phosphatidylinositol  and 
phosphatidylinositol phosphate. Class III PI3Ks, like class I PI3Ks, are also 
heterodimeric enzymes consisting of regulatory and catalytic subunits. 
 
The catalytic subunits of class I PI3K are activated by signals originating from 
upstream receptor tyrosine kinases (for Class IA PI3K) or G-protein-coupled 
receptors (for Class IB PI3K).  
 
Phosphoinositide 3-kinase catalyses the transfer of the gamma-phosphate 
from ATP to the 3’-OH position of the inositol ring in the membrane bound 
phosphatidylinositol (4, 5)-bisphosphate (PIP2) to phosphatidylinositol (3, 4, 
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5)-trisphosphate (PIP3). The reverse reaction to convert PIP3 back to PIP2 is 
catalysed by PTEN (phosphatase and tensin homolog deleted on 
chromosome 10), a phosphatase (Maehama and  Dixon, 1998).  
 
Downstream events following the formation of PIP3 lead to the activation of 
Akt or protein kinase B (PKB).  Akt is a serine/threonine protein kinase (Jones 
et al., 1991) and   a critical component of the PI3K  signalling. For example, 
PI3K transcriptional  regulation of genes  (e.g. induction of c-myc and Bcl-2) 
(Ahmed et al., 1997) and stimulation of protein synthesis by controlling the 
translation initiation factor eIF-4E via phosphorylation of 4E-BP1 (Gingras et 
al., 1998) are mediated via Akt. Akt-dependent regulation of  growth factor 
and anti-apoptotic signals, by PI3K, have been shown  in a variety of cell 
types including BAF/3 cells  (Ahmed et al., 1997), cerebellar neurons (Dudek 
et al., 1997), H19-7 cells (Eves et al., 1998) and human embryonic kidney 
293-EBNA cells (Kauffmann-Zeh et al., 1997). 
 
The PIP3 produced by the PI3K reaction activates the phosphatidylinositol-
dependent protein kinases (PDK-1 and PDK-2) by recruiting them to the 
plasma membrane. PIP3 also binds to the pleckstrin homology (PH) domain of 
Akt and anchors it to the plasma membrane (Klippel et al., 1997) where Akt is 
activated. The activation of Akt is regulated through two distinct 
phosphorylation events which have been reported to occur in a sequential 
manner. The PDK1-mediated phosphorylation of Akt at threonine 308 
(Thr308) in the domain activation loop precedes the PDK2-mediated 
phosphorylation at serine 473 (Ser473)  (Alessi et al., 1996; Alessi et al., 
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1997a; Alessi et al., 1997b). The phosphorylation of Akt at Thr308 by PDK-1 
is believed to render the Ser473 site at Akt C-terminal tail accessible to PDK-
2. Akt is fully activated only if it is phosphorylated at both Thr308 and ser473 
sites (Alessi et al., 1997a). Other downstream signalling molecules with PH 
domains that are target by PIP3 include protein kinase C and MAPK signalling 
pathway. 
 
In addition to Akt activation, PDK1 is also a  converging point for a number of 
different pathways including the phosphorylation conventional PKCs (Dutil et 
al., 1998), novel PKCs (Le Good et al., 1998; Cenni et al., 2002) and atypical 
PKCs (Chou et al., 1998; Le Good et al., 1998; Dong et al., 1999), p70 S6 
kinase (Pullen et al., 1998; Flynn et al., 2000; Kuemmerle, 2003) and 
glucocorticoid-regulated kinase (SGK) (Kobayashi and  Cohen, 1999; 
Kobayashi et al., 1999). 
 
PI3K signalling is terminated by the degradation of PIP3 by at least two 
different phosphatases known as SHIP (Src homology 2-containing inositol 5-
phosphatase) and PTEN (tensin homolog deleted on chromosome 10 protein 
(PTEN) (Koyasu, 2003).  PTEN and SHIP remove the 3-phosphate of PIP3 to 
re-generate PI(4,5)P2. This means that PTEN activity blocks all the main 
downstream effects of PI3K.  In contrast, SHIP removes the 5-phosphate from 
the inositol ring of PIP3 to generate PI(3,4)P2. This means that 
dephosphorylation of PIP3 by SHIP block some of the main downstream 
effects of PI3K. 
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7.1.2 PI3K and stem cell differentiation into cardiomyocytes 
 
The PI3K pathway is one of the well studied signalling pathways whose 
signalling mechanisms are well established. PI3K signalling has been 
implicated in the differentiation of stem cells into cardiomyocytes (Klinz et al., 
1999; Sauer et al., 2000; Naito et al., 2003).  Cardiogenesis or stem cell 
differentiation into cardiomyocytes is a very complex process. It is therefore 
very unlikely that this process will be controlled by a single signalling pathway. 
Interaction or cross-talk between pathways is more likely to be key mode of 
regulation of stem cells differentiation into cardiomyocytes. Our studies 
therefore take the approach of not only examining the role of PI3K but also 
investigated if  there is any  cross-talk between PI3K and PKC and also  
between PI3K and p38 MAPK during cardiac cardiomyocyte differentiation. 
Therefore the aim of this study is to investigate the role of the PI3K pathway 
and possible cross-talk between the PI3K and other well established 
pathways (i.e. PKC and p38 MAPK) that have been shown to have role to 
play in cardiac differentiation. To achieve the aims a specific PI3K inhibitor 
LY294002 [2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] (IC50=1.4µM) 
was used for this study (Vlahos et al., 1994). LY294002 is cell-permeable, 
potent and specific PI3K inhibitor that acts on the enzyme ATP-binding site 
(Vlahos et al., 1994). LY294002 (50µM) completely inhibited PI3K but failed to 
inhibit other kinases including  serine/ threonine kinases (e.g. PKC, PKA, 
MAP kinase and  S6 kinase),   protein tyrosine kinases (e.g. EGF receptor 
tyrosine kinase and  c-src kinase), lipid kinases (e.g. Pl 4-kinase and 
diacylglycerol kinase) and rabbit kidney ATPase  (Vlahos et al., 1994). 
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7.2 MATERIALS AND METHODS 
 
7.2.1 Culture and differentiation of H9c2 Cells  
 
The routine culture of H9c2 cells was carried out as described in section 2.3.1 
(Chapter 2). H9c2 cells were trypsinised and the appropriate cell density for 
the differentiation experiments was calculated as described in section 2.6 
(Chapter 2). H9c2 cells (2x103 cells/cm2) were seeded in p60 dishes or 6-well 
plates in full culture medium (i.e. DMEM supplemented with 10% FBS, 
100units/ml penicillin/100µg/ml streptomycin), placed in a  tissue culture 
incubator at 37oC, 95% air and  5% CO2 and allowed to become 60-70% 
confluent. The differentiation of H9c2 cells into cardiomyocytes was carried 
out in 1% serum as described in section 2.8.1 (Chapter 2). The role of PI3K 
signalling pathway in the differentiation of H9c2 cells into cardiomyocytes was 
investigated. The effects of the inhibition of the PI3K signalling pathway were 
investigated using 20µM of LY294002 as described in section 2.8.2 (Chapter 
2). A LY294002 stock (10mM solution) was prepared by dissolving 1mg of 
LY294002 in 325.3µl of DMSO. The stock solution was distributed into 10 or 
20µl aliquots and stored in the freezer at -20oC. The aliquots were protected 
from light during storage and use.  The differentiation medium was used to 
dilute (1:500) the frozen stock LY294002 solutions (10mM) to the LY294002 
concentration (20µM) used in the differentiation experiments. The preparation 
of stock LY294002 concentration was carried out as explained in appendix 
VIII.  More details about LY294002 are located in appendix VI (b). 
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7.2.2 Cross-talk studies  
 
To examine possible PI3K/PKC and PI3K/p38 MAPK cross-talk, cross-talk 
studies were designed and carried out.  In order to carried out the cross-talk 
investigation, the following procedures were carried out as described in the 
Chapter 2 under the sections indicated in parenthesis: time course of Akt 
phosphorylation at serine 473 (2.10.1) and the effects of drugs (inhibitors) on 
PI3K activation as determined by Akt phosphorylation at serine 473 (Section 
2.10.2). 
 
7.2.3 Culture and differentiation of P19 stem cells  
 
The routine culture of P19 stem cells was carried out as described in section 
2.3.2 (Chapter 2).  To initiate differentiation, P19 stem cells (1x106 cells) were 
seeded in P100 Petri (i.e. microbiological) dishes in the differentiation medium 
(i.e. α-MEM supplemented with 10% FBS, 100 units/ml penicillin/100 µg/ml 
streptomycin and 0.8% DMSO) and the differentiation of P19 stem cells into 
beating cardiomyocytes  carried out as described in section 2.9.1 (Chapter 2). 
The role of PI3K signalling pathway in the DMSO-induced differentiation of 
P19 stem cells into beating cardiomyocytes was investigated. The effect of 
the inhibition of PI3K signalling pathway by 20µM of LY294002 on the DMSO-
induced P19 stem cell differentiation into beating cardiomyocytes was 
investigated as described in section 2.9.2 (Chapter 2). Furthermore the effects 
of delayed inhibition of PI3K on P19 stem cell differentiation into 
cardiomyocytes were also investigated as described in section 2.9.3 (Chapter 
2). 
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7.2.4 Cell viability assay  
 
To examine the effects of the PI3K inhibition on H9c2 cell viability, the MTT 
assay was carried out as described in section 2.7 (Chapter 2). 
 
7.2.5 Western blot analysis  
 
In order to perform the western blot analysis, the following procedures were 
carried out as described in Chapter 2 under the sections indicated in 
parenthesis: cell lysate generation (section 2.11), preparation of BSA 
standards (section 2.12.1) and BCA assay (section 2.12.2). The western 
blotting was carried out as described in section 2.13. 
 
7.2.6 Data analysis  
 
Data obtained from independent experiments were used for statistical 
analysis as described in section 2.14 (Chapter 2). 
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7.3 RESULTS 
 
7.3.1 Effects of the PI3K Inhibition on H9c2 Cell Differentiation into 
Cardiomyocytes 
 
The differentiation of H9c2 cells in culture medium supplemented with the 
PI3K inhibitor, LY294002, was completely blocked throughout the 
differentiation period. Control H9c2 cells differentiated into cardiomyocytes as 
determined by the usual morphological changes of cell elongation, fusion and 
myotube formation. In contrast LY294002 treated H9c2 cells maintained their 
normal single cell and spindle shaped morphology (Figure 7.10).  By Day 4, 
the usual morphological changes that accompany H9c2 cell differentiation 
were visible in the control cells.  In contrast, these changes only began at day 
8 in LY294002 treated H9c2 cells and were never as extensive as those seen 
in the control cells by day 12. 
 
In agreement with the lack of morphological changes observed in LY294002 
treated H9c2 cells; the expression of MLC-1v protein was blocked at day 4 
(p<0.01), day 8 (p< 0.05) and at day 12 (p>0.05) (Figure 7.11).  The MLC-1v 
expression never reached the same levels as in control cells. MLC-1v levels 
in both control and LY294002 treated H9c2 cells were in agreement with the 
degree of differentiation or morphological changes observed in these cells. 
MLC-1v expression in LY294002 treated H9c2 cells was less than 25% of 
control by day 4 and the by day 8 the expression was still less than 50 % of 
the levels seen in the control cells. 
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Figure 7.10: Effects of the PI3K inhibition on H9c2 cell differentiation 
into cardiomyocytes: morphological changes. Control H9c2 cells were 
cultured in differentiation medium consisting of DMEM supplemented with 1% 
FBS and 100units/ml penicillin/100µg/ml streptomycin. The above 
differentiation medium was further supplemented with 20µM of LY294002 for 
the treated cells. Morphologically, LY294002 treatment significantly inhibited 
cell alignment, elongation and myotube formation. LY294002 treated H9c2 
cells largely maintained their normal single cell and spindle shaped 
morphology which is in contrast to control H9c2 cells which showed the usual 
morphological changes. The photographs were taken under 200X 
magnification and are representative of at least 3 differentiation experiments. 
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Figure 7.11: Effects of the PI3K inhibition on H9c2 cell differentiation 
into cardiomyocytes: cardiac ventricular myosin light 1(MLC-1v) 
expression. In agreement with the lack of morphological changes observed 
in LY294002 treated H9c2 cells, western blot analysis of MLC-1v revealed 
that LY294002 treatment significantly inhibited this protein expression up to 
day 8,   in comparison to the control expression (A). Marginal expression was 
seen after day 8. The blot is representative of at least 3 differentiation 
experiments (panel A). The densitometric data (mean ± SD), from three 
independent differentiation experiments, show the time dependent changes in 
MLC-1v expression in LY294002 treated H9c2 cells (panel B) 
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7.3.2 Effects of LY294002 (20µM) on the viability of H9c2 cells 
 
The widely reported concentration of 20µM for the PI3K inhibitor LY294002 
was selected for use in the experiments designed to investigate the effects of 
PI3K inhibition on H9c2 differentiation into cardiomyocytes. The cell viability 
test (MTT assay) was carried out to determine if this concentration was toxic 
to the cells over the period that the cells were left in this drug. LY294002 at 
the concentration of 20µM was not toxic to the cells. There was no statistical 
difference between the viability of control cells and the cells cultured in 
LY294002 (p > 0.05) (Figure 7.12). The average viability was about 85% of 
the viability determined in the control cells. By 48 hours the viability was about 
77% of the viability determined in the control cells. 
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Figure 7.12: The viability of H9c2 cells in the presence of the PI3K 
inhibitor, LY294002. Control H9c2 cells were seeded in 6-well plates in 
differentiation medium consisting of DMEM supplemented with 1% FBS and 
100units/ml penicillin/100µg/ml streptomycin. The above differentiation 
medium was further supplemented with 20µM of LY294002 for the treated 
cells as described in the method section above (Section 7.2.4). The MTT 
assay was carried out at the end of the treatment. Cell viability of LY29402 
treated cells at each time point was calculated as a percentage of the cell 
viability in the control cells at that time point. There was no statistical 
difference between the viability of control H9c2 cells and LY294002 treated 
H9c2 cells (p > 0.05). The data presented in the graph are the mean ± SD 
from three independent experiments. 
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7.3.3 Effects of PI3K inhibition on P19 stem cell differentiation into 
beating cardiomyocytes 
 
To investigate the effects of PI3K inhibition on the differentiation of P19 stem 
cells into cardiomyocytes, LY294002 was added to cell culture of P19 stem 
cells during DMSO induced differentiation. Control P19 stem cells were 
treated with DMSO only while the differentiation medium of the LY294002-
treated P19 cells was supplemented with 20µM of LY294002 at the EB 
formation stage.  Control and LY2940002 treated EBs followed their normal 
pattern of growth as already described in the establishment of the P19 
cardiomyocyte differentiation model (Chapter 3).  The EBs seen on day 1 
grew in size and number over time. Transfer of EBs from Petri dishes to 
standard tissue culture dishes resulted in cell adhesion and the subsequent 
growth pattern into a monolayer.  This was then followed by cell migration and 
proliferation. By day four, both treated and control cells were confluent. By 
day 7, the first beating clusters of cardiomyocytes appeared in the DMSO 
treated but not in the cells exposed to LY294002 (Figure 7.14).  No beating 
cardiomyocytes were observed in any of the dishes containing LY294002 
treated P19 cells over the whole course of the experiment (Figure 7.13 & 
Figure 7.14).  When present, the number of beating clusters of 
cardiomyocytes usually continues to increase up to day 14.  The patterns of 
cardiomyocyte beating clusters  (including number and beating rates) from 
P19 stem cells treated with DMSO in the absence of LY294002 (i.e. no 
inhibition of PI3K signalling pathway ) were as already described in Chapter 3 
(see Figure 7.14).  
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In agreement with the lack of appearance of beating cardiomyocytes 
LY294002 treated P19 stem cell, the expression of cardiac restricted protein 
troponin I was inhibited (Figure 7.15).  Troponin levels in the LY294002 
treated P19 stem cells were lower than those in the control cells at all  time 
points  between day 4 and day 12. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.13: A schematic diagram of the effects of the PI3K inhibition on 
DMSO-induced differentiation of P19 stem cells into cardiomyocytes. 
PI3K inhibition with LY294002 (20µM) blocked the differentiation of P19 stem 
cells into beating cardiomyocytes, when the inhibitors was added to the cells 
during the EB formation stage in the absence of LY294002  beating 
cardiomycytes were seen from day 6 to day 14 after the EB were transferred 
to cell culture dishes. 
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Figure 7.14: Effects of the PI3K inhibition on DMSO-induced 
differentiation of P19 stem cells into beating cardiomyocytes. Control 
P19 stem cell embryoid bodies were formed in differentiation medium 
consisting of α-MEM supplemented with 10% FBS, 100 units/ml penicillin/100 
µg/ml streptomycin and 0.8% DMSO. The above differentiation medium was 
further supplemented with 20µM of LY294002 for the treated P19 stem cells 
during the EB formation stage. DMSO caused the differentiation of P19 stem 
cells into beating cardiomyocytes. This DMSO-induced cardiac differentiation 
of the P19 stem cells was inhibited by LY294002. The areas of beating 
cardiomyocytes are shown within the closed figures drawn with white dotted lines. 
The beating focus of each beating area is shown by a black arrow.  Photographs 
and movie clips of beating cells were taken under 200X magnification on the 
days indicated and  are representative of microscope fields (for their 
respective days) from at least 3 differentiation experiments. 
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Figure 7.15: Effects of the PI3K inhibition on P19 stem cell differentiation 
into cardiomyocytes: cardiac troponin I expression. Control P19 stem 
cells were cultured in differentiation medium consisting of α-MEM 
supplemented with 10% FBS, 100 units/ml penicillin/100µg/ml streptomycin. 
The above differentiation medium was further supplemented with 20µM of 
LY294002 for the treated cells. In agreement with the lack of appearance of 
beating cardiomyocytes in LY294002-treated P19 stem cell, the expression of 
the cardiac restricted protein, troponin I was inhibited.  Troponin levels in the 
LY294002-treated P19 stem cells were lower than those in the control cells at 
all  time points  between day 4 and day 12. The blot is representative of three  
differentiation experiments.  
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7.3.4 Effects of delayed inhibition of PI3K   on P19 stem cell 
differentiation into beating Cardiomyocytes 
 
To determine the stage at which PI3K may regulate the differentiation of P19 
stem cells into cardiomyocytes, LY29402 was added to cell culture four days 
after exposure to DMSO. Control P19 stem cells were treated with DMSO and 
LY294002 at the EB formation stage and for comparison, parallel dishes of 
P19 cells (delay-inhibition P19 cells) were treated with DMSO only at EB 
formation stage and then only treated with LY294002 after the EB were 
transferred to culture dishes (see section 2.9.3). Four days later, after the 
transfer of EBs to cell normal culture dishes, the EBs in both groups of cells 
underwent normal adhesion, proliferation and migration were confluent by day 
4.  No beating cardiomyocytes were observed in both control P19 cell and 
delay-inhibition P19 cells before day 6. By day 6 or 7, the first beating cells 
appeared in the delay-inhibition P19 cells (Figure 7.17). As expected, DMSO 
failed to induce P19 stem cell differentiation into beating cardiomyocytes, 
when LY294002 was added at the EB formation stage. However when DMSO 
was allowed to initiate P19 stem cell differentiation before 20µM of LY294002 
was added to the cells, LY294002 failed to block the DMSO-induced 
differentiation of P19 stem cells into beating cardiomyocytes (Figure 7.16 & 
Figure 7.17). The patterns of cardiomyocyte beating clusters from P19 cells, 
in which DMSO was allowed to initiate their differentiation before the inhibition 
of the PI3K signalling pathway, were as already described in Chapter 3 (see 
Figure 7.17).  
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Figure 16: A schematic diagram of the effects of delayed inhibition of 
PI3K   on P19 stem cell differentiation into beating Cardiomyocytes. In 
P19 stem treated with LY294002 (20µM) four days after the initiation of 
DMSO-induced cardiac differentiation, LY294002 failed to block the cell 
differentiation into beating cardiomyocytes 
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Figure 7.17: Effects of delayed inhibition of PI3K on P19 stem cell 
differentiation into beating cardiomyocytes. Control EBs were formed in 
differentiation medium (i.e.  α-MEM supplemented with 10% FBS, 100 
units/ml penicillin/100 µg/ml streptomycin, 0.8% DMSO and 20µM of 
LY294002). For the delay inhibition of PI3K, EBs were initially formed in the 
above differentiation medium but in the absence of LY294002. DMSO failed to 
induce P19 stem cell differentiation into beating cardiomyocytes when 
differentiation was initiated in the presence of LY294002. However when 
DMSO was allowed to initiate P19 stem cell differentiation before the addition 
of LY294002, the cell differentiated into beating cardiomyocytes. The areas of 
beating cardiomyocytes are shown within the closed figures drawn with white dotted 
lines. The beating focus of each beating area is shown by a black arrow.  
Photographs and movie clips of beating cells were taken under 200X 
magnification on the days indicated and  are representative of microscope 
fields (for their respective days) from at least 3 differentiation experiments. 
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7.4 CROSS-TALK STUDIES 
 
7.4.1 Time course of Akt phosphorylation following the initiation of H9c2 
cell differentiation into cardiomyocytes by 1% serum 
 
Undifferentiating H9c2 cells maintained a baseline level of phosphorylated Akt 
The initiation of H9c2 cell differentiation into cardiomyocytes induced a more 
than 2-fold rapid increase in Akt phosphorylation at residue serine 473 within 
5 minutes. The increased phosphorylated Akt levels were sustained for 6 
hours  before declining . The levels of phosphorylated Akt gradually fell back 
to baseline levels after 24 hours and by 48-72 hours, phosphorylated Akt level 
fell below the baseline values (Figure 7.18) 
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Figure 7.18: Time course of Akt phosphorylation following the initiation 
of H9c2 cell differentiation into cardiomyocytes by 1% serum. Control 
H9c2 cells were cultured in serum-free medium consisting of DMEM 
supplemented with 100units/ml penicillin/100µg/ml streptomycin in the 
absence of FBS. Serum-treated (1% FBS) control H9c2 cells were cultured in 
above supplemented with 1% FBS. A more than 2-fold increase in 
phosphorylated was induced by 1% FBS treatment and this was  sustained for 
6 hours  before  declining. Fold increase was calculated as the ratio of 
induced phosphorylated Akt  level to baseline phosphorylated Akt. The blot is 
representative of at least 3 individual experiments (panel A). The 
densitometric data (mean ± SD), from three independent experiments, show 
the time dependent fold change in phosphorylated Akt in treated H9c2 cells 
(panel B). 
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7.4.2 Effects of PI3K inhibition on Akt phosphorylation at serine 473 in 
H9c2 cells differentiating into cardiomyocytes 
 
To examine the effects of inhibiting PI3K signalling on the activation of this 
pathway, H9c2 cells (LY294002-treated H9c2 cells) were treated with 20µM of 
LY294002. For parallel comparison, cells exposed only to serum-free medium 
in the absence of LY294002 (control H9c2 cells) and another batch of cell 
exposed only to 1% FBS medium in the absence of LY294002 (1 % FBS-
treated H9c2 cells) were included (see method section 2.10.2).  
 
The initiation of H9c2 cell differentiation into cardiomyocytes, by 1% serum 
(i.e. 1% FBS), induced a marginal increase in Akt phosphorylation at serine 
473 (p>0.05) (Figure 7.20). This differentiation associated increase in Akt 
phosphorylation (in the 1 % FBS treated cells) was completely abolished by 
20µM LY294002 (p<0.01) (PI3K inhibition) (Figure 7.19). There was a 
significant fold reduction in Akt phosphorylation at serine 473, between control 
cells and 20µM of LY294002-treated cells (p<0.05) (Figure 7.19). 
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Figure 7.19: Effects of PI3K inhibitor LY29402 on Akt-ser473 
phosphorylation in H9c2 cells differentiating into cardiomyocytes. 
Treatment of cells with 1% FBS induced a rapid increase in phosphorylated 
Akt levels. This increased Akt phosphorylation was completely abolished by 
20µM of LY294002. There was no significant fold increase, in Akt 
phosphorylation at serine 473, between control cells and 1% FBS-treated 
cells (p>0.05).  There was a significant fold reduction, in Akt phosphorylation 
at serine 473, between 1% FBS-treated cells and 20µM of LY294002-treated 
cells (p<0.01). There was also a significant fold reduction, in Akt 
phosphorylation at serine 473, between control cells and 20µM of LY294002-
treated cells (p<0.01).  Fold increase was calculated as the ratio of induced 
phosphorylated Akt level to baseline phosphorylated Akt. The comparisons 
between control vs 1% FBS (p>0.05), 1% FBS vs 20µM LY294002 (p<0.01) 
and control vs 20µM LY294002 (p<0.05) are indicated by lines connecting the 
respective pairs (i.e. treatments).  The blot is representative of three 
independent experiments (panel A). The densitometric data (mean ± SD), 
from the three independent experiments, show the time dependent fold 
change in phosphorylated Akt in respective treatment shown on the graph 
(panel B). 
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7.4.3 Effects of protein kinase C inhibition on Akt phosphorylation at 
serine 473 in H9c2 cell differentiating into cardiomyocytes 
 
To examine the effects of inhibiting PKC signalling on the activation of  the 
PI3K signalling pathway, H9c2 cells (BIM-I-treated H9c2 cells) were treated 
with 10µM of BIM-I. For parallel comparison, cells exposed only to serum-free 
medium in the absence of BIM-I (control H9c2 cells) and another batch of cell 
exposed only to 1% FBS medium in the absence of BIM-I (1 % FBS-treated 
H9c2 cells) were included (see method section 2.10.2).  
 
The initiation of H9c2 cell differentiation into cardiomyocytes, by 1% serum 
(i.e. 1% FBS), induced a marginal increase in Akt phosphorylation at serine 
473 (p>0.05) (Figure 7.20). This differentiation associated increase in Akt 
phosphorylation (in the 1 % FBS treated cells) was significantly enhanced by 
the 10µM BIM-I (i.e. PKC inhibition) (p<0.01) There was a significant fold 
increase, in Akt phosphorylation at serine 473, between control cells and 
10µM of BIM-I-treated cells (p<0.01) (Figure 7.20). 
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Figure 7.20: Effects of PKC inhibition on Akt phosphorylation at serine 
473 residue in H9c2 cells differentiating into cardiomyocytes: PI3K and 
PKC cross-talk.. Treatment of cells with 1% FBS induced a rapid increase in 
phosphorylated Akt levels. This increased Akt phosphorylation was further 
enhanced by 10µM of BIM-I. There was no significant fold increase, in Akt 
phosphorylation at serine 473, between control cells and 1% FBS-treated 
cells (p>0.05).  There was a significant fold increase, in Akt phosphorylation at 
serine 473, between 1% FBS-treated cells and 10µM of BIM-I-treated cells 
(p<0.01). There was a significant fold increase, in Akt phosphorylation at 
serine 473, between control cells and 10µM of BIM-I-treated cells (p<0.01).  
Fold increase was calculated as the ratio of induced phosphorylated Akt level 
to baseline phosphorylated Akt. The comparisons between control vs 1% FBS 
(p>0.05), 1% FBS vs 10µM BIM-I (p<0.01) and control vs 10µM BIM-I 
(p<0.01) are indicated by lines connecting the respective pairs (i.e. 
treatments).  The blot is representative of three independent experiments 
(panel A). The densitometric data (mean ± SD), from the three independent 
experiments, show the time dependent fold change in phosphorylated Akt in 
respective treatment shown on the graph (panel B). 
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7.4.4 Effects of p38 MAPK inhibition on Akt phosphorylation at serine 
473 in H9c2 cell differentiating into cardiomyocytes 
 
To examine the effects of inhibiting PKC signalling on the activation of the 
PI3K signalling pathway, H9c2 cells (SB203580-treated H9c2 cells) were 
treated with 10µM of SB203580. For parallel comparison, cells exposed only 
to serum-free medium in the absence of SB20580 (control H9c2 cells) and 
another batch of cell exposed only to 1% FBS medium in the absence of 
SB203580 (1 % FBS-treated H9c2 cells) were included (see method section 
2.10.2).  
 
Initiation of H9c2 cell differentiation into cardiomyocytes, by 1% serum, led to 
a marginal increase in Akt phosphorylation at serine 473 (p>0.05) (Figure 
7.21).This differentiation associated increase in Akt phosphorylation (in the 1 
% FBS treated cells) was significantly reduced by the 10µM SB203580 (i.e. 
p38 MAPK inhibition) (p<0.01). There was also a significant fold reduction, in 
Akt phosphorylation at serine 473, between control cells and 10µM 
SB203580-treated cells (p<0.01) (Figure 7.21). 
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Figure 7.21: Effects of protein p38 MAPK inhibition on Akt 
phosphorylation at serine 473 residue in H9c2 cells differentiating into 
cardiomyocytes: PI3K and p38 MAPK cross-talk. Treatment of cells with 
1% FBS induced a rapid increase in phosphorylated Akt levels. This 
increased Akt phosphorylation was significantly reduced by 10µM SB203580. 
There was no significant fold increase, in Akt phosphorylation at serine 473, 
between control cells and 1% FBS-treated cells (p>0.05).  There was a 
significant fold reduction, in Akt phosphorylation at serine 473, between 1% 
FBS-treated cells and 10µM SB203580-treated cells (p<0.01). There was also 
a significant fold reduction, in Akt phosphorylation at serine 473, between 
control cells and 10µM SB203580-treated cells (p<0.01).  Fold increase was 
calculated as the ratio of induced phosphorylated Akt level to baseline 
phosphorylated Akt. The comparisons between control vs 1% FBS (p>0.05), 
1% FBS vs 10µM SB203580-treated cells (p<0.01) and control vs 10µM 
SB203580-treated cells (p<0.01) are indicated by lines connecting the 
respective pairs (i.e. treatments).  The blot is representative of three 
independent experiments (panel A). The densitometric data (mean ± SD), 
from the three independent experiments, show the time dependent fold 
change in phosphorylated Akt in respective treatment shown on the graph 
(panel B). 
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7.5 DISCUSSION 
 
Published data suggest important roles for  PI3K signalling during the  
differentiation of ES cells into cardiomyocytes (Klinz et al., 1999; Sauer et al., 
2000). Treatment of differentiating ES cell cultures with the PI3K inhibitor 
LY294002 was shown to reduce the number of α-actinin positive 
cardiomyocytes and the number of embryoid bodies containing beating foci 
(Klinz et al., 1999). 
 
Our data showed that the activation of the PI3K signalling pathway may be 
essential for differentiation of H9c2 cells into cardiomyocytes. Cell elongation 
and fusion forming myotubes, the main morphological changes or features 
associated with H9c2 cell differentiation into cardiomyocytes, were 
significantly inhibited by LY294002.  The expression of cardiac specific 
ventricular myosin light chain 1 was also completely blocked in these cells. 
These results suggest that activation of the PI3K pathway may be essential 
for differentiation of H9c2 cells into cardiomyocytes.  
 
Consistent with the H9c2 cell data, the inhibition of PI3K signalling also 
completely blocked the differentiation of P19 stem cells into beating 
cardiomyocytes and also inhibited the expression of cardiac restricted 
troponin I in these cells. Moreover, our data suggest that not only is activation 
of PI3K signalling critical for P19 stem cell differentiation into cardiomyocytes 
but that the early timing of this pathway may be critical. The inhibition of PI3K 
signalling, by LY294002 (20µM), four days after the initiation of DMSO 
induced differentiation failed to blocked P19 stem cell differentiation into 
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beating cardiomyocytes. These results suggest that activation of the PI3K 
pathway may be essential for differentiation of P19 stem cells into 
cardiomyocytes. The failure of LY294002 to block the differentiation of P19 
stem cells into cardiomyocyte when added four days  after DMSO also 
suggests that that PI3K signalling pathway is activated during the very early 
stage of P19 stem cell differentiation into cardiomyocytes. The data also 
suggest that the activation of PI3K pathway may be transient since late 
inhibition of PI3K by LY294002 failed to inhibit the differentiation process. 
Whether PI3K activation is indeed transient or whether it is sustained but 
become irreverent after the initiation of the differentiation process remains to 
be determined. Our data are in agreement with similar observations in which 
late LY294002 treatment failed to suppress the expression of Nkx-2.5 and 
GATA-4 in P19CL6 cells (a clonal derivative of P19 stem cells) (Naito et al., 
2003).  
 
The 20µM concentration of LY294002  used in the present project was 
selected from published literature and appears to be a commonly used 
concentration for blocking PI3K activity (Qi et al., 1999; Tamir and  Bengal, 
2000; Du et al., 2001; Naito et al., 2003; Fukuda et al., 2005; Shaik et al., 
2008; Smyth et al., 2008). LY294002 is not only potent but is also a specific 
inhibitor for blocking PI3K signalling (Vlahos et al., 1994). LY294002, even at 
a higher concentration (50µM), specifically inhibited PI3K (Vlahos et al., 
1994). LY294002 (50µM) completely inhibited PI3K but failed to inhibit the 
activities of a wide range of other kinases including, PKC, PKA, MAP kinase, 
S6 kinase, EGF receptor tyrosine kinase, c-src kinase, Pl 4-kinase and 
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diacylglycerol kinase) and  ATPase  (Vlahos et al., 1994). Furthermore our 
cytotoxicity studies using MTT showed that LY294002, at 20uM concentration, 
had no cytotoxic effects. Thus, the inhibition of H9c2 and P19 stem cell 
differentiation   into cardiomyocytes by LY294002 (20µM), as shown by our 
data, is due to LY294002 inhibition of the PI3K signalling pathway. Our data 
therefore suggest that the activation of the PI3K signalling is required for stem 
cell differentiation into cardiomyocytes.  The data also suggest an early 
requirement for the activation of the PI3K signalling during the early stages of 
stem cell differentiation into cardiomyocytes. 
 
Our data have also shed some light on whether activation of Akt by 
phosphorylation is required to drive cardiomyocyte differentiation. Akt is 
activated by sequential phosphorylation, first at threonine 308 by PDK1, and 
then, finally at serine 473 by PDK2 (Alessi et al., 1996; Alessi et al., 1997a; 
Alessi et al., 1997b). Our data clearly showed that PI3K signalling is required 
for stem cell differentiation into cardiomyocytes. However the data obtained 
on Akt are less convincing. Indeed exposure of cells to LY294002 did result in 
inhibition of Akt phosphorylation at serine 473 which correlates well with the 
ability of the drug to modulate differentiation. However, our cross-talk studies  
using BIM-I, a specific and selective  PKC inhibitor,  to block the activation of 
the PKC signalling pathway, revealed an unexpected  increase in Akt 
phosphorylation at serine 473, even though BIM-I blocked cardiac 
differentiation of both H9c2 cells and P19 stem cells. This would strongly 
suggest that phosphorylation of Akt in differentiating stem cells may have no 
direct relevance to the process itself. 
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The enhanced Akt activation (phosphorylation at serine 473) by PKC inhibition 
cannot be explained by non-specificity of the concentration (10µM) of BIM-I 
used in these experiments. It has been reported, in haematopoietic progenitor 
cells, that PKC inhibition, using another PKC inhibitor, Ro-31-8220 
(bisindolylmaleimide IX) (5µM), enhanced Akt activation (increased 
phosphorylation at serine 473 and threonine 308), in response to c-Kit 
stimulation (Edling et al., 2007). It has also been shown that Ro 31-8220 
(3µM), bisindolylmaleimide VIII (3µM), and 30nM of LY 379196 (another 
bisindolylmaleimide) increase Akt phosphorylation at Serine 473 in A549 cells 
and HEK293 cells (Wen et al., 2003). Increased Akt phosphorylation in 
HEK293 cells over-expressing Akt was diminished by phorbol 12-myristate-
13-acetate (PMA) a potent PKC activator (Wen et al., 2003). Our data 
therefore suggest that PI3K may be activating alternative downstream targets 
independent of Akt (Figure 7.22). 
 
The question of whether Akt is required for stem cell differentiation into 
cardiomyocytes can be investigated by knocking out Akt, in stem cells. This 
could be done using pharmacological Akt specific inhibitors. Alternatively, Akt 
can be knocked out using molecular methods. For example, Akt siRNA can be 
used to block Akt mRNA translation into Akt protein. An Akt dominant 
negative stem cells, through the mutation of the critical amino acid residues 
(i.e. serine 473 or both threonine 308 and serine 473) can also be created. 
The mutant stem cells (either from Akt siRNA or Akt mutation) can then be 
induced to differentiate into cardiomyocytes. If Akt is not required, for stem 
cell differentiation into cardiomyocytes, then the mutant stem cells will retain 
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their ability to differentiate into cardiomyocytes. However, if Akt is required, for 
stem cell differentiation into cardiomyocytes, then the mutant stem cells will 
have reduced ability to differentiate into cardiomyocytes. 
 
The Wnt/β-catenin signalling pathway has been reported to be involved in the 
cardiac lineage specification or differentiation. Wnt ligands and receptors are 
expressed in a spatially and temporally manner and regulated during early 
heart development. (Ku and  Melton, 1993; Monkley et al., 1996; Eisenberg et 
al., 1997; Garriock et al., 2005). Moreover, the canonical Wnt/β-catenin 
signalling positively regulates ES cell differentiation. In the mouse, the 
expression of the early cardiac genes Nkx2.5 and Tbx5 (mesoderm marker) in 
EBs can be up-regulated by Wnt3a and down-regulated by Dkk-1(Wnt 
antagonist). The addition of Wnt3a to ES  cells during the early phase of EB 
formation increased the number of beating EBs by  more than 50% while the 
addition of Fz8/Fc (secreted or soluble Wnt  antagonist) or Dkk-1 and Fz8/Fc 
at this stage leads to a complete absence of beating EBs (Naito et al., 2006; 
Kwon et al., 2007). Constitutively active GSK-3β (i.e. degradation of  β-
catenin) also completely blocked  the expression of  Tbx5 and GATA4 
(Nakamura et al., 2003; Kwon et al., 2007). In contrast, lithium chloride  (a 
GSK-3β inhibitor) significantly increased the expression of Nkx2.5, GATA4, 
Tbx5 (Nakamura et al., 2003). The down-regulation of Nkx2.5, GATA4 and 
Tbx5 expression by Dkk-1, Fz8/Fc and constitutively active GSK-3β and the 
induction of these genes by lithium suggests that Wnt/β-catenin signalling play 
positive roles in driving ES cell differentiation into cardiomyocytes.   
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Previous studies have suggested that PI3K signalling could involve activation 
of the Wnt/β-catenin pathway and this may be independent of Akt.  Lithium 
treatment mimics Wnt/β-catenin signalling activation. Lithium induces the 
stabilisation and nuclear accumulation of β-catenin by inhibiting the 
phosphorylation of GSK-3β  (Klein and  Melton, 1996; Hedgepeth et al., 1997; 
Rao et al., 2005).  Our data showed that H9c2 cells in 10% serum do not 
differentiate into cardiomyocytes.  But it has been shown that treatment of 
H9c2 cells with lithium can overcome the inhibitory effects of serum  and drive 
the cell  differentiation into cardiomyocytes (Kashour et al., 2003). LY294002 
blocked lithium-induced differentiation of H9c2 cells (Kashour et al., 2003) 
thus suggesting a link between the PI3K and the Wnt/β-catenin pathway. In 
contrast, it was also found that over-expression of Akt in H9c2 did not 
increase stabilisation or nuclear accumulation of β-catenin or increased H9c2 
cell differentiation. Lithium also induced differentiation in H9c2 expressing 
dominant-negative Akt  (Kashour et al., 2003). These results suggest that 
PI3K signalling and Wnt/β-catenin signalling interacted in an Akt-independent 
manner or mechanism.  
 
Our data suggest that PI3K regulates cardiomyocyte differentiation in an Akt-
independent mechanism. Our data are in agreement with the previous data 
mentioned above. The new downstream target, independent of Akt, through 
which PI3K may cross-talk with Wnt/β-catenin signalling to regulate 
cardiomyocyte differentiation, is not known. Considering all of the above data, 
we are tempted to speculate that activation of PI3K in our cells models could 
drive differentiation mainly through activation of the Wnt/β-catenin signalling 
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pathway and not through phosphorylation of Akt. However further 
investigations (using Akt inhibitors, or Akt siRNA, or dominant negative Akt 
stem cells, along with studies to correlate the activation (or inhibition) of the 
Wnt/β-catenin signalling to stem cell cardiomyocyte differentiation) are 
required to confirm our data and  determine the exact role of PI3K activation 
and Akt during the differentiation of stem cell into cardiomyocytes. 
 
Further support of our suggestion that PI3K may regulate Wnt/β-catenin 
signalling through an Akt-independent mechanism comes from studies which 
showed that the activation of the Wnt/β-catenin signalling  did not lead to 
GSK-3β phosphorylation (Ding et al., 2000; McManus et al., 2005). While Akt 
can inactivate  GSK-3β by phosphorylation at serine 9  in  response to the 
activation of other pathways, for example in response to insulin-like growth 
factor (IGF) and other factors (Desbois-Mouthon et al., 2002), GSK-3β did  not 
become phosphorylated at serine 9 in response to Wnt signalling (Ding et al., 
2000; McManus et al., 2005).  
 
As already discussed, GSK-3β inactivation is necessary for ES cell 
commitment to cardiac lineage differentiation. GSK-3β is constitutively active 
and downstream of Akt. Since Akt negatively regulates the activity of GSK-3β 
then activated Akt, following the activation of the PI3K signalling pathway, 
would be expected to inactivate GSK-3β  and block its negative effects on 
cytoplasmic  β-catenin levels thus leading to enhanced activation of the Wnt 
signalling and subsequent increase in ES cell differentiation into 
cardiomyocytes. However Akt-mediated inactivation of GSK-3β may not be a 
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relevant or a major event for the Wnt/β-catenin signalling pathway.  In both 
wild type and knockin cells homozygous for both GSK-3β and GSK-3α, Wnt3a 
was found to inactivate GSK-3, stabilised β-catenin and stimulated Wnt-
dependent gene transcription but failed to induce a detectable increase in the 
phosphorylation of GSK-3α (at seine 21)  and  GSK-3β (at serine 9) in the 
wild-type cells (McManus et al., 2005). The above data show that Wnt-
mediated inactivation of GSK-3β is not dependent on GSK-3β 
phosphorylation at serine 9. Thus the inactivation of GSK-3β by the Wnt 
signalling pathway may be achieved through a mechanism that is 
independent of Akt inactivation of GSK-3β. The above is in line with our 
suggestion the Akt phosphorylation may not  be relevant for PI3K mediated 
regulatory effects on stem cell differentiation into cardiomyocytes. 
 
PI3K inhibition in our experiments inhibited the differentiation of P19 stem 
cells in beating cardiomyocytes and the expression of troponin I. PI3K 
inhibition also inhibited the differentiation of H9c2 cells as determined by the 
lack of differentiation associated morphological changes and the inhibition of 
MLC-1v expression. While PI3K inhibition blocked the differentiation of both 
P19 stem cells and H9c2 cells into cardiomyocytes, our cross-talk data 
showed that PKC inhibition enhanced Akt activation (i.e. phosphorylation at 
serine 473).  However as already shown (Chapter 5) PKC inhibition also 
blocked P19 stem cells and H9c2 cells into cardiomyocytes. Therefore our 
data suggest that PI3K positively regulates stem cell differentiation into 
cardiomyocytes not through Akt activation, but through a yet unknown 
signalling mechanism that is independent of Akt activation (Figure 7.22). 
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The data from the cross-talk studies suggested possible interactions between 
PI3K and PKC and also between PI3K and p38 MAPK signalling during 
cardiomyocyte differentiation. Our data suggest that activated PKC or p38 
MAPK pathways may modulate the activation of the PI3K pathways as 
determined by Akt phosphorylation at serine 473. The inhibition of PKC 
pathway led to an elevation of Akt phosphorylation at serine 473, thus 
suggesting a possible negative role for PKC in the regulation of PI3K at the 
Akt level. In contrast the inhibition of p38 MAPK pathway led to a reduction in 
Akt phosphorylation at serine 473, thus suggesting a possible positive role for 
p38 MAPK in the regulation of PI3K also at the level of Akt. It not clear how 
PKC or p38 MAPK may regulate PI3K pathway activation by modulating Akt 
phosphorylation at serine 473.  
 
The PI3K signalling controls many biological processes.  It is therefore more 
likely that this pathway may be regulated by cross-talk with different signalling 
pathways. The fact that the PKC specific inhibitor BIM-I caused increased Akt 
phosphorylation suggests that PKC may play a negative role in the regulation 
of PI3K pathway. PKC is downstream of both PI3K and PDK1 (Chou et al., 
1998; Dutil et al., 1998; Balendran et al., 2000) therefore the effects of any 
cross-talk between PI3K and PKC on cardiac cardiomyocyte differentiation 
cannot be attributed to direct effect on either PI3K or PDK1.   
 
Our data give ground for possible speculation about how BIM-I (i.e. PKC 
inhibition) might caused increase phosphorylation of Akt at serine 473. First, 
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PKC could inhibit Akt activation by targeting PDK2 (i.e. an elusive and 
currently unknown kinase that is thought to be responsible for Akt Akt 
phosphorylation at serine 473). If PKC does indeed control PDK2 as 
suggested by our data (i.e. increased Akt phosphorylation that accompanied 
the inhibition of PKC) then PKC may be a negative regulator of PDK2 since 
the inhibition of PKC by BIM-I appeared to “increase” the ability of “PDk2” to 
phosphorylate Akt-ser473.  
 
The action of the lipid phosphatase, PTEN on PIP3  limits  the activation of Akt 
(Maehama and  Dixon, 1998).  However since PTEN does not directly 
dephosphorylate Akt, it is currently not known how Akt signalling is terminated 
once it is activated. While the dephosphorylation mechanism to directly 
inactivate Akt is yet to be found, evidence  suggests that  a phosphatase 
known as  PHLPP (PH domain leucine-rich repeat protein phosphatase) 
selectively and specifically dephosphorylates  Akt at serine 473 (Gao et al., 
2005). The second speculation therefore is that PKC may be an activator (i.e. 
positive regulator) of PHLPP “a putative phosphatase” that may be 
responsible for dephosphorylating AKt at serine 473 back to the baseline level 
since BIM-I would reduce the ability of PKC to activate that “putative 
phosphatase”, thus limiting the ability of this “phosphatase to dephosphorylate 
phosphorylated Akt, hence the increased levels of phosphorylated Akt in 
presence of BIM-I.  
 
If indeed as suggested by our data, PKC does negatively regulate PI3K via 
PDK2 or Akt-related “phosphatase” then the significance of such negative 
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regulation of Akt by PKC is worth exploring in order to get a better 
understanding of the interaction between PI3K and PKC signalling events. 
However according to our data, PKC regulation of PI3K either via PDK2 or 
Akt-related “phosphatase” may be of no or little relevance to the differentiation 
of stem cells into cardiomyocytes since our data also suggested that Akt 
activation is of no or little relevance in this process.  
 
Our data also suggest a possible cross-talk between PI3K and p38 MAPK.  
PDK1 has been cloned and sequenced  (Alessi et al., 1997a) and it is well 
established that PDK1 phosphorylate Akt at threonine 308 (Alessi et al., 
1997a; Alessi et al., 1997b). However the identity of the kinase that is 
responsible for Akt phosphorylation at serine 473 remains unknown. Our data 
showed reduced phosphorylation of Akt at serine 473 in the presence of 
SB203580 (10µM). We speculate that p38 MAPK may have an additional 
activity that can phosphorylate Akt at serine 473 in a phosphoinositide-
dependent manner. Alternatively, p38 MAPK may be the unidentified PDK2.  
It is interesting to note that p38 MAPK is among a range of possible PDK2 
candidates. Other candidate kinases include mitogen-activated protein (MAP) 
kinase-activated protein kinase-2 (MK2) (Alessi et al., 1996), integrin-linked 
kinase (ILK) (Delcommenne et al., 1998; Persad et al., 2000), DNA-
dependent protein kinase (DNK-PK), cPKCα (Partovian and  Simons, 2004) 
and cPKCβ (Kawakami et al., 2004).  The question of whether p38 MAPK has 
a PI3K-dependent and phosphoinositide-dependent activity that can 
phosphorylate Akt at serine 473 or whether p38 MAPK and PDK2 are one and 
the same kinase remains. While Akt phosphorylation at serine 473 may not be 
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of major relevance to the differentiation of stem cells into cardiomyocytes 
since both PI3K and p38 MAPK are implicated in the differentiation of stem 
into cardiomyocytes, then the resolution of this question may help in 
advancing our understanding of the relationship between PI3K and p38 MAPK 
during cell differentiation and this needs further investigation. 
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Figure 7.22: PI3K and PKC regulate stem cell differentiation into 
cardiomyocytes through possible Akt-independent mechanisms. PI3K 
activation causes Akt activation (phosphorylation at both threonine 308 and 
serine 473) but PI3K may regulate stem cell differentiation into 
cardiomyocytes through a possible Akt-independent mechanism. PKC may 
modulate the phosphorylated states of Akt, since PKC inhibition enhanced Akt 
phosphorylation at serine 473. PKC inhibition also blocked the differentiation 
of H9c2 cells and P19 stem cells into cardiomyocytes. Therefore PKC may 
regulate H9c2 cells and P19 stem cell differentiation into cardiomyocytes 
through possible Akt-independent mechanism(s). PKC may negatively 
regulate the activity of 3-Phosphoinositide-Dependent Protein Kinase 2 
(PDK2) since the inhibition of PKC by BIM-I appeared to “increase” the ability 
of “PDK2” to phosphorylate Akt-ser473. Alternatively, PKC maybe an activator 
(i.e. positive regulator) of “a putative phosphatase” (PP) that may be 
responsible for dephosphorylating AKt at back to the baseline level.  The 
possible Akt-independent mechanisms or downstream target(s), through 
which PI3K and PKC may  regulate H9c2 cell and P19 stem cell differentiation 
into cardiomyocytes is/are currently unknown and warrants further 
investigation. 
 
 
PI3K
T308P
T308P
Ser473-P
Akt
Akt
PKC
Downstream 
Targets ??
Stem Cell
Cardiac Differentiation
?
?
PP
PDK2
??
 309 
As stated above, the phosphorylation of Akt in differentiating stem cells may 
have no direct relevance to the cell differentiation into cardiomyocytes. 
Therefore, in addition to any possible modulation of Akt activity (as suggested 
by the inhibition of Akt activation by SB203580), the data also suggest that 
p38 MAPK may cause cardiac differentiation independent of Akt (Figure 7.23). 
Like in the case of PKC, the data also point to a possible target, downstream 
of/ independent of Akt, through which p38 MAPK might cause the 
differentiation of H9c2 cell and stem cell into cardiomyocytes. This possible 
key downstream target is currently unknown and warrants further 
investigation. 
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Figure 7.23: PI3K and p38 MAPK regulate stem cell differentiation into 
cardiomyocytes through possible Akt-independent mechanisms. PI3K 
activation causes the Akt activation (phosphorylation at both threonine 308 
and serine 473) but PI3K may regulate stem cell differentiation into 
cardiomyocytes through a possible Akt-independent mechanism. P38 MAPK 
may modulate the phosphorylated states of Akt, since p38 MAPK inhibition 
inhibited Akt phosphorylation at serine 473. however, the inhibition of p38 
MAPK also blocked the differentiation of H9c2 cells and P19 stem cells into 
cardiomyocytes. Therefore p38 MAPK may regulate H9c2 cells and P19 stem 
cell differentiation into cardiomyocytes through a possible Akt-independent 
mechanism(s). The possible Akt-independent mechanisms or downstream 
target, through which PI3K and p38 MAPK may regulate H9c2 cell and P19 
stem cell differentiation into cardiomyocytes is/are currently unknown and 
warrants further investigation. 
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7.6 SUMMARY  
 
The inhibition of PI3K using 20µM of LY294002 completely blocked the 
differentiation of H9c2 cells into cardiomyocytes (as as determined by the 
usual morphological changes of cell elongation, fusion and myotube 
formation. LY294002 treated H9c2 cells largely maintained their normal single 
cell and spindle shaped morphology which was in contrast to control H9c2 
cells which showed the usual morphological changes. In agreement with the 
lack of morphological changes observed in LY294002 treated H9c2 cells, the 
expression of MLC-1v protein was significantly inhibited. Our data therefore 
suggest that activation of the PI3K signalling pathway is required for H9c2 cell 
differentiation into cardiomyocytes.   
 
Treatment of H9c2 cells with 1% FBS induced a rapid increase in 
phosphorylation (at serine 473) but this differentiation associated increase in 
Akt phosphorylation was completely abolished by 20µM of LY294002. This 
differentiation associated increase in Akt phosphorylation was significantly 
enhanced by BIM-I (10µM) but significantly reduced by SB203580 (10µM). 
Our data therefore showed that PI3K is activated during 1% FBS-induced 
differentiation of H9c2 cells into cardiomyocytes and also that PKC and p38 
MAPK may modulate Akt phosphorylation at serine 473. 
 
P19 stem cultured in the presence of 0.8% DMSO but in the absence of 
LY294002 (absence of PI3K inhibition) differentiated into beating 
cardiomyocytes.  However PI3K inhibition, with LY294002 (20µM), completely 
blocked the DMSO-induced differentiation of P19 stem cells into beating 
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cardiomyocytes. The expression of cardiac specific troponin I was also 
reduced in P19 stem cells treated with LY294002.  
 
When DMSO was allowed to initiate P19 stem cell differentiation, for 4 days 
before the addition of LY294002 to the cells, LY294002 completely failed to 
block the cell differentiation into beating cardiomyocytes.  Our data therefore 
suggest that activation of the PI3K signalling pathway is required for P19 stem 
cell differentiation into cardiomyocytes. In addition the data suggest that PI3K 
signalling is required during the early stages of P19 stem cell differentiation 
into cardiomyocytes.  
 
In conclusion, the activation of the PI3K signalling pathway is required for P19 
stem cells and H9c2 cell differentiation into cardiomyocytes.  The activation of 
PI3K signalling is required during the early stages of stem cell differentiation 
into cardiomyocytes. Our data also suggest that PI3K positively regulates 
stem cell differentiation into cardiomyocytes not through Akt activation, but 
through a yet unknown signalling mechanism that is independent of Akt 
activation. 
 
Our data also suggest that PKC may also be a negative regulator of Akt 
phosphorylation at serine 473 either via an unknown PDK2 or via positive 
regulation of a possible “phosphatase” that is responsible for the 
dephosphorylation of Akt at serine 473. It is also a suggestion from our data 
that p38 MAPK may have a PI3K-dependent and phosphoinositide-dependent 
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activity with the ability to phosphorylate Akt at serine 473 in or p38 MAPK and 
PDK2 may be one and the same kinase.  
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CHAPTER 8.0 
ROLE OF NF-kB IN H9C2 CELL DIFFERENTIATION 
INTO CARDIOMYOCYTES 
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8.1 INTRODUCTION 
 
NF-kB signalling pathway consists of a family of structurally related and 
evolutionarily conserved proteins known as NF-κB proteins. There are five 
mammalian NF-kB proteins:  RelA (p65), RelB, c-Rel, NF-κB1 (p50/105) (i.e. 
p50 and its precursor p105), and NF-κB2 (p52/p100) (i.e. p52 and its 
precursor p100).  These proteins can form homodimers and heterodimers. 
These dimers have different DNA site specificities and also different DNA 
binding affinities. 
 
A common structural feature of NF-kB proteins is the presence of a highly 
conserved 300 amino acid domain at their N-terminals. This conserved 
sequence is known as the Rel homology domain (RHD). Rel homology 
domain is responsible for DNA binding, dimerisation, and association with 
inhibitory proteins (Coleman et al., 1993; Toledano et al., 1993).  In 
unstimulated cells, NF-κB proteins exist in their transcriptionally inactive forms 
bound to proteins that inhibit their activation. These inhibitory proteins are 
known as inhibitors of NF-κB (IκB). Seven mammalian IκB proteins ( IκBα, 
IκBβ, IκBγ, IκBε, Bcl-3, p105 and p100) has been identified. This non-covalent 
interaction between the NF-kB dimers and the NF-kB inhibitors is thought to 
conceal the nuclear localisation signal (NLS) of NF-κB proteins thus 
preventing their translocation into the nucleus. Therefore inactive NF-kB 
proteins are retained in the cytoplasm. The NF-κB signalling can be activated 
either by the classical (canonical) pathway or by the alternative (noncanonical 
or novel) pathway.  
 
 316 
In the classical pathway, IκB is phosphorylated (Li et al., 1994; Naumann and  
Scheidereit, 1994; Traenckner et al., 1995; Zandi et al., 1998) by IκB kinase 
(IKK). This phosphorylation leads to polyubiquitination of IkB. This 
phosphorylation mediated polyubiquitination triggers IkB degradation by the 
ubiquitin-proteasome pathway. IkB degradation releases NF-κB of IkB 
inhibition and thereby activates NF-κB. The activated NF-κB then translocates  
into the nucleus  (Naumann and  Scheidereit, 1994) . In the nucleus , NF-kB  
activate  the expression of a various target genes including  genes coding for 
other transcription factors, cytokines, growth factors and regulators of 
apoptosis. 
 
NF-kB activation by the non-canonical pathway  involves the activation of NF-
kB inducing kinase (NIK) which in turn activates IKK (Tse et al., 2007).  The 
activated IKKα then phosphorylates p100 and this in turn undergoes 
proteasomal processing to generate p52. The generated p52 form a dimer 
with RelB (i.e. RelB/p52). The RelB/p52 complex then translocate to the 
nucleus to activate genes distinct from those regulated by the canonical 
pathway.  
 
To ensure that the activation of NF-kB signalling is transient and self-limiting, 
a series of mechanisms including a negative feedback loop regulates NF-κB 
activation. The negative feedback loop involves the induction of IkB genes by 
the activated NF-kB. This leads to the synthesis of new IkBα proteins. The 
newly synthesised IkB then enter the nucleus, bind to activated NF-KB and 
return it to the cytoplasm in the inactive form 
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8.1.1 NF-κB signalling and stem cell differentiation  
 
Transcription factors are among the key molecules for gene regulation at the 
level of transcription. Transcription factors are proteins that bind specific DNA 
or promoter sequences in promoters leading to the alteration of the 
transcription of downstream target genes under the promoter control. We 
have an understanding of the roles of cardiac transcription factors (e.g. 
GATA-4, Nkx.5) in cardiogenesis and ES cell differentiation into 
cardiomyocytes. However there is very little information  on the role of other or 
non-cardiac transcription factors which may be upstream and may be 
activated much earlier than  the cardiac transcription factors.  
 
If more information about transcription factors upstream of cardiac 
transcription factors  become available  then coupling that information with 
what we already known about cardiac transcription factors may tremendously 
increase our understanding of cardiogenesis and ES cell  differentiation into 
cardiomyocytes. This may lead to better and more cardiac specific 
differentiation of ES into cardiomyocytes. This in turn will help in the 
realization of the therapeutic potential of stem cell-derived cardiomyocytes for 
the treatment of cardiovascular diseases.  
 
We decided to investigate the role of NF-kB, which is downstream of PI3K. As 
already shown by our data, PI3K has role to play in the differentiation of stem 
cells into cardiomyocytes. The aim of this study is to investigate the role of 
NF-kB pathway in the cardiomyocyte differentiation.  To examine the specific 
roles of NF-kB action during cardiomyocyte differentiation, we chose CAPE  
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(caffeic acid phenethyl ester), an inhibitor of NF-kB activation (Natarajan et 
al., 1996) , in this study.   
 
CAPE inhibits the activation of the classical NF-kB pathway by suppressing 
the degradation of IkB-α (Natarajan et al., 1996; Abdel-Latif et al., 2005; Song 
et al., 2008). CAPE (IC50= 2µM) is a potent NF-kB activation inhibitor (Reddy 
et al., 2004). 
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8.2 MATERIALS AND METHODS 
 
8.2.1 Culture and differentiation of H9c2 Cells  
 
The routine culture of H9c2 cells was carried out as described in section 2.3.1 
(Chapter 2). H9c2 cells were trypsinised and the appropriate cell density for 
the differentiation experiments was calculated as described in section 2.6 
(Chapter 2). H9c2 cells (2x103 cells/cm2) were seeded in p60 dishes or 6-well 
plates in full culture medium (i.e. DMEM supplemented with 10% FBS, 
100units/ml penicillin/100µg/ml streptomycin), placed in a  tissue culture 
incubator at 37oC, 95% air and  5% CO2 and allowed to become 60-70% 
confluent. The differentiation of H9c2 cells into cardiomyocytes was carried 
out in 1% serum as described in section 2.8.1 (Chapter 2). The role of NF-kB 
signalling pathway in the differentiation of H9c2 cells into cardiomyocytes was 
investigated. The effects of the inhibition of the activation of NF-kB signalling 
pathway were investigated using 30µM of CAPE as described in section 2.8.2 
(Chapter 2). A CAPE stock (100mM solution) was prepared by dissolving 5mg 
of CAPE in 176µl of DMSO. The stock solution was distributed into 20 or 50µl 
aliquots and stored in the freezer at -20oC. The aliquots were protected from 
light during storage and use.  The differentiation medium was used to, first 
dilute the frozen stock CAPE solutions to 100µM (1:1000). The 100µM 
solution was then finally diluted (1:3.3) to the CAPE concentration (30µM) 
used in the differentiation experiments. The preparation of stock CAPE 
concentration was carried out as explained in appendix VIII.  More details 
about CAPE are located in appendix VI (d). 
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8.2.2 Cell viability assay  
 
To examine the effects of the NF-kB inhibition on H9c2 cell viability, the MTT 
assay was carried out as described in section 2.7 (Chapter 3). 
 
8.2.3 Western blot analysis  
 
In order to perform the western blot analysis, the following procedures were 
carried out as described in the Chapter 3 under the sections indicated in 
parenthesis: cell lysate generation (section 2.11), preparation of BSA 
standards (section 2.12.1) and BCA assay (section 2.12.2). The western 
blotting was carried out as described in section 2.13. 
 
8.2.4 Data analysis  
 
Data obtained from independent experiments were used for statistical 
analysis as described in section 2.14 (Chapter 3). 
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8.3 RESULTS 
 
8.3.1 Effects of inhibition of NF-kB activation on H9c2 cell differentiation 
into cardiomyocytes 
 
Consistent with previous data described above, culture of H9c2 cells in media 
with 1% serum resulted in a time dependent differentiation of the cells in to 
cardiomyocytes. More importantly, treatment with CAPE delayed the 
differentiation process with myotube formation becoming evident at day 8 to 
12 (Figure 8.10). This effect is more evident when MLC-1v expression was 
monitored. As shown in Figure 8.11, levels of MLC-1v were significantly 
reduced at day 4 when compared to controls and even though levels 
recovered at day 8 and 12, expression was still marginally lower than in 
controls.  
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Figure 8.10: Effects of inhibition of NF-kB activation on H9c2 cell 
differentiation into cardiomyocytes: morphological changes. Control 
H9c2 cells were cultured in differentiation medium consisting of DMEM 
supplemented with 1% FBS and 100units/ml penicillin/100µg/ml streptomycin. 
The differentiation medium of treated cells was further supplemented with 
30µM of CAPE. Incubation of H9c2 cells with CAPE, an inhibitor of the 
translocation of NF-kB into the nucleus, significantly inhibited H9c2 cell 
differentiation (i.e. cell alignment, elongation and myotube formation) into 
cardiomyocytes. CAPE treated H9c2 cells largely maintained their normal 
single cell and spindle shaped morphology (shown by black arrows in day 4 to 
day 12 NF-kB-treated cells). In contrast, control H9c2 cells showed the usual 
morphological changes (shown by black arrows in day 4 to day 12 control 
cells). Both control cells and NF-kB-treated cells showed the normal single 
cell morphology (shown by white arrows) at day 0. The photographs were 
taken under 200X magnification and are representative of at least three 
independent differentiation experiments. 
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Figure 8.11: Effects of inhibition of NF-kB activation on H9c2 cell 
differentiation into cardiomyocytes: cardiac ventricular myosin light 1 
expression. In agreement with the lack of morphological changes observed 
in CAPE treated H9c2 cells, western blot analysis of MLC-1v revealed that 
expression of this protein was also suppressed by CAPE in comparison to the 
control expression (panel A). The blot is representative of at least three 
differentiation experiments. The densitometric data (mean ± SD), from three 
independent experiments, show the time dependent changes in MLC-1v 
expression in CAPE treated H9c2 cells (panel B). 
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8.3.2 Viability of H9c2 cells in 30µM of NF-kB activation inhibitor CAPE 
 
The 30µM of CAPE, used our experiments that were designed to investigate 
the effects of the inhibition of NF-kB activation on H9c2 differentiation into 
cardiomyocytes was not toxic to the cells. The average viability was about 
89% of the viability determined in the control cells. Twenty four hours after the 
introduction of CAPE to the cells, there was no statistically significant 
difference between the viability calculated in control H9c2 cells and CAPE 
treated cells (p > 0.05) (Figure 8.12). By 48 hours, the maximum length of 
time for which the cells were exposed to CAPE, there was a slight reduction in 
viability of CAPE treated cells (p < 0.05). The viability of CAPE cells at this 
time was about 73% of the viability determined in the control cells. 
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Figure 8.12: The viability of H9c2 cells in the presence of the NF-kB 
activation inhibitor, CAPE. H9c2 cells were seeded in 6-well plates in 
differentiation medium consisting of DMEM supplemented with 1% FBS and 
100units/ml penicillin/100µg/ml streptomycin and  30µM of CAPE as  
described in the methods section above (Section 4.123). The MTT assay was 
carried out at the end of the treatment. Twenty four hours post CAPE, there 
was no difference in viability between control and CAPE treated cells (p > 
0.05). A slight reduction in cell viability (p < 0.05) was seen at 48 hours. The 
data presented in the graph are the mean ± SD from three independent 
experiments.  
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8.4 DISCUSSION 
 
There is a large amount of data on the role played by cardiac transcription 
factors in the differentiation process and this includes extended studies on  
the GATA factors (GATA 4, 5 and 6)  (Laverriere et al., 1994; Molkentin et al., 
1997; Murphy et al., 1997; Di Lisi et al., 1998; Charron et al., 1999; McBride 
and  Nemer, 2001), Nkx2.5   (Bodmer, 1993; Biben et al., 1997; Tanaka et al., 
1999; Bruneau et al., 2000; Jamali et al., 2001; Lee et al., 2004; Zaffran and  
Frasch, 2005) and T-box  factors (Chapman et al., 1996; Li et al., 1997; 
Bruneau et al., 1999; Bruneau et al., 2001; Jerome and  Papaioannou, 2001; 
Habets et al., 2002; Christoffels et al., 2004; Singh et al., 2005).  However 
there is very little clear information on the role of NF-kB during the 
differentiation of stem cells into cardiomyocytes. NF-kB, a ubiquitous 
transcription factor, is present in most cells  and   plays key roles  in many 
cellular processes including cell proliferation and  growth (Guttridge et al., 
1999; Hinz et al., 1999; Preciado et al., 2005), apoptosis (Wang et al., 1998; 
Kaltschmidt et al., 1999; Li et al., 2004; Tse et al., 2007) and in disease 
processes  including inflammation (Tsao et al., 1997; Miagkov et al., 1998).  
 
As far as we are aware, our data are the first to demonstrate a direct 
requirement of NF-kB activation for cardiac differentiation as demonstrated by 
the lack of differentiation of H9c2 cells into cardiomyocytes in the presence of 
the NF-kB inhibitor CAPE. CAPE is a  potent and specific inhibitor of NF-kB 
activation (Natarajan et al., 1996). CAPE was used at 30uM concentration 
and the MTT data showed that this compound was not markedly toxic at this 
concentration. Thus the effects of CAPE on the cell differentiation may be 
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mostly likely due to the inhibition of NF-kB signalling by blocking NF-kB 
translocation into the nucleus. 
 
Our data showed that blocking NF-kB activation with CAPE delayed the onset 
of the differentiation of H9c2 cells into cardiomyocytes. Inhibition of H9c2 
differentiation into cardiomyocytes as monitored by the morphological 
changes was evident upto day 8. While MLC-1v levels in CAPE treated cell 
recovered by day 8 and day 12 (the last day for this experiment), they were 
however never equal to the levels seen in the control cells.  Our data 
therefore suggest that activation of NF-kB may support H9c2 cell 
differentiation into cardiomyocytes.  
 
The suggestion by our data that NF-kB may have a role to play in H9c2 cell 
differentiation into cardiomyocytes is in agreement with recent emerging 
evidence that suggest  positive roles for NF-kB in the differentiation of various 
other cells  including osteoclast differentiation (Abu-Amer, 2001; Vaira et al., 
2008), the differentiation of HL-60 cells into monocytes (Tse et al., 2007), 
neuronal differentiation of neuroblastoma  cells  (Feng and  Porter, 1999), 
PC12  cells  (Foehr et al., 2000) and  P19 stem cells (Liu et al., 2004). 
 
While our data and the reports mentioned above from other studies suggest a 
positive role for NF-kB in cell differentiation, other studies  suggest that NF-kB 
may be a negative  regulator of  myogenesis  due to  its ability to promote cell 
proliferation or  growth activity (Lehtinen et al., 1996; Guttridge et al., 1999; 
Hinz et al., 1999; Guttridge et al., 2000). NF-kB (p50 subunit and  p65 
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subunit) activates the cyclin D1 promoter (Hinz et al., 1999) and inhibits 
C2C12 myogenesis by means of its growth-promoting activity through a direct 
transcriptional regulation of cyclin D1 (Guttridge et al., 1999). The inactivation 
of NF-kB caused a delayed and reduced expression of  cyclin D1 in the G1 
phase and also affected pRB phosphorylation and  cell cycle  progression 
from  G1 to S-phase (Hinz et al., 1999).  Cyclins are key regulatory proteins 
that are involved in the regulation of cell cycle progression. They regulate the 
cell cycle progression by controlling the activities of cyclin-dependent protein 
kinases (CDK). Mutated IkB-α, with serine residues (ser32 and ser36) 
changed to alanines, is not subject to phosphorylation and subsequent 
degradation following an NF-kB-activating stimulus (Brockman et al., 1995). 
C2C12 myoblasts containing this mutated IkB-α were found to proliferate 
slower than control cells and exit  the cell cycle faster than control cells when 
myogenesis was induced  (Guttridge et al., 1999).  Wild-type C2C12 
myoblasts were also found to down-regulate the expression of NF-kB before 
the induction of myogenin and the initiation of myotube formation (Lehtinen et 
al., 1996). In C2C12 myoblasts, the loss of p50 and p65 NF-kB DNA-binding 
activity, correlated with myogenic differentiation (Guttridge et al., 1999). The 
above therefore suggest that NF-kB may negatively regulate myogenesis. 
 
As cell proliferation and cell differentiation appear to be mutually exclusive 
processes, the growth promoting activity of NF-kB  and also its ability to inhibit 
myogenic transcription factors  (Guttridge et al., 2000) may consistent  with its 
role as a negative regulator of  myogenesis.  If NF-kB is fundamentally a 
negative regulator of cell differentiation then, CAPE would be expected to 
 329 
improve H9c2 differentiation into cardiomyocytes. However according to our 
data CAPE instead blocked H9c2 cell differentiation into cardiomyocytes. Our 
data may appear to contradict the negative role suggested for NF-kB during 
cell differentiation, by the other studies (Lehtinen et al., 1996; Guttridge et al., 
1999; Hinz et al., 1999; Guttridge et al., 2000). It should however be noted 
that an exit from the cell cycle is an essential condition for initiating 
differentiation. Therefore cells that have been induced to differentiate may 
transiently block NF-kB activation (i.e. transiently remove the growth 
promoting activity of NF-KB) in order to exit the cell cycle and initiate 
differentiation. However in the long term, after this transient inactivation of NF-
kB, the restored NF-kB activity may be beneficial for the proliferation of the 
cells that have already differentiated or committed to differentiation. Nuclear 
factor-kappa B may indirectly promote H9c2 cell differentiation into 
cardiomyocytes by promoting the survival and proliferation of H9c2 cells that 
have already differentiated or committed to differentiation.  
 
In an experimental condition, prolonged inhibition of NF-kB activation (for 
example in the presence of CAPE) may impair the ability of the cells, including 
those that have become committed to cardiomyocyte differentiation, to 
proliferate. In such experimental conditions, the inhibition of NF-kB activation  
may have a long term negative role on cell differentiation, due to its ability to 
impair cell proliferation, independent of any direct effect on the mechanisms 
mediating the differentiation. The grow-promoting activity of NF-kB, 
independent of any possible direct role on the induction of cell differentiation, 
is very important since cells undergoing differentiation are experiencing 
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tremendous stress in changing from cell type to another and need 
mechanisms that can enhance their survival. Thus the activation of NF-kB 
may be required during the differentiation of H9c2 cells into cardiomyocytes. 
 
8.5 Summary  
 
The time dependent differentiation of the H9c2 cells into cardiomyocytes in 
1% FBS culture medium was significantly delayed by the inhibition of NF-kB 
signalling by CAPE (30µM). CAPE inhibition of H9c2 differentiation was more 
evident when MLC-1v expression was monitored as marker of H9c2 cell 
cardiac differentiation.  
 
In conclusion, our data suggest that NF-kB activation may be required for 
H9c2 cell differentiation into cardiomyocytes. Whether NF-kB has a direct 
active role in inducing the differentiation of H9c2 cells into cardiomyocytes or 
that NF-kB promotes the survival of the cells that have already differentiated 
into cardiomyocytes or committed to cardiac differentiation, need further 
investigation. 
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CHAPTER 9.0 
GENERAL DISCUSSION 
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9.1 Establishment of cardiac differentiation models 
 
The aim of this thesis was to investigate the signal transduction pathways that 
that are involved in the differentiation of stem cells into cardiomyocytes. The 
first objective was to establish cardiomyocyte differentiation models using 
H9c2 and P19 stem cells and to use these models to accomplish the specific 
objectives of the thesis.  The specific objectives were the investigation of the   
roles of (i) nitric oxide, (ii) phosphoinositide 3-kinase (PI3K), (iii) protein kinase 
C (PKC), (vi) NF-kB and (vii) p38 MAP kinase signalling pathways in the 
differentiation of stem cells cardiomyocytes. Stem cell research is a new area  
in our laboratory and the models needed for the studies carried out in this 
thesis had to be established and validated. 
 
We have established the H9c2 cell line as a model of cardiomyocyte 
differentiation and used it for the investigation of the roles of various cell 
signalling pathways in the differentiation of stem cells into cardiomyocytes. 
The criteria used were relevance of the model to in vivo cardiomyocyte 
differentiation and simplicity in term of model manipulation. Both models met 
these conditions in term of being relevant and simple.  
 
The H9c2 cell line was chosen because of its relevance to cardiac 
regeneration and simplicity of use.  The H9c2  cell model has also extensively 
been used by other researchers not only as a cardiomyocyte differentiation 
model  (Kim et al., 1999; Menard et al., 1999; Hong et al., 2001; Kageyama et 
al., 2002; Giusti et al., 2004; Pagano et al., 2004) but also in the  investigation 
of  other biological processes in cardiomyocytes  (Ekhterae et al., 1999; 
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Kageyama et al., 2002; Armoni et al., 2005; Gross et al., 2006; Qin et al., 
2006; Salvatorelli et al., 2006). The H9c2 cell line is therefore an appropriate 
model for our studies aimed at investigating the signalling mechanisms that 
regulate differentiation into cardiomyocytes.   
 
Freshly cultured H9c2 cells in a suspension of complete medium were 
rounded. When undifferentiated H9c2 cells attach to culture dishes, they grow 
as spindle-shaped mononucleated cells and did not express cardiac specific 
markers. In agreement with the lack of morphological changes, undifferentiated 
cells did not expressed cardiac myosin heavy chain  as determined by western 
blotting. However H9c2 cells cultured in low serum medium differentiate, 
become elongated and fuse to form multinucleated myotubes and express 
cardiac specific markers (cardiac myosin heavy chain (α/β-MHC) and cardiac 
ventricular myosin light chain (MLC-1v). 
 
Despite the advantage of the simplicity of the H9c2 cardiac differentiation 
model, like most models, is not a perfect substitute for the in vivo processes. 
One of the limitations of the H9c2 model for cardiac differentiation is that the 
cell line was derived from an embryonic heart. This means that the cardiac 
lineage commitment may have already taken place. However cardiac specific 
genes such as that which code for cardiac specific myosin heavy chain and 
ventricular myosin light chain-1 are not constitutively expressed in 
undifferentiated H9c2 cells until the cells are induced to differentiate into 
cardiomyocytes.  This makes these cells very relevant for exploring of the 
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signalling transduction events that drives their differentiation into 
cardiomyocytes.  
 
The mouse P19 embryonal carcinoma cell line (P19 stem cells) was also 
developed as a model for stem cell differentiation into cardiomyocytes in 
parallel with the H9c2 cells. P19 embryonal carcinoma stem cells cultured in 
normal cell culture grade dishes in complete culture medium  whether in the 
presence or absence of 0.8% DMSO did not form embryoid bodies (EB) but 
grew as clusters, in a single cell monolayers. These clusters did not 
differentiate into cardiomyocytes. In contrast, P19 cells cultured in 
microbiological Petri dishes in complete culture medium, supplemented with 
0.8% DMSO, formed EBs. The transfer of EB from Petri dishes to standard 
tissue culture dishes resulted in cell adhesion, the formation of a two-
dimensional monolayer, cell migration and proliferation. The first beating 
clusters of cardiomyocytes were routinely detected by day 6 or 7. The size 
and number of beating clusters of cardiomyocytes usually increased up to day 
14. There was a high degree of variability both in term of the clusters of 
beating cells and in the frequency at which they appeared to beat. 
 
The P19 stem cell model, like the H9c2 cell model is relatively simple and can 
be easily   manipulated in experiments. P19 stem cells are pluripotent and can 
develop into cell types of the three germ layers.   With proper care during their 
routine culture and also during experiments P19 stem cell differentiation into 
cardiomyocytes appears to be highly regulated and reproducible.  Like other 
stem cell lines, P19 stem cells form embryoid bodies in suspension culture 
under non-adherent conditions. In the presence of DMSO, P19 stem cell 
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cardiomyocyte differentiation can be induced during the embryoid body 
formation.  
 
The major advantage of the P19 cell models is that this pluripotent cell line 
can be maintained continuously in serum-supplemented cell growth medium 
without the need for LIF or feeder cells to keep them in the undifferentiated 
state.  This allows stem cell research to be carried out at relatively very low 
cost in comparison to the use of other stem cells that may need special 
conditions such as knockout serum, LIF or feeder cells.  Another strong point 
for the use of P19 stem cells is that the cell line is a well-established model of 
cardiomyocyte differentiation (McBurney et al., 1982; Wobus et al., 1991; 
Monzen et al., 1999; Naito et al., 2003; Brown et al., 2004; Brewer et al., 
2005; Angello et al., 2006). The ability of P19 stem cells to differentiate into 
cardiomyocytes  has been clearly established  by the expression of cardiac 
transcription factors including Nkx2.5  (Skerjanc et al., 1998; Monzen et al., 
1999; Wen et al., 2007) GATA-4 (Monzen et al., 1999; Uchida et al., 2007; 
Wen et al., 2007), MEF2C  (Skerjanc et al., 1998; Wen et al., 2007) and other 
cardiac specific proteins including cardiac troponin I (Choi et al., 2004; Fathi 
et al., 2008) during the cardiac differentiation of these cells. 
 
In conclusion, models of cardiomyocyte differentiation using P19 cells and 
H9c2 cells were established. The established cardiac differentiation models 
were subsequently used in further studies exploring the mechanisms that may 
regulate stem cell differentiation into cardiomyocytes. New or better models 
may be used in future experiments. However these models, due to their 
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simplicity, relevance to cardiac differentiation and relative low cost may still be 
a good a starting point for researchers that are new to the study of signalling 
pathways in stem cell differentiation into cardiomyocytes. 
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9.2 Effects of nitric oxide donors on H9c2 differentiation into 
cardiomyocytes 
 
We examined the role of nitric oxide (NO)  in the differentiation of H9c2 cells 
into cardiomyocytes using fast NO releasing donors (NOC-5 and SIN-1)  and 
slow NO releasing donors (NOC-18 and SNAP). SIN-1 and NOC-5, markedly 
delayed the onset of differentiation of H9c2 cells into cardiomyocytes while 
SNAP and NOC-18, were not as effective in delaying the onset of 
differentiation or long term differentiation of H9c2 cells into cardiomyocytes.  
 
In parallel with the morphological changes, NOC-5 and SIN-1 also caused a 
reduction in the expression of MLC-1v in differentiating H9c2 cells. NOC-18 
also delayed the onset of H9c2 cell differentiation into cardiomyocytes but to a 
lesser extent than NOC-5 and SIN-1. Differentiation associated morphological 
changes in both control and SNAP-treated H9c2 cells were similar. In 
agreement with the morphological seen in the control cells and SNAP treated 
cells, MLC-1v levels in SNAP-treated and control H9c2 cells were almost 
equal. 8-Bromo-cGMP, an analogue of cGMP, appeared to delay the onset of 
H9c2 cell differentiation into cardiomyocytes. However, like NOC-5 and SIN-1, 
8-Bromo-cGMP failed to block the long term differentiation of H9c2 cells into 
cardiomyocytes. In parallel, expression of MLC-1v was reduced at day 4 but 
thereafter MLC-1v expression in controls and 8-Bromo-cGMP-treated cells 
were indistinguishable. 
 
Fast NO releasing donors including NOC-5 (t1/2 = 93 minutes) and SIN-1 (t1/2 
= 40 minutes) release a large part of their NO content in a matter of minutes. 
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In contrast, slow NO releasing donors including NOC-18 (t1/2 = 20 hours) and 
SNAP (t1/2 = 37 hours) release their NO content slowly over time in manner 
that may resemble the manner that NO is produced by constitutively 
expressed nNOS and eNOS. The differential affects of fast and slow releasing 
NO donors on the differentiation of H9c2 cells into cardiomyocytes may be 
due to their differences in the release of NO.  
 
Excessive NO can disrupt cellular functions and also induce oxidative stress 
via events that lead to formation of superoxide, peroxynitrite, hydroxyl radical 
and nitrite radicals, all of which can cause damage to cells and tissues. Nitric 
oxide released by NOC-18 and SNAP   may protect the cells against 
apoptosis  (Kim et al., 1997; Hebestreit et al., 1998) by the suppression of 
pro-apoptotic ghenes (Thippeswamy et al., 2001) and induction of anti-
apoptotic genes (Ciani et al., 2002).  NOC-18 and SNAP may therefore   
promote cell survival and contribute to differentiation of stem cells into 
cardiomyocytes.  In contrast, NOC-5 and SIN-1, by their excessive production 
of NO, may induce apoptosis and therefore have negative effects on stem 
cells into cardiomyocytes.  
 
Our findings with 8-Bromo-cGMP is in agreement with the data obtained with 
some of the NO donors used in that treatment of cells with 8-Bromo-cGMP 
also delayed the onset of differentiation. The 8-Bromo-cGMP data also 
suggest role of endogenous NO in H9c2 cell differentiation. The fact that NO 
(at least NO from fast-releasing NO donors) and also 8-Bromo-cGMP 
inhibited rather than enhance the differentiation process, at least over the 
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initial stages of the process, is clearly contradictory to the other studies which 
show a positive regulatory role of NO in the differentiation of stem cells into 
cardiomyocytes and also into other lineages.  Our studies, as they stand, give 
little indication as to conflicting findings and further experiments are clearly 
needed especially in real stem cells or stem cell lines. These studies although 
planned were not carried out because of time constraints but are clearly 
needed.  
 
In conclusion, our data would suggest that generation of cardiomyocytes from 
H9c2 cells may be negatively regulated by endogenous NO and this may 
occur through generation of cGMP. Our data are however preliminary and 
further studies are needed to confirm these findings. Moreover, a detailed 
study of the full signalling pathway activated by NO may prove important in 
understanding how this molecule regulates differentiation.   
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9.3 Effects of PKC inhibition on H9c2 and P19 stem cell 
differentiation into cardiomyocytes 
 
The inhibition of the PKC signalling pathway, using BIM-I (10µM), caused 
marked inhibition of differentiation associated morphological changes (i.e.  cell 
elongation, fusion and myotube formation)  that usually accompany H9c2 cell 
differentiation into cardiomyocytes. Control H9c2 cells cultured in the absence 
of BIM-I underwent differentiation and formed myotubes.  In agreement with 
the lack of morphological change observed in BIM-I-treated H9c2 cells, the 
expression of a cardiac specific maker (MLC-1v protein) in these cells was 
completely blocked up to day 4 and then significantly inhibited thereafter. This 
suggests that the activation of PKC may have fundamental roles in the events 
that are responsible for H9c2 cell differentiation into cardiomyocytes. 
 
Similarly PKC inhibition, with BIM-I (10µM), blocked the differentiation of P19 
stem into beating cardiomyocytes. P19 stem cells cultured in 0.8% DMSO in 
the absence of BIM-I differentiated into beating cardiomyocytes. In contrast, 
P19 stem cells treated with 0.8% DMSO in the presence BIM-I (10µM) did not 
differentiate into beating cardiomyocytes. In agreement with the lack of 
appearance of beating cardiomyocytes in BIM-I treated P19 stem cells, the 
long term expression of cardiac restricted protein troponin I (TnI) was 
inhibited. 
 
Our data also suggested that the PKC signalling events that are responsible 
for mediating P19 stem cell differentiation into cardiomyocytes are switched 
on very early following DMSO treatment since the PKC inhibitor, BIM-I was 
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only able to block P19 stem differentiation into beating cardiomyocytes only if 
added at the EB formation stage (i.e. at the time of initiating of P19 cell  
cardiac differentiation). BIM-I application to P19 stem cells during the four 
days of EB formation completely blocked cell differentiation into beating 
cardiomyocytes. However the treatment of P19 stem cells with BIM-I, four 
days after DMSO induced cardiac differentiation had started, had no effect on 
the ability of the cells to differentiate into beating cardiomyocytes. 
 
The cross-talk data, discussed below, also showed that PKC may regulate  
the PI3K signalling pathway, another key signalling pathway that has been  
widely reported to be required for stem cell differentiation  into cardiomyocytes 
and other cell types. This may however have no direct relevance to the 
differentiation process since PKC enhanced the phosphorylation of Akt, a 
protein that is thought to be central to many of PI3K biological effects, but 
blocked differentiation.  This  information suggests that while it is desirable to 
target and investigate the role of specific pathways individually, studies aimed 
at identifying points of convergence or divergence and indeed cross-talk 
between  pathways are needed  in order to get a clear and better 
understanding of the processes that regulate differentiation. 
 
In conclusion, our data therefore suggest that the activation of PKC signalling 
pathway may be required for the differentiation of H9c2 cell and P19 stem cell 
differentiation into cardiomyocytes. The data also suggest that the activation 
of PKC signalling pathway may be required during the early stages of P19 
stem cell differentiation into cardiomyocytes. 
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9.4 Effects of p38 MAPK inhibition on H9c2 and P19 stem cell 
differentiation into cardiomyocytes 
 
The differentiation of H9c2 cells into cardiomyocytes was blocked by the 
inhibition of p38 MAPK signalling using SB203580 (10µM). However 
SB203580 had little or no effect on the differentiation associated 
morphological changes in H9c2 differentiating into cardiomyocytes. In both 
control cell and SB203580-treated cells, morphological changes were visible. 
In contrast to the apparent lack of inhibition of morphological changes in 
SB203580-treated H9c2 cells, the expression of MLC-1v was decreased in 
these cells. Our data therefore suggest that p38 MAPK signalling pathway 
may have a role in the differentiation of H9c2 cells into cardiomyocytes. 
 
In contrast H9c2 cells, SB203580 markedly inhibited the expression of cardiac 
restricted protein troponin (TnI) and also blocked the cell differentiation into 
beating cardiomyocytes. The small expression of TnI seen in control P19 
stem cells, at the time of EB transfer to cell culture plates, increased upto day 
8. In comparison to control cells, TnI levels in SB203580-treated P19 stem 
cells were reduced. The inhibited or low levels of TnI detected in SB203580-
treated cells were in agreement with the lack of appearance of beating 
cardiomyocytes. It was also observed that SB203580 blocked P19 stem cell 
differentiation into beating cardiomyocytes, when added to the cells during the 
EB formation stage. In contrast, SB203580 failed to block the differentiation of 
P19 stem cells into beating cardiomyocytes, when the cells were treated, with 
this compound, four days after the initiation of DMSO-induced cardiac 
differentiation. Our data therefore suggest that p38 MAPK signalling pathway 
signalling has a role in the differentiation of P19 stem cells into 
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cardiomyocytes and also that this signalling pathway is switched on during the 
early stages of P19 stem cell differentiation into cardiomyocytes. 
 
While our data suggest that p38 MAPK signalling pathway may have roles to 
play in the differentiation of both H9c2 cells and P19 stem cells into 
cardiomyocytes, the data also showed that p38 MAPK signalling may have a 
more prominent role in the differentiation of P19 stem cells into 
cardiomyocytes than in the differentiation of H9c2 cells into cardiomyocytes. 
SB203580 (10µM) completely block the differentiation of P19 stem cells into 
beating cardiomyocytes and also markedly reduced the expression of troponin 
I. In contrast SB203580 failed to block the differentiation-induced 
morphological changes (i.e. cell elongation, cell fusion and formation of 
myotubes) in H9c2 cells but did delay the expression of MLC-1v during the 
differentiation of H9c2 cells into cardiomyocytes. The findings that SB203580 
blocked both the differentiation of P19 stem cells into beating cardiomyocytes 
and the expression of troponin I  (in P19 cells), while in H9c2 cells, only 
blocked the expression of MLC-1v but not  the differentiation-induced 
morphological changes of H9c2, may imply that p38 MAPK  have a lesser role 
in these differentiation-induced morphological changes. This question of 
whether this is the case was not investigated and it may need further 
investigation in future studies. Nevertheless, our data suggest that p38 MAPK 
may be involved in the cascade that drives the differentiation of both cell types 
into cardiomyocytes. P19 stem cells are undifferentiated cells without any 
prior cardiac lineage specification. In contrast, H9c2 cells were derived from 
an embryonic rat heart.  The apparent lesser effect of SB203580 on the 
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differentiation of H9c2 cells into cardiomyocytes and the inability of SB203580 
to block P19 cell differentiation into   cardiomyocytes, when added to P19 
stem cells four after DMSO-induced differentiation, may imply that p38 MAPK 
activation may be more relevant at early stages of cardiac differentiation. 
 
In conclusion, our data therefore suggest that the activation of p38 MAPK 
signalling pathway may be an essential signalling event during the 
differentiation of H9c2 cells and P19 stem cells into cardiomyocytes. The data 
also suggest that the p38 MAPK exerts its effects at the early stages of P19 
stem cell differentiation into cardiomyocytes. 
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9.5 Effects of the PI3K Inhibition on P19 stem and H9c2 Cell 
differentiation into cardiomyocytes 
 
Our data showed that the activation of the PI3K signalling pathway may be 
essential for differentiation of both H9c2 and P19 stem cells into 
cardiomyocytes. The differentiation of both P19 stem cells and H9c2 cells into 
cardiomyocytes were significantly inhibited by LY294002 (20µM) treatment of 
these cells.  
 
The inhibition of PI3K, using LY294002 (20µM), completely blocked the 
differentiation of H9c2 cells into cardiomyocytes (as as determined by the 
usual morphological changes of cell elongation, fusion and myotube 
formation). LY294002 treated H9c2 cells largely maintained their normal 
single cell and spindle shaped morphology which was in contrast to control 
H9c2 cells which showed the usual morphological changes. In agreement with 
the lack of morphological changes observed in LY294002 treated H9c2 cells, 
the expression of cardiac specific ventricular myosin light chain 1 (MLC-1v 
protein) was significantly inhibited. Our data therefore suggest that activation 
of the PI3K signalling pathway is required for H9c2 cell differentiation into 
cardiomyocytes.   
 
Treatment of H9c2 cells with 1% FBS induced a rapid increase in 
phosphorylation (at serine 473) but this differentiation associated increase in 
Akt phosphorylation was completely abolished by 20µM of LY294002. This 
differentiation associated increase in Akt phosphorylation was significantly 
enhanced by BIM-I (10µM) but significantly reduced by SB203580 (10µM). 
 346 
Our data therefore show that PI3K is activated during 1% FBS-induced 
differentiation of H9c2 cells into cardiomyocytes and also that PKC and p38 
MAPK may modulate Akt phosphorylation at serine 473. 
 
P19 stem cultured in the presence of 0.8% DMSO but in the absence of 
LY294002 (absence of PI3K inhibition) differentiated into beating 
cardiomyocytes.  However PI3K inhibition, with LY294002 (20µM), completely 
blocked the DMSO-induced differentiation of P19 stem cells into beating 
cardiomyocytes. The expression of cardiac specific troponin I was also 
reduced in P19 stem cells treated with LY294002.  
 
When DMSO was allowed to initiate P19 stem cell differentiation, for four days 
before the addition of LY294002 to the cells, LY294002 completely failed to 
block the cell differentiation into beating cardiomyocytes.  Our data therefore 
suggest that activation of the PI3K signalling pathway is required for P19 stem 
cell differentiation into cardiomyocytes. In addition, like the PKC and p38 
MAPK data, these results suggest that PI3K signalling is required during the 
early stages of P19 stem cell differentiation into cardiomyocytes.  
 
Akt activation by sequential phosphorylation is a critical event in the PI3K 
signalling and is generally thought to be a central event in most of the effects 
mediated by PI3K activation (Ahmed et al., 1997; Dudek et al., 1997; 
Kauffmann-Zeh et al., 1997; Eves et al., 1998; Gingras et al., 1998). Our data 
showed that while PI3K is required for stem cell differentiation into 
cardiomyocytes, Akt phosphorylation is not sufficient to induce cardiomyocyte 
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differentiation since enhanced Akt activation failed to induce H9c2 cell cardiac 
differentiation. Our cross-talk studies with PKC showed that PKC inhibition 
enhanced Akt phosphorylation at serine 473 (i.e. Akt activation). As already 
discussed (Chapter 7), the enhanced Akt activation by PKC inhibition cannot 
be explained by non-specificity BIM-I (10µM). Other studies using different 
PKC inhibitors including Ro-31-8220 (bisindolylmaleimide IX), 
bisindolylmaleimide VIII and LY 379196 (another bisindolylmaleimide) have 
shown that PKC inhibition increased Akt  activation (Wen et al., 2003; Edling 
et al., 2007). Akt phosphorylation, in HEK293 cells over-expressing Akt (i.e. 
cells that show higher levels of Akt activation), was inhibited by phorbol 12-
myristate-13-acetate (PMA) a potent PKC activator (Wen et al., 2003).  
 
The enhancement of Akt activation by PKC inhibition may therefore suggest 
that PKC modulates Akt activity. However, since PKC inhibition also inhibited 
the differentiation of both H9c2 cells and P19 stem cells into cardiomyocytes.  
These data suggest that the possible crucial role of PI3K in cardiac 
differentiation may be carried out via mechanism(s) that is/are independent of 
Akt activation since enhancement of Akt phosphorylation failed to enhance 
the differentiation of either P19 stem cell or H9c2 cells into cardiomyocytes. 
However, PI3K inhibition (i.e. prevention of Akt activation) by LY294002 also 
blocked H9c2 and P19 stem cell differentiation into cardiomyocytes.  The data 
suggest that the differentiation of H9c2 and P19 stem may be dependent on 
PI3K signalling, but independent of Akt activation. The data further point to a 
possible target downstream of PI3K through which the effects of PI3K on 
cardiomyocyte differentiation may be channelled independently of Akt. This 
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possible key downstream target is currently unknown and warrants further 
investigation.  
 
The fact that PKC inhibition enhanced the activation of  Akt but  at the same 
time also inhibited the cardiac differentiation of both H9c2 cells and P19 stem 
cells may suggest that, during cardiac differentiation, there is no cross-talk 
between PI3K and PKC, at least not at a level that involves Akt. The 
mechanism(s) by which BIM-I promotes Akt phosphorylation is not clear.  The 
enhancement of Akt by the PKC specific inhibitor BIM-I suggests that PKC 
may play a negative role in the regulation of PI3K pathway. PKC acts 
downstream of both PI3K and PDK1 (Chou et al., 1998; Dutil et al., 1998; 
Balendran et al., 2000). Therefore the potential negative regulation of the 
PI3K signalling pathway by PKC cannot be attributed to a direct effect on 
either PI3K or PDK1.  
 
Our data give ground for possible speculation about how BIM-I (i.e. PKC 
inhibition) might have increased Akt phosphorylation at serine 473. PKC could 
inhibit Akt activation by targeting PDK2, an elusive and currently unknown 
kinase that is thought to be responsible for Akt phosphorylation at serine 473.  
Available evidence also  suggests that  a phosphatase known as  PHLPP (PH 
domain leucine-rich repeat protein phosphatase) selectively and specifically 
dephosphorylates  Akt at Ser473 (Gao et al., 2005). Therefore another 
possible mechanism by which PKC inhibition might lead to increase Akt 
phosphorylation may be  that PKC is an activator (i.e. positive regulator) of 
PHLPP “a putative phosphatase” that may be responsible for 
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dephosphorylating AKt at serine 73 back to the baseline level, following  a 
phosphorylation event. If this is the case then the ability of BIM-I to increase 
Akt phosphorylation could be explained by the fact that BIM-I reduces the 
ability of PKC to activate that “putative phosphatase”, thus limiting the ability 
of this “phosphatase to dephosphorylate AKt-ser473, hence the increased 
AKt-ser473 levels in presence of BIM-I.  However it is not known whether 
PKC can regulate PHPLP. 
 
Our data suggest possible cross-talk between PI3K and p38 MAPK.  While 
PDK1 has been cloned and sequenced  (Alessi et al., 1997a) and it is 
established that PDK1 phosphorylates Akt at threonine 308 (Alessi et al., 
1997a; Alessi et al., 1997b), the identity of the kinase that is responsible for 
Akt phosphorylation at serine 473 remains unknown. Our data showed 
reduced phosphorylation of Akt at serine 473 when the p38 MAPK inhibitor 
SB203580 (10µM) was added to the cells.  While there is growing list of 
possible PDK2 candidates including p38 MAPK, the identity of PDK2 remains 
elusive. The question of whether p38 MAPK has a PI3K-dependent and 
phosphoinositide-dependent activity that can phosphorylate Akt at serine 473 
or whether p38 MAPK and PDK2 are one and the same kinase remains. This 
needs further investigation. 
 
In conclusion, the activation of the PI3K signalling pathway is required for P19 
stem cells and H9c2 cell differentiation into cardiomyocytes.  The activation of 
PI3K signalling is required during the early stages of stem cell differentiation 
into cardiomyocytes. Our data also suggest that PI3K positively regulates 
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stem cell differentiation into cardiomyocytes not through Akt activation, but 
through a yet unknown signalling mechanism that is independent of Akt 
activation. 
 
Our data suggest no possible cross-talk between PI3K and PKC, at least not 
at a level that involves Akt.  The data also suggest that PKC may also be a 
negative regulator of Akt phosphorylation at serine 473 either via an unknown 
PDK2 or via positive regulation of a possible “phosphatase” that is responsible 
for the dephosphorylation of Akt at serine 473. It is also a suggestion from our 
data that there may be a possible cross-talk between PI3K and p38 MAPK 
and that p38 MAPK may also have a PI3K-dependent and phosphoinositide-
dependent activity with the ability to phosphorylate Akt at Serine 473 or p38 
MAPK and PDK2 may be one and the same kinase.  
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Figure 9.10: PI3K, PKC and p38 MAPK regulate stem cell differentiation 
into cardiomyocytes through possible Akt-independent mechanisms. 
PI3K activation causes the Akt activation (phosphorylation at both threonine 
308 and serine 473) but PI3K may regulate stem cell differentiation into 
cardiomyocytes through a possible Akt-independent mechanism. Both PKC 
and P38 MAPK may modulate the phosphorylated states of Akt, However, the 
inhibition of PKC and p38 MAPK also blocked the differentiation of H9c2 cells 
and P19 stem cells into cardiomyocytes. Therefore PI3K, PKC, p38 MAPK 
may regulate H9c2 cells and P19 stem cell differentiation into cardiomyocytes 
through a possible Akt-independent mechanism(s). The possible Akt-
independent mechanisms or downstream target, through which PI3K, PKC  
and p38 MAPK may regulate H9c2 cell and P19 stem cell differentiation into 
cardiomyocytes is/are currently unknown 
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9.6 Effects of the inhibition of the activation of NF-kB on 
H9c2 cell differentiation into cardiomyocytes 
 
 
The differentiation of H9c2 cells into cardiomyocytes, in the presence of 1% 
FBS, was significantly delayed by the inhibition of NF-kB signalling by CAPE 
(30µM). CAPE inhibition of H9c2 differentiation was more evident when MLC-
1v expression was monitored as marker of H9c2 cell cardiac differentiation.  
 
There is a vast amount of data on the roles of cardiac transcription factors but 
very little information on other non cardiac transcription factors such as NF-κB 
on the differentiation of stem cells into cardiomyocytes. Our findings are the 
first to suggest a direct requirement for NF-kB activation for cardiac 
differentiation as shown by the lack of differentiation of H9c2 cells into 
cardiomyocytes in the presence of CAPE (30µM). Our data showed that 
blocking NF-kB activation using CAPE delayed the onset of the differentiation 
of H9c2 cells into cardiomyocytes.  
 
NF-kB plays a major role in promoting cell survival. It promotes cell 
proliferation through a direct transcriptional regulation of cyclin D1 (Guttridge 
et al., 1999). The inactivation of NF-B caused a delayed and reduced 
expression of cyclin D1 in the G1 phase and also affected pRB 
phosphorylation and cell cycle  progression from  G1 to S-phase (Hinz et al., 
1999). 
 
As cell proliferation and cell differentiation appear to be mutually exclusive 
processes. NF-kB, due  to its growth-promoting activity, may have negative 
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effect on cell  differentiation  (Lehtinen et al., 1996).  But in the long term, NF-
kB may indirectly promote H9c2 cell differentiation into cardiomyocytes by 
promoting the survival of H9c2 cells that have already differentiated or 
become committed to differentiation into cardiomyocytes.  This role of NF-kB 
is very important since cells undergoing differentiation are experiencing the 
stress of changing from one cell type to another and need mechanisms that 
can enhance their survival.  Our data constitute important preliminary findings 
that warrant further investigations. 
 
In conclusion, our data suggest that NF-kB activation may be required for 
H9c2 cell differentiation into cardiomyocytes. Whether NF-kB has a direct 
active role in inducing the differentiation of H9c2 cells into cardiomyocytes or 
that NF-kB promotes the survival of the cells that have already differentiated 
into cardiomyocytes or committed to cardiac differentiation, need further 
investigation. 
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9.7 CONCLUSION 
 
H9c2 and P19 stem cell lines are relevant and complementary models for the 
investigation of the intracellular signalling mechanisms that mediate stem cell 
differentiation into cardiomyocytes. The PKC, PI3K, p38 MAPK and NF-kB 
signalling pathways are relevant and are involved in the differentiation of stem 
cells into cardiomyocytes as inhibition of these pathways was  accompanied 
by inhibition of differentiation associated morphological changes (i.e. cell 
alignment, elongation and fusion to form myotubules in H9c2 cells), inhibition 
of functional or physiological changes (the appearance of beating 
cardiomyocytes in P19 stem cells)  and  inhibition of associated expression 
cardiac specific protein markers. The next logical stem step is to  determine 
the exact role of these pathways in the initiation of stem cell cardiac 
differentiation.  This would require the design of the experiments that will 
examine the direct effects of the inhibition or enhancement of these pathways 
on the expression of cardiac transcription factors (e.g. GATA-4, Nkx2.5). 
These further studies will establish whether they pathways are core key 
players or whether their role is the facilitation   of stem cardiac differentiation 
programme once it has been initiated.   
 
Our nitric oxide data suggested that NO delayed the onset of differentiation. 
This is clearly contradictory to the other studies cited which show a positive 
regulatory role of NO in the differentiation of stem cells not only into 
cardiomyocytes but also into other lineages. Our NO studies, as they stand, 
give little indication as to the reason for these conflicting findings and further 
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experiments, including concentration-effects curves, are clearly needed 
especially in real stem cells or stem cell lines.  
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FURTHER WORK 
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Further work 
 
This thesis produced important new data which in turn give rise to new 
questions (which in a year or so won’t seem to be important) that should be 
resolved in further work. 
 
1. Our data suggest that the PI3K, PKC and p38MAPK pathways may be 
required for stem cell differentiation into cardiomyocytes. These 
pathways were implicated by monitoring terminal cardiac differentiation 
(i.e. beating cells or cardiac structural proteins). They question of 
whether these pathways have direct active roles in inducing the 
differentiation of stem cells into cardiomyocytes or whether they just 
facilitate the differentiation of stem into cardiomyocytes needs to be 
resolved. For each of the signalling pathways implicated a direct 
connection between their activation and the specific induction of stem 
cell cardiac lineage commitment needs to be established by monitoring 
the specific induction of the expression of early cardiac genes and 
cardiac transcription factors. 
 
2. Our data suggest a role for NF-kB in the differentiation of H9c2 cells 
into cardiomyocytes. These are new data showing the involvement of 
this ubiquitous but non-cardiac transcription factor in cardiac 
differentiation. These data should be reproduced in stem cells or stem 
cell lines using the same criteria suggested for PI3K, PKC and p38 
MAPK. 
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3. If the results from 1 or 2 are positive for any of pathways implicated 
(i.e. PI3K, PKC, p38MAPK or NF-kB) then to get better insight on the 
role of the implicated pathway, these studies should be extended to the 
examination of the connection of that pathway to major cardiac 
differentiation related pathways such as the BMP and Wnt signalling 
pathways. 
 
4. For each of the pathways implicated, specific and selective activation 
should be carried out, in stem cells or stem cell lines, to complement 
the inhibition data obtained. 
 
5. Our nitric oxide studies were carried out in H9c2 cells and failed to 
resolve previous conflicting findings. Further experiments should be 
carried out in stem cells or stem cell lines to resolve these conflicting 
results by monitoring the specific induction  of the expression of early 
cardiac genes and cardiac transcription factors. 
 
6. While our data suggest that Akt phosphorylation at serine 473 may not 
be of major relevance to the differentiation of stem cells into 
cardiomyocytes since PI3K, p38 MAPK and PKC  are implicated in the 
differentiation of stem into cardiomyocytes then it may be worthwhile to 
use other p38 MAPK  and PKC inhibitors (preferably more specific  and 
selective)  to reproduce the inhibition of PI3K  ( inhibition of Akt 
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phosphorylation at serine 473) by the inhibition of p38 MAPK and the 
activation of PI3K by the inhibition of PKC. 
 
7. More specific and selective inhibitors for the various PKC isoforms 
should be examined in future studies in order to get a better insight of 
the role of individual PKC isoforms in the differentiation of stem cells 
into cardiomyocytes. 
 
8. The concentrations of the various inhibitors, used in our studies, are in 
agreement with published concentrations. However in future studies, 
concentration-effect experiments should be carried out  to examine the 
specificity of drugs used in our studies. 
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APPENDIX 
 
 
APPENDIX I: CELL LINES 
 
Appendix I (a):H9c2 (2-1) Cell Line 
 
  
Cell Line Name H9c2 (2-1) 
Description 
 
Rat BDIX heart myoblast . Cell form myotubes  in 1% 
serum (FBS) 
Species Rat 
Tissue heart 
Morphology Myoblast 
Growth Mode Adherent 
Culture Medium DMEM + 2mM Glutamine +  10 % FBS 
Subculture Routine 
Split cells at 70-80% confluency using trypsin/EDTA. 
Important to passage at sub-confluence to avoid 
spontaneous cell fusion to form myotubes 
Supplier 
 
European Collection of Cell Cultures (ECACC) 
http://www.hpacultures.org.uk/collections/ecacc.jsp 
Catalogue Number 88092904 
  
 
Appendix I (b):P19 Embryonal Carcinoma Stem Cell Line 
 
  
Cell Line Name P19 embryonal carcinoma stem cells 
Cell Line Description 
 
 
 
The mouse teratocarcinoma  pluripotent  cell line was 
derived from an embryonal carcinoma induced in a C3H/He 
strain mouse.  The P19 cells c differentiate into neuronal 
and glial cells in the presence of retinoic acid. The P19 cell 
Aggregates  differentiate into cardiac and skeletal muscle 
in the presence of DMSO 
Species Mouse 
Tissue embryo 
Growth Mode Adherent 
Culture Medium Alpha MEM + 2mM Glutamine +  10 % FBS 
Subculture Routine Split cells at 70-80% confluency using trypsin/EDTA. 
Karyotype: Euploid 
Supplier 
 
European Collection of Cell Cultures (ECACC) 
http://www.hpacultures.org.uk/collections/ecacc.jsp 
Catalogue No 95102107 
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APPENDIX II: CELL CULTURE REAGENTS 
 
 
Reagents 
 
Description 
 
Storage 
 
Supplier 
Minimal Essential 
Medium (MEM) 
Alpha Medium (α-
MEM) 
(Product 
code:22561021) 
 
Without but 
Ribonucleosides 
and 
Deoxyribonucleo
sides but 
Contains Earle's 
Salts and  L-
glutamine 
 
 
Fridge 4°C  Invitrogen, UK 
http://www.invitrogen.com 
Dulbecco's 
Modified Eagle 
Medium (D-MEM) 
(1X) (Low 
Glucose) 
(Product code: 
22320022) 
 
Contains L-
Glutamine, 1000 
mg/L D-Glucose, 
Sodium Pyruvate, 
25 mM HEPES. 
Fridge 4°C, Invitrogen, UK 
http://www.invitrogen.com 
Foetal Bovine 
Serum 
(Product code: 
10500064) 
 
Heat inactivated 
Foetal Bovine 
Serum  
 
Stock:  -20°C,  Invitrogen, UK 
http://www.invitrogen.com 
Penicillin-
Streptomycin, 
liquid (10,000 units 
penicillin;10,000 
µg streptomycin) 
(Product code: 
15140122) 
 
Contains 10,000 
units of penicillin 
and 10,000 µg of 
streptomycin  
kills  Gram-ve 
and +ve bacteria 
Stock:  -20°C, Invitrogen, UK 
http://www.invitrogen.com 
Trypsin, 0.5% 
(10x) with EDTA 
4Na, 
(Product code: 
15400054 ) 
Contains 5.0 g/L 
of trypsin,  2.0 g/L 
of EDTA.4Na, 8.5 
g/L of NaCl 
Stock : -20°C, 
dilutedstock 
solution 
Aliquots: 
Fridge 4°C, 
Invitrogen, UK 
http://www.invitrogen.com 
 
 
 
 
 
 
 APPENDIX III: NITRIC OXIDE DONORS AND 8
 
 
 
Appendix III (a): NOC-5
Alternate Names 
Size: 
Description 
CAS Number 
Molecular Weight 
Molecular Formula 
Structure: 
Solubility 
Stock Concentration 
Prepared 
Storage 
Supplier 
Catalogue Number 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
432 
-BROMO-
 
3-[2-Hydroxy-1-(1-methylethyl)-2-nitrosohydrazino]
propanamine 
10 mg 
A nitric oxide (NO) donor. Half-life (t½
min (PBS, pH 7.4, 22°C). 
146724-82-5 
176.2 
C6H16N4O2 
 
H2O or NaOH (0.1 N, ≥ pH 10) 
100mM (5mg/284µl of NaOH) 
Protect from light  
Solid: -20°C 
Alkaline stock  solution Aliquots: -20°C
Calbiochem 
http://www.merckbiosciences.co.uk 
487950 
CGMP 
-1-
) of NO release is 93 
   
  
Appendix III (b): NOC-18
Alternate Names: 
 
Description 
CAS Number 
Molecular Weight 
Molecular Formula 
Structure: 
Solubility 
Stock Concentration 
Prepared 
Storage 
Supplier 
Catalogue Number 
 
Appendix III (c): SNAP
Alternate Names 
Size: 
Description 
CAS Number 
Molecular Weight 
Molecular Formula 
Structure 
 
 
 
 
Solubility 
Stock Concentration 
Prepared 
Storage 
Supplier 
Catalogue Number 
433 
 
DETA NONOate; DETA/NO; 2,2′-
(Hydroxynitrosohydrazino)bis-ethanamine
 
A nitric oxide (NO) donor. Half-life for NO release (t
3400 min; PBS, pH 7.4, 22°C) 
146724-94-9 
163.2 
C4H13N5O2 
 
H2O or NaOH 
100mM (5mg/306µl of NaOH) 
Protect from light  
Solid: -20°C 
Stock  solution Aliquots: -20°C   
Calbiochem, http://www.merckbiosciences.co.uk
487957 
 
 (±)-S-Nitroso-N-acetylpenicillamine 
20 mg 
A Nitric oxide donor with a half-life (t1/2
begins to evolve nitric oxide immediately in a
buffers 
79032-48-7 
220.2 
C7H12N2O4S 
 
 
DMSO,  Ethanol  or Methanol 
100mM (5mg/227µl of DMSO) 
Protect from light store Solid: -20°C 
Stock  solution Aliquots: -20°C   
Calbiochem 
http://www.merckbiosciences.co.uk 
487910 
 
½ = 
 
 = 10 h). SNAP  
queous 
 Appendix III (d) : SIN-1, Hydrochloride
Alternate Names 
Size: 
Description 
CAS Number 
Molecular Weight 
Molecular Formula 
Structure 
Solubility 
Stock Concentration 
Prepared 
Storage 
Supplier 
Catalogue Number 
 
Appendix III (e): Guanosine 3
Alternate Names 
Description 
CAS Number 
Molecular Weight 
Molecular Formula 
 
 
 
 
 
Structure 
Solubility 
Stock Concentration 
Prepared 
Storage 
Supplier 
Catalogue Number 
434 
 
3-Morpholinosydnonimine, HCl 
20 mg 
Nitric oxide (NO) donor. Spontaneously decomposes to 
yield NO and superoxide anion radicals. 
16142-27-1 
206.7 
C6H10N4O2 · HCl 
 
DMSO or   Ethanol  
100mM (5mg/242µl of DMSO) 
Protect from light  
Solid: -20°C 
Stock  solution Aliquots: -20°C   
Calbiochem 
http://www.merckbiosciences.co.uk 
567028 
′,5′-cyclic Monophosphate 
8-Bromo-cGMP; Br-cGMP, Na 
Cell-permeable cGMP analog 
51116-01-9 
446.1 
C10H10BrN5O7P · Na 
  
 
 
 
 
 
 
 
 
H2O  
100mM (5mg/112µl of NaOH) 
Solid: -20°C,stock solution Aliquots: -
Calbiochem 
http://www.merckbiosciences.co.uk 
203820 
 
20°C 
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APPENDIX VI: INHIBITORS 
 
Appendix VI (a): Bisindolylmaleimide I 
Alternate Names Gö 6850; GF109203X, 2-[1-(3-Dimethylaminopropyl)-1H-
indol-3-yl]-3-(1H-indol-3-yl)-maleimide 
Description A reversible protein kinase C (PKC) inhibitor that acts as a 
competitive inhibitor for the ATP-binding site 
CAS Number 133052-90-1 
Molecular Weight 412.5 
Molecular Formula C25H24N4O2 
Structure:  
 
 
 
 
 
 
Solubility Anhydrous  DMSO 
Stock Concentration 
Prepared 
10mM (1mg/242µl of DMSO) 
Storage Solid: -20°C,stock solution Aliquots: -20°C 
Supplier Calbiochem 
http://www.merckbiosciences.co.uk 
Catalogue Number 203290  
 
Appendix VI (b): LY294002 
Alternate Names 2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 
Description A  phosphatidylinositol 3-kinase (PI 3-kinase) inhibitor that 
acts on the ATP-binding site of the enzyme 
CAS Number 154447-36-6 
Molecular Weight 307.4 
Molecular Formula C19H17NO3 
Structure:  
 
 
 
 
 
Solubility DMSO 
Stock Concentration 
Prepared 
10mM (5mg/1627µl)  of DMSO 
Storage Solid: -20°C,stock solution Aliquots: -20°C, Protect from 
light 
Supplier Calbiochem 
http://www.merckbiosciences.co.uk 
Catalogue Number 440202 
 436 
Appendix VI (c): SB203580 
Alternate Names 4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-
pyridyl)1H-imidazole 
Description A highly specific, cell-permeable inhibitor of p38 kinase 
(IC50 = 34 nM in vitro, 600 nM in cells). 
CAS Number 152121-47-6 
Molecular Weight 377.4 
Molecular Formula C21H16N3OSF 
Structure:  
 
 
 
Solubility DMSO  
Stock Concentration 
Prepared 
10mM (1mg/265µl of DMSO) 
Storage Protect from light  
Solid: -20°C 
Stock  solution Aliquots: -20°C   
Supplier Calbiochem 
http://www.merckbiosciences.co.uk 
Catalogue Number 559389 
 
Appendix VI (d): CAPE 
Alternate Names Caffeic Acid Phenethyl Ester 
Description An active component of propolis from honeybee hive and  
a potent and specific inhibitor of NF-κB activation 
CAS Number 104594-70-9 
Molecular Weight 284.3 
Molecular Formula C17H16O4 
Structure  
 
 
 
 
 
Solubility DMSO 
Stock Concentration 
Prepared 
100mM (5mg/176µl of DMSO) 
Storage Solid: -20°C,stock solution Aliquots: -20°C, Protect from 
light 
Supplier Calbiochem 
http://www.merckbiosciences.co.uk 
Catalogue Number 211200 
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APPENDIX VII: ANTIBODIES  
 
 
 
Appendix VII (a): Monoclonal Anti-Cardiac Myosin Light Chain I Antibody (MLC-
1v) Antibody 
 
Antibody Name   Cardiac Myosin light chain I antibody [MLM527] 
Antibody Type   Primary antibodies 
Description   Mouse monoclonal [MLM527] to Cardiac Myosin light chain  
Immunogen   Human ventricle myosin light chain I 
Reacts with   Human, Mouse, Rat, Cow, Pig 
Specificity   Antibody reacts with ventricle myosin light chain I (MLC-1v) 
Application used Western blotting  (can also be used for ELISA, ICC/IF) 
Band size 23 to 27kDa 
Raised in   Mouse 
Clonality   Monoclonal 
Clone number   MLM527 
Isotype   IgG2b 
Purity   Protein A purified 
Storage  Aliquot and store at -20°C or -80° 
Concentration   1.0 mg/ml 
Dilution  used  1:2500 in blocking buffer 
Secondary antibody 
required 
Anti-mouse antibody conjugated 
to horseradish peroxidase (HRP) 
Supplier Abcam, UK 
http://www.abcam.com 
Catalogue Number ab680 
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Appendix VII (b): Monoclonal Anti-Cardiac Myosin Heavy Chain (α& β 
isoforms) Antibody 
 
Antibody Name   Heavy Chain Cardiac Myosin antibody [3-48] 
Antibody Type   Primary antibodies 
Description   Mouse monoclonal [3-48] to heavy chain cardiac Myosin 
Immunogen   Full length native protein (purified) (Human). 
Reacts with   Human, Mouse, Rat, Cow, Dog, Pig, Rabbit 
Specificity   Antibody reacts with alpha and beta isoform of myosin heavy 
chain 
Application used Western blotting  (can also be used for ELISA, Flow Cyt, 
ICC/IF, IHC) 
Band size 223 kDa 
Raised in   Mouse 
Clonality   Monoclonal 
Clone number   3-48 
Isotype   IgG1 
Purity   IgG fraction 
Storage  Aliquot and store at -20°C or -80°C 
Concentration   1.0mg/ml 
Dilution  used 1:2500 in blocking buffer 
Secondary antibody 
required 
Anti-mouse antibody conjugated 
to horseradish peroxidase (HRP) 
Supplier Abcam, UK 
http://www.abcam.com 
Catalogue Number ab15 
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Appendix VII (c): Monoclonal Anti-cardiac Troponin I Antibody 
 
Antibody Name   Cardiac Troponin I antibody [284 (19C7)] 
Antibody Type   Primary antibodies 
Description   Mouse monoclonal [284 (19C7)] to cardiac Troponin 
Immunogen   Native troponin complex 
Reacts with   Human, Mouse, Rat, Cat, Cow, Dog, Fish, Goat, Monkey, Pig, 
Rabbit 
Specificity   Reacts equally with free cardiac troponin I and cardiac troponin 
I forming complexes with other troponin components. No cross-
reactivity with skeletal muscle troponin I.  
Application used Western blotting (can also be used for AP, ICC/IF, IHC-P, 
ELISA) 
Band size 24 kDa 
Raised in   Mouse   
Clonality   Monoclonal 
Clone number   284 (19C7) 
Isotype   IgG2b 
Purity   Protein A purified 
Storage  Aliquot and store at -20°C or -80°C 
Concentration   3.2 mg/ml  
Dilution  used 1:2500 in blocking buffer  
Secondary antibody 
required 
Anti-mouse antibody conjugated 
to horseradish peroxidase (HRP) 
Supplier Abcam, UK 
http://www.abcam.com 
Catalogue Number ab19615 
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Appendix VII (d): Monoclonal Anti- phospho-Akt  (Ser473) Antibody 
 
Antibody Name   Mouse Phospho-Akt (Ser473) (587F11) monoclonal antibody 
Antibody Type   Primary antibody 
Description   A mouse monoclonal antibody to Akt phosphorylated at serine 
473 (Ser473) 
Immunogen   A synthetic phospho-peptide (KLH-coupled) corresponding to 
residues around Ser47 of mouse Akt. 
Reacts with   Human, mouse Rat Hamster 
Specificity   Antibody reacts with Akt only when phosphorylated at serine 
473 and does not react with  related kinases such as PKC and 
p70 S6 kinase. 
Application used Western blotting (can also be used IP) 
Band size 60 kDa 
Raised in   mouse 
Clonality   monoclonal 
Clone number   587F11 
Isotype   IgG2b 
Purity   Protein A purified 
Storage  Whole tube (i.e. no aliquot) of the antibody was stored at -
20°C. Required portions of the antibody were taken from -20°C. 
Concentration   1.0 mg/ml 
Dilution  used 1:1000 
Secondary antibody 
required 
Anti-mouse antibody conjugated to horseradish peroxidase 
(HRP) 
Supplier Cell Signallng Technology  
http://www.cellsignal.com 
Catalogue Number 4051 
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Appendix VII (e): Monoclonal Anti-β-Actin antibody conjugated to 
horseradish peroxidise (HRP) 
Antibody Name   Monoclonal Anti-β-Actin-Peroxidase, Clone AC-15  
Antibody Type   Primary antibody 
Description   A Protein A purified fraction of mouse monoclonal anti-b-actin  
isolated from ascites fluid of the AC-15 and conjugated  
horseradish peroxidise (HRP) 
Immunogen   A synthetic peptide corresponding to a slightly modified b-
cytoplasmic actin 
N-terminal sequence: Ac-Asp-Asp-Asp-Ile-Ala-Ala-Leu-Val-Ile-
Asp-Asn-Gly-Ser-Gly-Lys conjugated to KLH 
Reacts with   Human,  mouse, rat, bovine, sheep, pig, rabbit, cat, dog,  
guinea pig, chicken, carp 
Specificity   Antibody reacts specifically with β-actin found many tissues 
and species 
Application used Loading control for western blotting 
Band size 42 kDa 
Raised in   mouse 
Clonality   Monoclonal 
Clone number   AC-15 
Isotype   IgG1 
Purity   Protein A purified 
Storage  Aliquot and store at -20°C or -80°C 
Concentration   Conjugate concentration: 2.5–6 mg/mL 
Antibody Concentration: 2–4 mg/mL 
Dilution  used 1:25000 
Secondary antibody 
required 
None required 
Supplier Sigma (Sigma-Aldrich), UK 
http://www.sigmaaldrich.com 
Catalogue Number A3854 
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APPENDIX VIII: PREPARATION OF STOCK SOLUTIONS 
 
Calculation of mole of a compound 
 
 
Mole of compound 
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Relationship between the mole, concentration and volume  of a 
compound in solution 
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Calculation of required volume for dissolving a compound   
 
The volume parameter from the above equation was made the subject 
and volume (µl) required to achieve a selected stock concentration of 
each compound was calculated. 
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An Example Calculation  
 
Example: Calculation of the volume of DMSO required for 
preparing the 10mM stock concentration of LY294002. 
 
Mass of LY294002 used = 1mg = 1 x 10-3 g 
Required Stock concentration = 10mM = 10 x 10-3 M = 10-2 M 
Molecular weight of LY294002 = 307.4 g/mole 
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In a tissue culture hood (i.e. laminar flow cabinet), 325.3µL of DMSO was 
added to 1mg of LY294002. The LY294002 solid was through dissolved, 
aliquots of 10µL and 20 µL portions were made and stored at -20oC. 
 
 
